daunorubicin has been researched along with Acute Myelogenous Leukemia in 1549 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 609 (39.32) | 18.7374 |
| 1990's | 286 (18.46) | 18.2507 |
| 2000's | 158 (10.20) | 29.6817 |
| 2010's | 352 (22.72) | 24.3611 |
| 2020's | 144 (9.30) | 2.80 |
| Authors | Studies |
|---|---|
| Braniecki, M; Gok Yavuz, B; Hwang, J; Quigley, JG; Singh, N; Tsoukas, MM | 1 |
| Alakel, N; Bornhäuser, M; Chemnitz, J; Döhner, H; Döhner, K; Fransecky, L; Gaidzik, V; Germing, U; Götze, KS; Haas, R; Hänel, M; Hanoun, M; Henning, L; Heuser, M; Holderried, TAW; Holtick, U; Jehn, CF; Kaiser, U; Kobbe, G; Koch, K; Kraus, S; Krause, SW; Kriege, O; Krüger, W; Lauseker, M; Middeke, JM; Morgner, A; Neuerburg, C; Platzbecker, U; Rautenberg, C; Röhnert, MA; Röllig, C; Sauer, T; Schäfer-Eckart, K; Schetelig, J; Schliemann, C; Scholl, S; Schröder, J; Schroeder, T; Severmann, J; Sockel, K; Stelljes, M; Stölzel, F; Thol, F; Unglaub, JM; Verbeek, M; Vucinic, V; Wagner-Drouet, E; Wass, M | 1 |
| Leiby, BE; Schmucker, AM; Wilde, L | 1 |
| Caldwell, KJ; Farrar, JE; Federico, SM; Hu, Y; Lei, S; Lewis, S; Nichols, KE; Onciu, M; Ribeiro, RC; Rubnitz, JE; Salek, M; Takemoto, CM; Triplett, BM; Wlodarski, MW; Zhang, J | 1 |
| Michaelis, LC | 1 |
| Thol, F | 1 |
| Al-Mansour, Z; Alonzo, TA; Aplenc, R; Cao, X; Cogle, C; Elsayed, AH; Gamis, A; Kolb, EA; Lamba, JK; Meshinchi, S; Mitra, AK; Pounds, S; Raimondi, S; Ribeiro, RC; Rubnitz, J; Wu, H | 1 |
| Akl, D; Baik, H; Bossis, G; Boulanger, M; Cartron, G; De Toledo, M; Gabellier, L; Gâtel, P; Gueret, E; Hallal, R; Moreaux, J; Paolillo, R; Piechaczyk, M; Recher, C; Sarry, JE; Tempé, D | 1 |
| Bewersdorf, JP; Goshua, G; Huntington, SF; Patel, KK; Podoltsev, NA; Shallis, RM; Zeidan, AM | 1 |
| Ali, S; Burnett, AK; Cahalin, P; Clark, RE; Hills, RK; Kjeldsen, L; Russell, NH; Thomas, IF | 1 |
| Ahmed, SO; Aljurf, M; Alotaibi, S; Mohty, M; Niederwieser, D; Sanz, J | 1 |
| Faderl, S; Goldberg, SL; Lancet, JE; Lin, TL; Newell, LF; Ryan, RJ; Uy, GL; Wieduwilt, MJ | 1 |
| Berezniuk, I; Chakraborty, S; Feller, F; Khalaj, M; Park, CY; Stranahan, AW | 1 |
| Feng, X; Gao, X; Li, H; Liu, Q; Luo, L; Mao, S; Yang, P; Zhang, D | 1 |
| Adès, L; Alexe, G; Belloucif, Y; Benaksas, C; Berrou, J; Braun, T; Castelli, FA; Chat, L; Chauvel, C; Clappier, E; Dal Bello, R; de Thé, H; Dombret, H; Duchmann, M; Fenaille, F; Fenouille, N; Forget, A; Gardin, C; Huntly, BJ; Itzykson, R; Joudinaud, R; Laiguillon, MC; Ling, F; Lobry, C; Meduri, E; Pacchiardi, K; Pardieu, B; Pasanisi, J; Penneroux, J; Puissant, A; Raffoux, E; Sodaro, G; Stegmaier, K; Su, A; Vaganay, C; Vasseur, L; Wu, HC | 1 |
| Babushok, DV; Bruno, XJ; Carroll, MP; Frey, NV; Gill, SI; Hexner, EO; Hwang, WT; Loren, AW; Luger, SM; Maillard, IP; Margolis, D; Martin, ME; Matthews, AH; McCurdy, SR; Paralkar, VR; Perl, AE; Porter, DL; Pratz, KW; Stadtmauer, EA | 1 |
| Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I | 1 |
| Choi, W; Kim, YH; Min, J | 1 |
| Fang, QY; Gong, BF; Gong, XY; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Qiu, SW; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, CX; Zhang, GJ; Zhou, CL | 1 |
| Bay, JO; Béné, MC; Bertrand, P; Bonmati, C; Carré, M; Darrouzain, F; Gallego-Hernanz, MP; Gyan, E; Hérault, O; Hunault, M; Lioure, B; Peterlin, P; Picou, F; Pigneux, A; Récher, C; Ternant, D; Vallet, N | 1 |
| Al-Kali, A; Alkhateeb, H; Begna, KH; Chen, D; Elliott, MA; Gangat, N; Hogan, WJ; Hook, CC; Ketterling, RP; Litzow, MR; Mangaonkar, A; Pardanani, A; Patnaik, MS; Shah, M; Tefferi, A; Viswanatha, D | 1 |
| Ai, J; Arnall, J; Avalos, BR; Boselli, D; Chen, T; Chiad, Z; Chojecki, AL; Copelan, EA; Cruz, A; DiSogra, KY; Grunwald, MR; Karabinos, A; Knight, TG; Patel, R; Ragon, BK; Sanikommu, SR; Shah, NA; Symanowski, J; Verbyla, A | 1 |
| Chan, O; Deutsch, Y; Eatrides, J; Jain, AG; Komrokji, R; Kuykendall, A; Lancet, J; Lee, D; Padron, E; Sallman, D; Sweet, K; Talati, C | 1 |
| Alsdorf, WH; Bokemeyer, C; Brauneck, F; Fiedler, W; Ghandili, S; Karagiannis, P; Klingler, F; Modemann, F; Wolschke, C | 1 |
| Budagaga, Y; Haddad, A; Haddad, M; Hofman, J; Laštovičková, L; Morell, A; Novotná, E; Portillo, R; Vagiannis, D; Wsól, V; Zhang, Y | 1 |
| Cao, J; Li, F; Li, ZY; Liu, J; Liu, Y; Lu, ZY; Mu, XR; Wu, QY; Xu, KL; Xue, YT; Zhang, S | 1 |
| Allert, C; Bauer, M; Besenbeck, B; Blank, MF; Bruckmann, M; Göllner, S; Heid, D; Janssen, M; Krijgsveld, J; Müller-Tidow, C; Pauli, C; Renders, S; Rohde, C; Trumpp, A; Waclawiczek, A; Wickenhauser, C; Zimmermann, SMN; Zinz, R | 1 |
| Bakhshi, S; Batra, A; Bisht, R; Chaudhary, S; Dubashi, B; Ganesan, TS; Kayal, S; Kumar, H; Radhakrishnan, V; Rajaraman, S; Shenoy, PK; Thampy, C | 1 |
| Brandts, CH; Koschade, SE; Münch, C; Parmar, BS; Tascher, G | 1 |
| Foutouhi, S; Kiuru, M; Simmons, E; Tartar, DM | 1 |
| Asubonteng, K; Cortes, JE; Faderl, S; Lancet, JE; Lin, TL; Prebet, T | 1 |
| Chen, S; Chu, X; Dan, W; Liu, B; Liu, Z; Lu, Y; Shao, X; Wang, X; Zhang, Z; Zhong, L; Zhou, Z | 2 |
| Chen, X; Gao, XH; Hao, HL; Huang, C; Li, J; Li, JY; Li, Y; Liu, JY; Tu, CQ; Wang, DW; Wang, RC; Xiong, X; Yang, J; Yang, YB; Yuan, J; Zhang, XX; Zhang, XY; Zheng, CF; Zou, LL | 1 |
| Matthews, A; Pratz, KW | 1 |
| Ball, B; Baron, J; Famulare, C; Fazal, S; Goldberg, AD; Griffiths, EA; Przespolewski, A; Sanikommu, SR; Stahl, M; Sweet, K; Talati, C; Thompson, JE; Thota, S; Vachhani, P; Waksal, J; Wang, ES | 1 |
| Bae, KH; Chen, Q; Kurisawa, M; Lai, F; Oruc, B; Osato, M | 1 |
| Al-Kali, A; Alkhateeb, HB; Atherton, P; Begna, K; Gangat, N; Hashmi, S; He, R; Litzow, M; Palmer, J; Patnaik, M; Tibes, R | 1 |
| Cairoli, R; Di Virgilio, R; Ferrara, F; Furneri, G; Veggia, B | 1 |
| Al-Ali, HK; Aul, C; Balleisen, L; Berdel, WE; Cross, M; Dörken, B; Dreger, P; Eimermacher, H; Florschütz, A; Giagounidis, A; Hähling, D; Hegenbart, U; Hehlmann, R; Heinicke, T; Heyn, S; Hiddemann, W; Hirt, C; Hochhaus, A; Hoffmann, VS; Jentzsch, M; Junghanss, C; Kahl, C; Kiehl, M; Krahl, R; Krämer, A; Krug, U; Lang, T; Lengfelder, E; Maschmeyer, G; Mügge, LO; Müller-Tidow, C; Naumann, R; Niederwieser, D; Oldenkott, B; Opitz, B; Peter, N; Pfirrmann, M; Pönisch, W; Reifenrath, K; Sauerland, C; Sayer, H; Schliemann, C; Scholl, S; Schulze, A; Schütte, W; Schwind, S; Serve, H; Späth, C; Staib, P; Vucinic, V; Wolf, HH; Wörmann, B; Zojer, N | 1 |
| Huang, X; Jin, J; Lou, Y; Ma, L; Mao, L; Ren, Y; Tong, H; Wang, H; Wang, Y; Wu, J; Xu, H; Yang, M; Yao, Y; Ye, X; Zhang, Y; Zhou, Y; Zhu, HH | 1 |
| Jain, A; Lemoli, RM; Montesinos, P | 1 |
| Charoenlappanit, S; Norkaew, C; Roytrakul, S; Tanyong, D; Thaisakun, S | 1 |
| Arnold, C; Batten, LM; Betteridge, S; Canham, J; Cavenagh, J; Dennis, M; Dillon, R; Freeman, SD; Gilkes, A; Hemmaway, C; Hinson, EL; Kleeman, M; Knapper, S; Kottaridis, P; Mehta, P; Othman, J; Overgaard, UM; Potter, N; Russell, NH; Villiers, W; Wilhelm-Benartzi, C; Wych, J | 1 |
| Bennett, JM; Cripe, LD; Fernandez, HF; Foran, JM; Ketterling, RP; Lai, C; Lazarus, HM; Levine, RL; Litzow, MR; Luger, SM; Paietta, E; Racevskis, J; Rowe, JM; Sun, Z; Tallman, MS; Zhang, Y | 1 |
| de Witte, T; Muus, P | 1 |
| Feng, B; Fu, JF; Kan, WJ; Li, J; Li, JN; Liu, MM; Luo, GH; Song, N; Tu, YT; Wang, HL; Wei, G; Wu, WB; Xu, GY; Xu, R; Zhou, YB | 1 |
| Akl, D; Andrieu-Soler, C; Aqrouq, M; Bossis, G; Boulanger, M; Cartron, G; Carusi, A; de Toledo, M; Forné, T; Gabellier, L; Gueret, E; Hallal, R; Hicheri, Y; Kaoma, T; Kifagi, C; Olsen, JV; Piechaczyk, M; Ristic, M; Sigurdsson, JO; Soler, E; Tempé, D; Vallar, L | 1 |
| Broe, A; Lambova, A; Legg, A; Levy, J; Medalla, G | 1 |
| Bengoudifa, BR; Caillot, D; Cluzeau, T; Farkas, F; Gilotti, G; Griskevicius, L; Hodzic, S; Legrand, O; Luppi, M; Minotti, C; Montesinos, P; Rambaldi, A; Sierra, J; Thomas, X; Venditti, A | 1 |
| Almuina, NM; Andrew, G; Burns, S; Cahalin, P; Dennis, M; Freeman, SD; Gallagher, KME; Gilkes, A; Hills, RK; Jakobsen, NA; Kennedy, A; King, S; Knapper, S; Mehta, P; Metzner, M; Moore, R; Russell, NH; Sellar, RS; Thomas, A; Thomas, I; Vyas, P; Weber, D | 1 |
| Chan, G; Cortes, JE; DiRienzo, CG; Dombret, H; Jeyakumar, D; Jou, E; Liu, X; Ma, W; Mayer, J; Merchant, A; Montesinos, P; Novak, J; O'Brien, T; Robak, T; Roh, W; Sekeres, MA; Shaik, N; Taussig, DC; Tomlinson, B; Wang, J | 1 |
| Choi, W; Kim, YH; Min, J; Shin, WR | 1 |
| Goedtel-Armbrust, U; Hähnel, PS; Hartwig, UF; Kindler, T; More, P; Ngaffo, JAM; Wojnowski, L | 1 |
| Ichinohe, T; Inaba, T; Kashimoto, N; Mino, T; Naka, K; Ueshima, T; Ureshino, H; Yamaguchi, T | 1 |
| Gou, J; He, H; Liu, B; Liu, Z; Tang, X; Wang, P; Yin, T; Zhang, J; Zhang, Y | 1 |
| Liu, M; Liu, X; Lu, Y; Luo, J; Nie, Z; Pan, Y; Wang, T; Wang, Z; Yang, L; Zhan, Y; Zhang, X | 1 |
| Bonmati, C; Campidelli, A; D'Aveni-Piney, M; Divoux, M; Kicki, C; Notarantonio, AB; Pagliuca, S; Roth-Guépin, G; Rubio, MT | 1 |
| Sasaki, K | 1 |
| Apel, A; Aviram, A; Berger, T; Frisch, A; Hellmann, I; Koren-Michowitz, M; Moshe, Y; Ofran, Y; Raanani, P; Ram, R; Rozovski, U; Wolach, O; Yaari, S; Yeshurun, M | 1 |
| Alfayez, M; Daver, N; Kadia, T; Kantarjian, H; Ravandi-Kashani, F | 1 |
| Alex, AA; Balasubramanian, P; Balasundaram, N; David, S; Ganesan, S; George, B; Korula, A; Lakshmanan, V; Mathews, V; Palakodeti, D; Palani, HK; Venkatraman, A; Vyas, N | 1 |
| Deotare, U; Deschner, M; Phua, C; Saini, L; Xenocostas, A | 1 |
| Duan, XL; Hua, J; Luan, J; Ma, CC; Xiao, TW | 1 |
| Chavez, J; Cubitt, CL; Dawson, JL; Komrokji, R; Lancet, JE; List, AF; Padron, E; Sallman, DA; Shah, BD; Sullivan, DM; Sweet, K; Turner, JG; Zhou, J | 1 |
| Akhter, N; Altman, JK; Canaani, J; Cascino, GJ; Foran, JM; Furiasse, N; Ky, B; Litzow, MR; Luger, S; Rademaker, A; Rigolin, V; Tallman, MS; Voss, WB | 1 |
| Chandra, D; Gupta, A; Gupta, R; Nityanand, S; Parashar, Y; Rahman, K; Singh, MK; Yadav, S | 1 |
| Chiarella, M; Cortes, JE; Goldberg, SL; Hogge, D; Kolitz, JE; Lancet, JE; Louie, AC; Ritchie, EK; Ryan, RJ; Strickland, SA; Stuart, RK; Villa, KF | 1 |
| DiNardo, CD; Wei, AH | 1 |
| Amaral, FM; Simeoni, F; Somervaille, TC; Williams, MS | 1 |
| Au-Yeung, R; Kwong, YL; Sim, JPY | 1 |
| Derman, BA; Larson, RA | 1 |
| DiNardo, CD; Richard-Carpentier, G | 1 |
| Chen, H; Hu, JW; Li, XS; Lou, X; Mao, N; Ning, HM; Su, YF; Wang, J; Xu, C | 1 |
| Choi, W; Heo, MY; Kim, SY; Kim, YH; Min, J; Wee, JH | 1 |
| Kasner, MT | 1 |
| Oliai, C; Schiller, G | 1 |
| Cao, S; Qiu, L; Zhou, G | 1 |
| Emadi, A; Estey, E; Gale, RP; Karp, JE; Othus, M | 1 |
| Gale, RP; Gong, B; Gong, X; Gu, R; Li, W; Li, Y; Lin, D; Liu, B; Liu, K; Liu, Y; Mi, Y; Qiu, S; Song, Z; Wang, J; Wang, Y; Wei, H; Wei, S; Zhang, G; Zhao, X; Zhou, C | 1 |
| Asghari, H; Lancet, J | 1 |
| Blaise, D; Bonnet, S; Bouchacourt, B; Charbonnier, A; Collignon, A; d'Incan, E; Gelsi-Boyer, V; Hospital, MA; Mohty, B; Mozziconacci, MJ; Rey, J; Saillard, C; Vey, N; Zemmour, C | 1 |
| Bloomfield, CD; Blum, W; Bucci, D; Eisfeld, AK; Geyer, S; Kohlschmidt, J; Kolitz, JE; Larson, RA; Laumann, K; Marcucci, G; Mrózek, K; Pardee, TS; Stock, W; Stone, RM; Uy, GL; Wang, ES; Zhao, W | 1 |
| Cheng, J; Jiang, Y; Li, Q; Li, Y; Ma, J; Pang, T | 1 |
| An, Q; Chiarella, M; Larson, ML; Lin, TL; Louie, AC; Roboz, GJ; Rubenstein, SE; Schiller, GJ; Solomon, SR | 1 |
| Borthakur, G; Bueso-Ramos, C; Class, CA; Cortes, JE; Daver, N; DiNardo, CD; Do, KA; Garcia-Manero, G; Issa, GC; Jabbour, E; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Khoury, JD; Konopleva, M; Montalban-Bravo, G; Naqvi, K; Patel, K; Pierce, S; Ravandi, F; Routbort, M; Sasaki, K; Short, NJ; Takahashi, K | 1 |
| Burnett, A; Stone, R | 1 |
| Floren, M; Gillette, JM; Lidke, KA; Marjon, KD; Restrepo Cruz, S; Termini, CM | 1 |
| Advani, AS; Appelbaum, FR; Ganapathi, MK; Ganapathi, RN; Godwin, JE; Koegle, ER; List, AF; McDonough, S; Michelson, AP; Othus, M; Petersdorf, SH; Radich, JP; Willman, CL | 1 |
| Honda, S; Katayama, O; Kawano, R; Morita, T; Nagamatsu, K; Narahara, H; Nishida, Y; Ogata, M; Sakata, M; Shirao, K; Takano, K; Yanai, Y; Yoshida, N | 1 |
| Deng, T; Ming, X; Xiao, Y; Xu, J | 1 |
| Huang, L; Hui, Y; Li, Y; Mao, X; Shang, Z; Wang, Y; Wang, Z; Wei, J; Xiao, M; Zhang, D; Zheng, L | 1 |
| Barbachano, Y; Cole, S; Coppola, P; Flores, B; Freire, J; Hemmings, R; Koenig, J; Lapveteläinen, T; Márcia, S; Penttilä, K; Pignatti, F; Roige, SD; Tzogani, K | 1 |
| Bossis, G; Brockly, F; Cartron, G; Gâtel, P; Hicheri, Y; Pastore, M; Piechaczyk, M; Reynes, C | 1 |
| Apperley, JF; Bain, BJ; Brown, L; Hastings, A; Nadal-Melsio, E | 1 |
| Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Büküm, N; Danielisová, P; Hofman, J; Morell, A; Novotná, E; Wsól, V | 1 |
| Baker, R; Burt, R; Farah, N; Ibrahim, AR; Kottaridis, PD | 1 |
| Guo, W; Huang, J; Huang, S; Huang, X; Jin, J; Li, F; Li, X; Ling, Q; Pan, J; Ye, W | 1 |
| Bakhshi, S; Chopra, A; Ganguly, S; Garg, A; Vishnubhatla, S | 1 |
| Liang, M; Wei, F; Xu, H; Zhang, H; Zhang, R; Zhao, X | 1 |
| Bhatnagar, B; Koenig, KL; Sahasrabudhe, KD; Sigmund, AM | 1 |
| Bhatnagar, B; Blachly, JS; Blum, WG; Byrd, JC; Crosswell, HE; Lin, TL; Liu, J; Long, L; Mims, AS; Minden, MD; Munugalavadla, V; Oellerich, T; Orwick, S; Pan, Y; Rao, AV; Serve, H; Walker, AR; Zhang, D | 1 |
| Estey, EH | 1 |
| Cai, B; Deng, L; Ying, S; Zhang, C; Zhou, F | 1 |
| Arber, DA; Erba, HP | 1 |
| Dang, FT; Wan, YM; Yang, J; Yang, QJ; Zheng, J | 1 |
| Lanchote, VL; Nardotto, GHB; Oliveira, ML; Pippa, LF; Rocha, A; Simões, BP | 1 |
| Cavo, M; Curti, A; Iannarone, C; Ocadlikova, D; Redavid, AR | 1 |
| Archetti, S; Bellotti, D; Bertoli, D; Borlenghi, E; Carbone, C; Cattaneo, C; Cerqui, E; Crippa, C; Dalceggio, D; Farina, M; Gramegna, D; Oberti, M; Pagani, C; Passi, A; Rossi, G; Schieppati, F; Sciumé, M; Soverini, G; Tucci, A | 1 |
| Cafaro, A; Cangini, D; Cerchione, C; Ghelli Luserna Di Rorà, A; Giannini, MB; Martinelli, G; Masini, C; Silimbani, P; Simonetti, G | 1 |
| Cangini, D; Cerchione, C; Ghelli Luserna Di Rorà, A; Giannini, MB; Gottardi, M; Martinelli, G; Padella, A; Simonetti, G; Sperotto, A | 1 |
| Alati, C; Audisio, E; Bertani, G; Bilio, A; Caizzi, M; Candoni, A; Carnevale-Schianca, F; Cerrano, M; Cignetti, A; Clavio, M; D'Ardia, S; Dargenio, M; Ferrara, F; Fianchi, L; Fracchiolla, N; Galimberti, S; Gottardi, M; Grimaldi, F; Guolo, F; Gurreri, C; Lemoli, RM; Minetto, P; Morselli, M; Musto, P; Pagano, L; Pasciolla, C; Pavesi, F; Pietrantuono, G; Rizzuto, G; Rondoni, M; Rossi, G; Scappini, B; Scattolin, AM; Tafuri, A; Zappasodi, P | 1 |
| Büküm, N; Danielisová, P; Milan, J; Morell, A; Novotná, E; Wsól, V | 1 |
| Chen, J; Gong, B; Gong, X; Gu, R; Jin, J; Li, Y; Lin, D; Liu, B; Liu, K; Liu, Y; Mi, Y; Qiu, S; Wang, J; Wang, Y; Wei, H; Wei, S; Zhang, G; Zhang, J; Zhao, X; Zhou, C | 1 |
| Abe, K; Dowsett, L; Hutchins, K; Wada, R | 1 |
| Adinolfi, E; Curti, A; De Marchi, E; Di Virgilio, F; Milani, A; Orioli, E; Pegoraro, A; Salvestrini, V | 1 |
| Arellano, M; Baer, MR; Ball, B; Blum, W; Borate, U; Boyiadzis, M; Brennan, T; Burd, A; Byrd, JC; Chen, T; Collins, R; Deininger, M; Druker, B; Duong, VH; Foran, J; Foster, MC; Heerema, NA; Kovacsovics, T; Levine, RL; Lin, TL; Litzow, M; Marcus, S; Miller, M; Mims, AS; Odenike, O; Olin, R; Patel, P; Rosenberg, L; Ruppert, AS; Schiller, G; Severson, E; Shoben, AB; Stefanos, M; Stein, EM; Stock, W; Traer, E; Vergilio, JA; Vietz, C; Walker, A; Yocum, A | 1 |
| Bollaert, E; Demoulin, JB; Essaghir, A; Graux, C; Havelange, V; Lenglez, S; Michaux, L; Saussoy, P; Schoemans, H; Valk, PJM; Vandewalle, V | 1 |
| Chiang, T; Miller, C; Seabury, R; Triesel, K | 1 |
| Burnett, AK; Clark, RE; Drummond, M; Freeman, S; Hills, RK; Huntly, B; Kell, J; Kjeldsen, L; Knapper, S; McMullin, MF; Russell, NH; Spearing, R; Thomas, IF | 1 |
| Battle, L; Dusza, SW; Markova, A; Moy, A; Park, JH; Stoll, JR; Tallman, MS; Taylor, J | 1 |
| Tallman, MS; Waksal, JA | 1 |
| Ades, L; Auberger, P; Bertoli, S; Bonmati, C; Caulier, A; Chevallier, P; Chiche, E; Cluzeau, T; Dumas, PY; Genthon, A; Hicheri, Y; Joris, M; Legrand, O; Lejeune, C; Loschi, M; Micol, JB; Mohty, M; Pasquier, F; Peterlin, P; Pigneux, A; Raffoux, E; Rahmé, R; Recher, C; Roth-Guepin, G; Thomas, X; Vey, N | 1 |
| Lin, N; Wang, L | 1 |
| Newman, MJ | 1 |
| Foster, MC; Green, SD; Richardson, DR; Zeidner, JF | 1 |
| Al-Malki, M; Aldoss, I; Ali, H; Aribi, A; Arslan, S; Artz, A; Budde, E; Dadwal, S; Forman, S; Khaled, S; Koller, P; Marcucci, G; Nakamura, R; Ngo, D; Pullarkat, V; Salhotra, A; Sandhu, K; Snyder, DS; Stein, A; Zhang, J | 1 |
| Cortes, JE; Faderl, S; Hogge, DE; Kolitz, JE; Lancet, JE; Lin, TL; Rizzieri, DA; Ryan, DH; Ryan, RJ; Schiller, GJ; Solomon, SR; Uy, GL; Wieduwilt, MJ | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Konopleva, M; Saxena, K | 1 |
| Etzler, J; Grandits, AM; Grebien, F; Hackl, H; Heller, G; Heyes, E; Nguyen, CH; Schlerka, A; Sill, H; Stoiber, D; Wieser, R | 1 |
| Benitez, LL; Bixby, DL; Burke, PW; Clark, SM; Crain, M; Filtz, M; Griffin, S; Kadia, T; Klaus, J; Marini, BL; Olson, M; Perissinotti, AJ; Pettit, K; Ratermann, K; Rausch, CR; Treptow, C | 1 |
| Cappelleri, JC; Heeg, B; Mamolo, C; Mokgokong, R; Muresan, B; Palaka, A; Soikkeli, F | 1 |
| Fang, Z; Feng, Y; Khadka, B; Liu, J; Wu, J; Zhang, L | 1 |
| Emadi, A; Faderl, S; Finn, L; Garcia, R; Jacoby, MA; Male, HJ; Powell, BL; Saba, NS; Seiter, K | 1 |
| Chang, LS; Chiou, JT; Huang, CH; Huang, NC; Lee, YC; Shi, YJ; Wang, LJ | 1 |
| Bollaert, E; Claus, M; Demoulin, JB; Essaghir, A; Havelange, V; Lenglez, S; Vandewalle, V | 1 |
| Bai, H; Dong, H; Gu, N; Kong, F; Liu, F; Ma, M; Sun, Q; Wang, C; Xu, H; Zhang, Y | 1 |
| Plesa, A; Thomas, X | 1 |
| Cortes, JE; Faderl, S; Lancet, JE; Lin, TL; Ryan, RJ; Uy, GL | 1 |
| Wang, D; Wang, ZD; Zhang, CH; Zhang, Q | 1 |
| Cacic, D; Hervig, T; Meyer, P; Nordgård, O | 1 |
| Schuh, AC; Tang, K; Yee, KW | 1 |
| Balsat, M; Barraco, F; Baudouin, A; Cadassou, O; Ducastelle, S; Elhamri, M; Fossard, G; Gutrin, J; Hayette, S; Heiblig, M; Labussière, H; Larcher, MV; Plesa, A; Roumier, C; Sujobert, P; Thomas, X; Tigaud, I | 1 |
| Gupta, A; Patnaik, MM; Viswanatha, DS | 1 |
| Binner, M; Bornhäuser, M; Bray, LJ; Körner, Y; von Bonin, M; Werner, C | 1 |
| Alonzo, TA; Berman, JN; Campana, D; Coustan-Smith, E; Gamis, AS; Ge, Y; Gerbing, RB; Head, D; Hirsch, B; Hitzler, JK; Lacayo, NJ; Mast, K; Mathew, P; Raimondi, S; Sorrell, AD; Taub, JW; Wang, YC | 1 |
| Abraham, A; Balasubramanian, P; Karathedath, S; Krishnamurthy, P; Mathews, V; Musheer Aalam, SM; Rajamani, BM; Varatharajan, S; Velayudhan, SR | 1 |
| Benner, A; Bentz, M; Brossart, P; Döhner, H; Döhner, K; Fiedler, W; Ganser, A; Göhring, G; Götze, K; Heil, G; Held, G; Hertenstein, B; Horst, HA; Jaramillo, S; Kindler, T; Kirchen, H; Köhne, CH; Koller, E; Krauter, J; Kremers, S; Kündgen, A; Lübbert, M; Martin, H; Nachbaur, D; Raghavachar, A; Runde, V; Russ, G; Salih, HR; Salwender, H; Schlenk, RF; Wattad, M; Weber, D; Wulf, G | 1 |
| Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L | 1 |
| Chen, C; Jin, H; Li, H; Li, M; Liu, FR; Mao, SJ; Wang, Q; Wang, Y | 1 |
| Jin, H; Li, H; Liu, F; Mao, S; Wang, Q; Wang, Y; Xiang, H | 1 |
| Amadori, S; Appelbaum, FR; Bloomfield, CD; Brandwein, JM; de Witte, T; Döhner, H; Döhner, K; Ehninger, G; Ganser, A; Geyer, S; Klisovic, RB; Krauter, J; Larson, RA; Laumann, K; Lo-Coco, F; Mandrekar, SJ; Marcucci, G; Medeiros, BC; Niederwieser, D; Prior, TW; Sanford, BL; Sanz, MA; Schlenk, RF; Serve, H; Sierra, J; Stone, RM; Tallman, MS; Thiede, C; Wei, A | 1 |
| Chidini, G; Cortelezzi, A; Dambrosi, F; Fracchiolla, NS; Gianelli, U; Guidotti, F; Merlo, D; Ossola, MW; Sciumè, M | 1 |
| Killian-Benigno, C; Kuo, DJ | 1 |
| Miyawaki, S | 2 |
| Cuglievan, B; Garces, S; Menegaz, BA; Rytting, ME | 1 |
| Chen, K; Deng, M; Deng, S; Li, J; Li, P; Li, Y; Wang, Y; Xu, B; Zhang, L; Zhou, Y | 1 |
| Ali Baig, MF; Khan, BA; Siddiqui, N | 1 |
| Murphy, T; Yee, KWL | 1 |
| Alvaro, F; Arceci, RJ; Arndt, C; Barnette, P; Boklan, J; Carpten, J; Cooper, T; Farrar, JE; Gooden, GC; Gore, L; Lee, D; Legendre, C; Liang, WS; Macy, ME; Martin, L; Meshinchi, S; Narendran, A; Pollard, J; Salhia, B; Triche, TJ; Wai, D | 1 |
| Tiong, IS; Wei, AH | 2 |
| Luger, SM | 1 |
| Capparelli, EV; Lancet, JE; Louie, A; Nikanjam, M; Schiller, G | 1 |
| Perl, AE | 1 |
| Kim, M; Williams, S | 2 |
| Arnovitz, S; Chen, CH; Chen, J; Chen, Y; Cheng, L; Cui, X; Diao, J; Dong, L; Ferchen, K; He, C; Hu, C; Huang, H; Jiang, X; Jin, J; Li, C; Liu, PP; Lu, J; Mulloy, JC; Nie, J; Qin, X; Reinhold, WC; Seibel, W; Shen, C; Skibbe, JR; Su, R; Tang, Y; Ulrich, B; Wang, Y; Weng, H; Wunderlich, M; Zheng, Y; Zuo, Z | 1 |
| Becker, PS; Chiarella, MT; Estey, EH; Hendrie, PC; Louie, AC; McDaniel, EN; Medeiros, BC; Orlowski, KF; Othus, M; Percival, MM; Scott, BL; Walter, RB | 1 |
| Beck, M; Buske, C; Kirsten, N; Lindén, M; Mandal, T | 1 |
| Lancet, JE; Talati, C | 1 |
| Duan, M; Liang, G; Xu, X; Zhang, L | 1 |
| Berdel, WE; Bornhäuser, M; Ehninger, G; Einsele, H; Fetscher, S; Gabrecht, M; Hänel, M; Heits, F; Herbst, R; Kaiser, U; Krämer, A; Kramer, M; Krümpelmann, U; Kullmer, J; Link, H; Mantovani-Löffler, L; Mohr, B; Neuhaus, T; Platzbecker, U; Ritter, B; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Schmitz, N; Schuler, US; Serve, H; Thiede, C | 1 |
| Füreder, W; Gleixner, K; Grünberger, B; Hoermann, G; Kornauth, C; Schwarzinger, I; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Burnett, AK; Cahalin, P; Cavenagh, JD; Couzens, S; Dillon, R; Freeman, SD; Gilkes, A; Grimwade, D; Hills, RK; Jones, G; Khan, N; Khwaja, A; Nielsen, OJ; Russell, NH; Thomas, I; Upton, L; Virgo, P | 1 |
| Huang, WB; Li, MW; Lin, P; Wang, W; Yang, XN; Yao, HY | 1 |
| Erfurt-Berge, C; Krause, SW; Schröder, SD | 1 |
| Coltoff, A; Houldsworth, J; Keyzner, A; Mascarenhas, J; Renteria, AS | 1 |
| O'Dwyer, K; Wang, ES | 1 |
| Houssou, B; Lamchahab, M; Massi, R; Oukkache, B; Quessar, A | 1 |
| Ali, A; Burnett, AK; Cahalin, P; Freeman, S; Hills, RK; Hunter, A; Nielsen, OJ; Russell, NH; Thomas, IF | 1 |
| Banerjee, K; Bixby, DL; Chiarella, M; Cortes, JE; Hoering, A; Hogge, D; Kolitz, JE; Lancet, JE; Lin, TL; Louie, AC; Medeiros, BC; Newell, LF; Ritchie, EK; Ryan, DH; Schiller, GJ; Solomon, SR; Stone, RM; Strickland, SA; Stuart, RK; Uy, GL; Wieduwilt, MJ | 1 |
| Della Pepa, R; Giordano, C; Grimaldi, F; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, P; Sirignano, C; Trastulli, F; Zacheo, I | 1 |
| Killock, D | 1 |
| Battaion, HL; Cafariello, C; Dilworth, FJ; Grzybowski, AT; Howard, JP; Ito, CY; Jrade, H; Khan, ST; Li, Y; Maganti, HB; Manias Rothberg, JL; Perkins, TJ; Porter, CJ; Ruthenburg, AJ; Sabloff, M; Sabri, E; Stanford, WL; Yockell-Lelièvre, J | 1 |
| Blackford, AL; Bose, P; Doyle, LA; Foster, MC; Gocke, CD; Gojo, I; Karp, JE; Lancet, JE; Levy, MY; Little, RF; Litzow, MR; Morris, LE; Rosner, GL; Smith, BD; Strickland, SA; Tibes, R; Wright, JJ; Zeidner, JF | 2 |
| Anderson, E; Bone, H; Heywood, J; Mayer, L; Mehta, P; Rees, B; Reynolds, D; Robinson, G; Salisbury, V | 1 |
| Sweet, K; Talati, C | 1 |
| Kungwankiattichai, S; Owattanapanich, N; Owattanapanich, W; Ruchutrakool, T; Ungprasert, P | 1 |
| Huang, Y; Liu, DD; Lv, TT; Xu, J; Yuan, GL; Zhou, XF | 1 |
| Anderson, JE; Appelbaum, FR; Erba, HP; Estey, EH; Garcia-Manero, G; Godwin, JE; Othus, M; Stirewalt, DL; Walter, RB; Weick, JK; Wood, BL | 1 |
| Avramova, BE; Bachvarov, KN; Belcheva, MI; Bobev, D; Burnusuzov, HA; Hristozova, H; Ivanova, LR; Kaleva, VI; Konstantinov, DN; Muchinova, AB; Mumdzhiev, IN; Peteva, ET; Spasov, NY; Spasova, MI; Stoyanova, AA; Vlahova, IH; Yordanova, MN; Yurukova, NN | 1 |
| Alonzo, T; Aplenc, R; Gamis, A; Gerbing, RB; Getz, KD; Ky, B; Leahy, AB; Leger, KJ; Sack, L; Sung, L; Woods, WG | 1 |
| Bhattacharyya, S; Bonifacio, G; Duchesneau, E; Guerin, A; Joseph, G; Li, N; Ndife, B; Stein, E; Vudumula, U; Xie, J | 1 |
| Bérard, E; Bertoli, S; Delabesse, E; Huguet, F; Picard, M; Récher, C; Sarry, A; Tavitian, S; Vergez, F | 1 |
| Ashaye, AO; Cappelleri, JC; Fahrbach, K; Khankhel, Z; Lang, K; Mamolo, C; Mokgokong, R; Orme, ME; Xu, Y | 1 |
| Lancet, JE | 1 |
| Abdel-Wahab, O; Bennett, JM; Dewald, GW; Fernandez, HF; Ketterling, RP; Lazarus, HM; Levine, RL; Litzow, MR; Luger, SM; Paietta, E; Patel, JP; Racevskis, J; Rowe, JM; Sun, Z; Tallman, MS | 1 |
| Anstee, NS; Bilardi, RA; Cory, S; Ng, AP; Robati, M; Vandenberg, CJ; Xu, Z | 1 |
| Howell, G; Oliai, C; Schiller, G | 1 |
| Blair, HA | 1 |
| Mueller, BU; Pabst, T; Seipel, K | 1 |
| Banerjee, A; Bateman, DA; Blumenthal, GM; Farrell, AT; Fu, W; Gao, X; Gieser, G; Goldberg, KB; Janoria, KG; Krauss, AC; Li, L; Liu, J; Manning, ML; Patel, P; Pazdur, R; Przepiorka, D; Shen, YL; Sheth, CM; Shord, SS | 1 |
| Banerjee, K; Gibbons, JA; Marier, JF; Vasilinin, G; Wang, Q | 1 |
| Benitez, LL; Bixby, DL; Brown, J; Burke, PW; Cheung, E; Marini, BL; Perissinotti, AJ; Pettit, KM; Scappaticci, GB | 1 |
| Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Poveda, JL; Sanz, MÁ | 1 |
| Ashizawa, M; Fujiwara, SI; Hatano, K; Kako, S; Kanda, Y; Kawaguchi, SI; Kawasaki, Y; Kimura, SI; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nagayama, T; Nakano, H; Ochi, SI; Oh, I; Ohmine, K; Sato, K; Shirato, Y; Toda, Y; Yamamoto, C; Yamasaki, R | 1 |
| Baskhaeva, GA; Davidiva, JO; Drokov, MY; Dvirnik, VN; Fidarova, ZT; Galtseva, IV; Gavrilina, OA; Kokhno, AV; Kulikov, SM; Kuzmina, LA; Kuznetsova, SA; Lobaova, TI; Loukianova, IA; Obukhova, TN; Parovichnikova, EN; Savchenko, VG; Sokolov, AN; Sudarikov, AB; Troitskaya, VV; Vasilyeva, VA | 1 |
| Chung, KC; Deger, KA; Fisher, V; Hogge, D; Howell, TA; Koetter, K; Louie, AC; Matza, LS; Yeager, AM | 1 |
| Penning, TM; Trippier, PC; Verma, K; Zang, T | 1 |
| Ayatollahi, H; Bagheryan, Z; Colagar, AH; Zidanloo, SG | 1 |
| Ding, H; Flatten, KS; Hess, AD; Huehls, AM; Karnitz, LM; Kaufmann, SH; Kelly, RL; Kohorst, MA; Pratz, KW; Vincelette, ND; Webster, J | 1 |
| Beck, A; Hunter, H; Jackson, S; Sheridan, D | 1 |
| Choi, EJ; Jeon, M; Kang, YA; Lee, JH; Lee, KH; Lee, YS; Park, HS; Seol, M; Woo, JM | 1 |
| Ali, S; Barbachano, Y; Bjerrum, OW; Dunmore, HM; Gisselbrecht, C; Hay, JL; Hovgaard, D; Karres, D; Nagercoil, N; Pignatti, F; Salmonsson, T; Sarac, SB | 1 |
| Chang, YT; Ghiaur, G; Hernandez, D; Jones, RJ; Su, M | 1 |
| Shea, LK; Uy, GL | 1 |
| Amin, S; Cabot, MC; Claxton, DF; Conaway, MR; Desai, D; Doi, K; Dunton, W; Feith, DJ; Fox, TE; Kester, M; Liu, X; Loughran, TP; Morad, SAF; Tan, SF; Wang, HG | 1 |
| Adige, S; Ambulos, NP; Baer, MR; Bentzen, SM; Carter-Cooper, BA; Duffy, A; Emadi, A; Lapidus, RG; Law, JY; Patzke, C; Zou, Y | 1 |
| Aurelius, J; Ewald Sander, F; Hellstrand, K; Kiffin, R; Martner, A; Möllgård, L; Nilsson, S; Thorén, FB | 1 |
| Jonas, BA; Keck, J; Lam, KS; Li, Y; Lin, TY; Long, Q; Ma, AH; Pan, CX; Zhang, H; Zhu, Y | 1 |
| Alvarez, D; Banerjee, K; Callahan, T; Liboiron, BD; Lin, TL; Louie, AC; Mayer, LD; Michaelis, LC; Newell, LF; Pentikis, HS; Rubenstein, E; Stuart, RK; Wang, Q | 1 |
| Furevik, SMV; Haugse, R; Herfindal, L; Myklebust, NN; Singh, A | 1 |
| Baker, SD; Behbehani, G; Bhatnagar, B; Blachly, J; Blum, W; Buelow, DR; Byrd, JC; Garzon, R; Jeon, JY; Klisovic, RB; Mims, AS; Phelps, M; Vasu, S; Walker, AR; Zhao, Q | 1 |
| Bakhshi, R; Bakhshi, S; Pramanik, R; Singh, A; Tyagi, A; Vishnubhatla, S | 1 |
| Borthakur, G; Economides, MP; McCue, D; Pemmaraju, N | 1 |
| Chen, S; Gu, Y; Hu, Q; Wang, G; Wang, Y; Yang, S; Zhao, M | 1 |
| Maakaron, JE; Mims, AS | 1 |
| DiNardo, C; Guerra, VA; Konopleva, M | 1 |
| Bao, F; Chen, W; Lei, P; Li, Y; Lian, C; Liu, Y; Lu, X; Qiao, H; Sun, K; Xue, F; Yu, R | 1 |
| He, R; Li, J; Liu, X; Pan, R; Wang, C | 1 |
| Aplenc, R; Bagatell, R; Fisher, BT; Huang, YS; Kavcic, M; Lee, GE; Li, Y; Seif, AE; Tasian, SK; Torp, K; Vujkovic, M; Walker, DM | 1 |
| Berger, W; Filipits, M; Glimm, H; Hackl, H; Hartl, K; Heffeter, P; Heilos, D; Hemmati, S; Herbacek, I; Herbst, F; Karakaya, K; Krämer, A; Rommer, A; Rondou, P; Schwarzinger, I; Steinleitner, K; Steinmetz, B; Wieser, R | 1 |
| Chen, H; Hu, J; Hu, L; Jiang, M; Li, B; Li, Y; Lou, X; Ning, H; Wang, J; Xu, C; Yu, Z | 1 |
| Appelbaum, FR; Brandwein, J; Erba, HP; Kopecky, KJ; Larson, RA; Nevill, T; Petersdorf, SH; Slovak, M; Stenke, L; Stiff, PJ; Stuart, RK; Tallman, MS; Walter, RB; Willman, C | 1 |
| Chen, B; Ouyang, J; Wang, J; Xu, JY; Yang, YG; Zhang, QG; Zhou, M; Zhou, RF | 1 |
| Li, XY; Li, Y; Wang, X | 1 |
| Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Ehninger, G; Einsele, H; Hänel, M; Ho, AD; Illmer, T; Kramer, M; Krause, SW; Mayer, J; Neubauer, A; Parmentier, S; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Schmitz, N; Serve, H; Stölzel, F; Thiede, C | 1 |
| Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U | 1 |
| Alonzo, TA; Cesano, A; Cohen, AC; Dahl, GV; Gamis, A; Gayko, U; Gerbing, R; Hackett, J; Lacayo, NJ; Louie, B; Meshinchi, S; Purvis, N; Putta, S; Ravindranath, Y; Rosen, DB; Westfall, M | 1 |
| Creutzig, U; Dworzak, MN; Reinhardt, D; Ritter, J; Schellong, G; Zimmermann, M | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, MN; Fleischhack, G; Graf, N; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Ritter, J; Sander, A; Schrauder, A; Starý, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M | 1 |
| Falk, IJ; Fyrberg, A; Gréen, H; Hermanson, M; Höglund, M; Lotfi, K; Nahi, H; Palmqvist, L; Paul, E; Rosenquist, R; Stockelberg, D; Wei, Y | 1 |
| Graham, J; Grigliatti, TA; Heffner, D; Hogge, D; Liu, J; Lubieniecka, JM; Reid, R; Riggs, WK | 1 |
| Bhatia, R; Dos Santos, C; Forman, SJ; Ho, YW; Kuo, YH; Lin, A; Liu, H; McDonald, T | 1 |
| He, GS; He, XF; Ji, CF; Jin, ZM; Liu, LM; Ma, X; Sun, AN; Wu, DP; Xue, SL; Yang, Y; Zhang, YM | 1 |
| Singh-Rambiritch, S; Wood, NH | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Bowman, WP; Campana, D; Coustan-Smith, E; Dahl, G; Inaba, H; O'Hear, C; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shi, L; Taub, JW | 1 |
| Block, AW; Deeb, G; Ford, LA; Greene, JD; Griffiths, EA; Sait, SN; Starostik, P; Tan, W; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Handa, H; Hatsumi, N; Jimbo, T; Miyawaki, S; Nojima, Y; Saitoh, T; Sakura, T; Shimizu, H; Takada, S | 1 |
| Gruber, A; Levine, RL; McCarty, OJ; Recht, O; Tormoen, GW | 1 |
| Béné, MC; Bonmati, C; Bouscary, D; Cahn, JY; Delaunay, J; Dreyfus, F; Escoffre-Barbe, M; Fegueux, N; Guardiola, P; Guièze, R; Guyotat, D; Harousseau, JL; Hunault, M; Ifrah, N; Jourdan, E; Lioure, B; Lissandre, S; Luquet, I; Ojeda-Uribe, M; Pigneux, A; Randriamalala, E; Récher, C; Vey, N | 1 |
| Amadori, S; Buccisano, F; Isidori, A; Loscocco, F; Manduzio, P; Maurillo, L; Sparaventi, G; Venditti, A; Visani, G | 1 |
| Baker, SD; Buck, SA; Caldwell, JT; Chen, W; Drenberg, C; Edwards, H; Ge, Y; Inaba, H; Taub, JW; Xie, C; Xu, X | 1 |
| Adami, F; Bertorelle, R; Bonaldi, L; Brancalion, A; Gurrieri, C; Lessi, F; Manni, S; Pavan, L; Piazza, F; Pinna, LA; Quotti Tubi, L; Ruzzene, M; Semenzato, G; Trentin, L; Zambello, R | 1 |
| Amadori, S; Beksac, M; Berneman, Z; Bron, D; Camera, A; Cantore, N; Cilloni, D; de Witte, T; Fabbiano, F; Fazi, P; Fillet, G; Guimaraes, JE; Hagemeijer, A; Halkes, CJ; Jansen, J; Labar, B; Lefrère, F; Leoni, P; Luppi, M; Magro, D; Mancini, M; Mandelli, F; Marie, JP; Marijt, EW; Meert, L; Melillo, L; Meloni, G; Mistrik, M; Mitra, ME; Muus, P; Nobile, F; Sborgia, M; Selleslag, DL; Sica, S; Specchia, G; Suciu, S; Thomas, X; Trisolini, SM; Venditti, A; Vignetti, M; Willemze, R | 1 |
| Akasaka, T; Honjo, G; Izumi, K; Kishimori, C; Maesako, Y; Ohno, H; Okamori, S; Okumura, A; Takeoka, K | 1 |
| Rowe, JM | 1 |
| Chen, CC; Chen, MF; Chen, PT; Chen, YY; Chou, HJ; Huang, CE; Lee, KD; Lu, CH; Lung, J; Tsai, PS | 1 |
| Castaigne, S; Farhat, H; Garcia, I; Ghez, S; Merabet, F; Pilorge, S; Preudhomme, C; Rabian, F; Raggueneau, V; Renneville, A; Rigaudeau, S; Rousselot, P; Sarkozy, C; Taksin, AL; Terré, C | 1 |
| Baer, MR; Bär, C; Becker, H; Bloomfield, CD; Bucci, D; Bundschuh, R; Byrd, JC; Caligiuri, MA; Carroll, AJ; Carter, TH; Curfman, JP; Eisfeld, AK; Frankhouser, D; Garzon, R; Kohlschmidt, J; Kolitz, JE; Maharry, K; Marcucci, G; Mendler, JH; Metzeler, KH; Mrózek, K; Nicolet, D; Plass, C; Powell, BL; Schwind, S; Stone, RM; Volinia, S; Wetzler, M; Whitman, SP; Wu, YZ; Yan, P | 1 |
| Allen, SL; Bakan, CE; Benson, DM; Bloomfield, CD; Caligiuri, MA; Deangelo, DJ; George, SL; Hars, V; Hoke, E; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Powell, BL; Shea, TC; Stock, W; Vij, R | 1 |
| Abkowitz, JL; Buckley, SA; Estey, EH; Othus, M; Vainstein, V; Walter, RB | 1 |
| Chung, NG; Jang, W; Kim, M; Lee, JW | 1 |
| Chen, M; Haddad, AS; Henderson, PT; Jonas, BA; Lam, KS; Li, Y; Lin, TY; Liu, R; Pan, CX; Xiao, K; Xiao, W; Zhang, H | 1 |
| Alghamdi, S; Elhammady, G; Poppiti, RJ; Zeichner, SB | 1 |
| Cooper, M; Cortes, JE; Damon, LE; Feldman, EJ; Hogge, DE; Kolitz, JE; Komrokji, R; Kovacsovics, TJ; Lancet, JE; Louie, AC; Solomon, SR; Tallman, MS; Yeager, AM | 1 |
| Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH | 1 |
| Barratt, G; Døskeland, SO; Herfindal, L; Myhren, L; Nicolas, V; Nilssen, IM | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Abrahamsson, J; Bertrand, Y; Creutzig, U; Dworzak, MN; Gibson, B; Ha, SY; Hasle, H; Kaspers, GL; Leverger, G; Maschan, A; Razzouk, B; Reinhardt, D; Rizzari, C; Smisek, P; Smith, OP; Stark, B; Tamminga, R; von Neuhoff, C; Zimmermann, M | 1 |
| de Revel, T; Eddou, H; Jennane, S; Konopacki, J; Mahtat, EM; Malfuson, JV; Souleau, B | 1 |
| Cheng, M; Chu, T; Larregieu, CA; Li, H; Li, W; Liu, M; Mao, SJ; Yan, B | 1 |
| Amin, S; Barth, BM; Claxton, D; Doi, K; Gowda, K; Liu, Q; Loughran, TP; Wang, HG | 1 |
| Chen, J; Chen, L; Gao, L; Gong, S; Hu, X; Liu, M; Lu, S; Ni, X; Qiu, H; Song, X; Wang, J; Wang, L; Xu, S; Xu, X; Yang, J; Zhang, W | 1 |
| Baik, H; Bossis, G; Boutzen, H; Brockly, F; Kaoma, T; Kifagi, C; Manenti, S; Pelegrin, M; Piechaczyk, M; Récher, C; Ristic, M; Saland, E; Salem, T; Sarry, JE; Vallar, L; Vergez, F | 1 |
| Barber, L; Clay, J; Devlia, V; Feliu, J; Mufti, G; Pagliuca, A; Raj, K; Shaw, B | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Cruciani, F; De Astis, E; Di Grazia, C; Galaverna, F; Ghiggi, C; Ghiso, A; Gobbi, M; Guolo, F; Lemoli, RM; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G; Raiola, AM; Varaldo, R | 1 |
| Anoun, S; Benchekroun, S; Lamchahab, M; Oukkache, B; Qachouh, M; Quessar, A | 1 |
| Bae, SH; Bang, SM; Cheong, JW; Han, BR; Jo, DY; Joo, YD; Kim, DY; Kim, HJ; Kim, KH; Kim, SJ; Kim, SY; Kim, YK; Kwak, JY; Lee, JH; Lee, JO; Lee, KH; Lee, MH; Lee, NR; Lee, WS; Maeng, CH; Min, YH; Moon, JH; Park, J; Ryoo, HM; Sohn, SK; Song, IC; Won, JH; Yoon, HJ; Zang, DY | 1 |
| Appelbaum, FR; Burnett, AK; Cahn, JY; Castaigne, S; Chevret, S; Chilton, L; Delaunay, J; Dombret, H; Estey, EH; Hills, RK; Ifrah, N; Moorman, AV; Othus, M; Petersdorf, S; Récher, C | 1 |
| Castaigne, S; Cayuela, JM; Chevret, S; Dombret, H; Hayette, S; Lambert, J; Nibourel, O; Pautas, C; Preudhomme, C; Renneville, A; Rousselot, P; Terré, C | 1 |
| Baer, MR; Becker, H; Bloomfield, CD; Bundschuh, R; Carroll, AJ; Carter, TH; Curfman, JP; Eisfeld, AK; Frankhouser, D; Kohlschmidt, J; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Mendler, JH; Metzeler, KH; Moore, JO; Mrózek, K; Nicolet, D; Niederwieser, C; Powell, BL; Schwind, S; Stone, RM; Volinia, S; Whitman, SP; Wu, YZ; Yan, P | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Chai, Q; Fang, Q; Wang, J; Wang, Y; Wei, S; Zhang, Y | 1 |
| Berdel, WE; Braess, J; Buechner, T; Greif, PA; Heinecke, A; Hiddemann, W; Krug, U; Ksienzyk, B; Mellert, G; Pastore, F; Sauerland, CM; Schneider, S; Spiekermann, K; Woermann, B; Zellmeier, E | 1 |
| Drokov, MIu; Galstian, GM; Kessel'man, SA; Kliasova, GA; Kulikov, SM; Kuz'mina, LA; Obukhova, TN; Paramonova, EV; Parovichnikova, EN; Savchenko, VG; Sokolov, AN; Troitskaia, VV; Vasil'eva, VA | 1 |
| Lima, KM; Morais, VD; Onsten, TG; Ribeiro, RA; Sekine, L; Ziegelmann, PK | 1 |
| Bertoli, S; Blaise, D; Charbonnier, A; D'Incan, E; Delabesse, E; Devillier, R; Etienne, A; Huguet, F; Huynh, A; Prébet, T; Récher, C; Rey, J; Vey, N | 1 |
| Amadori, S; Arcese, W; Buccisano, F; Cerretti, R; De Angelis, G; Del Principe, MI; Di Veroli, A; Ditto, C; Irno-Consalvo, M; Lo-Coco, F; Maurillo, L; Nasso, D; Panetta, P; Piciocchi, A; Refrigeri, M; Sarlo, C; Sconocchia, G; Venditti, A | 1 |
| DeFilippis, EM; Gaan, J; Garshick, M; Harp, J | 1 |
| Hebeda, KM; Janssen, NA; Stevens, WB; van der Velden, WJ | 1 |
| Baczyńska, D; Butrym, A; Kuliczkowski, K; Mazur, G; Rybka, J; Tukiendorf, A | 1 |
| Bahl, A; Bakhshi, S; Gupta, R; Kumar, L; Kumar, R; Raina, V; Sharma, A | 1 |
| Fritz, G; Kassel, S; Proksch, P; Schumacher, L; Stuhldreier, F; Wesselborg, S | 1 |
| Curti, A; Jandus, C; Lecciso, M; Ochsenbein, A; Riether, C; Romero, P; Salomé, B; Trabanelli, S | 1 |
| Allen, SL; Damon, L; Egyed, M; Erba, HP; Horst, HA; Jang, JH; Lundberg, AS; Masszi, T; Mazzola, E; Neuberg, D; Pigneux, A; Powell, B; Rizzieri, D; Sekeres, MA; Selleslag, D; Solomon, SR; Stone, RM; Stuart, RK; Tallman, MS; Venugopal, P; Warzocha, K; Wetzler, M | 1 |
| Arruda, A; Dzneladze, I; Gabra, M; Greenberg, SA; Hakem, A; He, R; Ibrahimova, N; Langlois, C; Löwenberg, B; Minden, MD; Rashid, A; Salmena, L; Sharobim, MH; Son, MH; Valk, PJ; Woolley, JF | 1 |
| Alonzo, TA; Aplenc, R; Bagatell, R; Fisher, BT; Gamis, A; Gerbing, RB; Hall, M; Huang, YS; Li, Y; Luger, S; Miller, TP; Rubin, D; Seif, AE; Sung, L; Torp, K; Troxel, AB | 1 |
| Abdel-Wahab, O; Estey, EH; Fernandez, HF; Gönen, M; Lee, JW; Levine, RL; Othus, M; Paietta, EM; Patel, J; Racevskis, J; Sun, Z; Tallman, MS; Walter, RB | 1 |
| Roboz, GJ | 1 |
| Burnett, AK; Cahalin, P; Cavenagh, J; Clark, RE; Dennis, M; Friis, L; Hills, RK; Kell, J; Kjeldsen, L; McMullin, MF; Milligan, D; Russell, NH; Thomas, IF | 1 |
| Brill, JM; DiPersio, JF; Erba, HP; Larson, RA; Luger, SM; Rouits, E; Sorensen, JM; Tallman, MS; Vuagniaux, G; Zanna, C | 1 |
| Björkholm, M; Blennow, O; Cederlund, K; Dahlén, T; Kalin, M; Ljungman, P; Nordlander, A | 1 |
| Gill Super, HJ | 1 |
| Chen, J; Gong, Q; Li, X; Xu, S; Zhou, L; Zou, Y | 1 |
| Ding, C; Jiao, W; Li, X; Liu, L; Qu, Q; Wu, D; Zhang, Y | 1 |
| Koyakutty, M; Menon, D; Menon, KN; Mony, U; Nair, MS; Nair, SV; Pavithran, K; Sidharthan, N | 1 |
| Chen, J; Li, X; Tan, Y; Xu, S | 1 |
| Cardin, MS; Castillo, JJ; Lansigan, F; Reagan, JL; Sullivan, MR; Winer, ES | 1 |
| Ali, S; Craddock, C; Culligan, DJ; Embleton, ND; Jones, GL; Marsden, PJ; Russell, N | 1 |
| Abraham, A; Balasubramanian, P; Chandy, M; George, B; Janet, NB; Jayavelu, AK; Karathedath, S; Lakshmi, KM; Mathews, V; Mohanan, E; Philip, C; Shaji, RV; Srivastava, A; Srivastava, VM; Varatharajan, S; Viswabandya, A; Zhang, W | 1 |
| Fernandez, HF | 1 |
| Su, YZ; Sun, NT; Wang, CB; Zhou, Y | 1 |
| Busfield, SJ; Cummings, N; Lee, EM; Lewis, ID; Lock, RB; Lopez, AF; McCall, MN; McManus, JF; Powell, JA; Ramshaw, HS; Vairo, G; Wei, A; Yee, D | 1 |
| Alebouyeh, M; Faranoush, M; Hedayati Asl, AA; Mehrvar, A; Niktoreh Mofrad, N; Reinhardt, D; Tashvighi, M | 1 |
| Cameron, WD; Gronda, M; Hurren, R; Minden, MD; Nirmalanandhan, VS; Rocheleau, JV; Schimmer, AD; Shamas-Din, A; You, L | 1 |
| Chai, Q; Chen, S; Fang, Q; Lin, X; Wang, J; Zhang, Y; Zhao, J; Zhe, N | 1 |
| Kopeček, J; Shami, PJ; Yang, J; Zhang, R; Zhou, Y | 1 |
| Archer, K; Aust, M; Beckta, J; Dumur, C; Ginder, GD; Grant, S; Hawkins, E; Podder, S; Rahmani, M; Sperlazza, J; Wang, SZ; Zu Zhu, S | 1 |
| Altmann, KH; Ambati, S; Calvo-Vidal, MN; Cerchietti, L; Díaz, JF; Fang, W; Jordi, M; Kahn, A; Moore, MAS; Pera, B | 1 |
| Abdul-Aziz, A; Bowles, KM; Lawes, M; MacEwan, DJ; Pillinger, G; Rushworth, SA; Zaitseva, L | 1 |
| Baty, J; Chang, GS; Christopher, M; Demeter, RT; DiPersio, JF; Duncavage, EJ; Fronick, C; Fulton, R; Graubert, TA; Griffith, M; Griffith, OL; Heath, SE; Helton, NM; Hundal, J; Ketkar-Kulkarni, S; Klco, JM; Kulkarni, S; Lamprecht, TL; Larson, DE; Ley, TJ; Link, DC; Magrini, V; Mardis, ER; Miller, CA; O'Laughlin, M; Ozenberger, BA; Payton, JE; Petti, A; Radich, JP; Shen, D; Spencer, DH; Walter, MJ; Wartman, LD; Welch, JS; Westervelt, P; Wilson, RK | 1 |
| Cai, Z; Han, Y; Jiang, S; Sun, L; Wang, W; Wu, J; Ye, A; Yu, K; Zhang, S; Zhang, Y | 1 |
| Culen, M; Dvorakova, D; Horky, O; Jeziskova, I; Mayer, J; Racil, Z; Semerad, L; Sustkova, Z; Weinbergerova, B | 1 |
| Lynch, RC; Medeiros, BC | 1 |
| Jamy, O; Martin, MG; Wiedower, E | 1 |
| Baldus, CD; Berdel, WE; Brümmendorf, TH; Butterfaß-Bahloul, T; Dugas, M; Ehninger, G; Eveslage, M; Frickhofen, N; Gerss, J; Giagounidis, A; Görner, M; Götze, K; Hänel, M; Herr, W; Kaiser, U; Kaufmann, M; Kiani, A; Kiehl, M; Koschmieder, A; Koschmieder, S; Krause, SW; Krug, U; Kunzmann, V; Link, H; Müller-Tidow, C; Naumann, R; Neubauer, A; Noppeney, R; Peceny, R; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schmitz, N; Serve, H; Steffen, B; Stelljes, M; Thiede, C; Thiem, U; Tschanter, P; Wagner, R | 1 |
| Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Brandts, CH; Burchert, A; Dürk, H; Ehninger, G; Einsele, H; Frickhofen, N; Geer, T; Giagounidis, A; Görner, M; Hänel, M; Hase, J; Heits, F; Herbst, R; Hüttmann, A; Illmer, T; Junghanß, C; Kaiser, U; Kiani, A; Klut, IM; Krämer, A; Kramer, M; Krause, SW; Krug, U; Kullmer, J; Kunzmann, V; Link, H; Mackensen, A; Müller-Tidow, C; Neubauer, A; Noppeney, R; Parmentier, S; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Serve, H; Thiede, C; von Bonin, M | 1 |
| Borg, K; Calbecka, M; Czekalska, S; Ejduk, A; Florek, I; Gadomska, G; Gajkowska-Kulik, J; Giebel, S; Grosicki, S; Haus, O; Holowiecki, J; Jakobczyk, M; Jazwiec, B; Jedrzejczak, WW; Karabin, K; Kata, D; Kielbinski, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Libura, J; Libura, M; Matiakowska, K; Paluszewska, M; Pawelczyk, M; Piatkowska-Jakubas, B; Skotnicki, A; Solarska, I; Warzocha, K; Wierzbowska, A; Zawada, M | 1 |
| Spagnuolo, P | 1 |
| Gou, H; Hu, X; Lu, X; Peng, W; Shang, M; Song, X; Ye, Y; Ying, B; Zhang, J; Zhao, Z; Zhou, J; Zhou, Y | 1 |
| Gronda, M; Hurren, R; Minden, MD; Rotin, LE; Schimmer, AD; Slassi, M; Wang, X | 1 |
| Alfaro, EM; Alonso, CN; Bernasconi, AR; Coccé, MC; Eberle, SE; Felice, MS; Gallego, MS; Guitter, MR; Rossi, JG; Rubio, PL; Zubizarreta, PA | 1 |
| Abdel-Wahab, O; Bennett, JM; Fernandez, HF; Ketterling, RP; Lazarus, HM; Lee, JW; Levine, RL; Litzow, MR; Luger, SM; Luskin, MR; Paietta, EM; Patel, JP; Racevskis, J; Rowe, JM; Sun, Z; Tallman, MS | 1 |
| Ashizawa, M; Fujiwara, S; Hatano, K; Ito, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Okazuka, K; Sato, K; Sugimoto, M; Suzuki, T; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Bochennek, K; Creutzig, U; Gilfert, J; Hassler, A; Lehrnbecher, T; Perner, C; Reinhardt, D; Schöning, S | 1 |
| Fang, L; Hu, N; Lin, Y; Pan, L; Qin, T; Qu, S; Ru, K; Wang, J; Xiao, Z; Xing, R; Xu, Z; Zhang, H; Zhang, Y | 1 |
| Appelbaum, FR; Erba, H; Estey, E; Godwin, J; Mukherjee, S; Othus, M; Petersdorf, S; Sekeres, MA | 1 |
| Caldwell, JT; Chu, R; Edwards, H; Ge, Y; Lin, H; Ma, J; Niu, X; Taub, JW; Wang, G; Wang, ZJ; Xiang, S; Xie, C; Zhang, X; Zhao, J | 1 |
| Gao, S; Li, W; Liu, X; Su, L; Tan, Y; Zhu, X | 1 |
| Adam, H; Colle, J; Costello, R; Fanciullino, R; Farnault, L; Ivanov, V; Labiad, Y; Mercier, C; Suchon, P; Venton, G | 1 |
| Batár, P; Illés, Á; Kiss, A; Mezei, G; Miltényi, Z; Rejtő, L; Reményi, G; Simon, Z; Szász, R; Telek, B; Udvardy, M; Ujj, Z | 1 |
| Arihara, Y; Hayasaka, N; Hirakawa, M; Iyama, S; Kato, J; Kobune, M; Matsuno, T; Miura, S; Miyanishi, K; Okagawa, Y; Ono, M; Osuga, T; Sato, T; Sato, Y; Takada, K; Takimoto, R; Tamura, F; Uemura, N; Yoshida, M | 1 |
| Dolberg, OJ; Ellis, M; Hellmann, I; Huitema, AD; Krashin, E; Rosing, H | 1 |
| Collin, M; Creasey, T; Jones, GL | 1 |
| Chang, CL; Chi, HS; Cho, YU; Jang, S; Jo, SY; Kim, HH; Kim, IS; Lee, EY; Park, CJ; Park, SH; Yi, J | 1 |
| Chen, Y; Hu, J; Liu, T; Yang, T; Yang, X; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Anstee, NS; Bilardi, RA; Cory, S; Glaser, SP; Robati, M; Vandenberg, CJ | 1 |
| Ali, S; Burnett, AK; Burns, S; Cahalin, P; Clark, RE; Dennis, M; Freeman, S; Hills, RK; Kell, J; Milligan, D; Nielsen, OJ; Pocock, C; Russell, NH | 1 |
| Ding, K; Fu, R; Li, L; Liu, H; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wu, Y | 1 |
| Abraham, A; Arthur, N; Balasubramanian, P; George, B; Karathedath, S; Lakshmi, KM; Mathews, V; Mohanan, E; Nemani, S; Panetta, JC; Srivastava, A; Srivastava, VM; Varatharajan, S | 1 |
| Bouillaud, F; Bouscary, D; Candalh, C; Chapuis, N; De Chiara, A; Frachet, P; Haddaoui, L; Hermine, O; Ifrah, N; Mocek, J; Ohayon, D; Ribeil, JA; Witko-Sarsat, V | 1 |
| Kobos, R; LaQuaglia, MP; Modak, S; Pandit-Taskar, N; Sait, S | 1 |
| Abdel-Wahab, O; Arcila, ME; Armstrong, SA; Bastian, L; Chramiec, AG; Cross, JR; Durham, BH; Ganzel, C; Garrett-Bakelman, FE; Gönen, M; Gonzalez, AR; Guryanova, OA; Hoermann, G; Keller, MD; Koche, RP; Krivtsov, AV; Kubicek, S; Levine, RL; Lieu, YK; Loizou, E; Luciani, L; Mason, CE; McKenney, AS; Melnick, AM; Mohanty, A; Mukherjee, S; Nimer, SD; Paietta, EM; Pastore, F; Pronier, E; Rivera, SA; Rowe, JM; Shank, K; Sperr, WR; Spitzer, B; Staber, PB; Tallman, MS; Tovbin, D; Weinstein, AR | 1 |
| Beltrão, EI; Benicio, MT; Bezerra, MA; Bezerra, MF; Coelho-Silva, JL; Lucena-Araujo, AR; Machado, CG; Nascimento, JC; Rego, EM; Rocha, CR | 1 |
| Basso, G; Bisio, V; Di Giacomo, D; Di Meglio, A; Leszl, A; Locatelli, F; Manara, E; Masetti, R; Mecucci, C; Minuzzo, S; Pession, A; Pigazzi, M; Rondelli, R; Salsi, V; Togni, M; Tregnago, C; Zampini, M; Zappavigna, V | 1 |
| Gullbo, J; Haglund, C; Hassan, SB; Höglund, M; Larsson, R; Strese, S; Velander, E | 1 |
| Andresen, V; Bruserud, Ø; Gjertsen, BT; Omsland, M | 1 |
| Baldauf, HM; Berdel, WE; Bohnenberger, H; Cinatl, J; Comoglio, F; Cremer, A; Ferreirós, N; Flick, R; Geisslinger, G; Hansmann, ML; Hartmann, W; Hornung, V; Kaderali, L; Keppler, OT; Lohmeyer, J; Martin, M; Michaelis, M; Oellerich, T; Schliemann, C; Schneider, C; Schwarz, SM; Serve, H; Stegmann, L; Ströbel, P; Thomas, D; Wardelmann, E; Yakunin, AF | 1 |
| Barraco, F; Ducastelle-Leprêtre, S; Labussière-Wallet, H; Nicolini, FE; Paubelle, E; Plesa, A; Salles, G; Thomas, X; Wattel, E | 1 |
| Edwards, H; Ge, Y; Taub, JW; Wang, G; Xie, C; Zhao, J | 1 |
| Butrym, A; Czemerska, M; Giebel, S; Golos, A; Grosicki, S; Holowiecka-Goral, A; Holowiecki, J; Katarzyna Budziszewska, B; Kloczko, J; Kuliczkowski, K; Kyrcz-Krzemien, S; Lange, A; Madry, K; Mordak-Domagala, M; Piszcz, J; Pluta, A; Razny, M; Robak, T; Sulek, K; Szydlo, R; Warzocha, K; Wawrzyniak, E; Wierzbowska, A; Wiktor-Jedrzejczak, W; Wrzesien-Kus, A; Zwolinska, M | 1 |
| Choi, CW; Kang, KW; Kim, BS; Kim, DS; Kim, SJ; Lee, SR; Park, Y; Sung, HJ | 1 |
| Hayakawa, M; Ichihashi, T; Iida, H; Iino, M; Kiyoi, H; Naoe, T; Narimatsu, H; Sawamoto, A; Sugiura, I; Suzuki, R; Takeo, T; Tsuzuki, M; Yanada, M; Yokozawa, T | 1 |
| Breitenbuecher, F; Fischer, T; Heidel, F; Hoehn, Y; Huber, C; Kasper, S; Kindler, T; Lipka, DB; Markova, B | 1 |
| Bloomfield, CD; Larson, RA; Liu, ET; Maharry, K; Marcucci, G; Mayer, RJ; Mrózek, K; Neubauer, A; Paschka, P; Thiede, C | 1 |
| Baer, MR; Baldus, CD; Bloomfield, CD; Caligiuri, MA; Carroll, AJ; Kolitz, JE; Langer, C; Larson, RA; Maharry, K; Marcucci, G; Mrózek, K; Paschka, P; Powell, BL; Ruppert, AS; Whitman, SP; Zhao, W | 1 |
| Attarian, H; Ghadiany, M; Hajifathali, A; Khosravi, A; Molanaee, S | 1 |
| Bai, CH; Kim, YD; Song, SY; Woo, HJ | 1 |
| Brandt, M; Estey, E; Freireich, EJ; Kantarjian, HM; Keating, MJ; Medeiros, LJ; O'Brien, S; Pierce, S; Tsimberidou, AM; Wen, S | 1 |
| Dimas, K; Karakantza, M; Kokkinou, D; Lagadinou, ED; Pantazis, P; Spyridonidis, A; Thanopoulou, E; Tsopra, OA; Ziros, PG; Zoumbos, NC | 1 |
| Camera, A; Cantore, N; Ferrara, F; Grimaldi, F; Guerriero, A; Luciano, L; Mastrullo, L; Mele, G; Mettivier, V; Miraglia, E; Palmieri, S; Rinaldi, CR; Rotoli, B | 1 |
| Lackner, H; Sovinz, P; Urban, C | 1 |
| Bordessoule, D; Contentin, N; de Revel, T; Dombret, H; Etienne, A; Gardin, C; Malfuson, JV; Rigaudeau, S; Terré, C; Thomas, X; Turlure, P; Vey, N | 1 |
| Alimena, G; Amadori, S; Baccarani, M; Breccia, M; Candoni, A; Caramatti, C; Di Raimondo, F; Fabbiano, F; Falzetti, F; Fazi, P; Iacobelli, S; Latagliata, R; Mandelli, F; Martinelli, G; Mattei, D; Morselli, M; Pirrotta, MT; Sborgia, M; Vignetti, M; Zaccaria, A | 1 |
| Brandwein, JM; Gupta, V; Howson-Jan, K; Leber, BF; MacAlpine, K; Minden, MD; Moore, M; Schimmer, AD; Schuh, AC; Wright, J; Yee, KW | 1 |
| Chen, ZC; Wu, YH; You, Y; Zou, P | 1 |
| Chen, SG; Li, GY; Liu, JZ; Wang, CB; Wang, LX; Zhang, B | 1 |
| Baer, MR; Duran, GE; Fielding, R; Lancet, JE; List, AF; Marcelletti, JF; Multani, PS; Sikic, BI | 1 |
| Dorn, DC; Kou, CA; Moore, MA; Png, KJ | 1 |
| Mori, N; Motoji, T; Shiseki, M; Takanashi, M; Tanaka, N; Tsuji, K; Wang, YH | 1 |
| Tallman, M | 1 |
| Karp, J | 1 |
| Burns, LA; D'Orazio, JA; Farhoudi, N; Kesler, MV; McBride, MT | 1 |
| Horacek, JM; Jakl, M; Jebavy, L; Pudil, R | 1 |
| Adams, JA; Liu Yin, JA; Morris, KL | 1 |
| Burnett, AK; Dennis, M; Goldstone, A; Hills, RK; McMullin, MF; Milligan, D; Pallis, M; Prentice, A; Russell, N; Sellwood, E; Wheatley, K | 1 |
| Giles, FJ | 1 |
| Darzynkiewicz, Z; Halicka, HD; Jayabose, S; Kajstura, M; Levendoglu-Tugal, O; Ozkaynak, MF; Sandoval, C; Seiter, K; Traganos, F | 1 |
| Kumar, V; Pal, J; Shrivastav, A | 1 |
| Bian, S; Fu, M; Lin, D; Liu, J; Mi, Y; Wang, J; Wang, Y; Yu, W | 1 |
| Betancourt-García, RD; Castro, J; Fernández, AC; Fradera, J; López-Enríquez, A; Pacheco, E | 1 |
| Cario, G; Coulthard, SA; Dördelmann, M; Eichelbaum, M; Kaatsch, P; Möricke, A; Reiter, A; Riehm, H; Schaeffeler, E; Schrappe, M; Schrauder, A; Schwab, M; Stanulla, M; Welte, K; Zimmermann, M | 1 |
| Hu, NP; Hu, XM; Li, L; Liu, C; Liu, F; Ma, R; Wang, HZ; Xiao, HY; Xu, YG; Yang, XH; Zhang, SS; Zheng, CM | 1 |
| Dutka, M; Flont, M; Gawronski, K; Giebel, S; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Konopka, L; Kuliczkowski, K; Lech-Maranda, E; Paluszewska, M; Palynyczko, G; Piatkowska-Jakubas, B; Robak, T; Seweryn, M; Skotnicki, A; Sokolowski, J; Sulek, K; Szpila, T; Warzocha, K; Wegrzyn, J; Zdziarska, B | 1 |
| Heinrich, MC; Kampa, KM; Schittenhelm, MM; Yee, KW | 1 |
| Carrier, M; Cencic, R; Minden, M; Pelletier, J; Porco, JA; Trnkus, A | 1 |
| Gilbert, GE; Hou, J; Lu, C; Qi, S; Qiao, X; Shi, J; Yu, H; Zheng, Y; Zhou, J | 1 |
| Bennett, JM; Cripe, LD; Dewald, GW; Gore, SD; Lazarus, HM; Lee, SJ; Litzow, MR; Othus, M; Paietta, EM; Rowe, JM; Tallman, MS | 1 |
| Bousquet-Dubouch, MP; Burlet-Schiltz, O; Gallay, N; Manenti, S; Matondo, M; Monsarrat, B; Payrastre, B; Recher, C; Uttenweiler-Joseph, S | 1 |
| Bhuiyan, H; Bogason, A; Gruber, A; Masquelier, M; Paul, C; Vitols, S | 1 |
| Appelbaum, FR; Chauncey, TR; Chen, IM; Dakhil, SR; Erba, HP; Gundacker, H; Kopecky, KJ; List, AF; Shadman, M; Slovak, ML; Willman, CL | 1 |
| Höglund, M; Paul, C; Prenkert, M; Tidefelt, U; Tina, E | 1 |
| Eilers, M; Illmer, T; Meyer, M; Neubauer, A; Roth, P; Rübsamen, D; Slany, R; Stabla, K; Stiewe, T | 1 |
| Matsumura, I | 1 |
| Miyazaki, Y | 1 |
| Chao, TY; Huang, TC | 1 |
| Schiffer, CA | 1 |
| Burnett, AK; Duncombe, A; Gibson, B; Goldstone, AH; Hills, RK; McMullin, MF; Milligan, DW; Prentice, AG; Wheatley, K | 1 |
| Bordessoule, D; Bourhis, JH; Castaigne, S; Chevret, S; Contentin, N; Corm, S; de Revel, T; Dombret, H; Fenaux, P; Gardin, C; Merabet, F; Michallet, M; Pautas, C; Preudhomme, C; Raffoux, E; Reman, O; Rousselot, P; Terré, C; Thomas, X; Turlure, P | 1 |
| Dessalvi, P; Di Tucci, AA; Emanuele, A; Pettinau, M; Romani, C | 1 |
| Dvoráková, D; Gáliková, J; Lemez, P; MacWhannell, A; Michalová, K; Stejskal, J; Zemanová, Z | 1 |
| Ahn, JS; Bae, SH; Bang, SM; Choi, SJ; Chung, JS; Hong, DS; Jo, DY; Joo, YD; Jung, CW; Kim, HJ; Kim, I; Kim, SH; Kim, SJ; Lee, JH; Lee, JL; Lee, KH; Min, YH; Shin, HJ; Sohn, SK; Won, JH; Yoon, HJ; Zang, DY | 1 |
| Dedhar, S; Hogge, DE; Muranyi, AL | 1 |
| Bubanska, E; Hrebik, M; Mladosievicova, B; Urbanova, D | 1 |
| Borthakur, G; Estey, EE | 1 |
| Catania, R; De Grandi, C; Di Cataldo, A; La Spina, M; Lo Nigro, L; Palmucci, S | 1 |
| Advani, AS; Bates, J; Copelan, EA; Cotta, CV; Egorin, MJ; Howard, M; Hsi, E; Jin, T; Kalaycio, M; Lim, K; Maciejewski, J; Noon, E; Price, C; Rush, ML; Salvado, A; Saunthararajah, Y; Sekeres, MA; Sobecks, R; Tiu, R; Tripp, B | 1 |
| Aulitzky, W; Bodenstein, H; Bornhäuser, M; Ehninger, G; Gramatzki, M; Kramer, M; Mohr, B; Oelschlaegel, U; Platzbecker, U; Röllig, C; Schaich, M; Schuler, U; Soucek, S; Stölzel, F; Stuhlmann, R; Thiede, C; von Bonin, M; Wandt, H; Wermke, M | 1 |
| Airewele, G; Bowman, WP; Campana, D; Cao, X; Coustan-Smith, E; Dahl, G; Degar, B; Downing, JR; Inaba, H; Lacayo, NJ; Leung, W; Meshinchi, S; Onciu, M; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Taub, J | 1 |
| Bay, JO; Béné, MC; Bernard, M; Bouscary, D; Bulabois, CE; Chevallier, P; Daliphard, S; Delain, M; Fegueux, N; Fornecker, L; Harousseau, JL; Himberlin, C; Ifrah, N; Lioure, B; Luquet, I; Pigneux, A; Recher, C; Turlure, P; Vey, N; Witz, B | 1 |
| Capobianchi, A; Capria, S; Cardarelli, L; Foà, R; Gentile, G; Gianfelici, V; Martino, P; Meloni, G; Trisolini, SM | 1 |
| Cheong, SK; Leong, CF; Maha, A; Seow, HF | 1 |
| Allen, SL; Baer, MR; Bloomfield, CD; DeAngelo, DJ; George, SL; Hars, V; Hoke, E; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Powell, BL; Shea, TC; Stock, W; Vardiman, JW; Vij, R | 1 |
| Bae, JY; Kim, BK; Kim, HK; Kim, I; Koh, Y; Lee, DS; Park, MH; Park, S; Park, SS; Song, EY; Yoon, SS | 1 |
| Eskew, A; Grier, DD; McLean, TW; White, T | 1 |
| Bocchia, M; Crupi, R; Defina, M; Gozzetti, A; Lauria, F; Pietrini, A; Raspadori, D; Rondoni, M | 1 |
| Kantarjian, H; O'Brien, S | 1 |
| Cassileth, PA; Kim, HT; Lazarus, HM; Litzow, MR; Rowe, JM; Tallman, MS; Wiernik, PH | 1 |
| Andresen, S; Bolwell, B; Chan, J; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sproat, L; Sweetenham, J; Tench, S | 1 |
| Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Jeha, S; Kantarjian, H; Ouzounian, S; Pierce, S; Ravandi, F; Rytting, M | 1 |
| Bogason, A; Gruber, A; Lafolie, P; Masquelier, M; Paul, C; Skogastierna, C; Vitols, S | 1 |
| Asou, N; Fujieda, A; Fujita, H; Handa, H; Honda, S; Kimura, Y; Kiyoi, H; Miyamura, K; Miyawaki, S; Miyazaki, Y; Nagai, T; Nakaseko, C; Naoe, T; Ohnishi, K; Ohno, R; Ohtake, S; Okumura, H; Sakamaki, H; Shinagawa, K; Takahashi, M; Taniwaki, M; Usui, N; Yagasaki, F; Yamane, T | 1 |
| Bennett, JM; Cripe, LD; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, S; Paietta, EM; Rowe, JM; Tallman, MS; Uno, H | 1 |
| Chang, YH; Cho, EH; Hong, SI; Hong, YJ; Kang, HJ; Kim, M; Lee, JK; Lee, JW | 1 |
| Baer, MR; Becker, H; Bloomfield, CD; Caligiuri, MA; Carroll, AJ; Carter, TH; Holland, KB; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Margeson, D; Metzeler, KH; Moore, JO; Mrózek, K; Powell, BL; Radmacher, MD; Schwind, S; Whitman, SP; Wu, YZ | 1 |
| Cros-Perrial, E; Demangel, D; Dreano, M; Dumontet, C; Herveau, S; Jordheim, LP; Keime, C; Plesa, A; Vendrell, JA | 1 |
| Briel, J; Gocke, CD; Hess, AD; Kanakry, CG; Karp, JE; Kos, F; Levitsky, H; Luznik, L; Meyer, C; Smith, BD; Thoburn, C | 1 |
| Hill, A; Pol, RR; Wright, A | 1 |
| Ali, D; Bengtzén, S; Deneberg, S; Jönsson-Videsäter, K; Lehmann, S; Nahi, H; Paul, C | 1 |
| Døskeland, SO; Herfindal, L; Oftedal, L; Selheim, F; Sivonen, K; Wahlsten, M | 1 |
| Berdel, WE; Braess, J; Büchner, T; Ehninger, G; Haferlach, C; Haferlach, T; Heinecke, A; Hiddemann, W; Koschmieder, A; Koschmieder, S; Kramer, M; Krug, U; Müller-Tidow, C; Rohde, C; Röllig, C; Sauerland, MC; Schaich, M; Serve, H; Spiekermann, K; Thiede, C; Wörmann, B | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Bogason, A; Gruber, A; Karlsson, MO; Lafolie, P; Masquelier, M; Paul, C; Quartino, AL; Vitols, S | 1 |
| Guo, XN; Li, JM; Shen, ZX; Sheng, XM; Sun, H; Wang, X; Wang, YY; Zhang, JL; Zhang, RY | 1 |
| Huang, BT; Liu, XL; Xiao, Z; Yu, J; Zeng, QC; Zhu, HQ | 1 |
| Allen, SL; Asatiani, E; Feldman, EJ; Kolitz, JE; Lancet, JE; List, AF; Louie, AC; Mayer, LD; Ritchie, EK; Roboz, GJ; Swenson, C | 1 |
| Hedvat, CV; Park, JH; Tallman, MS | 1 |
| Gong, YP; Yang, X; Zheng, BH; Zhou, RQ | 1 |
| Baer, MR; Bloomfield, CD; Caligiuri, MA; George, SL; Kolitz, JE; Larson, RA; Moore, JO; Mrózek, K; Powell, BL; Sanford, BL; Stone, RM | 1 |
| Du, QF; Huang, BT; Liu, XL; Luo, XJ; Wang, Y; Wei, YQ; Xu, LL; Xu, N; Yang, J; Yu, J; Zeng, QC; Zhang, JF | 1 |
| Aiba, K; Dobashi, N; Ogasawara, Y; Saito, T; Sugiyama, K; Takahara, S; Takei, Y; Usui, N; Yahagi, Y; Yamaguchi, Y; Yano, S; Yokoyama, H | 1 |
| Agrawal, AK; Golden, C; Guo, H | 1 |
| Czarnik-Matusewicz, H; Ganczarski, G; Gąsiorowski, J; Głowacka, K; Kuliczkowski, K; Orzechowska-Juzwenko, K; Wiela-Hojeńska, A; Wołowiec, D; Łapiński, Ł | 1 |
| Chen, J; Gu, L; Liu, Y; Pan, C; Tang, J; Xue, H | 1 |
| Dobashi, N; Fujita, H; Kiyoi, H; Kobayashi, Y; Miyawaki, S; Miyazaki, Y; Nakaseko, C; Naoe, T; Ohnishi, K; Ohtake, S; Ohwada, C; Sakura, T; Shigeno, K; Takeshita, A; Usui, N; Yahagi, Y | 1 |
| Huang, RW; Huang, SS; Liu, Q; Long, ZJ; Rao, J; Wu, X; Xu, DR; Zheng, FM; Zhou, WH | 1 |
| Grundy, M; Pallis, M; Russell, NH; Seedhouse, C | 1 |
| Ahmad, J; Hussain, G; Kausar, S; Zafar, L | 1 |
| Dym, H; Movahed, R | 1 |
| Solis, EC | 1 |
| Bakhshi, S; Singhal, M | 1 |
| Alonzo, TA; Arceci, RJ; Cooper, TM; Feusner, J; Franklin, J; Gamis, A; Gerbing, RB; Hirsch, B; Hurwitz, C; Iannone, R; Lavey, RS; Mathew, P; Meshinchi, S; Raimondi, SC; Smith, FO | 1 |
| Berdel, WE; Brunnberg, U; Büchner, T; Dührsen, U; Dürk, HA; Ehninger, G; Kessler, T; Kosch, M; Koschmieder, S; Krug, U; Mesters, RM; Mohr, M; Müller-Tidow, C; Noppeney, R; Sauerland, MC; Schulz, C; Serve, H | 1 |
| Bae, SH; Hyun, MS; Jang, YE; Joo, YD; Kim, DY; Kim, H; Kim, HJ; Kim, MK; Lee, GW; Lee, JH; Lee, JL; Lee, KH; Lee, WS; Min, YJ; Park, JH; Ryoo, HM; Zang, DY | 1 |
| Bolaños-Meade, J; Villela, L | 1 |
| De Graaf, SS; Gibson, BE; Harrison, CJ; Howman, AJ; Webb, DK; Wheatley, K | 1 |
| Bowles, KM; Heasman, SA; Macewan, DJ; Rushworth, SA; Zaitseva, L | 1 |
| Bain, BJ; Innes, A; May, PC; Pavlů, J | 1 |
| Fleckman, P; George, E; Yeh, I | 1 |
| Abe, A; Akahori, Y; Akatsuka, Y; Emi, N; Inaguma, Y; Kurosawa, Y; Murayama, Y; Sumitomo, M; Tokuda, M; Tsuzuki, S; Ukai, Y; Yamamoto, K; Yamamoto, Y | 1 |
| Berthon, C; Castaigne, S; Chantepie, S; Chevret, S; Dombret, H; Farhat, H; Gardin, C; Kammoun, L; Pautas, C; Raffoux, E; Reman, O; Rousselot, P | 1 |
| Bertoli, S; Cavelier, C; Creancier, L; Dastugue, N; Delabesse, E; Demur, C; Dobbelstein, S; Huguet, F; Huynh, A; Kruczynski, A; LaRochelle, O; Mansat-De Mas, V; Pillon, A; Récher, C; Sarry, A; Sarry, JE; Strzelecki, AC; Vergez, F | 1 |
| Eyre, T; Grech, H; King, AJ; Rangarajan, D; Sampson, R | 1 |
| Fondaw, MB; Khaled, YA; Reddy, VS; Shroff, SK; Ward, DE | 1 |
| Henderson, PT; Lam, KS; Li, Y; Luo, J; Pan, CX; Wachsmann-Hogiu, S; Wang, Y; Zhang, H; Zhao, W | 1 |
| Bender, B; Friberg, LE; Honoré, PH; Jensen, MK; Krogh-Madsen, M; Nielsen, OJ | 1 |
| Avilia, S; Battipaglia, G; Camera, A; Caranci, F; Morelli, E; Perna, F | 1 |
| Allan, DS; Huang, H; Luo, Y; Sun, J; Tan, Y; Wang, Z | 1 |
| Burnett, AK | 2 |
| Chiba, S; Enami, T; Hasegawa, Y; Nanmoku, T; Obara, N; Okoshi, Y; Suzukawa, K; Yokoyama, Y | 1 |
| Christos, PJ; Feldman, EJ; Gergis, U; Mayer, S; Ritchie, EK; Roboz, GJ; Scandura, JM; Wissa, U | 1 |
| Qiu, HY; Sun, AN; Wang, WJ | 1 |
| Barnard, MR; Chang, H; Chuang, WY; Sun, CF | 1 |
| Abdel-Wahab, O; Aminova, O; Cheng, J; Cherry, A; Dolgalev, I; Fernandez, H; Ferrando, A; Figueroa, ME; Gallagher, RE; Gönen, M; Heguy, A; Higgins, RR; Huberman, K; Ketterling, RP; Lazarus, HM; Levine, RL; Litzow, M; Luger, S; Melnick, A; Paietta, E; Patel, JP; Racevskis, J; Rowe, JM; Socci, ND; Sun, Z; Tallman, MS; Thomas, S; van den Brink, MR; Van Vlierberghe, P; Vance, G; Viale, A | 1 |
| Berkowitz, J; Bernard, L; Hogge, DE; Kim, HP; Nitta, J | 1 |
| Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Robak, T; Skotnicki, AB; Sulek, K; Wach, M; Warzocha, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
| Letendre, L; Tefferi, A | 1 |
| Abraham, A; Ahmed, R; Balasubramanian, P; Chandy, M; George, B; Mathews, V; Shaji, RV; Srivastava, A; Varatharajan, S; Zhang, W | 1 |
| Goozner, M | 1 |
| Appelbaum, FR; Geraghty, DE; Godwin, JE; Ho, PA; Kutny, M; Meshinchi, S; Ostronoff, F; Othus, M; Petersdorf, SH; Radich, JP; Stirewalt, DL; Willman, CL | 1 |
| Alibhai, SM; Brandwein, JM; Breunis, H; Buckstein, R; Gupta, V; Li, M; Minden, MD; Mohamedali, H; Timilshina, N; Tomlinson, G | 1 |
| Colovic, M; Floros, KV; Gourgiotis, D; Pavlovic, S; Scorilas, A; Thomadaki, H; Tosic, N | 1 |
| Imada, K; Kitagawa, T; Mori, M; Onaka, T; Sasaki, Y; Yamamoto, K; Yonezawa, A | 1 |
| Alonzo, TA; Aplenc, R; Gamis, AS; Gerbing, RB; Sung, L | 1 |
| de Revel, T; Eddou, H; Foissaud, V; Konopacki, J; Malfuson, JV; Thepenier, C | 1 |
| Ganesan, P; Majhi, U; Rajendranath, R; Sagar, TG; Udupa, K | 1 |
| Burnett, AK; Craddock, CF; Dufva, IH; Freeman, S; Hills, RK; Hunter, AE; Kell, J; Kjeldsen, L; Milligan, D; Russell, NH; Wheatley, K; Yin, J | 1 |
| Abdel-Wahab, O; Fernandez, H; Figueroa, ME; Gönen, M; Ketterling, RP; Levine, RL; Melnick, A; Paietta, E; Patel, JP; Racevskis, J; Rowe, JM; Sun, Z; Tallman, MS | 1 |
| Hwang, YY; Kwong, YL; Leung, RY; Tsui, P | 1 |
| Esfahani, A; Ghorbanihaghjo, A; Ghoreishi, Z; Nikanfar, A; Sanaat, Z | 1 |
| Gotoh, M; Ito, Y; Mihara, M; Miyawaki, S; Naoe, T; Ohnishi, K; Ohtake, S; Ohyashiki, K; Takada, S; Wakita, A | 1 |
| Berdel, WE; Büchner, T; Döhner, H; Döhner, K; Ehninger, G; Ganser, A; Hasford, J; Hehlmann, R; Heil, G; Heinecke, A; Hiddemann, W; Hoelzer, D; Hoffmann, VS; Krahl, R; Kramer, M; Krauter, J; Krug, U; Niederwieser, DW; Pfirrmann, M; Sauerland, MC; Schaich, M; Schlenk, RF; Scholl, S; Späth, D | 1 |
| Anchukova, LV; Bondarenko, SN; Gavrilova, LV; Ialykomov, IV; Kaplanov, KD; Kaporskaia, TS; Kliasova, GA; Kokhno, AV; Kondakova, EV; Konstantinova, TS; Kravchenko, SK; Kulikov, SM; Kuz'mina, LA; Lapin, VA; Moskov, VI; Parovichnikova, EN; Pristupa, AS; Ryzhko, VV; Samoĭlova, OS; Savchenko, VG; Shaforostova, II; Sokolov, AN; Troitskaia, VV; Volodicheva, EM; Zagoskina, TP | 1 |
| Cunha, BA; Desai, A; Staszewski, H | 1 |
| Colovic, N; Djunic, I; Djurasinovic, V; Jankovic, G; Palibrk, V; Suvajdzic, N; Tomin, D; Vidovic, A; Virijevic, M | 1 |
| Brierley, CK; DeAngelo, DJ; Morgan, EA; Odejide, OO; Sprague, JR; Steensma, DP | 1 |
| Amrein, PC; Attar, EC; Bloomfield, CD; Blum, W; DeAngelo, DJ; Johnson, JL; Kolitz, JE; Larson, RA; Lozanski, G; Marcucci, G; Moser, B; Powell, BL; Stone, RM; Voorhees, P; Wadleigh, M; Wang, ES | 1 |
| Lichtman, MA | 1 |
| Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M | 1 |
| Levine, RL; Patel, JP | 1 |
| Boissel, N; Bordessoule, D; Castaigne, S; Celli-Lebras, K; Chevret, S; de Botton, S; de Revel, T; Dombret, H; Fenaux, P; Gachard, N; Gardin, C; Pautas, C; Preudhomme, C; Quesnel, B; Raffoux, E; Renneville, A; Terré, C; Thomas, X; Turlure, P | 1 |
| Chen, F; Fan, Z; Feng, R; Guo, X; Huang, F; Liu, X; Meng, F; Shi, P; Xu, B; Zha, J | 1 |
| Chen, H; Liu, J; Liu, L; Liu, M; Shi, B; Ye, L; Yu, L; Zhang, Y | 1 |
| Berdel, WE; Brandts, CH; Büchner, T; Bug, G; Dührsen, U; Ehninger, G; Gerss, J; Koschmieder, A; Koschmieder, S; Krug, U; Müller-Tidow, C; Noppeney, R; Röllig, C; Schaich, M; Schwammbach, D; Serve, H; Steffen, B; Stelljes, M; Thiede, C; Tidow, N | 1 |
| Aleinikova, O; Armendariz, H; Bertrand, Y; Creutzig, U; Dworzak, M; Gibson, BE; Ha, SY; Hasle, H; Hovi, L; Kaspers, GJ; Leverger, GG; Maschan, A; Razzouk, BI; Reinhardt, D; Rizzari, C; Smisek, P; Smith, O; Stark, B; Tamminga, RY; Zimmermann, M | 1 |
| Béné, MC; Bories, P; Bouscary, D; Cahn, JY; Chapuis, N; Chevallier, P; Delepine, R; Demur, C; Dreyfus, F; Ifrah, N; Lacombe, C; Lamy, T; Leguay, T; Mayeux, P; Merlat, A; Park, S; Prebet, T; Recher, C; Saint Marcoux, F; Tamburini, J; Vey, N; Witz, F | 1 |
| Chen, Y; Ding, Q; Gu, R; Liang, J; Zhang, X | 1 |
| Atenafu, EG; Brandwein, JM; Gupta, V; Hassanein, M; Minden, MD; Schimmer, AD; Schuh, AC; Yee, KW | 1 |
| Attal, M; Bérard, E; Bertoli, S; Dastugue, N; Delabesse, E; Demur, C; Dobbelstein, S; Duchayne, E; Huguet, F; Huynh, A; Laurent, G; Lauwers-Cances, V; Mansat-De Mas, V; Récher, C; Sarry, A; Tavitian, S; Vergez, F | 1 |
| Alonzo, TA; Beyene, J; Lehrnbecher, T; Leibundgut, K; Sung, L; Teuffel, O | 1 |
| Alexander, HD; Humphreys, MW; Kettle, PJ; McGrattan, P | 1 |
| Balcerska, A; Balwierz, W; Chybicka, A; Debski, R; Kowalczyk, J; Kurylak, A; Matysiak, M; Rokicka-Milewska, R; Sońta-Jakimczyk, D; Styczyński, J; Wachowiak, J; Wysocki, M | 1 |
| Fenske, N; Morgan, MB; Sakalosky, PE | 1 |
| Anastasi, J; Baer, MR; Bloomfield, CD; Caligiuri, MA; Dodge, RK; George, SL; Kolitz, JE; Larson, RA; Minderman, H; O'Loughlin, KL; Powell, BL; Schiffer, CA | 1 |
| Baccarani, M; Bonini, A; Fanin, R; Gobbi, M; Gugliotta, L; Michelutti, T; Michieli, M; Piccaluga, PP; Piccolrovazzi, S; Pierri, I; Russo, D; Tiribelli, M; Visani, G | 1 |
| Björeman, M; Björkholm, M; Gahrton, G; Grimfors, G; Gruber, A; Hast, R; Killander, A; Lerner, R; Liliemark, J; Mattson, S; Oberg, G; Paul, C; Simonsson, B; Stalfelt, AM; Stenke, L; Tidefelt, U; Udén, AM | 1 |
| Ikeda, Y; Matsuzaki, M; Sakemi, T; Sano, M | 1 |
| Lockwood, L; Marshall, GM; O'Brien, TA; Oswald, CM; Rice, M; Russell, SJ; Shaw, PJ; Teague, L; Tiedemann, K; Vowels, MR | 1 |
| Behm, FG; Crews, KR; Gandhi, V; Plunkett, W; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Srivastava, DK; Stewart, CF; Tong, X | 1 |
| Bruyere, H; Copland, M; Hogge, DE; Horsman, DE; Lavoie, JC; Le, A; Nantel, SH; Nevill, TJ; Seftel, MD; Shepherd, JD; Sutherland, HJ; Toze, CL | 1 |
| Breitenbuecher, F; Fischer, T; Gamm, H; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A | 1 |
| Adil, SN; Burney, IA; Kakepoto, GN; Khurshid, M; Zaki, S | 1 |
| Albitar, M; Andreeff, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Thomas, D | 1 |
| Auvrignon, A; Bastard, C; Blaise, D; Castaigne, S; Dastugue, N; Delaunay, J; Dombret, H; Fenaux, P; Fière, D; Harousseau, JL; Lamy, T; Leblanc, T; Leverger, G; Mugneret, F; Pigneux, A; Reiffers, J; Rigal-Huguet, F; Van den Akker, J; Vey, N; Witz, F | 1 |
| Bishop, WR; Nakajima, A; Ohyashiki, K; Sumi, M; Tauchi, T | 1 |
| Creutzig, U; Griesinger, F; Hählen, K; Harbott, J; Huismans, DR; Kaspers, GJ; Meshinchi, S; Munske, L; Pieters, R; Podleschny, M; Radich, JP; Reinhardt, D; Veerman, AJ; Zimmermann, M; Zwaan, CM | 1 |
| Anagnostopoulos, A; Buffels, R; Fassas, A; Kaloyannidis, P | 1 |
| Chen, Y; He, M; Li, H; Wu, Y; Xiang, Z; Yu, D; Yue, B | 1 |
| Higa, T; Imai, A; Imamura, M; Kasai, M; Kiyama, Y; Kobayashi, N; Kondo, Y; Miyokawa, N; Ogasawara, M; Ogawa, T; Sato, K; Tanaka, J; Toubai, T | 1 |
| Apostolidou, E; Cortes, J; Estey, E; Giles, FJ; Kantarjian, H; Tsimberidou, A | 1 |
| Bertolini, B; Buratti, M; Mussini, C; Pinelli, A; Trivulzio, S | 1 |
| Furuta, GT; Glickman, J; Köhler, H; Nurko, S | 1 |
| Ogawa, M | 1 |
| Boiron, JM; Boucheix, C; Bourhis, JH; Dhedin, N; Fière, D; Gallo, JH; Lhéritier, V; Reman, O; Rubio, MT; Thomas, X; Vernant, JP | 1 |
| Colovic, M; Jankovic, G; Kraguljac, N; Suvajdzic, N | 1 |
| Aul, C; Berdel, WE; Büchner, T; Fonatsch, C; Frickhofen, N; Gruneisen, A; Haferlach, T; Heinecke, A; Hiddemann, W; Kern, W; Lengfelder, E; Löffler, H; Ludwig, WD; Maschmeyer, G; Mesters, RM; Sauerland, MC; Schoch, C; Serve, HL; Staib, P; Wörmann, B | 1 |
| Blijlevens, N; de Pauw, B; Donnelly, P; Levenga, H; Shirango, H; Verweij, P | 1 |
| Takeshita, A | 1 |
| Baran, W; Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jagoda, K; Jakubas, B; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Konopka, L; Kuliczkowski, K; Kyrcz-Krzemien, S; Marianska, B; Paluszewska, M; Pluta, A; Robak, T; Skotnicki, A; Stella-Holowiecka, B; Sulek, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
| Gruber, A; Masquelier, M; Vitols, S; Zhou, QF | 1 |
| Abrahams, A; Eggener, SE; Keeler, TC | 1 |
| Arnold, R; Bergmann, L; Fiedler, W; Ganser, A; Heil, G; Hoelzer, D; Kirchner, H; Krauter, J; Lübbert, M; Noens, L; Raghavachar, A; Schlimok, G | 1 |
| Cunningham, MT; Davis, MK; Imkie, M; Persons, DL | 1 |
| Masquelier, M; Vitols, S | 1 |
| Berdel, WE; Büchner, T; Hiddemann, W | 1 |
| Fonatsch, C; Geissler, K; Jäger, U; Knöbl, P; Lechner, K; Piribauer, M; Schwarzinger, I; Sperr, WR; Thalhammer-Scherrer, R; Valent, P; Wimazal, F | 1 |
| Baumann, MA; Bernstein, JM; Kumar, G; Waibel, JS | 1 |
| Choi, CH; Kim, JH; Kim, SH | 1 |
| Abdalla, SH; Bain, BJ; Foot, N; Wrench, D | 1 |
| Amirkhosravi, A; Eifrig, B; Fiedler, W; Francis, JL; Hossfeld, DK; Langer, F; Loges, S; Meyer, T | 1 |
| Kiyoi, H; Kohno, S; Miyazaki, M; Nabeshima, T; Noda, Y; Senzaki, K | 1 |
| Bennett, JM; Cassileth, PA; Dewald, GW; Lazarus, HM; Lee, SJ; Litzow, MR; Miller, KB; Paietta, E; Rowe, JM; Stadtmauer, EA; Tallman, MS | 1 |
| Chae, SC; Kim, DH; Kim, JG; Lee, GS; Lee, KB; Lee, NY; Sohn, SK; Suh, JS; Won, DI | 1 |
| Chaoui, D; Legrand, O; Marie, JP; Peffault De Latour, R | 1 |
| Bloomfield, CD; Blum, W; Byrd, JC; Chan, KK; Dai, G; Green, M; Grever, MR; Kefauver, C; Klisovic, MI; Klisovic, RB; Larson, RA; Liu, S; Maharry, K; Marcucci, G; Moran, M; Novick, S; Sher, DA; Stock, W; Zwiebel, JA | 1 |
| Attal, M; Bauduer, F; Blaise, D; Bordessoule, D; Cailleres, S; Dastugue, N; Fegueux, N; Gastaut, JA; Jourdan, E; Legros, L; Marit, G; Molina, L; Pigneux, A; Rigal-Huguet, F; Vey, N; Zerazhi, H | 1 |
| Cai, KR; Chen, MZ; Chen, RL; Fang, XM; Ye, ZL | 1 |
| Böhm, A; Fonatsch, C; Geissler, K; Gisslinger, H; Jäger, U; Knöbl, P; Kyrle, PA; Lechner, K; Piribauer, M; Sperr, WR; Valent, P; Wimazal, F | 1 |
| Das-Gupta, E; Pallis, M | 1 |
| Schinköthe, T; Staib, P; Strunk, T; Tiehen, J | 1 |
| Burnett, AK; Crump, M; Dugan, M; Ferrant, A; Fey, MF; Knauf, WU; Löwenberg, B; Ossenkoppele, GJ; Piccaluga, PP; Selleslag, D; Shepherd, J; Sonneveld, P; Theobald, M; van der Holt, B; Vellenga, E; Verhoef, GE | 1 |
| Anagnostopoulos, A; Fassas, A | 1 |
| Hassan, HT; Lu, C | 1 |
| Barbier, M; Bignon, J; Boutonnat, J; Colle, PE; Faussat, AM; Marie, JP; Ronot, X; Thierry, J; Wdzieczak-Bakala, J | 1 |
| Ao, ZF; Chen, BA; Gao, F; Shen, HL; Xia, W; Xu, WL; Zhang, YN | 1 |
| Aul, C; Balleisen, L; Berdel, WE; Büchner, T; Eimermacher, H; Grüneisen, A; Haferlach, T; Heinecke, A; Hiddemann, W; Kern, W; Kienast, J; Lengfelder, E; Mesters, RM; Rasche, H; Reichle, A; Sauerland, MC; Schnittger, S; Schoch, C; Schumacher, A; Serve, HL; Staib, P; Wörmann, B | 1 |
| Asou, N; Emi, N; Honda, S; Kishimoto, Y; Matsuda, S; Matsushima, T; Mitani, K; Miyawaki, S; Miyazaki, Y; Ogawa, Y; Ohno, R; Ohtake, S; Sakamaki, H; Takahashi, M; Yagasaki, F | 1 |
| Gratwohl, A; Rimner, T; Tichelli, A; Went, P | 1 |
| Gujral, S; Gupta, S; Kelkar, R; Maheshwari, A; Parikh, P; Tongaonkar, H | 1 |
| Allouche, M; Cariven, C; Chicanne, G; De Toni, F; Demur, C; Manenti, S; Mas, VM; Mesange, F; Payrastre, B; Racaud-Sultan, C; Salles, JP; Ysebaert, L | 1 |
| Burnett, AK; Craig, JI; Littlewood, T; Milligan, DW; Wheatley, K | 1 |
| Hou, Y; Hu, Q; Liu, AG; Liu, SY; Zhang, LQ | 1 |
| Bhattacharyya, J; Dutta, P; Hasan, S; Kumar, R; Mahapatra, M; Pati, HP; Saxena, R; Sazawal, S; Tyagi, S | 1 |
| Gu, C; Wells, RA; Ye, T | 1 |
| Martin, PL; McLean, TW; White, MS | 1 |
| Gibson, BE; Goemans, BF; Hählen, K; Kaspers, GJ; Reinhardt, D; Zwaan, CM | 1 |
| Azzam, K; Hasmann, M; Nüssler, V; Pelka-Fleischer, R; Pogrebniak, A; Schemainda, I | 1 |
| Lane, SW; Marlton, P; Mollee, PN | 1 |
| Fletcher, DA; Lam, WA; Rosenbluth, MJ | 1 |
| Bruserud, Ø; Døskeland, SO; Gjertsen, BT; Huang, TS; Kjarland, E; Lillehaug, JR; Myklebust, LM; Pendino, F | 1 |
| Grigoriyan, A; Homer, R; Manthous, CA; Molina, J; Rishi, A | 1 |
| Bruserud, Ø; Gjertsen, BT; Haaland, I; Hovland, R; Sjøholt, G; Wergeland, L | 1 |
| Berdel, WE; Brunnberg, U; Büchner, T; Kessler, T; Krug, U; Mesters, RM; Mohr, B; Mohr, M; Müller-Tidow, C; Sauerland, C; Schliemann, C; Serve, H | 1 |
| Appelbaum, FR; Balcerzak, SP; Dakhil, SR; Head, DR; Karnad, AB; Petersdorf, SH; Rankin, C; Terebelo, HR; Willman, CL | 1 |
| Alghzaly, AA; Alkindi, S; Muralitharan, S; Pathare, AV; Raeburn, JA; Udayakumar, AM | 1 |
| Hao, Y; Li, R; Xiao, Z; Xue, H; Yu, M; Zhang, L | 1 |
| Hassan, M; Jönsson-Videsäter, K; Lehmann, S; Linder, O; Löfgren, C; Möllgård, L; Paul, C; Tidefelt, U | 1 |
| Fujiwara, M; Higashimura, M; Izumi, N; Koike, T; Satou, N; Shibasaki, Y; Tsukada, N | 1 |
| Grosicki, S; Hołowiecki, J; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Seferynska, I; Skotnicki, AB; Warzocha, K; Zdziarska, B | 1 |
| Chi, HS; Choi, SJ; Im, HJ; Jang, S; Jun, KR; Lee, JH; Lee, KH; Moon, HN; Park, CJ; Seo, JJ | 1 |
| Ho, MM; Hogge, DE; Ling, V | 1 |
| Fujisawa, S; Fujita, A; Hyo, R; Ishigatsubo, Y; Kuwabara, H; Tomita, N; Yamazaki, E | 1 |
| Bian, S; Liu, S; Meng, Q; Mi, Y; Wang, J; Xue, Y; Yu, W; Zhao, Y | 1 |
| Chi, HS; Cho, YU; Lee, JH; Lee, SG; Park, CJ; Seo, EJ | 1 |
| Bengtzen, S; Concha, H; Lehmann, S; Merup, M; Möllgård, L; Nahi, H; Paul, C; Selivanova, G; Svensson, A; Wiman, KG | 1 |
| Arruga, F; Bracco, E; Carturan, S; Catalano, R; Cilloni, D; Defilippi, I; Iacobucci, I; Martinelli, G; Messa, E; Messa, F; Morotti, A; Nicoli, P; Panuzzo, C; Pautasso, M; Rosso, V; Saglio, G | 1 |
| Kurahashi, S; Narimatsu, H; Sugimoto, T; Sugiura, I; Yamamoto, F | 1 |
| Erdodi, F; Hajas, G; Kiss, A; Lontay, B; Márkász, L; Oláh, E; Rajnavölgyi, E | 1 |
| Aoki, FY; Bow, EJ; Sitar, DS | 1 |
| Comijn, EM; Hubeek, I; Kaspers, GJ; Merriman, RL; Padron, JM; Peters, GJ; Van der Wilt, CL | 1 |
| Virgolini, L | 1 |
| Isbister, JP; Ma, DD | 1 |
| Bielawiec, M; Kłoczko, J; Zuch, A | 1 |
| Anger, G; Fink, R; Herold, M; Höche, D | 1 |
| Cabanillas, F | 1 |
| Flemans, RJ; Hayhoe, FG; Li, YS; Matthews, JG; Rees, JK; Swirsky, DM | 1 |
| Duraj, M; Holowiecka, B; Holowiecki, J; Japa, J; Jarczok, K; Krawczyk, M; Rudzka, E | 1 |
| Boccia, R; Champlin, R; Elashoff, R; Foon, K; Gale, RP; Jacobs, A; Zighelboim, J | 1 |
| Go, B; Gordon, DS; Meyer, L; Raney, MR; Vogler, WR; Winton, EF | 1 |
| Obrecht, JP | 1 |
| Arimori, S; Nagao, T | 1 |
| Lindner, HJ; Linker, H; Schaefer, HE | 1 |
| Grianti, C; Izzi, T; Moretti, L; Muretto, P | 1 |
| Burke, PJ; Karp, JE; Vaughan, WP | 4 |
| Batten, E; Eridani, S; Sawyer, B | 1 |
| Lefante, J; Stein, RS; Vogler, WR | 1 |
| Growe, GH; Mangal, AK | 1 |
| Ambinder, E; Button, G; Cuttner, J; Holland, JF; Meyer, RJ; Norton, L | 1 |
| Brodin, B; Liedén, G; Malm, C; Vikrot, O | 1 |
| Bolanowska, W; Gessner, T; Preisler, H | 1 |
| Himori, T; Ohnuma, T; Wakui, A | 2 |
| Kobayashi, M; Tahara, T | 1 |
| D'Cruz, CA; Harcke, HT; Huff, DS; Naiman, JL; Wimmer, RS | 1 |
| Killmann, SA; Nielsen, HR | 1 |
| Kalliomäki, JL; Korvenranta, H; Meurman, L; Nikoskelainen, J; Rajamäki, A; Söderström, KO; Toivanen, A | 1 |
| Arlin, Z; Chaganti, RS; Clarkson, B; Gee, T; Higgins, C; Jhanwar, S; Kempin, S; Mertelsmann, R | 1 |
| Kochupillai, V; Raina, V | 1 |
| Alvez González, F; Couselo Sánchez, JM; Fernández Iglesias, A; Fuster Siebert, M; Gallego García, D; Iglesias Diz, JL | 1 |
| Greenberg, PL; Mackintosh, FR; Schrier, SL; Schwartz, RS | 1 |
| Kato, Y; Kawashima, K; Ohno, R; Yamada, K | 1 |
| Casassus, P; Chaux, F; Cupa, M; Larmignat, P; Leroux, G; Pourriat, JL | 1 |
| Abakumov, EM; Faĭnshteĭn, FE; Isaev, VG; Kovaleva, LG; Vakhrusheva, MV | 2 |
| Arita, N; Kajiwara, S; Kono, H; Ohmori, T; Tabei, R | 1 |
| Bernard, P; Boisseau, MR; Broustet, A; Dachary, D; Lacombe, F; Reiffers, J | 1 |
| Bloch, A; Craig, RW; Frankfurt, OS; Sakagami, H; Takeda, K | 1 |
| Himori, T; Holland, JF; Ohnuma, T | 1 |
| Cantini, E; Yanes, B | 1 |
| Gustavsson, A; Olofsson, T | 1 |
| Kato, Y; Kawashima, K; Kodera, Y; Morishima, Y; Nagura, E; Ogura, M; Ohno, R; Sugihara, T; Suzuki, H; Watanabe, E | 1 |
| Murase, T; Ogata, H; Oheda, Y; Okamoto, S; Toyama, K; Yoshida, T | 1 |
| Christensson, B; Engsted, L; Gyllenhammar, H; Lindström, P; Ost, A | 1 |
| Apperley, J; Boughton, BJ; Franklin, IM; Knight, D | 1 |
| Dohy, H; Kamada, N; Kuramoto, A; Maehama, S; Mandai, K; Oguma, N; Tahara, E; Takimoto, Y; Tanaka, K | 1 |
| Brugués, R; Del Cañizo, MC; Ríos, A; Rozman, C | 1 |
| Karanes, C; Kessel, D; Ratanatharathorn, V; Wilberding, C | 1 |
| Catovsky, D; Galton, DA; Goldman, JM; Islam, A | 1 |
| Chen, PM; Chiang, BN; Chiou, TJ; Chiu, CF; Tzeng, CH | 1 |
| Berger, R; Boiron, M; Degos, L; Fischer, J; Flandrin, G; Ganem, G; Marty, M; Schaison, G | 1 |
| Flexner, JM; Kayser, J; Stein, RS | 1 |
| Baker, MA; Carter, WH; Taub, RN | 1 |
| Aderka, D; Berliner, S; Pinkhas, J; Santo, M; Shaklai, M; Shoenfeld, Y; Weinberger, A | 1 |
| Barbui, T; Bassan, R; Battista, R; Capnist, G; Chisesi, T; Cortelazzo, S; D'Emilio, A; Dini, E; Rodeghiero, F; Viero, P | 1 |
| Barrat, H; Blum, F; Cloup, M; Colbert, N; Duhamel, G; Gorin, NC; Lasfargues, G; Najman, A; Treisser, A | 1 |
| Aggio, MC; Krauss, S; Latif, ZA; Lozzio, BB; Lozzio, CB; Wust, CJ | 1 |
| Bhaduri, S; Heimpel, H; Hoelzer, D; Krieger, D; Kubanek, B; Kurrle, E; Vanek, E | 1 |
| Berthier, R; Hollard, D; Leger, J; Michallet, M; Sotto, JJ | 1 |
| Broustet, A; Raynal, F; Reiffers, J | 1 |
| Giannoulis, NE; Johansson, NO; Reizenstein, P | 1 |
| Berger, NA; Klahr, C; Phillips, GL; Presant, CA | 1 |
| Rumiantsev, AG | 1 |
| Baurain, R; Gahrton, G; Paul, C; Peterson, C | 1 |
| Popov, VM; Vinogorova, GF | 1 |
| Flexner, JH; Graber, SE; Stein, RS | 1 |
| Tisman, G; Wu, SJ | 1 |
| Preisler, HD | 1 |
| Daly, PA; Schiffer, CA; Wiernik, PH | 1 |
| Clodfelter, K; Foon, KA; Gale, RP; Yale, C | 1 |
| Daher, O; Flatau, E; Kohn, D; Zuckerman, F | 1 |
| Ballard, JO; Dougherty, JB; Eyster, ME; Gevirtz, NR; Hamilton, RW; Patel, SB; Shaikh, BS | 1 |
| Apel, D; Maj, S; Pawelski, S; Sobczyńska, Z; Sylwestrowicz, T; Zdziechowska, H; Zywicka-Lopaciuk, H | 1 |
| Krykowski, E; Mazurowa, A; Olszańska-Skorek, T; Polkowska-Kulesza, E; Płuzańska, A; Robak, T | 1 |
| Bauters, F; Goudemand, M; Huart, JJ; Jouet, JP; Jude, B; Toussaint, B | 1 |
| De Vries, EG; De Vries-Hospers, HG; Haaxma-Reiche, H; Houwen, B; Mulder, NH | 1 |
| Bloomfield, CD; Peterson, BA | 1 |
| Cline, MJ; Foon, KA; Gale, RP; Zighelboim, J | 1 |
| Biernacka, I; Brzuchowska, W; Grazybek-Hryncewicz, K; Kotlarek-Haus, S; Kuliczkowski, K; Luczkiewicz-Mulczykowa, A | 1 |
| Loth, H; Seeber, S | 1 |
| Foon, KA; Gale, RP; Yale, C; Zighelboim, J | 1 |
| Benjamin, RS; Bodey, GP; Freireich, EJ; Keating, MJ; McCredie, KB; Smith, TL; Zander, A | 1 |
| Cooperman, BS; Klinger, HP | 1 |
| Eichelkraut, A; Orłowska-Westwood, B; Polakowski, P | 1 |
| Cikos, J; Pejin, D; Popović, K; Topalov, V; Uzurov, V | 1 |
| Omura, GA | 2 |
| Gahrton, G; Lockner, D; Lönnqvist, B; Paul, C; Peterson, C | 1 |
| Begg, CB; Bennett, JM | 1 |
| Golik, A; Kaufman, S; Reif, R; Yona, R | 1 |
| Bank, A; Blom, J; Bloomfield, CD; Brunner, K; Carey, RW; Cooper, MR; Ellison, RR; Falkson, G; Glidewell, OJ; Gottlieb, A; Haurani, F; Henry, P; Hoagland, HC; Holland, JF; Hutchison, JL; James, GW; Kaan, SK; Kung, F; McIntyre, OR; Nawabi, IW; Nissen, NI; Obrecht, JP; Prager, D; Preisler, HD; Rai, KR; Ramanan, SV; Silver, RT; Weinberg, V; Wiernik, P | 1 |
| Kanter, PM; Schwartz, HS | 1 |
| Epstein, J; Preisler, H | 1 |
| Fülle, HH; Koeppen, KM; Rühl, H; Schwerdtfeger, R | 1 |
| Alegre, A; Chunchurreta, R; Cruz, E; Prada, M; Rodriguez-Alarcon, J | 1 |
| Hamami, T; Haruyama, H; Ijichi, H; Isemura, T; Nakagawa, M; Nakajima, Y; Shimazaki, C; Ura, Y | 1 |
| Ekert, H; Matthews, RN; Paton, CM; Toogood, IR; Waters, KD | 1 |
| Bodey, GP; Estey, EH; Freireich, EJ; Keating, MJ; McCredie, KB | 1 |
| Berenberg, J; Cooper, MR; Cornell, C; Dosik, H; Ellison, RR; Falkson, G; Frelick, R; Glidewell, O; Gottlieb, A; Green, M; Haurani, F; Henderson, E; Henry, P; Hoagland, C; Holland, JF; Hutchison, JL; James, GW; Leone, L; Levy, R; Nissen, N; Raich, P; Silver, RT; Steinberg, D; Wiernik, P; Yates, J | 1 |
| Beswick, W; Chesterman, CN; Firkin, FC; Garson, OM; Januszewicz, E; Keating, MJ; Penington, DG | 1 |
| Kondrat'eva, NA; Mazurok, AA; Orel, VG; Vygovskaia, IaI | 1 |
| Ishigami, S; Kubota, Y; Masaoka, T; Nakamura, H; Shibata, H; Takubo, T; Tanaka, T; Ueda, T; Yoshitake, J | 1 |
| Kinsella, IA; Lawlor, E; McCann, SR; Temperley, IJ | 1 |
| Büchner, T; Emmerich, B; Fischer, JT; Fülle, HH; Heinecke, A; Hossfeld, DK; Koeppen, KM; Labedzki, L; Löffler, H; Nowrousian, MR; Pfreundschuh, M; Pralle, H; Rühl, H; Urbanitz, D; Wendt, FC | 1 |
| Carrera, CJ; DeGregorio, MW; Klock, JC; Wilbur, JR | 1 |
| Gerecke, D; Gross, R | 1 |
| Gottlieb, JE; Pauker, SG | 1 |
| Adachi, T; Endo, Y; Fujimoto, S; Hara, M; Kimura, I; Kitajima, K; Kohi, F; Lai, M; Oda, Y; Ohmoto, E; Sanada, H; Takahashi, I; Takaoka, K; Tokioka, M; Uchida, K; Watanabe, S; Yorimitsu, S | 1 |
| Brecher, M; Browman, G; Early, AP; Freeman, A; Preisler, HD; Raza, A; Walker, IR | 1 |
| Dabich, L | 1 |
| Stuart, J | 1 |
| Barros, CA; Birman, V; Cavagnaro, F; Dragosky, MO; Dupont, J; Eppinger-Helft, M; Garay, G; Macchi, A; Muriel, FS; Pavlovsky, S; Scaglione, C; Suarez, A | 1 |
| Duncan, M; Haggard, ME; Sabio, H; Steuber, P; van Eys, J | 1 |
| Bagarry-Liégey, D; Carcassonne, Y; Ciardelli, P; Favre, R; Gastaut, JA; Imbert, C; Meyer, G; Sebahoun, G | 1 |
| Gordon, D; Jarrell, R; Knospe, W; Lefante, J; Omura, GA; Silberman, H; Vogler, WR | 1 |
| Gale, RP | 2 |
| Büchner, T; Hiddemann, W; Jahns-Streubel, G; Reuter, C; Schleyer, E; Unterhalt, M; Wörmann, B | 1 |
| Ehninger, G; Fackler-Schwalbe, E; Freund, M; Heil, G; Hoelzer, D; Link, H; Mitrou, PS; Ohl, S; Steinke, B; Wandt, H | 1 |
| Kaya, H; Matano, S; Matsuda, T; Nakamura, S; Ohtake, S; Okafuji, K; Tanaka, N; Yoshida, T | 1 |
| Deguchi, M; Kitazawa, S; Maeda, S; Mochizuki, M; Ohara, N; Ohta, T; Takeuchi, S | 1 |
| Abe, A; Hayatsu, K; Murakawa, E; Nagai, K; Sekiya, M | 1 |
| Andreeff, M; Chen, R; Clarkson, BD; Gulati, SC; Lemoli, RM; Tafuri, A | 1 |
| Bassini, A; Celeghini, C; Gibellini, D; Manfroi, S; Ottaviani, E; Pagliarini, C; Tosi, P; Tura, S; Visani, G; Zauli, G | 1 |
| Kurokawa, H; Nagata, K; Nara, N; Tanikawa, S; Tohda, S; Tomiyama, J | 1 |
| Bartolucci, AA; Moore, JO; Omura, GA; Stagg, M; Volger, WR; Weiner, RS | 1 |
| Berman, E; Lin, S; McBride, M; Menedez-Botet, C; Tong, W | 1 |
| Godwin, J | 1 |
| Dittus, RS; Freund, DA | 1 |
| Efferth, T; Fabry, U; Glatte, P; Osieka, R | 1 |
| Schiller, G | 1 |
| Basara, N; Bosković, D; Colović, M; Radosević-Radojković, N; Rolović, Z | 1 |
| Abe, T; Hirao, A; Kawano, Y; Okamoto, Y; Saito, S; Sato, J; Shimizu, T; Suzue, T; Takaue, Y; Watanabe, T | 1 |
| de Leeuw, K; Hagemeijer, A; Löwenberg, B; Nooter, K; Schoester, M; Sonneveld, P; te Boekhorst, PA; Wittebol, S | 1 |
| Cancelas, JA; Cerveró, C; García-Laraña, J; Hernández-Jodra, M; Lasa, E; López-Jimenez, J; Megido, M; Pérez-Oteyza, J; Sastre, JL; Zamora, C | 1 |
| Appelbaum, FR; Bigelow, CL; Files, JC; Grever, M; Head, D; Kopecky, K; Lipschitz, DA | 1 |
| Berg, DT; Dodge, RK; George, SL; Lee, EJ; Moore, JO; Paciucci, PA; Powell, BL; Schiffer, CA; Schulman, P; Stone, RM | 1 |
| Eguchi, H; Ikuno, Y; Inada, H; Ishii, E; Koga, H; Matuzaki, A; Miyazaki, S; Nibu, K; Okamura, J; Ueda, K | 1 |
| Berman, E | 3 |
| McCulloch, EA; Minden, MD; Yang, GS | 1 |
| Damasio, E; de Witte, T; Labar, B; Leoni, F; Mandelli, F; Papa, G; Resegotti, L; Visani, G; Willemze, R; Zittoun, RA | 1 |
| Doyle, LA; Fojo, AT; Kaufmann, SH; Lee, EJ; Ross, DD; Schiffer, CA; Sridhara, R | 1 |
| Banavali, SD; Gaskins, F; Li, YQ; Preisler, HD; Raza, A; Venu, G; Yin, M | 1 |
| Fisher, GR; Gutiérrez, PL; Lenehan, PF; Milak, N; Ross, DD; Wagner, JL | 1 |
| Bishop, JF; Cobcroft, R; Dodds, A; Herrman, R; Joshua, DE; Laidlaw, CR; Ma, D; Matthews, JP; Szer, J; Young, G | 1 |
| Reilly, JT; Snowden, JA; Wodziński, MA | 1 |
| Antin, JH; Miller, KB; Mitus, AJ; Parsons, SK; Ryan, HF; Schenkein, DP; Wheeler, C | 1 |
| Ohno, R | 2 |
| Burke, PJ; Cowan, K; Jones, RJ; Karp, JE; Kaufmann, SH; Miller, CB; Schneider, E; Wendel, K; Zwelling, LA | 1 |
| Imai, A; Kawabata, I; Morishita, S; Tamaya, T | 1 |
| Bailly, JD; Cassar, G; Demur, C; Huynh, A; Jaffrézou, JP; Laredo, J; Laurent, G; Muller, C | 1 |
| Bernell, P; Hast, R; Kimby, E | 1 |
| Fridborg, H; Killander, A; Kristensen, J; Larsson, R; Liliemark, J; Nygren, P; Oberg, G; Simonsson, B | 1 |
| Artlich, A; Gortner, L; Kruse, K; Möller, J; Schwinger, E; Tschakaloff, A | 1 |
| Cedrych, I; Hołowiecka, B; Hołowiecki, J; Kachel, L; Krawczyk, M; Krzemień, S; Rudzka, E; Wacławik, A; Wojciechowska, M; Wojnar, J | 1 |
| Bow, EJ; Cheang, MS; Clinch, JJ; Kilpatrick, MG; Scott, BA | 1 |
| Aikawa, K; Furukawa, T; Gotoh, J; Ishibashi, T; Maruyama, Y; Shichishima, T; Shiga, Y; Yamagiwa, A | 1 |
| Eppinger-Helft, M; Fernandez, I; Garcia Martinez, MA; Gonzalez Llaven, J; Ibarra, S; López-Hernández, M; Marin, A; Pavlovsky, S; Rubio, ME; Sobrevilla, P | 1 |
| Dalla Pozza, L; Goleta-Dy, A; Shaw, PJ; Stevens, MM | 1 |
| Preisler, H | 1 |
| Lee, EJ; Ordóñez, JV; Ross, DD; Schiffer, CA; Sridhara, R; Wooten, PJ | 1 |
| Cornblatt, B; Lee, EJ; Levy, C; Ross, DD; Schiffer, CA; Sridhara, R; Tong, Y; Wooten, PJ | 1 |
| Djaldetti, M; Floru, S; Mittelman, M | 1 |
| Griggs, JJ; Henley, SE; Rowe, JM | 1 |
| Liu, HC; Lou, FD; Meng, FY; Wang, YZ; Zhou, Q | 1 |
| García, R; Gomis, F; Guinot, M; Jarque, I; Palau, J; Pérez-Sirvent, ML; Sanz, GF; Sanz, MA; Sempere, A; Senent, L | 1 |
| Chubachi, A; Imai, H; Miura, AB; Miura, I; Nimura, T; Takahashi, N | 1 |
| Paul, C; Sundman-Engberg, B; Tidefelt, U | 1 |
| Jehn, U | 1 |
| Belloc, F; Boiron, JM; Cony-Makhoul, P; Dumain, P; Lacombe, F; Lopez, F; Mahon, FX; Marit, G; Montastruc, M; Puntous, M | 1 |
| Kaletin, GI; Pirogova, NA; Volkova, MA | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Ohhashi, Y; Yamada, K | 1 |
| Hossfeld, DK; Shi, G; Weh, HJ | 1 |
| Abe, Y; Hatanaka, T; Ito, T; Kamiya, O; Nagata, K; Ohara, K; Ono, Y; Saito, M | 1 |
| Cenacchi, A; Fogli, M; Gamberi, B; Manfroi, S; Ottaviani, E; Tosi, P; Tura, S; Visani, G | 1 |
| Bloch, A | 1 |
| Fujimura, T; Iwabuchi, A; Kawakubo, K; Kodama, A; Ohyashiki, JH; Ohyashiki, K; Toyama, K | 1 |
| Chen, LM; Huang, SH; Hwang, WS; Tseng, MT; Wang, CC | 1 |
| Bailey, CC; Curzon, ME; Duggal, MS; Hart, P; O'Sullivan, EA | 1 |
| Delmer, A; Marie, JP; Suberville, AM; Thevenin, D; Zittoun, R | 2 |
| An, E; Gomi, S; Inokuchi, K; Ito, T; Miyake, K; Ogata, K; Ohki, I; Tanabe, Y; Yamada, T; Yokose, N | 1 |
| Advani, SH; Gopal, R; Hegde, UP; Iyer, RS; Kurkure, PA; Nadkarni, KS; Nair, CN; Pai, SK; Pai, VR; Saikia, TK | 1 |
| Filippi, C; Garbe, L; Garnier, G; Gratecos, N; Michiels, JF; Pesce, A; Poitou, G; Rosenthal, E; Taillan, B; Vinti, H | 1 |
| Ikeda, K; Inoo, M; Murao, S; Murata, M; Nagai, M; Sasaki, K; Takahara, J; Tasaka, T; Tokuda, M | 1 |
| Fujiyama, Y; Hiramitu, Y; Hodohara, K; Hosoda, S; Kitoh, K; Sugiura, H; Sumiyoshi, K | 1 |
| Amadori, S; Aricò, M; Comelli, A; Giuliano, M; Madon, E; Mandelli, F; Masera, G; Rondelli, R; Testi, AM; Zanesco, L | 1 |
| de Witte, T; Delmer, A; Ferrini, PR; Mandelli, F; Rio, B; Stryckmans, P; Tura, S; Vekhof, A; Willemze, R; Zittoun, R | 1 |
| Groenewegen, A; Löwenberg, B; Sonneveld, P; Vellenga, E; Wielenga, JJ | 1 |
| Cole, SP; Deeley, RG; Doyle, LA; Grant, CE; Lee, EJ; Ross, DD; Schiffer, CA; Tong, Y; Yang, W | 1 |
| Bow, EJ; Cheang, MS; Loewen, R; Schacter, B | 1 |
| Ino, Y; Moriwaki, H; Murakami, N; Muto, Y; Tsurumi, H; Yamada, T | 1 |
| Falk, RE; Fuerst, MM; Giles, FJ; Kusuanco, DA; Lawrence, GN; Lim, SW; Look, RM | 1 |
| Bamberger, U; Esteban, M; Heckel, A; Kasimir-Bauer, S; Müller, MR; Scheulen, ME; Schröder, J; Seeber, S | 1 |
| DeLima, M; Estey, E; Ghaddar, H; Pierce, S | 1 |
| Areström, I; Gruber, A; Knaust, E; Lundeberg, J; Palucka, K; Peterson, C; Pisa, P; Xu, D | 1 |
| Attal, M; Berthaud, P; Broustet, A; Danel, P; Fabères, C; Gastaut, JA; Hollard, D; Huguet, F; Hurteloup, P; Lepeu, G; Maraninchi, D; Marit, G; Mercier, M; Michallet, M; Molina, L; Pris, J; Reiffers, J; Stoppa, AM; Tellier, Z | 1 |
| Bandini, G; Belardinelli, A; Fiacchini, M; Geromin, A; Gherlinzoni, F; Manfroi, S; Mangianti, S; Miggiano, MC; Motta, MR; Ricci, P; Rizzi, S; Rosti, G; Testoni, N; Tura, S; Visani, G | 1 |
| Hu, ZB; McCulloch, EA; Minden, MD | 1 |
| Allouche, M; Bailly, JD; Bordier, C; Come, MG; Duchayne, E; Laurent, G; Mansat, V; Quillet-Mary, A | 1 |
| Fey, MF; Hardegger, TP; Tobler, A; von Rohr, A | 1 |
| Gieseler, F; Glasmacher, A; Kämpfe, D; Kunze, J; Nuessler, V; Valsamas, S; Wandt, H; Wilms, K | 2 |
| Cadiou, M; de Witte, T; Hayat, M; Mandelli, F; Peetermans, M; Petti, MC; Solbu, G; Stryckmans, P; Suciu, S; Thaler, J; Willemze, R; Zittoun, R | 1 |
| Brack, N; Ehninger, G; Fackler-Schwalbe, I; Freund, M; Geer, T; Gramatzki, M; Hübner, G; Link, H; Löffler, B; Ohl, S; Poliwoda, H; Queisser, W; Raab, M; Schneider, B; Schneider, C; Schönrock-Nabulsi, P; Wandt, H | 1 |
| Dabadghao, S; Dennison, D; Srivastava, A | 1 |
| Jowitt, SN; Yin, JA | 1 |
| Kearns, P; Majumdar, G; Partridge, F; Richardson, W; Wilcox, R | 1 |
| Audhuy, B; Baranger, L; Berthaud, P; Berthou, C; Briere, J; Cahn, JY; Caillot, D; Casassus, P; Desablens, B; Francois, S; Guyotat, D; Harousseau, JL; Herve, P; Hurteloup, P; Leprise, PY; Linassier, C; Lioure, B; Pignon, B; Polin, V; Sadoun, A; Vilque, JP; Witz, F | 1 |
| Chong, R; Goh, YT; Lee, LH; Ng, HS; Tan, P; Wong, GC | 1 |
| Clark, M; Gieseler, F; Glasmacher, A; Kämpfe, D; Kunze, J; Valsamas, S; Zernak, C | 1 |
| Ezaki, K; Hirano, M; Ino, T; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Nomura, T; Okamoto, M; Tsuzuki, M; Wakita, M; Yamaguchi, T | 1 |
| Kimura, K; Masaoka, T; Ogawa, M; Ohashi, Y; Yamada, K | 1 |
| Hirakawa, S; Kato, M; Nakayama, M; Shikoshi, K; Takata, M; Tanaka, M; Umeda, M | 1 |
| Ando, T; Ariyoshi, K; Hikiji, K; Kobayashi, M; Shinohara, K; Toyosawa, M | 1 |
| Enomoto, S; Ishida, Y; Ito, S; Ito, T; Kaneko, J; Kuriya, S; Miyairi, Y; Murai, K; Narigasawa, Y; Numaoka, H; Ono, Y; Shimosegawa, K; Sugawara, T; Utsugisawa, T | 1 |
| Abe, F; Fujii, H; Maruyama, S; Yosizawa, K | 1 |
| Abenhardt, W; Diem, H; Gieseler, F; Gullis, E; Kolb, HJ; Langenmayer, I; Nüssler, V; Pelka-Fleischer, R; Schmitt, R; Wilmanns, W; Wohlrab, A; Zwierzina, H | 1 |
| Beguin, Y; Bury, J; Fillet, G; Forget, P; Sautois, B | 1 |
| Ezaki, K; Hirano, M; Ino, T; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Nomura, T; Okamoto, M; Tsuzuki, M; Yamaguchi, T | 1 |
| Appelbaum, FR; Chen, IM; Godwin, J; Head, DR; Kopecky, KJ; Leith, CP; McConnell, T; Slovak, ML; Willman, CL | 1 |
| Di Leone, L; Fernandes, MS; Gerhardt, LM; Kalakun, L; Loitzembauer, B; Moschen, M; Schaan, MD; Schwartsmann, G | 1 |
| Bailly, JD; Bousquet, C; Demur, C; Herbert, JM; Laurent, G; Lautier, D | 1 |
| Sundström, GM; Wahlin, A | 1 |
| Kane, D; Keating, S; McCann, S; Mulcahy, F | 1 |
| Björkholm, M; Eksborg, S; Fagerlund, E; Hast, R | 1 |
| Choi, CH; Ling, V | 1 |
| Broxterman, HJ; Eekman, CA; Lankelma, J; Ossenkoppele, GJ; Pinedo, HM; Schuurhuis, GJ; Währer, DC | 1 |
| Fujimoto, T | 1 |
| Aoki, H; Iinuma, M; Miyata, Y; Takeyama, H; Watanabe, E; Yamada, H; Yamamoto, Y | 1 |
| Björkholm, M; Engervall, P; Kalin, M | 1 |
| Anand, KP; Jaiprakash, MP; Kasthuri, AS; Kumar, R | 1 |
| Barnett, MJ; Dalal, BI; Horsman, DE; Klingemann, HG; Naiman, SC; Nantel, SH; Phillips, GL; Reece, DE; Shepherd, JD; Spinelli, JJ; Sutherland, HJ; Wu, V | 1 |
| Alpdoğan, O; Alpdoğan, TB; Bayik, M; Demirçay, Z; Gürbüz, O; Kurtkaya, O; Yücelten, D | 1 |
| Cuttner, J; Davis, RB; Gottlieb, A; Holland, JF; Martelo, O; Paciucci, PA | 1 |
| Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M | 1 |
| Pallis, M; Russell, NH | 1 |
| Delannoy, A; Doyen, C; Ferrant, A; Martiat, P; Michaux, JL; Mineur, P; Van Den Neste, E; Zenebergh, A | 1 |
| Ryo, R; Saigo, K; Sugimoto, T; Yamaguchi, N | 1 |
| Amemiya, Y; Furukawa, Y; Hoshino, M; Imagawa, S; Izumi, T; Kawano, C; Kirito, K; Komatsu, N; Kuribara, R; Miura, Y; Miyazato, A; Muroi, K; Omine, K; Otsuki, T; Shimizu, R; Suzuki, T; Tabata, M; Takahashi, H; Takatoku, M; Terui, Y; Tomizuka, H; Toshima, M; Tsunoda, J; Uchida, M; Yoshida, M | 1 |
| Li, S; Wang, C; Yao, C | 1 |
| Baccarani, M; Candoni, A; Damiani, D; Ermacora, A; Geromin, A; Grimaz, S; Masolini, P; Michelutti, A; Michieli, M; Raspadori, D; Scheper, RJ; Stocchi, R | 1 |
| Qiau, Z; Wang, C; Yang, L | 1 |
| Lokhorst, HM; Roovers, DJ; van Heugten, HG; Verdonck, LF | 1 |
| Asai, O; Dobashi, N; Funakoshi, S; Kato, A; Katori, M; Kobayashi, T; Kuraishi, Y; Maki, N; Nagamine, M; Ogawa, M; Ogihara, A; Saito, T; Tajima, N; Takei, Y; Usui, N; Watanabe, H; Yamaguchi, Y; Yamazaki, H; Yano, S | 1 |
| Arthur, DC; Bloomfield, CD; Heinonen, K; Lawrence, D; MacCallum, J; Mrózek, K; Pettenati, MJ; Qumsiyeh, MB; Schiffer, CA; Stamberg, J; Verma, RS | 1 |
| Almqvist, A; Elonen, E; Hänninen, A; Jansson, SE; Järventie, G; Koistinen, P; Koivunen, E; Lahtinen, R; Lehtinen, M; Nousiainen, T; Pelliniemi, TT; Rajamäki, A; Remes, K; Ruutu, T; Timonen, T; Vilpo, J; Volin, L | 1 |
| Black, P; Gutjahr, P; Stopfkuchen, H | 1 |
| Areström, I; Gruber, A; Jacobsson, H; Larsson, SA; Liliemark, J; Xu, D | 1 |
| Akiba, J; Fuyama, S; Hayashi, T; Kosugi, S; Maeda, K; Sasaki, H; Satoh, S; Suzuki, K; Tajima, K; Yahagi, A | 1 |
| Asai, O; Dobashi, N; Kato, A; Katori, M; Kobayashi, T; Kuraishi, Y; Maki, N; Nagamine, M; Ogihara, A; Saito, T; Tajima, N; Usui, N; Watanabe, H; Yamazaki, H; Yano, S | 1 |
| Lemez, P; Maresová, J | 1 |
| Montes, A; Nandi, A; Powles, RL; Talbot, DC; Teh, WL | 1 |
| Akan, H; Arat, M; Arslan, O; Beksaç, M; Gürman, G; Ilhan, O; Koç, H; Konuk, N; Ozcan, M; Uysal, A | 1 |
| Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P | 1 |
| Helm, KF; Long, D; Williams, JV | 1 |
| Mosher, D; Stein, JH; Vidarsson, B; Woods, T | 1 |
| Aul, C; Büchner, T; Fonatsch, C; Gassmann, W; Haase, D; Haferlach, T; Heinecke, A; Heyll, A; Hiddemann, W; Hossfeld, D; Lengfelder, E; Löffler, H; Ludwig, WD; Maschmeyer, G; Sauerland, MC; Schoch, C; Wörmann, B | 1 |
| Aoba, M; Fujisawa, S; Fujita, H; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Matsuzaki, M; Mohri, H; Murata, T; Tanaka, M; Togawa, J | 1 |
| Kuraishi, Y; Masaoka, T; Mizoguchi, H; Ogawa, M; Okabe, K; Saito, H; Sampi, K; Takemoto, Y; Tamura, K | 1 |
| de Witte, T; Pennings, AH; Raymakers, RA; Smeets, ME; Vierwinden, G; Wessels, H | 1 |
| Elgie, AW; Lewandowicz, GM; Sargent, JM; Taylor, CG; Williamson, CJ | 1 |
| Langabeer, S; Pallis, M; Russell, NH; Turzanski, J | 1 |
| Filipits, M; Geissler, K; Jäger, U; Lechner, K; Pirker, R; Pohl, G; Scheper, RJ; Stranzl, T; Suchomel, RW | 1 |
| Abboud, B; Chahine, G; Ferran, F | 1 |
| Prince, HM; Speed, BR; Westerman, DA | 1 |
| Gujral, S; Kochupillai, V; Kumar, L; Mohanti, BK; Wadhwa, J | 1 |
| Kasimir-Bauer, S; Scheulen, ME; Schröder, JK; Seeber, S | 1 |
| Hamaguchi, H; Hara, M; Kikuchi, M; Makino, S; Mori, M; Nisimura, H; Okabe, K; Saburi, Y; Sato, H; Tamura, K; Tanimoto, M; Tomiyama, J; Urabe, A | 1 |
| Bodalski, J; Bolanowski, W; Nowak, K; Stolarska, M; Zalewska-Szewczyk, B | 1 |
| Choi, CH; Chung, MH; Jeong, JH; Kim, HS; Kim, MS; Kweon, OS; Lee, TB; Lim, DY; Min, YD; Rha, HS; You, HJ | 1 |
| Covelli, A; Elmhorn-Rosenborg, A; Gruber, A; Gustavsson, B; Juliusson, G; Lehman, S; Liliemark, E; Liliemark, J; Möllgård, L; Paul, C; Stenke, L; Sundman-Engberg, B; Tidefelt, U; Xu, D | 1 |
| Akiyama, Y; Eguchi, M; Hayashi, Y; Hosoi, G; Ishii, E; Kato, K; Koike, K; Kojima, S; Nishimura, S; Ohara, A; Okamura, J; Okimoto, Y; Sako, M; Sato, T; Tsukimoto, I; Ueda, K; Yazaki, M; Yoshikawa, T | 1 |
| Fujii, S; Fukushi, Y; Futagami, M; Higuchi, T; Saito, Y; Sakamoto, T; Sato, S; Takami, H; Yokoyama, Y | 1 |
| Ezaki, K; Hasegawa, A; Hirano, M; Ino, T; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Okamoto, M; Tsuzuki, M | 1 |
| Gáliková, J; Haas, T; Lemez, P | 1 |
| Mori, M | 1 |
| Gao, H; Ren, X; Wang, S | 1 |
| Hu, Y; Zang, Y; Zhao, X | 1 |
| Bian, S; Luo, M; Xue, Y | 1 |
| Asai, O; Dobashi, N; Kasama, K; Kato, A; Katori, M; Kobayashi, T; Kuraishi, Y; Nagamine, M; Ogawa, M; Ogihara, A; Osawa, H; Saito, T; Tajima, N; Takei, Y; Uno, S; Usui, N; Yahagi, Y; Yamaguchi, Y; Yamazaki, H; Yano, S | 1 |
| Hatake, K; Kobayashi, T; Kuriyama, K; Minami, S; Miyawaki, S; Ohno, R; Omoto, E; Saito, K; Tamura, J; Tanimoto, M | 1 |
| Bruno, AP; d'Orgeix, AT; Laurent, G; Lautier, D; Quillet-Mary, A | 1 |
| Amouri, A; Bouaouina, N; Chatti, S; Chehata, S; Ennabli, S; Laatiri, MA; Saad, A | 1 |
| Cortes, JE; Hui, YF | 1 |
| Higashi, Y; Pallis, M; Russell, NH; Turzanski, J | 1 |
| Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
| Boos, J; Creutzig, U; Feldges, A; Gadner, H; Hermann, J; Kühl, J; Niemeyer, CM; Ritter, J; Sawatzki, DB; Schwabe, D; Selle, B; Zimmermann, M | 1 |
| Bieri, S; Chapuis, B; Helg, C; Miralbell, R | 1 |
| Appelbaum, FR; Banker, DE; Garrido, SM; Willman, CL | 1 |
| Berthold, F; Creutzig, U; Gadner, H; Havers, W; Henze, G; Hermann, J; Jürgens, H; Kabisch, H; Kluba, U; Niggli, F; Reinhardt, D; Reiter, A; Ritter, J; Zimmermann, M | 1 |
| Ajchenbaum-Cymbalista, F; Delmer, A; Marie, JP; Radosevic, N; Tang, R | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Shen, Y; Thomas, D | 1 |
| Erikson, C; Florschütz, A; Rosahl, W; Schreiber, J; Schumann, HJ; Zugehör, M | 1 |
| Appelbaum, FR; Bennett, CL; Godwin, J; Golub, RM; Hynes, D; Stinson, TJ | 1 |
| Bowers, DC; Civin, CI; Friedman, AD; Loeb, DM | 1 |
| Carneiro, RC; Chamone, DA; Dorlhiac-Llacer, PE; Maranhão, RC; Marquezini, MV; Toffoletto, O | 1 |
| Cobos, E; Keung, YK; Morgan, D | 1 |
| Appelbaum, FR; Doroshow, JH; Dorr, R; Head, DR; Hynes, HE; Karanes, C; Kopecky, KJ; List, AF; Persons, DL; Shurafa, M; Slovak, ML; Willman, CL | 1 |
| Heller, G | 1 |
| Allan, A; Kroumpouzos, G; Travers, R | 1 |
| Anagnostopoulos, A; Buffels, R; Fassas, A; Gacos, E; Haloudis, P; Kaloyannidis, P; Vadikolia, C | 1 |
| Cañete, A; Carvajal, E; Castel, V; Fernández, JM; Verdeguer, A | 1 |
| Balwierz, W; Bogusławska-Jaworska, J; Dluzniewska, A; Dobaczewski, G; Januszkiewicz-Lewandowska, D; Kowalczyk, J; Kołecki, P; Krenke, K; Matysiak, M; Moryl-Bujakowska, A; Rokicka-Milewska, R; Rola-Kurc, E; Sońta-Jakimczyk, D; Stefaniak, MJ; Tomaszewska, R | 1 |
| Cline, MJ; Fahey, J; Feig, S; Gale, RP; Opelz, G; Sarna, G; Territo, M; Young, L | 1 |
| Haanen, C; Hillen, H; Wessels, J | 1 |
| Burge, PS; Prankerd, TA; Richards, JD; Sare, M; Thompson, DS; Wright, P | 1 |
| Durack, DT; Starkebaum, GA | 1 |
| Bear, RA; Garvey, MB; Ho, M | 1 |
| Cline, MJ; Gale, RP | 1 |
| Bocaccino, CA; Greenberger, JS; Moloney, WC; Szot, SJ | 1 |
| Hayhoe, FG; Rees, JK | 1 |
| Alexander, P; Clink, HM; McElwain, TJ; Morgenstern, G; Palu, G; Powles, RL; Selby, PJ | 1 |
| Cassileth, PA; Cooper, RA; Katz, ME; Petrillo, MH | 1 |
| Anteunis, A; Audebert, AA; Debray, J; Krulik, M; Robineaux, R | 1 |
| Barabash, G; Benjamin, D; Djaldetti, M; Douer, D; Pinkhas, J; Weinberger, A | 1 |
| Amadori, S; Mastrovincenzo, C; Petti, MC; Testa, MG | 1 |
| Gustavsson, A; Olofsson, T; Olsson, I | 1 |
| Engelhard, D; Polliack, A; Rachmilewitz, EA; Yatziv, S | 1 |
| Sullivan, MP; Sutow, WW | 1 |
| Bekesi, JG; Holland, JF | 1 |
| Al-Ismail, SA; Parry, DH; Whittaker, JA | 1 |
| Fülle, HH | 2 |
| Buskard, NA; Catovsky, D; Costello, C; Galton, DA; Goldman, JM; Spiers, AS | 1 |
| Catovsky, D; Costello, C; Galton, DA; Goldman, JM; Pitcher, CS; Spiers, AS | 1 |
| Auclerc, MF; Holland, JF; Jacquillat, C; Schaison, G; Weil, M | 1 |
| Benjamin, RS; Bodey, GP; Freireich, EJ; Keating, MJ; McCredie, KB | 1 |
| Bekesi, JG; Cuttner, J; Glidewell, O; Holland, JF | 1 |
| Cowall, DE; Trump, DL | 1 |
| Brand, A; den Ottolander, GJ; Eernisse, JG; Haak, HL; Hartgrink-Groeneveld, CA; Heering, KJ; Jansen, J; Willemze, R; Zwaan, FE | 1 |
| Layard, M; Muggia, FM; Rozencweig, M; Von Hoff, DD | 1 |
| Challener, J; Hayhoe, FG; Rees, JK; Sandler, RM | 1 |
| Killmann, SA; Wantzin, GL | 1 |
| Domján, O; Horváth, A; István, L; Kassai, P; Kemény, P; Koós, R; Laub, MW; Révész, T; Schuler, D; Székely, K; Velkey, L; Vincellér, M; Virág, I | 1 |
| Gjemdal, T; Ly, B; Stavem, P | 1 |
| Delamore, IW; Freeman, CB; Geary, CG; Harris, R; Hull, PJ; MacIver, JE; Taylor, GM; Tooth, JA; Zuhrie, SR | 1 |
| Badia, L; Besalduch, J; Marty, ML; Mayans, J; Prieto, F | 1 |
| Dienstl, F; Frisch, H; Gstöttner, M | 1 |
| Genova, R; Laini, C; Livieri, C; Marchi, A; Marni, E; Martini, A; Zanol, MG | 1 |
| Becher, R; Firusian, N | 1 |
| Bauters, F; Clarisse, J; Goudemand, M; Huart, JJ; Jouet, JP | 1 |
| Cavalli, F | 1 |
| Pfrimmer, WJ; Sartiano, GP; Turner, AR | 1 |
| Amadori, S; De Lipsis, E; Grignani, F; Liso, V; Mandelli, F; Martelli, M | 1 |
| Buick, RN; McCulloch, EA; Till, JE | 1 |
| Ichimiya, M; Ishiguro, J; Kamiya, T; Kawashima, K; Kobayashi, M; Koie, K; Morishima, Y; Murakami, S; Nishiwaki, H; Ogata, K; Ohno, R; Sako, F; Takeyama, H; Uetani, T; Yamada, K; Yamaguchi, H; Yoshikawa, H; Yoshikawa, S | 1 |
| Aoki, N; Kawada, K; Matsumoto, K; Taya, T | 1 |
| Bloomfield, CD; Collins, AJ; Edson, JR; McKenna, RW; Peterson, BA | 1 |
| Baikie, MJ; Campbell, SN; Lowenthal, RM; Marsden, KA; Newman, NM | 1 |
| Yoshikawa, H | 1 |
| Büchner, T; Hiddemann, W; Kamanabroo, D; Urbanitz, D | 1 |
| Rustum, YM | 1 |
| Garratty, G; Morel, PA; Ness, PM; Perkins, HA | 1 |
| Colombetti, V; Coser, P; Delucca, A; Fabris, P; Mengarda, G; Prinoth, O | 1 |
| Riehm, H; Scheer, U; Schellong, G | 1 |
| Baudet, D; Besancenot, JF; Bonhomme, J; Cortet, P; Guy, H; Schadeck, C | 1 |
| Libánský, J; Lukásová, M; Sedlácková, M | 1 |
| Chiyoda, S; Kubota, K; Miura, Y; Mizoguchi, H; Muto, Y; Takaku, F | 1 |
| Flexner, JM; Graber, SE; Stein, RS | 1 |
| Foon, KA; Gale, RP; Naiem, F; Yale, C | 1 |
| Alfano, G; Leone, G; Mango, G | 1 |
| Gahrton, G; Granström, M; Hörnsten, P; Wahren, B | 1 |
| Asherson, GL; Athanassiades, PH; Oliver, RT; Platts-Mills, TA | 1 |
| Buick, RN; McCulloch, EA; Messner, HA; Till, JE | 1 |
| Zighelboim, J | 1 |
| Anderton, KJ; Hill, AS; Lilleyman, JS | 1 |
| Braunsteiner, H | 1 |
| Whittaker, JA | 1 |
| Mauer, AM | 1 |
| Bodey, GP; Rodriguez, V | 1 |
| Carpenter, JL; Old, CW; Torrington, KG; Urban, ES | 1 |
| Dietrich, BE; Jacobs, P; Miller, JL; Uys, CJ | 1 |
| Brunner, KW; Carey, RW; Cuttner, J; DelDuca, V; Glidewell, OJ; Hoagland, HC; Holland, JF; Kung, FH; Silver, RT; Spurr, CL; Wiernik, PH | 1 |
| Fujiwara, Y; Furukawa, K; Hirota, Y; Nakaide, Y; Tanaka, M | 1 |
| Ellman, L; Groopman, J | 1 |
| Baccarani, M; Fiacchini, M; Gobbi, M; Guarini, A; Gugliotta, L; Lauria, F; Ricci, P; Ruggero, D; Santucci, MA; Tomasini, I; Tura, S; Zaccaria, A | 1 |
| Delamore, IW; Geary, CG; Milner, GR; Sumner, C; Wilkinson, PM | 1 |
| Davies, JE; Khurshid, M; Whittaker, JA | 1 |
| Walters, TR | 1 |
| Henderson, ES | 2 |
| Barbui, T; Battista, R; Dini, E | 1 |
| Fennelly, JJ; Gorman, AM; Keane, TJ; O'Connell, LG | 1 |
| Eppinger-Helft, M; Hidalgo, G; Muriel, FS; Pavlovsky, A; Pavlovsky, S; Suarez, A; Vilaseca, G | 1 |
| Ansari, BM; Thompson, EN | 1 |
| Brincker, H | 4 |
| Eernisse, JG; Hartgrink-Groeneveld, CA; Speck, B; Willemze, R | 1 |
| Kremer, WB | 1 |
| Bleich, HL; Boro, ES | 1 |
| Mandelli, F | 1 |
| Cimino, R; Di Girolamo, R; Montuori, R; Quattrin, N | 1 |
| Barbui, T; Battista, R; Cartei, G; Cazzavillan, M; Chisesi, T; Dini, E | 1 |
| Bernard, J | 2 |
| Burchenal, JH; Clarkson, BD; Cunningham, IB; Dowling, MD; Gee, TS | 1 |
| Bódis, L; Herr, G; Nagy, L; Patakfalvi, A | 1 |
| Goodall, PT; Vosti, KL | 1 |
| George, S; Komp, DM; Lyon, GM; Ragab, AH; Starling, KA; Sutow, WW | 1 |
| Bryon, PA; Fière, D; Martin, C; Péaud, PY | 1 |
| Brenning, G; Engstedt, L; Franzén, S; Gahrton, G; Gullbring, B; Höglund, S; Holm, G; Jameson, S; Killander, A; Killander, D; Lockner, D; Mellstedt, H; Palmblad, J; Reizenstein, P; Skårberg, KO; Swedberg, B; Udén, AM; Wadman, B; Wide, L | 1 |
| Bateman, CJ; Beard, ME; Crowther, DC; Fairley, GH; Scott, RB; Whitehouse, JM; Wrigley, PF | 1 |
| Ansari, BM; Thompson, EN; Whittaker, JA | 1 |
| Evans, DI; Jones, PH; Morley, CJ | 1 |
| Blom, J; Carey, RW; Cuttner, J; Eagan, RT; Ellison, RR; Glidewell, O; Harley, JB; Haurani, F; Holland, JH; Kyle, R; Lee, ST; Levy, RN; Moon, JH; Ribas-Mundo, M; Silver, R; Spurr, CL | 1 |
| Bruntsch, U; GAllmeier, WM; Osieka, R; Schmidt, CG; Seeber, S | 1 |
| Khvatova, NV; Zhukovskaia, ES | 1 |
| Alekseev, NA | 1 |
| Hirano, M; Imai, K; Imamura, K; Ishiguro, J; Kamiya, T; Koie, K; Nishiwaki, H; Ohno, R; Sako, F; Uetani, T | 1 |
| di Cato, MA | 1 |
| Henderson, ES; Leventhal, BG; Pizzo, PA | 1 |
| Sauter, C | 1 |
| Gmür, J; Gürtler, J; Straub, PW | 1 |
| Bernard, J; Boiron, M; Bussel, A; Gemon-Auclerc, MF; Izrael, V; Jacquillat, C; Weil, M | 1 |
| Fisher, V; Flessa, HC; Hake, DA; Lampkin, BC; Mauer, AM; McWilliams, NB | 1 |
| Beaujan, F; Brun, B; Dreyfus, B; Gouault, M; Lenoir, MP; Mannoni, P; Reyes, F | 1 |
| Amaki, I; Ohshima, T | 1 |
| Javier, G; Ortega, JJ; Sáenz, A; Tusell, J | 1 |
| Bosković, D; Ruvidić, R | 1 |
| Kundu, D; Smith, BJ | 1 |
| Karle, H; Killmann, SA; Philip, P; Wantzin, GL | 1 |
| Nomura, T | 1 |
| Liong, SK; Uzuka, Y; Yamagata, S | 1 |
| James, PD; Toghill, PJ; Wilcox, RG | 1 |
| Cauchi, MN; Paton, C; Stone, J; Whiteside, MG | 1 |
| D'auteuil, P; Harel, P | 1 |
| Bernard, J; Boiron, M; Chastang, CL; Gemon-Auclerc, MF; Izrael, V; Jacyuillat, CI; Weil, M | 1 |
| Aisner, J; Fortner, C; Lichtenfeld, JL; O'Connell, MJ; Schiffer, CA; Schimpff, SC; Wiernik, PH | 1 |
| Alberto, P; Cavalli, F; Sauter, C; Senn, HJ | 1 |
| Powles, R; Toy, JL | 1 |
| Garwood, FA; Groth, D; Vogler, WR | 1 |
| Bryon, PA; Fiere, D; Martin, C; Revol, L | 3 |
| Zittoun, R | 1 |
| Jastrzebska, M; Lukowska, K; Pacholska, J; Paciorkiewicz, W; Rokicka-Milewska, R | 1 |
| Andreeff, M; Bettelheim, P; Geissler, K; Lechner, K; Schulz, G; Sillaber, C; Tafuri, A; Valent, P; Vieder, L | 1 |
| Garewal, HS; Roe, DJ; Shamdas, GJ | 1 |
| Damiani, D; Dinota, A; Fanin, R; Geromin, A; Michelutti, A; Michieli, M; Pileri, S; Raspadori, D; Russo, D; Visani, G | 1 |
| Delmer, A; Helou, C; Marie, JP; Thevenin, D; Zittoun, R | 1 |
| Canty, A; Dyson, PG; Haylock, DN; Juttner, CA; Thorp, D; To, LB | 1 |
| Archimbaud, E; Campos, L; Guyotat, D; Jaffar, C; Solary, E; Treille, D | 1 |
| Bethell, H; Grace, AA; Hall, JA; Petch, MC; Schofield, PM | 1 |
| Legrand, O; Marie, JP; Russo, D; Suberville, AM; Zhou, D; Zittoun, R | 1 |
| Belt, J; Brenner, MK; Crom, W; Hurwitz, CA; Krance, R; Mahmoud, H; Ribeirio, R; Roberts, WM; Santana, VM; Schell, MJ | 1 |
| Chiba, S; Hanazono, Y; Hirai, H; Miura, Y; Miyagawa, K; Miyazono, K; Piao, YF; Sakamoto, S; Taketazu, F; Yazaki, Y | 1 |
| Lou, FD; Meng, FY; Zhou, Q | 1 |
| Bajko, G; Drozdowska, D; Hansz, J; Woźny, T | 1 |
| Sauter, C; Zahner, M | 1 |
| Alvarez, MA; Castillo, D; Gomez, P; Rojas, R; Torres, A; Velasco, F | 1 |
| Brinch, L; Evensen, SA; Stavem, P; Tjønnfjord, G | 1 |
| Balcar-Boroń, A; Graduszewska-Czerebiej, K; Nowaczyk-Michalak, A | 1 |
| Braunsteiner, H; Dietze, O; Herold, M; Nachbaur, K; Thaler, J; Vogel, W | 1 |
| Belin, T; Champlin, R; Gajewski, J; Lee, M; Nimer, S; Schiller, G; Territo, M | 1 |
| Sasaki, A; Tsukaguchi, M | 1 |
| Eguchi, T; Iwahara, Y; Kubonishi, I; Miyagi, T; Muneishi, H; Sugito, S; Taguchi, H; Takehara, N; Tanaka, Y; Uemura, Y | 1 |
| Kimura, F; Mizukami, H; Motoyoshi, K; Nagata, N; Ohtsuki, T; Takagi, S; Takemura, Y; Yamamoto, K | 1 |
| Di Mario, A; Etuk, B; Leone, G; Pagano, L; Salutari, P; Sica, S | 1 |
| McCauley, DL | 1 |
| Grever, MR; Gumbart, CH; Head, D; Hynes, HE; Kopecky, KJ; Lipschitz, DA; Ryan, DH; Shiaer, SM; Veith, RW; Vial, RH | 1 |
| Anderson, LL; Berger, TG; Thomas, DE; Vukelja, SJ | 1 |
| Beran, M; Deisseroth, A; Estey, E; Gutterman, J; Kantarjian, H; Keating, M; Koller, CA; O'Brien, S; Thall, PF | 1 |
| de Witte, T; Ferrini, PR; Gattringer, C; Mandelli, F; Petti, MC; Solbu, G; Stryckmans, P; Tura, S; Willemze, R; Zittoun, R | 1 |
| Resegotti, L | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W | 1 |
| Björkholm, M; Gahrton, G; Grimfors, G; Hast, R; Järnmark, M; Juliusson, G; Killander, A; Kimby, E; Paul, C; Tidefelt, U | 1 |
| Amadori, S; Avvisati, G; Cacciola, E; Cantore, N; De Laurenzi, A; De Rosa, C; Fioritoni, G; Mandelli, F; Spadea, A; Vegna, ML | 1 |
| Grimfors, G; Järnmark, M; Lerner, R; Ljungman, P; Lönnqvist, B; Nyström-Rosander, C; Oberg, G; Palmblad, J; Samuelsson, J | 1 |
| Berman, E; McBride, M | 1 |
| Elmhorn-Rosenborg, A; Eriksson, LC; Hao, XY; Mannervik, B; Paul, C; Tidefelt, U | 1 |
| Banks, PL; Bartolucci, AA; Flaum, MA; Gerber, MC; Omura, GA; Velez-Garcia, E; Vogler, WR; Weiner, RS | 1 |
| Bisserbe, S; Marie, JP; Wdowik, T; Zittoun, R | 1 |
| Athens, JW; Balcerzak, SP; Coltman, CA; Costanzi, JJ; Dabich, L; Gumbart, C; Head, DR; Kopecky, KJ; Morrison, FS; Saiki, JH | 1 |
| Hatanaka, T; Ito, T; Kamiya, O; Nagata, K; Ohara, K; Ono, Y; Saito, M | 1 |
| Aoki, N; Goto, Y; Kanemoto, N | 1 |
| Champlin, R; Gajewski, J; Ho, W; Lee, M; Nimer, S; Schiller, G; Territo, M | 1 |
| Chao, TY; Chen, LM; Hwang, SH; Hwang, WS; Kao, WY; Ko, WS; Lee, WC; Wang, CC | 1 |
| Ross, DD | 1 |
| Cao, LX; Chen, H; Zeng, TQ | 1 |
| Gray, RG; Rees, JK | 1 |
| Fiere, D; Haanen, C; Jehn, U; Löwenberg, B; Peetermans, M; Solbu, G; Stryckmans, P; Suciu, S; Willemze, R; Zittoun, R | 1 |
| Buckley, JD; Hammond, GD; Lampkin, BC; Woods, WG | 1 |
| Heinemann, V; Jehn, U | 1 |
| Champlin, R; Gajewski, J; Ho, W; Landaw, E; Nimer, S; Schiller, G; Vollset, S; Winston, D | 1 |
| Andoh, T; Ito, Y; Kawashima, K; Morishima, Y; Morishita, Y; Saito, H; Tanimoto, M; Towatari, M | 1 |
| Challis, J; Farag, S; Garson, OM; White, J | 1 |
| Arlin, ZA; Banks, PL; Case, DC; Enck, RE; Periman, PO; Ritch, PS; Todd, MB; Weitberg, AB; Wiernik, PH | 1 |
| Bennett, J; Browman, G; Day, R; Goldberg, J; Gottlieb, A; Larson, RA; Preisler, HD; Raza, A; Vardiman, JW; Vogler, R | 1 |
| Domula, M; Dörffel, W; Eggers, G; Exadaktylos, P; Fuchs, D; Hermann, J; Krause, M; Palme, H; Prager, J; Zintl, F | 1 |
| Cuddy, DP; de Valeriola, DL; Egorin, MJ; Forrest, A; Ross, DD | 1 |
| Brandalise, S; De Bellis, R; Fernández, I; Jiménez-Fonseca, E; Palau, V; Pavlovsky, S; Ruiz-Argüelles, G; Santarelli, MT | 1 |
| Ardia, A; Di Pietro, N; Di Raimondo, F; Falconi, E; Ganzina, F; Geraci, E; Ladogana, S; Latagliata, R; Mandelli, F; Petti, MC | 1 |
| Brugnatelli, S; Danova, M; Giordano, M; Girino, M; Mazzini, G; Riccardi, A; Ucci, G | 1 |
| Bastida Vila, P; Giralt López, J; Javier Manchón, G; Olivé Oliveras, T; Ortega Aramburu, JJ; Sánchez, C | 1 |
| Browman, G; Goldberg, J; Kukla, C; Larson, R; Preisler, HD; Raza, A | 1 |
| Almenoff, JS; Blake, K; Kindman, LA; Narurkar, VA | 1 |
| Attal, M; Broustet, A; Corront, B; Gastaut, JA; Hollard, D; Marit, G; Michallet, M; Reiffers, J; Rigal-Huguet, F; Stoppa, AM | 1 |
| Hanrahan, A; Lobo, PJ; Powles, RL; Reynold, DK | 1 |
| Carey, M; Goldberg, J; Kukla, C; Larson, R; Preisler, H; Raza, A; Tricot, G | 1 |
| Dölken, G; Fauser, AA; Herbst, EW; Kreisel, W | 1 |
| Gotohda, Y; Iwasaki, H; Kakinoki, Y; Katagiri, M; Kobayashi, T; Miyazaki, T; Morioka, M; Sakurada, K; Tanaka, M | 1 |
| Ben-Bassat, I; Ra'anani, P; Ramot, B; Shpilberg, O | 1 |
| Feng, CS | 1 |
| Hagenbeek, T; Herweijer, H; Nooter, K; Oostrum, R; Sonneveld, P; Valerio, D | 1 |
| Civin, C; Culbert, S; Krischer, J; Leventhal, B; Ragab, A; Ravindranath, Y; Ruymann, FB; Steuber, CP; Vietti, TJ; Wilkinson, R | 1 |
| Andreeff, M; Bettelheim, P; Gorischek, C; Haas, O; Haimi, J; Muhm, M; Sillaber, C; Tafuri, A; Valent, P; Vieder, L | 1 |
| Adams, M; Andreeff, M; Berman, E; Clarkson, B; Duigou-Osterndorf, R; Godfrey, L | 1 |
| Guo, WJ; Masterson, M; Mayers, GL; Mehdi, I; Mirto, S; Motyka, LE; Raza, A; Yousuf, N | 1 |
| Barnett, MJ; Bolwell, BJ; Brown, RA; Frei-Lahr, DA; Herzig, RH; Klingemann, HG; Phillips, GL; Reece, DE; Shepherd, JD; Spinelli, JJ | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, S; Kolitz, J; McKenzie, S; Santorsa, J | 1 |
| Barzi, A; Lepri, E; Liberati, M; Menconi, E; Portuese, MG; Santucci, A | 1 |
| Fujita, N; Gotoh, H; Inaba, T; Itoh, K; Murakami, S; Nakagawa, M; Nakanishi, S; Oku, N; Shimazaki, C | 1 |
| Andoh, K; Kobayashi, N; Kubota, T; Sadakata, H; Tanaka, H | 1 |
| Bandini, G; Barbui, T; Bassan, R; Battista, R; Ciolli, S; D'Emilio, E; Leoni, F; Rosti, G; Todeschini, G; Zuffa, E | 1 |
| Mansberg, R; Rowlings, PA; Rozenberg, MC; Yip, MY | 1 |
| Hellmann, A; Koberda, J | 1 |
| Bettelheim, P; Dudczak, R; Hinterberger, W; Kyrle, PA; Lechner, K; Niessner, H; Pabinger, I; Schwarzinger, I; Speiser, W | 1 |
| Boesen, AM; Brincker, H; Christensen, BE; Drivsholm, A; Ellegaard, J; Hansen, OP; Hippe, E; Jans, H; Jensen, KB; Pedersen-Bjergaard, J | 1 |
| Creutzig, U; Ritter, I; Schellong, G | 1 |
| Preĭsler, KhD; Raza, A | 1 |
| Potter, MN; Rogers, S; Slade, RR | 1 |
| Akazawa, K; Asano, Y; Harada, M; Morioka, E; Niho, Y; Okamura, S; Shibuya, T | 1 |
| Ciolli, S; Leoni, F; Morfini, M; Patriarchi, S; Rossi Ferrini, P | 1 |
| Docherty, JG; la Ferla, G; Lucie, NP; McKay, PJ | 1 |
| Aul, C; Büchner, T; Heinecke, A; Hiddemann, W; Löffler, H; Ludwig, W; Maschmeyer, G; Nowrousian, M | 1 |
| Arlin, Z; Cartwright, K; Case, DC; Desai, P; Feldman, E; Moore, J; Saletan, S; Sia, L; Wiernik, P | 1 |
| Huet, S; Hurteloup, P; Pris, J; Rigal-Huguet, F; Robert, J | 1 |
| Creutzig, U; Ritter, J; Schellong, G | 3 |
| Camitta, BM; Clavell, LA; Garcea, MJ; Gelber, RD; Grier, HE; Link, MP; Weinstein, HJ | 1 |
| Broccia, G; Caronia, F; Di Raimondo, F; Fioritoni, G; Ladogana, S; Leone, G; Liso, V; Musso, M; Neri, A; Petti, MC | 1 |
| Ehninger, G; Fackler-Schwalbe, E; Freund, M; Heil, G; Hoelzer, D; Kurrle, E; Link, H; Löffler, B; Lösch, A; Mitrou, PS | 1 |
| Blasius, S; Büchner, T; Hiddemann, W; Koch, P; Kuse, R; Ludwig, WD; Maschmeyer, G; Sodomann, H; Thiel, E; Tirier, C | 1 |
| Bennett, JM; Cassileth, PA; Harrington, DP; Hines, JD; Lynch, E; Mazza, JJ; McGlave, P; O'Connell, MJ; Oken, MM | 1 |
| Appelt, M; Büchner, T; Eichelbaum, M; Grille, W; Hiddemann, W; Hossfeld, DK; Koslowski, B; Kraft, J; Kuse, R; Quabeck, K | 1 |
| Aul, HC; Donhuijsen-Ant, R; Grüneisen, T; Hiddemann, W; Köppler, H; Lathan, B; Ludwig, WD; Maschmeyer, G; Reichle, A; Urbanitz, D | 1 |
| Abels, J; de Gast, GC; Dekker, AW; Löwenberg, B; Sonneveld, P; van der Lelie, J; van Putten, WL; Verdonck, LF; Willemze, R; Zwaan, FE | 1 |
| Bayle, C; el Zimeity, M; Sabbour, MS | 1 |
| Burke, PJ; Geller, RB; Karp, JE; Santos, GW; Saral, R | 1 |
| Benjamin, DR; Bernstein, ID; Buckley, JD; Feig, SA; Kim, TH; Lampkin, BC; Ruymann, FB; Smithson, WA; Srivastava, AK; Woods, WG | 1 |
| Barbui, T; Biondi, A; Catapano, C; D'Incalci, M; Giudici, G; Limonta, M; Masera, G; Specchia, G | 1 |
| Chan, TK; Chiu, E; Liang, R; Todd, D | 1 |
| Barcos, M; Bennett, J; Browman, G; Day, R; Kukla, C; Lykins, J; Preisler, HD; Raza, A; White, M; Yasin, Z | 1 |
| Bartolucci, A; Cohen, HJ; Raney, MR; Stein, RS; Vogler, WR; Winton, EF | 1 |
| Liliemark, J; Paul, C; Sundman-Engberg, B; Tidefelt, U | 1 |
| Bordessoule, D; Casassus, P; Castaigne, S; Degos, L; Desablens, B; Henry-Amar, M; Le Prisé, PY; Tertian, G; Tilly, H | 1 |
| Büchner, T; Heinecke, A; Hiddemann, W; Martin, WR; Sauerland, CM | 1 |
| Bär, BM; de Pauw, BE; de Witte, T; Haanen, C | 1 |
| Kramer, B; Reich, WK; Scheulen, ME; Skorzec, M | 1 |
| Briere, J; Casassus, P; Desablens, B; Gandhour, C; Harousseau, JL; Ifrah, N; Le Prise, PY; Milpied, N | 1 |
| Dekker, AW; Nieuwenhuis, HK; Verdonck, LF; Witteveen, EO | 1 |
| Aul, C; Schneider, W | 1 |
| Büchner, T; Essink, ME; Hiddemann, W; van de Loo, J; von Eiff, M | 1 |
| Delwel, R; Löwenberg, B; Nooter, K; Santini, V | 1 |
| Cosson, A; Estienne, MH; Fenaux, P; Lai, JL; Lepelley, P; Preudhomme, C; Zandecki, M | 1 |
| Han, P; Kueh, YK; Suri, R; Tan, YO | 1 |
| Advani, SH; Banavali, SD; Charak, BS; Gopal, R; Kurkure, PA; Nadkarni, KS; Nair, CN; Pai, SK; Pai, VR; Saikia, TK | 1 |
| Nooter, K; Sonneveld, P | 1 |
| Boughton, BJ; Franklin, I; Goldstone, AH; Gribben, JG; Leyland, MM; Linch, DC; McMillan, AK; Milligan, DW; Patterson, KG; Richards, JD | 1 |
| Saito, Y; Uzuka, Y | 2 |
| Bian, SG; Hao, YS; Wang, ZC | 1 |
| Bishop, JF; Cobcroft, R; Dodds, A; Joshua, D; Kronenberg, H; Lowenthal, RM; Ma, D; Matthews, JP; Todd, D; Whiteside, MG | 1 |
| Heimpel, H; Hoelzer, D; Kurrle, E | 1 |
| Nieuwenhuis, HK; Sixma, JJ | 1 |
| Center, MS; Marsh, W; Sicheri, D | 1 |
| Burnison, M; Champlin, R; Decker, R; Gale, RP; Greenberg, P; Ho, W; Holly, FE; Winston, D | 1 |
| Catovsky, D; Chessells, JM; Galton, DA; Goldman, JM; Hann, IM; Hoffbrand, AV; Marcus, RE; Newland, AC; Prentice, HG; Stevens, RF | 1 |
| Gray, R; Hayhoe, FG; Rees, JK | 1 |
| Baehner, RL; Buckley, JD; Chard, RL; Hammond, GD; Lampkin, BC; Nesbit, ME; Woods, WG | 1 |
| Archimbaud, E; Fiere, D; Sebban, C | 1 |
| Bernasconi, C; Bernasconi, P; Bonfichi, M; Castagnola, C; Colombo, A | 1 |
| Aso, T; Hino, H; Hirota, Y; Kondou, S; Makuuchi, M; Matsumoto, I; Nishiura, S; Takata, K | 1 |
| Bardy, P; Branford, AL; Dart, GD; Dyson, PG; Haylock, DN; Ho, JQ; Horvath, N; Roberts, MM; Thorp, D; To, LB | 1 |
| Bernard, P; Boiron, JM; Marit, G; Reiffers, J; Rice, A; Vezon, G | 1 |
| Jehn, U; Zittoun, R | 1 |
| Bernabei, PA; Dal Pozzo, O; Rossi Ferrini, P; Saccardi, R; Santini, S; Santini, V | 1 |
| Kyo, T; Maehama, S | 1 |
| Ohshima, T | 1 |
| Huijgens, PC; Langenhuijsen, MM; Ossenkoppele, GJ; van Geel, BM; Wijermans, PW | 1 |
| Ihle, H; Ihle, R; Matthes, H | 1 |
| Abels, J; Bury, J; Fière, D; Haanen, C; Hayat, M; Jehn, U; Löwenberg, B; Peetermans, M; Willemze, R; Zittoun, R | 1 |
| Carr, T; Chang, J; Coutinho, LH; Deakin, DP; Dexter, TM; Morgenstern, GR; Scarffe, JH; Testa, NG | 1 |
| Haanen, C; Minderman, H; Speth, PA | 1 |
| Omura, G; Raney, M; Velez-Garcia, E; Vogler, WR | 1 |
| Aegerter, P; Gorin, NC; Gratwohl, A; Hayat, M; Hermans, J; Stijnen, T; Stryckmans, P; Suciu, S; Zittoun, R; Zwaan, FE | 1 |
| Amadori, S; Ceci, A; Comelli, A; Defazio, D; Madon, E; Mandelli, F; Masera, G; Nespoli, L; Paolucci, G; Zanesco, L | 1 |
| Broccia, G; Carotenuto, M; De Rosa, F; Di Marco, P; Di Raimondo, F; Fioritoni, G; Leone, G; Mandelli, F; Petti, MC; Vegna, ML | 1 |
| Arlin, ZA | 1 |
| Morgan, HJ; Schreiner, RD | 1 |
| Düllmann, J; Gerhartz, H; Illinger, H; Keilhauer, R; König, H; Linkesch, W; Michlmayr, G; Moldrzyk, D | 1 |
| Dohy, H; Kyo, T | 3 |
| Bustelo, P; Freigeiro, D; Jiménez, E; Kohan, R; Kvicala, R; Pavlovsky, S; Richard, L; Sackmann Muriel, F; Santarelli, MT; Scaglione, C | 1 |
| Burke, PJ; Geller, RB; Karp, JE; Vaughan, WP | 1 |
| Braine, HG; Burke, PJ; Fox, MG; Geller, RB; Hall, KL; Humphrey, RL; Karp, JE; Morrell, L; Tucker, RW; Zahurak, M | 1 |
| Bernstein, ID; Buckley, JD; Feig, SA; Hammond, GD; Kersey, JH; Kim, T; Lampkin, BC; Nesbit, ME; Piomelli, S | 1 |
| Bogdanić, V; Jaksić, B; Labar, B; Malesević, M; Minigo, H; Mrsić, M; Nemet, D | 1 |
| Andreeff, M; Berman, E; Clarkson, BD; Gabrilove, J; Gee, TS; Gulati, S; Kempin, SJ; Raymond, V; Wiernik, PH; Young, CW | 1 |
| Boughton, BJ; Donohue, SM | 1 |
| Gahrton, G; Liliemark, J; Paul, C; Peterson, C; Tidefelt, U | 1 |
| Kodera, Y; Minami, S; Morishima, Y; Morishita, Y; Nagai, T; Ohno, R; Saito, H; Tanimoto, M; Yokomaku, S | 1 |
| Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Itami, S; Mizunuma, N; Mukaiyama, T; Ogawa, M; Tabata, M | 1 |
| Aoki, N; Maruyama, Y; Murohashi, I; Nara, N | 1 |
| Castaman, G; Castronovo, S; Cortesi, S; Dini, E; Quaglio, R; Rodeghiero, F; Soffiati, G | 1 |
| Hayashi, K; Ito, T; Kamiya, O; Kinoshita, T; Nagata, K; Ohara, K; Ono, Y; Saito, M; Sugiura, I; Yamamoto, K | 1 |
| Asano, Y; Hirota, Y; Morioka, E; Niho, Y; Okamura, S; Shibuya, T | 1 |
| Champlin, RE; Gajewski, JL; Gekelman, L; Hirji, KF; Ho, WG; Jacobs, AD; Nimer, SD | 1 |
| Ito, T; Komatu, M; Saito, Y; Takahashi, H; Uzuka, Y | 1 |
| Castaman, G; Rodeghiero, F; Ruggeri, M | 1 |
| Caro, J; Erslev, AJ; Piroso, E | 1 |
| Gray, RG; Hayhoe, FG; Rees, JK; Swirsky, D | 1 |
| Andreeff, M; Arlin, ZA; Berman, E; Gaynor, J; Gee, T; Kempin, SJ; Mertelsmann, R; Miller, W; Nahmias, N; Reich, L | 1 |
| de Arriba, G; Hernando, L; Oliva, H; Ordi, J; Thomson, M | 1 |
| Burns, CP; Lazarus, HM; Vogler, WR; Winton, EF | 1 |
| Liliemark, J; Paul, C; Peterson, C; Tidefelt, U | 1 |
| Mandelli, F; Petti, MC | 1 |
| Arlin, ZA; Case, DC; Periman, PO; Ritch, PS; Todd, MB; Weitberg, AB; Wiernik, PH | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, SJ; Kolitz, J; Raymond, V; Young, CW | 1 |
| Corbo, S; De Santis, F; Loperfido, F; Pennestrì, F; Vigna, C | 1 |
| Gustavsson, A; Kjellén, E; Olofsson, T; Pero, RW | 1 |
| Capizzi, RL; Cooper, MR; Lyerly, ES; Powell, BL | 1 |
| Oberg, G; Venge, P | 1 |
| Kamiyama, T; Katoh, A; Kobayashi, H; Koyama, T; Maruyama, Y; Miura, O; Murakami, N; Nakamura, Y; Suzuki, T; Tohda, S | 1 |
| Advani, SH; Gopal, R; Kurkure, PA; Nadkarni, KS; Nair, CN; Pai, SK; Pai, VR; Rajni, A; Saikia, TK | 1 |
| Estey, E; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, T; Walters, R | 1 |
| Comelli, A; Cordero di Montezemolo, L; Fiandino, G; Madon, E; Miniero, R; Saracco, P | 1 |
| Faucon, G; Fiere, D; Lakhal, M; Lang, J; Timour Chah, Q; Trillet, V | 1 |
| Simonson, GM | 1 |
| Foon, KA; Gale, RP | 1 |
| Hagenbeek, A; Kokenberg, E; Löwenberg, B; Sizoo, W; Sonneveld, P | 1 |
| Delwel, R; Hagenbeek, A; Kokenberg, E; Löwenberg, B; Sizoo, W; Sonneveld, P | 1 |
| Gorin, NC; Isnard, F; Laporte, JP; Lemonnier, MP; Najman, A | 1 |
| Adachi, Y; Murohashi, I; Nagata, K; Nara, N; Suzuki, T; Yamashita, Y | 1 |
| Juttner, CA; Kimber, RJ; Roberts, MM; To, LB | 1 |
| Aiba, K; Ichiba, K; Isogai, Y; Kobayashi, T; Kuraishi, Y; Nagata, T; Nakamura, T; Ogawa, M; Usui, N; Yamazaki, H | 1 |
| Furukawa, Y; Inoue, T; Kishida, T; Kojima, K; Sagawa, H; Sannomiya, Y; Sasaki, A; Yamane, T; Yokomatsu, Y; Yoshikawa, T | 1 |
| Marie, JP; Thevenin, D; Zittoun, R | 2 |
| Ishikawa, E; Kawakami, M; Kuraishi, Y; Meguro, S; Tanaka, H | 1 |
| Masuda, M; Mizoguchi, H; Mori, S; Motoji, T; Osada, K; Oshimi, K; Shimizu, M; Takanashi, M | 1 |
| Kamiyama, T; Kato, A; Koyama, T; Maruyama, Y; Miura, O; Murakami, N; Nagata, K; Nakamura, Y; Suzuki, T; Tohda, S | 1 |
| Gomis, F; Lorenzo, JI; Martín Aragonés, G; Martínez, JA; Rafecas, FJ; Sanz, GF; Sanz, MA | 1 |
| Nara, N | 1 |
| Jehn, U; Knüppel, W; Wilmanns, W | 1 |
| Ehninger, G; Freund, M; Heil, G; Hoelzer, D; Kurrle, E; Link, H; Mitrou, PS; Ohl, S; Queisser, W; Schlimok, G | 2 |
| Bolwell, BJ; Cassileth, PA; Gale, RP | 1 |
| Cuttner, J; Davis, R; Holland, JF; Mayer, R; McIntyre, OR; Preisler, H; Rai, KR; Yates, J | 1 |
| Anders, C; Niederle, N; Nowrousian, MR; Osieka, R; Pfeiffer, R; Schaefer, UW; Schmidt, CG | 1 |
| Alberto, P; Berchtold, W; Fopp, M; Gmür, J; Gratwohl, A; Imbach, P; Maurice, P; Obrecht, P; Sauter, C; Senn, HJ | 1 |
| Fink, FM; Gadner, H; Grümayer, ER; Kardos, G; Revesz, T; Schuler, D | 2 |
| Boiron, M; Bordessoule, D; Desablens, B; Guilhot, F; Guy, H; Harousseau, JL; Lepage, E; Leverger, G; Marty, M; Schaison, G | 1 |
| Büchner, T; Gassmann, W; Hiddemann, W; Kreutzmann, H; Kuse, R; Löffler, H; Maschmeyer, G; Mohr, A; Urbanitz, D; Wendt, F | 1 |
| Büchner, T; Heinecke, A; Koch, P; Ludwig, WD; Maschmeier, G; Pielken, H; Urbanitz, D; van de Loo, J | 1 |
| Budde, M; Creutzig, U; Riehm, H; Ritter, J; Schellong, G | 1 |
| Dahl, GV; Kalwinsky, DK; Look, AT; Mirro, J | 1 |
| Aggarwal, S; Dua, H; Francis, S; Kochupillai, V; Kumar, L; Nanu, A; Sharma, S; Singh, S; Verma, IC | 1 |
| Gomis, F; Jarque, I; Lorenzo, I; Martín, G; Martínez, J; Pastor, E; Rafecas, J; Sanz, G; Sanz, MA; Sayas, MJ | 1 |
| Baquerizo, H; Byrnes, JJ; Gonzalez, M; Hensely, GT | 1 |
| Archimbaud, E; Bryon, PA; Campos, L; Coiffier, B; Extra, JM; Fière, D; Guyotat, D; Milan, JJ; Van, HV; Viala, JJ | 1 |
| Kadomatsu, K; Miyamoto, S; Nakano, H; Niho, Y; Noma, M; Sato, S; Shimokawa, H; Tono, A; Uchino, H; Yamamoto, Y | 1 |
| Iida, H; Tsuruo, T | 1 |
| Ahmed, NK; Vasanthakumar, G | 2 |
| Kokenberg, E; Löwenberg, B; Nooter, K; Sonneveld, P; van der Steuyt, K | 1 |
| Cork, A; Dalton, WT; Estey, EH; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, TL; Trujillo, JM; Walters, RS | 1 |
| Benny, WB; Moir, CR; Scudamore, CH | 1 |
| Dahl, GV; Dow, LW; Kalwinsky, DK; Mirro, J; Nash, MB; Roberson, PK | 1 |
| Bourguignat, A; Eydoux, P; Floiras, JL; Le Doussal, V; Trassard, M; Turpin, F | 1 |
| Amaki, I; Hayakawa, Y; Horikoshi, A; Kawamura, M; Murakami, J; Ohshima, T; Sakurai, T; Takeo, H; Takeuchi, J | 1 |
| Hayashi, M; Hozumi, M; Okabe-Kado, J | 1 |
| Bodey, GP; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Walters, RS | 1 |
| Compagnoni, G; Falda, M; Genazzani, E; Infelise, V; Lovisone, E; Silvestro, L; Viano, I | 1 |
| Carter, JM; Dewar, JM; Pease, C | 1 |
| Bloch, A; Honma, C; Honma, Y | 1 |
| Kato, Y; Minami, S; Morishima, Y; Murase, T; Nagura, E; Ogura, M; Ohno, R; Okumura, M; Suzuki, H; Yamada, H | 1 |
| Gomis, F; Jarque, I; Lorenzo, JI; Martín-Aragonés, G; Martínez, J; Marty, ML; Rafecas, FJ; Sanz, GF; Sanz, MA; Sayas, MJ | 1 |
| Honma, Y; Hozumi, M; Kasukabe, T; Nishii, Y; Suda, T | 1 |
| Löwenberg, B; Schölzel, C; van Putten, W | 1 |
| Arlin, Z; Büchner, T; Donhuijsen-Ant, R; Hiddemann, W; Kreutzmann, H; Lengfelder, E; Ludwig, WD; Mertelsmann, R; Straif, K | 1 |
| Baker, MA; Case, N; Gleyzer, E; Hindenburg, AA; Stewart, VJ; Taub, RN | 1 |
| Baba, N; Harasawa, N; Ito, H; Kurayashiki, R; Miyawaki, S; Nemoto, K; Tobe, I; Uchida, S; Wakamatsu, R; Yashiro, K | 1 |
| Cararach, V; Carreras, E; Fortuny, A; Grañena, A; Rozman, C; Sierra, J; Urbano Ispizua, A | 1 |
| Aoki, N; Imai, Y; Murohashi, I; Nara, N; Tanikawa, S; Yamashita, Y | 1 |
| Bénichou, J; Chastang, C; Lepage, E | 1 |
| Delanian, S; Marie, JP; Suberville, AM; Thevenin, D; Zittoun, R | 1 |
| Gray, R; Rees, JK | 1 |
| Estey, E; Freireich, EJ; Keating, MJ; McCredie, KB; Plunkett, W | 1 |
| Arlin, Z; Büchner, T; Donhuijsen-Ant, R; Hiddemann, W; Kreutzmann, H; Lengfelder, E; Ludwig, WD; Mertelsmann, R; Planker, M; Straif, K | 1 |
| Boogaerts, MA; Emonds, MP; Tricot, G; Verwilghen, RL; Vlietinck, R | 1 |
| Estey, EH; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Walters, RS | 1 |
| Camitta, BM; Delorey, MJ; Gelber, RD; Grier, HE; Leavitt, PR; Link, MP; Price, KN; Weinstein, HJ | 1 |
| Kokenberg, E; Löwenberg, B; Nooter, K; Sonneveld, P; van der Steuijt, K | 1 |
| Bauch, HJ; Pielken, HJ; Preusser, P | 1 |
| Heidrich, T; Host, G; Kramer, B; Lennartz, K; Scheulen, ME | 1 |
| Aul, C; Heyll, A | 1 |
| Fülle, HH; Hellriegel, KP | 2 |
| Kubaschinski, G; Nowrousian, MR; Pfeiffer, R; Schaefer, UW; Schmidt, CG | 1 |
| Brilhante, D; Delmer, A; Marie, JP; Zittoun, R | 1 |
| Camitta, B; Delorey, M; Gelber, R; Grier, H; Link, M; Price, K; Weinstein, H | 1 |
| Amadori, S; Ceci, A; Comelli, A; Covelli, A; Madon, E; Mandelli, F; Masera, G; Nespoli, L; Paolucci, G; Zanesco, L | 1 |
| Catovsky, D; Dharmasena, F; Drysdale, HC; Englert, H; Galton, DA | 1 |
| Carcassonne, Y; Dufour, P; Harousseau, JL; Hayat, M; Hurteloup, P; Jaubert, J; Le Prise, PY; Monconduit, M; Reiffers, J; Rigal-Huguet, F | 1 |
| Kokenberg, E; Nooter, K; Sonneveld, P; van der Steuijt, K | 1 |
| Jones, RJ; Karp, JE; Roubenoff, R; Stevens, MB | 1 |
| Harousseau, JL; Huet, S; Hurteloup, P; Pris, J; Reiffers, J; Rigal-Huguet, F; Robert, J; Tamassia, V | 1 |
| Islam, A | 1 |
| Balaian, LN; Kravtsova, VM; Patterson, D; Petrova, EM; Zabelina, TS | 1 |
| Colly, LP; Peters, WG; Willemze, R | 1 |
| De Cataldo, F; Haanen, C; Hayat, M; Jehn, U; Lowenberg, B; Monconduit, M; Peetermans, M; Stryckmans, P; Willemze, R; Zittoun, R | 1 |
| Frauer, HM; Heil, G; Heimpel, H; Hoelzer, D; Kurrle, E; Link, H; Ostendorf, P; Waller, HD; Wilms, K | 1 |
| Ehninger, G; Freund, M; Heil, G; Hoelzer, D; Kurrle, E; Link, H; Mitrou, PS | 1 |
| Cassileth, PA; Gale, RP | 1 |
| Boiron, M; Gisselbrecht, C; Lenoble, M; Lepage, E; Marty, M | 1 |
| Bauters, F; Boiron, M; Bordessoule, D; Gemont-Auclerc, MF; Gisselbrecht, C; Guy, H; Lepage, E; Marty, M; Schaison, G | 1 |
| Adeleine, P; Archimbaud, E; Fiere, D; Guyotat, D; Sebban, C; Treille-Ritouet, D; Viala, JJ; Vuvan, H | 1 |
| Bierling, P; Brun, B; Cordonnier, C; Duedari, N; Farcet, JP; Heilmann, MG; Imbert, M; Kuentz, M; Rodet, M; Vernant, JP | 1 |
| Fibbe, WE; Kootte, AM; Lie, R; Peters, WG; Rodenburg, CJ; van Berkel, M; van Hennik, MB; Veltkamp, JJ; Willemze, R | 1 |
| Bron, D; Debusscher, L; Malarme, M; Rozencweig, M; Stryckmans, P | 1 |
| Giordano, P; Mazzini, G; Montecucco, C; Riccardi, A; Traversi, E | 1 |
| Grützmeier, S | 1 |
| Brommer, EJ; Haak, HL; Nieuwenhuizen, W; Sterrenberg, L | 1 |
| Burke, PJ; Karp, JE | 1 |
| Imamura, N; Kuramoto, A; Miura, K | 1 |
| Jensen, JH; Nielsen, HK; Orntoft, T; Petersen, EL | 1 |
| Bukowski, R; Fishleder, A; Ganapathi, R; Grabowski, D; Gulick, P; Miller, R; Turinic, R; Valeunzuela, R | 1 |
| Bayle, C; Berger, R; Carde, P; Finaud, M; Hayat, M; Hurteloup, P; Morardet, N; Parmentier, C; Schlumberger, M | 1 |
| Champlin, RE; Elashoff, R; Feig, SA; Gale, RP; Ho, WG; Lenarsky, C; Mitsuyasu, R; Selch, M; Winston, D; Zighelboim, J | 1 |
| Jehn, U; Löwenberg, B | 1 |
| Champlin, R; Feig, SA; Gale, RP; Ho, W; Jacobs, A; Lenarsky, C; Selch, M | 1 |
| Bodenstein, H; Eisert, R; Freund, M; Poliwoda, H | 1 |
| Büchner, T; Heinecke, A; Hiddemann, W; Koch, P; Maschmeier, G; Pielken, HJ; Urbanitz, D; van de Loo, J; Wendt, F | 1 |
| Jehn, U; Löwenberg, B; Zittoun, R | 1 |
| Aul, HC; Büchner, T; Fischer, J; Hiddemann, W; Kuse, R; Ludwig, WD; Rühl, H; Urbanitz, D; Vaupel, HA; Zeile, G | 1 |
| Ahmed, NK | 1 |
| Höcker, P | 1 |
| Francis, S; Gokhale, U; Kochupillai, V; Kumar, S; Mehra, NK; Nanu, A; Sharma, S; Takkar, D; Verma, IC | 1 |
| Faucon, G; Lakhal, M; Lang, J; Timour Chah, Q; Trillet, V | 1 |
| Canellos, GP; Whang-Peng, J | 1 |
| Barkhan, P; Black, PJ; Rose, MS | 1 |
| Beard, ME; Fairley, GH | 1 |
| Chan, YK; Vogler, WR | 1 |
| McElwain, TJ; Smith, IE | 1 |
| Haas, H; Kurz, R | 1 |
| Danieli, G | 1 |
| Atkinson, K; Clink, HM; Kay, HE; McElwain, TJ; Powles, R; Wells, DG | 1 |
| Willoughby, ML | 1 |
| Malpas, JS; Scott, RB | 1 |
| Bachur, N; Benjamin, R; Greene, W; Huffman, D; Schimpff, S; Wiernik, PH | 1 |
| Buja, LM; Ferrans, VJ; Henderson, ES; Mayer, RJ; Roberts, WC | 1 |
| Alexander, P; Bateman, CJ; Beard, ME; Crowther, D; Fairley, GH; Lister, TA; McElwain, TJ; Pike, M; Powles, RL; Russell, J; Whitehouse, JM; Wrigley, PF | 1 |
| Zubrod, CG | 3 |
| Fortuna, E; Fossati-Guglielmoni, A; Massimo, L | 1 |
| Lampkin, B; Mauer, AM; McWilliams, NB | 1 |
| Anderson, JC; Henderson, WG; Palmer, CA; Rogers, RT | 1 |
| Bourdarias, H; Caruel, N; Najman, A; Singer, B | 1 |
| Bateman, CJ; Beard, ME; Crowther, D; Malpas, JS; Whitehouse, JM | 1 |
| Grignani, F; Martelli, MF; Soldani, M; Tonato, M | 1 |
| Giralt, M; Raichs, A; Torres, A | 2 |
| Cheung, WH; Rai, KR; Sawitsky, A | 1 |
| Moloney, WC; Rosenthal, DS | 1 |
| Frei, E | 1 |
| Massimo, L | 1 |
| Bachur, NR; Huffman, DH | 1 |
| Amar, M; Boivin, P; Hakim, J; Kahn, A | 1 |
| Moloney, WC; Rosenthal, DS; Wiernik, PH | 1 |
| Praga, C | 1 |
| Amiel, JL; Beyer, HP; de Vassal, F; Fajbisowicz, S; Hayat, M; Jasmin, C; Mathé, G; Pouillart, P; Schneider, M; Schwarzenberg, L; Weiner, R | 1 |
| Brunel-Kotschi, R; Bussel, A; Delobel, J; Gemon, MF; Jacquillat, C; Loisel, JP; Schaison, G; Weil, M | 1 |
| Böhnel, J; Höcker, P; Stacher, A | 1 |
| Bauters, F; Goudemand, M; Lerche, B; Samsoen, J | 1 |
| Wilmanns, W; Wilms, K | 2 |
| Fennelly, JJ; Gorman, A; O'Connell, LG | 1 |
| Bernard, J; Boiron, M; Delobel, J; Gémon, MF; Izrael, V; Jacquillat, C; Schaison, G; Weil, M | 1 |
| Bastrup-Madsen, P; Jensen, KB; Petersen, HS; Thorling, K | 1 |
| Brunning, RD; Kennedy, BJ; Weiss, RB | 1 |
| Lachapelle, F; Manaster, J; Socquet, M; Stryckmans, PA | 1 |
| Akabane, T; Eguchi, M; Komiyama, A; Tsukada, M | 1 |
| Salvati, A | 1 |
| Bergna, L; Eppinger-Helft, M; Muriel, FS; Pavlovsky, A; Pavlovsky, AA; Pavlovsky, S; Peñalver, J; Suárez, A; Vilaseca, G | 1 |
| Bernard, J; Boiron, M; Gemon, MF; Izrael, V; Jacquillat, C; Schaison, G; Weil, M | 1 |
| Bernard, J; Boiron, M; Flandrin, G; Gemon, MF; Jacquillat, C; Weil, M | 1 |
| Granatir, RG; Moquin, RB; Perlin, E; Roche, J | 1 |
| Basch, A; Dreyfus, B; Gluckman, E; Varet, B | 1 |
| Duttera, MJ; Geelhoed, GW; Graff, KS; Henderson, ES | 1 |
| Bloomfield, CD; Brunning, RD; Kennedy, BJ; Theologides, A | 1 |
| Bateman, CJ; Beard, ME; Crowther, D; Fairley, GH; Gauci, CL; Malpas, JS; Powles, RL; Scott, RB; Wrigley, PF | 1 |
| Flieder, J; Gehanno, P; Lallemant, Y | 1 |
| Khan, MH | 2 |
| Infelise, V; Paolino, W; Resegotti, L; Rossi, M | 1 |
| Gemon, MF; Jacquillat, C; Weil, M | 1 |
| Nagao, T; Tashiro, Y; Toyosaka, H; Tsukimoto, I | 1 |
| Abbrederis, K; Braunsteiner, H; Huber, H; Michlmayr, G; Schmalzl, F | 1 |
| Bull, JM; Carbone, PP; Duttera, MJ; Henderson, E; Northup, J; Stashick, ED | 1 |
| Bloomfield, CD; Theologides, A | 1 |
| Ernst, P | 2 |
| Delamore, IW; Freeman, CB; Geary, CG; Harris, R; Leyland, MJ; MaCiver, JE | 1 |
| Eppinger-Helft, M; Pavlovsky, S; Sackmann Muriel, F | 1 |
| Jungi, WF | 1 |
| Greene, WH; Schimpff, SC; Wiernik, PH | 1 |
| Frei, E; Goldin, A; Schabel, FM | 1 |
| Hamblin, TJ; Jones, JV | 1 |
| Alberto, P; Brunner, KW; Martz, G; Nagel, G; Obrecht, JP; Senn, HJ | 1 |
| Delamore, IW; Mir, MA | 2 |
| Bleihöfer, B; Englebert, B; Gerhartz, H; Paulisch, R; Schneider, J | 1 |
| Burchenal, JH; Cole, MT; Dowling, MD | 1 |
| Bodey, GP; Coltman, CA; Freireich, EJ; Hewlett, JS; Rodriguez, V | 1 |
| Gahrton, G; Jonasson, J; Lindsten, J; Simonsson-Lindemalm, C; Zech, L | 1 |
| Litwin, J; Stacher, A | 1 |
| Friend, JH; Giles, C; Richardson, SG | 1 |
| Brun, B; Dreyfus, B; Gluckman, E; Reyes, F; Rochant, H | 1 |
| Brincker, H; Hansen, PB | 1 |
| Abbrederis, K; Michlmayr, G; Schmalzl, F | 1 |
| Buckley, J; Metcalf, D; Moore, MA; Spitzer, G; Williams, N | 1 |
| Sakurai, M; Sandberg, AA | 1 |
| Amar, M; Bernard, JF; Boivin, P; Garbaz, M; Hakim, J; Kahn, A | 1 |
| Abe, T; Furusawa, S; Kashiwagi, H; Nakajima, T; Normura, T | 1 |
| Keating, MJ; Penington, DG | 1 |
| Aye, MT; McCulloch, EA; Niho, Y; Till, JE | 1 |
| Bergna, L; Eppinger-Helft, M; Hidalgo, G; Macchi, A; Pavlovsky, A; Pavlovsky, S; Sackmann Muriel, F; Suarez, A; Vilaseca, G | 1 |
| Cline, MJ; Haskell, CM | 1 |
| Baroncelli, PG; Cordero di Montezemolo, L; Madon, E; Roberi, PL; Sacerdote, A | 1 |
| Burchenal, JH; Clarkson, BD; Cunningham, B; Dowling, MD; Gee, TS; Haghbin, M; Tan, CT | 1 |
| Bernard, J; Boiron, M; Gemon, MF; Izrael, V; Jacquillat, C; Weil, M | 1 |
| Amiel, JL; Cattan, A; De Vassal, F; Hayat, M; Jasmin, C; Mathé, G; Pouillart, P; Rosenfeld, C; Schneider, M; Schwarzenberg, L; Weiner, R | 1 |
| Sakai, Y; Sakano, T | 1 |
| Powles, R | 3 |
| Bricteux, N | 1 |
| Ono, R | 1 |
| Bernard, J; Jacquillat, C; Weil, M | 2 |
| Donner, L; Klener, P; Kozená, J | 1 |
| Delalieux, G; Manaster, J; Stryckmans, P | 1 |
| Brilliant, MD | 1 |
| Faĭnshteĭn, FE | 1 |
| Gralnick, HR; Tan, HK | 1 |
| Schrier, SL; Silvergleid, AJ | 1 |
| Bauters, F; Caulier, MT; Goudemand, M; Mouton, J; Plouvier, B | 1 |
| Buckner, CD; Clift, RA; Fefer, A; Lerner, KG; Neiman, PE; Storb, R; Thomas, ED | 1 |
| Baccarani, M; Lauria, F; Ricci, P; Santucci, MA; Tura, S | 1 |
| Holland, JF | 3 |
| Armata, J; Garwicz, S; Halikowski, B; Wyszkowski, J | 1 |
| Bateman, CJ; Crowther, D; Fairley, GH; Malpas, JS; Scott, RB; Vartan, CP; Whitehouse, JM | 1 |
| Esposito, L | 1 |
| Fairley, GH | 2 |
| Hawk, IA; Levy, CC; Russell, DH; Schimpff, SC | 1 |
| Henderson, ES; Serpick, AA | 1 |
| La Grutta, A; Lo Curto, M | 1 |
| Esposito, S; Taylor, LA | 1 |
| Gerhartz, H | 1 |
| Baudo, F; Bussi, L; Camera, G; Cipriani, D; de Cataldo, F; Pensabene, A; Tiso, R | 1 |
| Maurice, PA | 1 |
| Dano, K; Nissen, NI | 1 |
| Dano, K; Nissen, NI; Pedersen-Bjergaard, J; Thiede, T | 1 |
| Donaldson, MH; Holton, CP; Lane, DM; Nora, AH; Stuckey, WJ; Vietti, TJ; Watkins, WL | 1 |
| Lee, SL; Rosner, F | 1 |
| Crosby, WH | 1 |
| Bornstein, RS; Kennedy, BJ; Theologides, A | 1 |
| Wróblewska, B; Zinkiewicz, Z | 1 |
| Mathé, G | 1 |
| Begemann, H; Kreiter, H; Rastetter, J | 1 |
| Baccarani, M; Storti, EF; Tura, S | 1 |
| Armata, J; Cyklis, R; Garwicz, S; Halikowski, B; Wyszkowski, J | 1 |
| Bauters, F; Goudemand, M; Lerche-Habart, B; Sautière-Habay, D | 1 |
| Cipriani, D | 1 |
| Burgess, MA; de Gruchy, GC; Garson, OM | 1 |
| Prankerd, TA; Souhami, RL | 1 |
| Amiel, JL; de Vassal, F; Hayat, M; Jasmin, C; Mathé, G; Rosenfeld, C; Schneider, M; Schwarzenberg, L | 1 |
| Delalieux, G; Manaster, J; Socquet, M; Stryckmans, P | 1 |
| Lane, DM; Lonsdale, D; Starling, K; Vietti, TJ; Wilbur, JR | 1 |
| Bryon, PA; Dechavanne, M; Fiere, D; Guyon, JM; Kahi, S; Revol, L | 1 |
| Armata, J; Cyklis, R; Wyszkowski, J | 1 |
| Crowther, D | 1 |
| Foadi, M; Shaw, MT | 1 |
| Fujinaga, S; Hattori, K; Kitanaka, I; Kitao, T | 1 |
| Frenkel', MA; Khvatova, NV; Lorie, IuI; Solov'eva, EA | 1 |
| Hocking, DR | 1 |
| Hirano, M; Koie, K; Morita, A; Sako, F; Uetani, T | 1 |
| Honetz, N; Neumann, E | 1 |
| Wilmanns, W | 1 |
| Begemann, H; Gerhartz, H | 1 |
| Bernard, J; Boiron, M; Bussel, A; Dreyfus, B; Jacquillat, C; Larrieu, MJ; Loisel, JP; Rouesse, T; Weil, M | 1 |
| de Vaan, GA; Marcar, JR; Schretlen, ED | 1 |
| Blom, J; Burningham, R; Cuttner, J; Falkson, G; Glidewell, O; Holland, JF; Levy, RN; Moon, JH; Onuma, T; Rosner, F; Silver, RT | 1 |
127 review(s) available for daunorubicin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Is there an optimal adjunct therapy to traditional cytotoxic induction?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction | 2021 |
Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
Real-world experience with CPX-351 in high-risk acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes | 2023 |
CPX-351 (vyxeos) in AML.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2020 |
Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
Topics: Allografts; Cytarabine; Daunorubicin; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precision Medicine; Remission Induction | 2019 |
Single-agent and combination biologics in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Neoplasm Proteins; Sulfonamides; Survival Rate | 2019 |
How to address second and therapy-related acute myelogenous leukaemia.
Topics: Age Factors; Allografts; Antibodies, Bispecific; Antineoplastic Agents, Immunological; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Remission Induction; Stem Cell Transplantation | 2020 |
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Topics: Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Drug Approval; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Staurosporine; Sulfonamides; United States; United States Food and Drug Administration | 2020 |
AML: New Drugs but New Challenges.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrazines | 2020 |
EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Ireland; Leukemia, Myeloid, Acute; Liposomes | 2020 |
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Safety; Survival Analysis; Topoisomerase II Inhibitors; Treatment Outcome; United States; Young Adult | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis | 2020 |
Acute myeloid leukemia: 2021 update on risk-stratification and management.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Risk Assessment; Staurosporine; Sulfonamides; United States | 2020 |
Effect of Dose Ratio on Mitoxantrone and Daunorubicin in Acute Myeloid Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Randomized Controlled Trials as Topic | 2021 |
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).
Topics: Aged; Aminopyridines; Antineoplastic Agents; Blood Cells; Bone Marrow; Bone Marrow Examination; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Daunorubicin; DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; PubMed; Triazines | 2020 |
CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Topics: Age Factors; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Middle Aged; Mutation; Myelodysplastic Syndromes | 2020 |
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Topics: Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Calicheamicins; Chlorides; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Approval; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Middle Aged; Multicenter Studies as Topic; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Tretinoin | 2020 |
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Topics: Animals; Antineoplastic Agents; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Prognosis; Sulfonamides | 2021 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
New Treatment Options for Older Patients with Acute Myeloid Leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mutation; Patient Selection; Stem Cell Transplantation; Sulfonamides | 2021 |
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Risk Assessment; Staurosporine | 2021 |
Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature.
Topics: Abortion, Therapeutic; Adult; Cesarean Section; Child; Cytarabine; Daunorubicin; Female; Fetal Death; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic | 2017 |
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Treatment Outcome | 2017 |
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins c-bcl-2; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Treatment Outcome; Triazines | 2017 |
How can one optimize induction therapy in AML?
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Gemtuzumab; History, 20th Century; History, 21st Century; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute | 2017 |
The role of targeted therapy in the management of patients with AML.
Topics: Cytarabine; Daunorubicin; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute | 2017 |
Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2018 |
CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Carriers; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Liposomes; Prognosis; Survival Rate; Treatment Outcome | 2018 |
Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Combinations; Drug Interactions; Humans; Leukemia, Myeloid, Acute; Liposomes; Myelodysplastic Syndromes | 2018 |
Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Bone Marrow; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease Management; Female; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prognosis; Risk Assessment; RUNX1 Translocation Partner 1 Protein; Sequence Analysis, DNA | 2018 |
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Female; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyridines; Staurosporine; Triazines | 2018 |
Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Odds Ratio; Remission Induction; Treatment Outcome; Young Adult | 2018 |
A comparative evaluation of gemtuzumab ozogamicin + daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Publication Bias; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2019 |
Is the overall survival for older adults with AML finally improving?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Survival Rate | 2018 |
Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chest Tubes; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Liposomes; Vascular Access Devices | 2018 |
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Approval; Europe; Humans; Leukemia, Myeloid, Acute; Liposomes; Remission Induction; United States | 2018 |
Myelodysplastic syndromes and acute myeloid leukemias in the elderly.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Gemtuzumab; Geriatric Assessment; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Staurosporine | 2018 |
The leukemia strikes back: a review of pathogenesis and treatment of secondary AML.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mutation; Tumor Suppressor Protein p53 | 2019 |
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Mutation; Prognosis; Randomized Controlled Trials as Topic | 2019 |
New drugs creating new challenges in acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration | 2019 |
Choosing induction chemotherapy in therapy-related acute myeloid leukemia.
Topics: Cytarabine; Daunorubicin; Enzyme Inhibitors; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mutation; Neoplasms, Second Primary | 2019 |
Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2019 |
Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles.
Topics: Animals; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Carriers; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid, Acute; Liposomes; Nanoparticles | 2019 |
Topoisomerase II inhibitors in AML: past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Salvage Therapy; Topoisomerase II Inhibitors | 2019 |
Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
Topics: Aged; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Survival Rate | 2019 |
Venetoclax-based therapies for acute myeloid leukemia.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sulfonamides; Triazines | 2019 |
Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Publication Bias; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Development of a curative treatment within the AML-BFM studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Methotrexate; Multicenter Studies as Topic; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Thioguanine; Vincristine | 2013 |
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cytarabine; Daunorubicin; Humans; Immunoconjugates; Immunologic Factors; Leukemia, Myeloid, Acute; Prognosis; Purine Nucleosides; Risk Factors; Stem Cell Transplantation; Transplantation, Autologous | 2013 |
Important milestones in acute leukemia in 2013.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Hematopoietic Stem Cell Transplantation; History, 20th Century; History, 21st Century; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Proteins; Remission Induction; Survival Analysis | 2013 |
[Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Discovery; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Molecular Targeted Therapy; Mutation; Recurrence; Tretinoin; Vincristine | 2014 |
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemtuzumab; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Odds Ratio; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Survival Rate; Treatment Outcome | 2014 |
Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Remission Induction | 2015 |
A role for epigenetics in the formation of chromosome translocations in acute leukemia.
Topics: Chromatin Assembly and Disassembly; Daunorubicin; DNA Breaks, Double-Stranded; Epigenesis, Genetic; Etoposide; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Myeloid-Lymphoid Leukemia Protein; Translocation, Genetic | 2015 |
High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials.
Topics: Antibiotics, Antineoplastic; Daunorubicin; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Prospective Studies | 2015 |
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; Doxorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mitoxantrone; Randomized Controlled Trials as Topic | 2015 |
Chemotherapy options for previously untreated acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colony-Stimulating Factors; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Remission Induction | 2015 |
High-dose versus standard-dose daunorubicin in induction therapy for young patients with de novo acute myeloid leukaemia: a meta-analysis of randomised trials.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2016 |
[Drug treatment of acute myelogenous leukaemia. Current options and future perspectives].
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Induction Chemotherapy; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Middle Aged; Molecular Targeted Therapy; Quality of Life; Survival Analysis; Treatment Outcome | 2016 |
Dermatomyositis associated with acute myelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marrow Examination; Cytarabine; Daunorubicin; Dermatomyositis; Electromyography; Fatal Outcome; Female; Glucocorticoids; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Paraneoplastic Syndromes; Prednisolone; Quadriceps Muscle; Treatment Failure | 2010 |
Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Synergism; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Monosomy; Neoplasms, Second Primary; Translocation, Genetic; Tretinoin | 2009 |
[Standard therapies for acute myeloid leukemia].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Cytarabine; Daunorubicin; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Remission Induction | 2009 |
[Acute myeloid leukemia trials by Japan Adult Leukemia Study Group (JALSG)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Evidence-Based Medicine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Young Adult | 2009 |
Therapy of acute myelogenous leukemia in adults.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Clinical Trials as Topic; Combined Modality Therapy; Core Binding Factors; Cytarabine; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Remission Induction; Risk; Salvage Therapy; Treatment Outcome | 2010 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Granulocytic sarcoma of palate. Case report and review of literature.
Topics: Adolescent; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; Hand; Humans; Leukemia, Myeloid, Acute; Palatal Neoplasms; Sarcoma, Myeloid | 2011 |
Acute myeloid leukaemia: optimal management and recent developments.
Topics: Adenine Nucleotides; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Daunorubicin; Flavonoids; Humans; Leukemia, Myeloid, Acute; Piperidines | 2011 |
New induction and postinduction strategies in acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mitoxantrone; Prognosis | 2012 |
[A systematic review of MA versus IA regimen for patients with acute myelogenous leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Young Adult | 2011 |
How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
Topics: Alleles; Animals; Carrier Proteins; Daunorubicin; Dioxygenases; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Mutational Analysis; DNA-Binding Proteins; Genetic Markers; Genome-Wide Association Study; Genomics; Hematology; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Medical Oncology; Mice; Models, Genetic; Mutation; Proto-Oncogene Proteins; Repressor Proteins | 2012 |
Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis.
Topics: Adult; Antibiotics, Antineoplastic; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate | 2013 |
Tetrasomy 13 as the sole cytogenetic abnormality in acute myeloid leukemia M1 without maturation.
Topics: Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 13; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine; Vidarabine | 2002 |
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Clinical Trials as Topic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; France; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2003 |
[Hematologic tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Hematologic Neoplasms; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Mechlorethamine; Prednisone; Procarbazine; Vinblastine; Vincristine | 2003 |
Fatal hemorrhagic pneumonia caused by infection due to Kytococcus sedentarius--a pathogen or passenger?
Topics: Actinomycetales; Actinomycetales Infections; Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Translocation; Cefepime; Cephalosporins; Clostridium Infections; Colistin; Cytarabine; Daunorubicin; Drug Therapy, Combination; Etoposide; Fatal Outcome; Hemoptysis; Humans; Hydroxyurea; Immunocompromised Host; Intestinal Mucosa; Leukemia, Myeloid, Acute; Male; Metronidazole; Middle Aged; Neutropenia; Pneumonia, Bacterial; Superinfection; Teicoplanin; Trimethoprim, Sulfamethoxazole Drug Combination | 2004 |
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents].
Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cyclosporine; Cytarabine; Daunorubicin; Drug Design; Farnesyltranstransferase; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Nucleosides; Oxides; Prognosis; Radioisotopes; Remission Induction; Tetrahydronaphthalenes; Topoisomerase Inhibitors; Tretinoin; Verapamil | 2003 |
Granulocytic sarcoma of the testis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Nucleolus; Chemotherapy, Adjuvant; Chromatin; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Orchiectomy; Radiotherapy, Adjuvant; Sarcoma, Myeloid; Testicular Neoplasms | 2004 |
The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 2005 |
Treatment of older patients with AML.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Protein Kinase Inhibitors; Remission Induction; Stem Cell Transplantation; Thioguanine; Transplantation, Homologous | 2005 |
[Acute promyelocytic leukemia. Review of the literature].
Topics: Acute Disease; Adolescent; Adult; Aged; Anemia; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Heparin; Humans; Inclusion Bodies; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Neoplastic Stem Cells; Thioguanine; Translocation, Genetic | 1984 |
Adult acute nonlymphocytic leukemias.
Topics: Acute Disease; Aged; Anemia; Anemia, Aplastic; Anemia, Sideroblastic; Blood Transfusion; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Drug Resistance; Female; Hemorrhage; Humans; Immunotherapy; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Transfusion; Spinal Cord; Syndrome | 1980 |
Chemotherapy in acute myelogenous leukemia: high dose, higher expectations?
Topics: Age Factors; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Remission Induction | 1995 |
Toxic megacolon complicating chemotherapy for acute myeloid leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Megacolon, Toxic | 1994 |
[Progress of chemotherapy in adult acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Remission Induction; Survival Rate | 1995 |
[A case of acute nonlymphocytic leukemia with leukemic cell infiltration to the uterus followed by bone marrow relapse].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Mercaptopurine; Prednisolone; Recurrence; Remission Induction; Uterus; Vincristine | 1994 |
Poor prognosis acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Cell Division; Cytarabine; Daunorubicin; Drug Resistance; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Neoplasms, Second Primary; Neoplastic Stem Cells; Preleukemia; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Treatment Failure | 1993 |
Acute myelogenous leukemia associated with a mediastinal tumor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Mediastinal Neoplasms; Mercaptopurine; Middle Aged; Prednisolone; Radiography, Thoracic; Remission Induction; Time Factors; Tomography, X-Ray Computed | 1993 |
A review of idarubicin in acute leukemia.
Topics: Adult; Aged; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Daunorubicin; Europe; Humans; Idarubicin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 1993 |
Two additional cases of acute myeloid leukemia with t(7;11)(p15;p15) having low neutrophil alkaline phosphatase scores.
Topics: Acute Disease; Adult; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Neutrophils; Prednisolone; Primary Myelofibrosis; Remission Induction; Translocation, Genetic | 1993 |
Chemotherapy for minimally differentiated acute myeloid leukemia (AML-M0). A report on five cases and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthalenes; Peroxidase; Prednisolone; Remission Induction | 1993 |
The management of acute myeloid leukaemia (AML) in human immunodeficiency virus (HIV) infection: a case report and review.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Drug Therapy, Combination; HIV Infections; Humans; Leukemia, Myeloid, Acute; Male; Thioguanine; Zidovudine | 1997 |
[Recent advances on the treatment of acute childhood leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Remission Induction; Survival Rate; Treatment Outcome; Vincristine | 1997 |
[Progress in the treatment of adult acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prednisolone; Tretinoin | 1997 |
Fatal disseminated infection by Scedosporium prolificans during induction therapy for acute leukemia: a case report and literature review.
Topics: Aged; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Microbial; Fatal Outcome; Female; Fungemia; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Mycetoma; Pseudallescheria | 1999 |
[Acute myelogenous leukemia in elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quality of Life; Remission Induction | 2000 |
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
Consequences of acute myelogenous leukemia in early pregnancy.
Topics: Abortion, Therapeutic; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant Mortality; Infant, Newborn; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Risk; Teratogens; Thioguanine; Vincristine | 1977 |
[Prognostic significance of cytochemical findings in differentiated myelogenous leukaemias of adults (author's transl)].
Topics: Acid Phosphatase; Adult; Aged; Alkaline Phosphatase; Bone Marrow Cells; Cerebral Hemorrhage; Daunorubicin; Female; Gastrointestinal Hemorrhage; Glucuronidase; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Monocytes; Muramidase; Naphthol AS D Esterase; Periodic Acid-Schiff Reaction; Peroxidases; Pregnancy; Prognosis; Remission, Spontaneous | 1977 |
Approaches to the treatment of acute leukemia and lymphoma in adults.
Topics: Acute Disease; Adult; Animals; BCG Vaccine; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Environment, Controlled; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Mice; Prednisone; Vincristine | 1978 |
Advances in the treatment of acute myelogenous leukemia.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Hemorrhage; Humans; Immunotherapy; Infections; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Meningeal Neoplasms; Preleukemia; Prognosis; Remission, Spontaneous; Transplantation, Homologous | 1979 |
Acute promyelocytic leukemia.
Topics: Blood Coagulation Disorders; Bone Marrow; Cell Line; Chromosome Banding; Daunorubicin; Fibrinogen; Fibrinolysis; Hemorrhage; Heparin; Humans; Leukemia, Myeloid, Acute; Prognosis; Prothrombin Time; Thromboembolism; Vitamin B 12 | 1979 |
The definitive treatment of children with acute leukemia.
Topics: Asparaginase; Central Nervous System Diseases; Child; Cyclophosphamide; Daunorubicin; Drug Therapy, Combination; Humans; Immunotherapy; Infections; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Neoplasms, Multiple Primary; Prednisone; Psychology; Remission, Spontaneous; Vincristine | 1976 |
Aggressive chemotherapy for acute leukemia relapsed after bone marrow transplantation: a second chance?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Time Factors; Vincristine | 1992 |
Treatment of adult acute leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prevalence; Prognosis; Remission Induction; United States | 1992 |
New drugs in acute myelogenous leukemia: a review.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Isomerism; Leukemia, Myeloid, Acute; Mitoxantrone; Remission Induction; Survival Rate; Tretinoin | 1992 |
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine | 1992 |
Cellular and pharmacologic aspects of drug resistance in acute myeloid leukemia.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Resistance; Gene Amplification; Humans; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Neoplastic Stem Cells; Retrospective Studies | 1991 |
Gelatinous transformation of marrow in a case of acute myelogenous leukemia post-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrophy; Biopsy; Bone Marrow; Cytarabine; Daunorubicin; Female; Humans; Hyaluronic Acid; Leukemia, Myeloid, Acute; Middle Aged | 1991 |
Cure of acute myelocytic leukemia in adults: a reality.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction | 1990 |
Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies.
Topics: Animals; Cells, Cultured; Daunorubicin; Humans; Idarubicin; Leukemia; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice | 1989 |
Mitoxantrone and amsacrine: two important agents for the treatment of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL).
Topics: Amsacrine; Daunorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction | 1989 |
[Progress in the treatment of acute myelogenous leukemia].
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Daunorubicin; Heart; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prednisolone; Prognosis; Remission Induction; Vincristine | 1989 |
[Acute pericarditis caused by daunorubicin in acute myelocytic leukemia].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Pericarditis | 1988 |
High dose cytarabine: a review.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Pancytopenia | 1988 |
Amsacrine: a review.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation; Drug Resistance; Humans; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma | 1986 |
Acute leukemia in adults.
Topics: Adult; Alkaline Phosphatase; BCG Vaccine; Blood Transfusion; Bone Marrow Examination; Central Nervous System Diseases; Cytarabine; Daunorubicin; Diagnosis, Differential; Drug Combinations; Drug Therapy, Combination; Esterases; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Meningitis; Microscopy, Electron; Neutrophils; Staining and Labeling; Subarachnoid Hemorrhage; Thioguanine | 1974 |
Treatment of acute leukemia.
Topics: Asparaginase; Bacterial Infections; Central Nervous System Diseases; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Hemorrhage; Humans; Immunotherapy; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Mitosis; Neoplasms, Nerve Tissue; Prednisone; Remission, Spontaneous; Testicular Neoplasms; Uric Acid; Vincristine | 1972 |
[Treatment of acute leukemia. Controlled clinical trials and experimental data with a view to a more rational administration of anti-leukemic drugs].
Topics: Clinical Trials as Topic; Cytarabine; Daunorubicin; DNA, Neoplasm; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Prednisolone; Vincristine | 1973 |
[Treatment of acute leukemias].
Topics: Acute Disease; Adult; Age Factors; Antineoplastic Agents; Asparaginase; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methods; Methotrexate; Prednisolone; Recurrence; Remission, Spontaneous; Vincristine | 1973 |
[Clinical aspects of the problem of treating leukemias].
Topics: Acute Disease; Antineoplastic Agents; Chlorambucil; Chlorine; Chronic Disease; Daunorubicin; Dimethoate; Drug Therapy, Combination; Ethylamines; Glucocorticoids; Humans; Immunoglobulins; Immunosuppression Therapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocytosis; Mercaptopurine; Methotrexate; Prednisolone; Remission, Spontaneous | 1973 |
Treatment of acute granulocytic leukemias.
Topics: Adult; Age Factors; Antineoplastic Agents; Blood Cell Count; Blood Platelets; Bone Marrow Examination; Child; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Heart; Hemorrhage; Humans; Hydrazones; Injections, Intravenous; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocyte Count | 1974 |
Present treatment of acute leukemias.
Topics: Asparaginase; Blood Transfusion; Cytarabine; Daunorubicin; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Meninges; Mercaptopurine; Methotrexate; Prednisone; Remission, Spontaneous | 1973 |
[On the use of daunomycin in acute leukemias in childhood].
Topics: Blood Cell Count; Blood Cells; Blood Transfusion; Child; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone | 1969 |
The treatment of acute myeloblastic leukaemia.
Topics: Child; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Meningitis; Mercaptopurine; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine | 1971 |
Combination chemotherapy in malignant diseases.
Topics: Adult; Antineoplastic Agents; Asparaginase; Carmustine; Child; Cyclophosphamide; Cytarabine; Cytosine; Daunorubicin; Drug Therapy, Combination; Hodgkin Disease; Humans; Immunotherapy; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Nitrogen Mustard Compounds; Prednisolone; Prednisone; Procarbazine; Remission, Spontaneous; Vincristine | 1971 |
337 trial(s) available for daunorubicin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cyclophosphamide; Cytarabine; Daunorubicin; Down-Regulation; Drug Eruptions; Hidradenitis; Homoharringtonine; Humans; Incidence; Leukemia, Myeloid, Acute; Mercaptopurine; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neutrophils; Protein Kinase Inhibitors; Sweat Glands | 2021 |
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate | 2021 |
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Clofarabine; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; United Kingdom; Vidarabine | 2022 |
Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Remission Induction | 2022 |
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 2023 |
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Humans; Karyotype; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; United Kingdom | 2023 |
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.
Topics: Aged; Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Staurosporine | 2023 |
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Nausea | 2023 |
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.
Topics: Adult; Aged; Aged, 80 and over; Critical Care; Daunorubicin; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Staurosporine; Survival Rate | 2019 |
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Patient Safety; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles | 2020 |
Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cardiotoxicity; Clofarabine; Cytarabine; Daunorubicin; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2020 |
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.
Topics: Adult; Aged; Cytarabine; Dasatinib; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2020 |
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins; Sulfonamides; Survival Rate | 2020 |
Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Prospective Studies; Recurrence; Survival Rate | 2020 |
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of
Topics: Adult; Cytarabine; Daunorubicin; Female; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Indazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Ecotropic Viral Integration Site 1 Protein; Pyrazines; Syk Kinase | 2020 |
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.
Topics: Aged; Allografts; Compassionate Use Trials; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Survival Rate | 2020 |
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Daunorubicin; Female; Genomics; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Precision Medicine; Survival Analysis; Treatment Outcome | 2020 |
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nucleophosmin; Prognosis; Survival Rate; Young Adult | 2021 |
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
Topics: Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes | 2021 |
Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Survival Rate | 2021 |
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Quality of Life; Survival Analysis | 2021 |
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Down Syndrome; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm, Residual; Treatment Outcome | 2017 |
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Filgrastim; Humans; Length of Stay; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Transfusion; Polyethylene Glycols; Survival Rate | 2017 |
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Clinical Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Recurrence; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2017 |
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Staurosporine; Young Adult | 2017 |
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Topics: Adolescent; Azacitidine; Child; Child, Preschool; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Epigenesis, Genetic; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Promoter Regions, Genetic; Treatment Outcome | 2017 |
Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Liposomes; Male | 2018 |
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.
Topics: Adult; Aged; Aged, 80 and over; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Physical Fitness; Survival Analysis; Treatment Outcome | 2018 |
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis | 2018 |
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary | 2018 |
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Flavonoids; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Risk Factors | 2018 |
Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Echocardiography; Humans; Incidence; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Mitoxantrone; Proportional Hazards Models; Risk Factors; Survival Rate; Treatment Outcome | 2019 |
Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Double-Blind Method; Female; fms-Like Tyrosine Kinase 3; Health Care Costs; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Theoretical; Quality-Adjusted Life Years; Staurosporine; Survival Rate; Treatment Outcome; United States | 2019 |
Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate | 2019 |
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Approval; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; United States; United States Food and Drug Administration | 2019 |
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Combinations; Female; Half-Life; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Treatment Outcome | 2019 |
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cell Line, Tumor; Cell Survival; Cytarabine; Daunorubicin; Decitabine; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pilot Projects; Protein Kinase Inhibitors; Pyrimidines | 2020 |
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate | 2013 |
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
Topics: Adult; Aged; Busulfan; Case-Control Studies; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Infant; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Single-Cell Analysis; Thioguanine; Treatment Outcome | 2013 |
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Topics: Adolescent; Antibiotics, Antineoplastic; Bone Marrow; Child; Child, Preschool; Daunorubicin; Dose-Response Relationship, Drug; Female; Heart Diseases; Humans; Idarubicin; Leukemia, Myeloid, Acute; Liposomes; Male; Multivariate Analysis; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Risk Factors; Treatment Outcome | 2013 |
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Survival Analysis; Treatment Outcome | 2013 |
Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate | 2013 |
Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; BRCA1 Protein; Checkpoint Kinase 1; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Agonism; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Leukemic; Heterografts; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; M Phase Cell Cycle Checkpoints; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Panobinostat; Protein Kinases; Rad51 Recombinase; U937 Cells | 2013 |
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Humans; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Risk Assessment; Risk Factors; Treatment Outcome | 2014 |
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Interleukin-2; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Survival Rate; Treatment Outcome | 2014 |
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged | 2014 |
The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Child; Child, Preschool; Daunorubicin; Drug Monitoring; Female; Humans; Leukemia, Myeloid, Acute; Male; Prognosis; Recurrence; Remission Induction; Survival Analysis | 2014 |
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Gemtuzumab; Genes, Wilms Tumor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prognosis; RNA, Messenger; Treatment Outcome; WT1 Proteins | 2014 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
The NPM1 mutation type has no impact on survival in cytogenetically normal AML.
Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Mutation; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Risk Factors; Survival Analysis; Thioguanine; Treatment Outcome | 2014 |
[Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Mitoxantrone; Russia | 2014 |
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Recurrence; Remission Induction; Survival Analysis | 2015 |
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Prospective Studies; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2015 |
Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Young Adult | 2015 |
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Young Adult | 2015 |
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azocines; Benzhydryl Compounds; Cytarabine; Cytokines; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Male; Middle Aged | 2015 |
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Flavonoids; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Survival Rate | 2015 |
Family History and Relapse in Pediatric Acute Myeloid Leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Survival Rate | 2015 |
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis | 2016 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Recurrence; Risk Factors; Sorafenib; Time Factors; Transplantation, Homologous; Treatment Outcome | 2015 |
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Cytogenetics; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Prognosis; Survival Analysis; Young Adult | 2016 |
Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Infections; Leukemia, Myeloid, Acute; Male; Mitoxantrone | 2016 |
Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Poland; Remission Induction | 2017 |
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Genes, ras; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Remission Induction; Statistics, Nonparametric; Survival Rate | 2008 |
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Sarcoma, Myeloid; Survival Rate; Treatment Outcome | 2008 |
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Time Factors; Vidarabine | 2009 |
Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Proportional Hazards Models; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2008 |
A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug-Related Side Effects and Adverse Reactions; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Quinolones; Remission Induction | 2009 |
Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Cyclosporine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Dyes; Humans; Idarubicin; Inhibitory Concentration 50; K562 Cells; Leukemia, Myeloid, Acute; Male; Rhodamine 123; Time Factors; Treatment Outcome; Verapamil | 2009 |
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Daunorubicin; Dibenzocycloheptenes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinolines; Time Factors | 2009 |
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Cytogenetic Analysis; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate | 2009 |
Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosome Aberrations; Cytarabine; Daunorubicin; Drugs, Chinese Herbal; Etoposide; Female; Humans; Immunophenotyping; Integrative Medicine; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Treatment Outcome; Young Adult | 2009 |
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Candida; Cladribine; Cytarabine; Daunorubicin; Female; Fungemia; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Poland; Treatment Outcome; Young Adult | 2010 |
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Gemtuzumab; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Topotecan | 2010 |
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epidemiologic Methods; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Treatment Outcome | 2010 |
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Thioguanine; Treatment Outcome; Tretinoin; Young Adult | 2010 |
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Interleukin-2; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Recurrence; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Daunorubicin; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; STAT5 Transcription Factor | 2010 |
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Nuclear Proteins; Nucleophosmin; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Risk Factors | 2010 |
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Gemtuzumab; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Remission Induction; Survival Rate; Young Adult | 2010 |
Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Daunorubicin; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Survival Rate; Transplantation, Autologous; Treatment Outcome; Young Adult | 2010 |
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine | 2010 |
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Analysis; Young Adult | 2011 |
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Dibenzocycloheptenes; Female; Humans; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Placebos; Prognosis; Quinolines; Remission Induction; Survival Analysis; Treatment Outcome | 2010 |
High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.
Topics: Aged; Antineoplastic Agents; China; Daunorubicin; Female; Harringtonines; Homoharringtonine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models | 2012 |
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Recurrence; Salvage Therapy; Treatment Outcome; Young Adult | 2011 |
Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia.
Topics: Acetylation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytochrome P-450 CYP2D6; Daunorubicin; Drug Interactions; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Oxidation-Reduction; Phenotype; Young Adult | 2011 |
Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Sialic Acid Binding Ig-like Lectin 3 | 2011 |
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2012 |
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Treatment Outcome; Young Adult | 2011 |
Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Survival Analysis; Thioguanine; Treatment Outcome | 2011 |
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Salvage Therapy; Treatment Outcome | 2012 |
Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Chromatography, High Pressure Liquid; Creatinine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Prospective Studies; Tissue Distribution; Young Adult | 2012 |
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine; Young Adult | 2012 |
Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Alcohol Oxidoreductases; Antibiotics, Antineoplastic; Cells, Cultured; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Polymorphism, Single Nucleotide; RNA, Messenger; Young Adult | 2012 |
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Etoposide; Exons; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Mutation; Neoplasm Staging; Prognosis; Survival Rate | 2013 |
Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Leukocytosis; Male; Survival Rate | 2012 |
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Gemtuzumab; Humans; Immunotoxins; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Odds Ratio; Remission Induction; Secondary Prevention; Treatment Outcome | 2012 |
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Biomarkers, Tumor; Cohort Studies; Daunorubicin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Granulocyte Precursor Cells; Humans; Interleukin-2 Receptor alpha Subunit; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Nucleophosmin; Prognosis; Survival Analysis; Young Adult | 2012 |
Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Japan; Leukemia, Myeloid, Acute; Male; Neoplasm Staging; Recurrence; Treatment Outcome | 2012 |
Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
[The first results of treatment for adult acute myeloid leukemia according to the AML-01.10 protocol of the Research Group of the Hematology Centers of Russia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Russia; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2012 |
Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Cell Count; Bone Marrow Cells; Comorbidity; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hemoglobins; Humans; Immunophenotyping; Kaplan-Meier Estimate; Karyotyping; Kidney Function Tests; Leukemia, Myeloid, Acute; Liver Function Tests; Logistic Models; Male; Middle Aged; Prognosis; Remission Induction; Risk Factors; Treatment Outcome | 2012 |
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Topics: Aged; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Follow-Up Studies; Histocompatibility Antigens Class II; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Nervous System; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
Topics: Aged; Aged, 80 and over; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Proportional Hazards Models; Time; Treatment Outcome | 2013 |
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Feasibility Studies; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Survival Analysis; Treatment Outcome | 2012 |
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; International Cooperation; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Odds Ratio; Remission Induction; Research Design; Treatment Outcome; Vidarabine | 2013 |
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Everolimus; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2013 |
High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Risk Factors; Survival Rate | 2013 |
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Remission Induction | 2002 |
Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Disease-Free Survival; Drug Carriers; Drug Resistance, Multiple; Female; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Patient Selection; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Risk Factors; Treatment Outcome | 2002 |
Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapy.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged; Survival Rate; Thioguanine; Time Factors | 2002 |
Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Australia; Bone Marrow Transplantation; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; New Zealand; Recurrence; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Bone Marrow; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction | 2002 |
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Liposomes; Lymphokines; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prognosis; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Pilot Projects; Remission Induction; Salvage Therapy; Treatment Outcome | 2003 |
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by seq
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Survival Analysis; Thioguanine | 2003 |
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2004 |
Risk-adapted induction and consolidation therapy in adults with de novo AML aged
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Risk Assessment; Stem Cell Transplantation; Survival Analysis | 2004 |
Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Stem Cell Transplantation; Survival Analysis; Thioguanine | 2004 |
Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2005 |
Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Genes, MDR; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Treatment Outcome | 2005 |
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotides, Antisense; Probability; Prognosis; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Thionucleotides; Treatment Outcome | 2005 |
One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Recurrence; Remission Induction; Risk Factors; Survival Analysis | 2005 |
High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Risk Factors; Survival Analysis; Treatment Outcome | 2005 |
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
Topics: Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Treatment Outcome | 2005 |
Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Cytarabine; Daunorubicin; Etoposide; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Recurrence | 2006 |
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult L
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Probability; Remission Induction; Risk Assessment; Treatment Outcome; Vincristine; Vindesine | 2005 |
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Tretinoin | 2006 |
Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis.
Topics: Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Matched-Pair Analysis; Middle Aged; Thioguanine | 2008 |
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Ethnicity; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Time Factors; Treatment Outcome; United States | 2007 |
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Poland; Remission Induction; Vidarabine | 2008 |
Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine.
Topics: Acyclovir; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Biological Availability; Cross-Over Studies; Cytarabine; Daunorubicin; Drug Interactions; Female; Humans; Intestinal Absorption; Leukemia, Myeloid, Acute; Male; Middle Aged | 2008 |
[Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)].
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Leukemia, Myeloid, Acute; Mitoguazone; Recurrence | 1981 |
A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; BCG Vaccine; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Deoxyguanosine; Female; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Thioguanine; Thionucleosides; United States | 1984 |
Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Male; Middle Aged; Neoplasms; Prospective Studies; Risk | 1983 |
Failure of lithium to limit neutropenia significantly during induction therapy of acute myelogenous leukemia. A Southeastern Cancer Study Group study.
Topics: Age Factors; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Female; Fever; Humans; Infections; Leukemia, Myeloid, Acute; Lithium; Lithium Carbonate; Male; Middle Aged; Neutropenia; Random Allocation; Thrombocytopenia | 1984 |
Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Daunorubicin; Disseminated Intravascular Coagulation; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1984 |
Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Amphotericin B; Anti-Bacterial Agents; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Pneumonia | 1982 |
Immunotherapy for remission maintenance in acute myeloblastic leukemia.
Topics: Adult; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Mycobacterium bovis | 1982 |
Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.
Topics: Adolescent; Adult; BCG Vaccine; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Thioguanine; Time Factors | 1980 |
Intensive chemotherapy for acute myelogenous leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sex Factors; Thioguanine | 1981 |
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.
Topics: Acute Disease; Adolescent; Adult; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Time Factors | 1981 |
Adjuvant specific immunotherapy in maintenance treatment of adult acute non-lymphocytic leukemia.
Topics: Adolescent; Adult; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Thioguanine; Vincristine | 1981 |
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Colitis, Ulcerative; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Stomatitis | 1982 |
Two years' experience in the treatment of acute myeloid leukaemia using a three-drug regimen: daunorubicin, cytosine arabinoside and 6-thioguanine.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1982 |
Chemotherapy of the myeloid leukaemias.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Remission, Spontaneous; Thioguanine | 1980 |
Androgen therapy during myeloblastic leukemia remission induced by two drug combinations.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Stanozolol; Vincristine | 1981 |
Trial of daunomycin in acute promyelocytic leukemia of childhood: a Southwest Oncology Group Study.
Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Daunorubicin; Disseminated Intravascular Coagulation; Humans; Infant; Leukemia, Myeloid, Acute | 1981 |
Maintenance chemoimmunotherapy of nonlymphoblastic acute leukemias.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Immunotherapy; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukocyte Count; Leukocytes; Male; Middle Aged; Mycobacterium bovis; Thioguanine | 1982 |
Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Probability; Random Allocation; Thioguanine; Vincristine | 1982 |
Progress in acute myelogenous leukemia.
Topics: Bone Marrow Transplantation; Clinical Trials as Topic; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Graft vs Host Reaction; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Middle Aged; Thioguanine; Time Factors | 1981 |
High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Survival Rate | 1995 |
Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Selection; Remission Induction; Thioguanine | 1995 |
Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administration Schedule; Drug Resistance, Multiple; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tamoxifen | 1995 |
Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Double-Blind Method; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Recombinant Proteins | 1995 |
Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpatient r
Topics: Aged; Antineoplastic Agents; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Double-Blind Method; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Outpatients; Randomized Controlled Trials as Topic; Recombinant Proteins | 1995 |
In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplastic Stem Cells; Remission Induction | 1995 |
Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Thioguanine; United States | 1995 |
Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
Topics: Aged; Aged, 80 and over; Cytarabine; Daunorubicin; Double-Blind Method; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Regression Analysis; Remission Induction; Treatment Outcome | 1995 |
[Treatment results of acute nonlymphocytic leukemia in childhood--Kyushu Yamaguchi Children's Cancer Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Recurrence; Remission Induction; Survival Rate; Vincristine | 1995 |
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Transplantation, Autologous; Transplantation, Homologous | 1995 |
The influence of induction chemotherapy dose and dose intensity on the duration of remission in acute myeloid leukemia. Australian Leukemia Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia, Myeloid, Acute; Life Tables; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Treatment Outcome | 1994 |
Improved survival for patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Rate; Transplantation, Autologous; Transplantation, Homologous; United States | 1995 |
Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Recombinant Proteins; Remission Induction; Thioguanine | 1994 |
[Results of induction treatment with idarubicin for acute nonlymphoblastic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome | 1994 |
A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Time Factors | 1994 |
Phase II-trial of double-consolidation following intensive induction treatment for improvement of survival in elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate | 1994 |
[A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Electrocardiography; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1993 |
Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prospective Studies; Remission Induction; Survival Rate; Thioguanine | 1993 |
[Comparison between intensive consolidation by bone marrow autograft or by chemotherapy of acute myeloblastic leukemias in 1st complete remission: AML8A protocol of the Leukemia Cooperative Group of the European Organization for Research and Treatment of
Topics: Actuarial Analysis; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction; Survival Analysis; Transplantation, Autologous | 1993 |
Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Platelet Count; Recombinant Proteins; Recurrence; Remission Induction | 1996 |
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Rate | 1996 |
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Prognosis; Proportional Hazards Models; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous | 1996 |
Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Survival Rate | 1996 |
[Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Survival Rate; Treatment Outcome | 1996 |
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group.
Topics: Aged; Antibiotics, Antineoplastic; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome | 1996 |
[Treatment results for unselected patients with acute myelogenous leukemia. During a 10-year period, August 1984 to July 1994].
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Patient Selection; Prednisolone; Remission Induction; Retrospective Studies; Treatment Outcome | 1996 |
A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
Topics: Adolescent; Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Data Interpretation, Statistical; Daunorubicin; Electrocardiography; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1996 |
[Short-term intensive treatment for acute myelogenous leukemia (excluding M3 subtype) in adults].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Mitoxantrone; Time Factors; Vinblastine; Vincristine | 1997 |
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
Topics: Age Factors; Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Double-Blind Method; Drug Resistance, Multiple; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recombinant Proteins | 1997 |
Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Daunorubicin; Decitabine; Drug Administration Schedule; Female; Humans; Immunophenotyping; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged | 1997 |
Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Amsacrine; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Ondansetron; Phenothiazines; Pilot Projects; Serotonin Antagonists; Vomiting | 1997 |
Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Area Under Curve; Chromatography, Liquid; Cross-Over Studies; Daunorubicin; Female; Humans; Idarubicin; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Spectrometry, Fluorescence | 1997 |
Induction failure in de novo acute myelogenous leukemia is associated with expression of high levels of CD34 antigen by the leukemic blasts.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction | 1997 |
Sequential mitoxantrone, daunorubicin, and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects | 1997 |
2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cladribine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Rate; Treatment Outcome | 1998 |
P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias.
Topics: Adult; Aged; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Cells; Cell Line; Daunorubicin; Humans; Intracellular Fluid; Leukemia, Myeloid, Acute; Leukocytes; Middle Aged; Neoplasm Proteins; Neoplasms, Second Primary; Prognosis; Treatment Outcome; Vault Ribonucleoprotein Particles | 1998 |
Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.
Topics: Adult; Antibiotics, Antineoplastic; Daunorubicin; Drug Resistance, Multiple; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1998 |
Role of daunorubicin in the induction therapy for adult acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome | 1998 |
Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group.
Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Prospective Studies; Remission Induction; Vincristine | 1998 |
Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Daunorubicin; Female; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Razoxane | 1998 |
Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis | 1998 |
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Humans; Karyotyping; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Leukocyte Count; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Thioguanine; Treatment Outcome | 1999 |
A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carubicin; Central Nervous System Diseases; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome | 1999 |
[A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Prognosis; Prospective Studies; Remission Induction; Vincristine | 2000 |
P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Daunorubicin; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 2000 |
An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Down Syndrome; Etoposide; Female; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Probability; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2000 |
[The role of daunorubicin in induction therapy for adult acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate | 2000 |
[Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia--the JALSG-AML-92 Study. Japan Adult Leukemia Study Group].
Topics: Adolescent; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prospective Studies | 2000 |
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Treatment Outcome | 2001 |
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Risk Factors; Survival Rate | 2001 |
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Carriers; Humans; Leukemia, Myeloid, Acute; Liposomes; Middle Aged; Recurrence; Treatment Outcome | 2001 |
Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Costs and Cost Analysis; Cytarabine; Daunorubicin; Disease-Free Survival; Fever; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Infections; Leukemia, Myeloid, Acute; Middle Aged; Placebos; Southwestern United States | 2001 |
Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction; Survival Rate; Thioguanine; Time Factors; Treatment Outcome | 2001 |
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Drug Interactions; Drug Resistance, Neoplasm; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk Factors | 2001 |
Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction | 2002 |
Feasibility and efficacy of 5-azacytidine used early in the therapy of adult acute nonlymphocytic leukemia: an ECOG pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1979 |
Active immunotherapy in leukemia with neuraminidase-modified leukemic cells.
Topics: Animals; Antigens, Neoplasm; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Hypersensitivity, Delayed; Immunization; Immunotherapy; Leukemia Virus, Murine; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice; Mice, Inbred AKR; Mice, Inbred C57BL; Mice, Inbred DBA; Neuraminidase; Tumor Virus Infections | 1977 |
Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: a randomized collaborative study.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Meningeal Neoplasms; Methotrexate; Middle Aged; Prednisone; Remission, Spontaneous; Thioguanine; Time Factors; Vincristine | 1978 |
Lithium and granulocytopenia during induction therapy of acute myelogenous leukemia.
Topics: Agranulocytosis; Bacterial Infections; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Lithium; Neutropenia; Remission, Spontaneous | 1979 |
The effect of thioguanine on a combination of daunorubicine, cytarabine and prednisone in the treatment of acute leukaemia in adults. The Finnish Leukaemia Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Prognosis; Remission, Spontaneous; Thioguanine | 1979 |
[Use of carminomycin on adult patients with acute leukemias].
Topics: Adult; Antibiotics, Antineoplastic; Bone Marrow; Carubicin; Clinical Trials as Topic; Daunorubicin; Drug Evaluation; Drug Tolerance; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Time Factors | 1977 |
Chemotherapy and immunotherapy interspersion: clinical studies in acute myeloblastic leukaemia.
Topics: Adult; Antineoplastic Agents; BCG Vaccine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous; Skin Tests | 1977 |
Chemotherapy of acute myeloid leukaemia in adults: Medical Research Council.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Random Allocation; Thioguanine; Vincristine | 1979 |
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Remission, Spontaneous; Thioguanine | 1979 |
Interhospital differences in the treatment of acute leukaemia in adults. The Finnish Leukaemia Group.
Topics: Acute Disease; Adult; Aged; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Finland; Humans; Leukemia; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Prognosis; Remission, Spontaneous | 1979 |
[Revaluation of the two step DCMP chemotherapy for acute leukemias (author's transl)].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1979 |
L-asparaginase and prednisolone pretreatment followed by rubidomycin and cytosine arabinoside for induction of remission in adult patients with acute myeloblastic leukaemia.
Topics: Adolescent; Adult; Age Factors; Aged; Asparaginase; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Nausea; Prednisolone; Remission, Spontaneous; Vomiting | 1975 |
Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia.
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Remission, Spontaneous; Thioguanine; Time Factors | 1975 |
Acute myelogenous leukemia in children: a preliminary report of combination chemotherapy.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Prednisolone; Remission, Spontaneous; Vincristine | 1976 |
Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia.
Topics: Acute Disease; Aged; Antineoplastic Agents; Bone Marrow; Central Nervous System Diseases; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Guanazole; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Meninges; Middle Aged; Pyrimethamine; Remission, Spontaneous; Skin Tests; Thioguanine | 1976 |
The effect of immunotherapy on survival of patients with acute myelogenous leukaemia after relapse.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1976 |
Cell kinetics in leukemia. Correlation with clinical features and response to chemotherapy.
Topics: Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Therapy, Combination; Humans; Kinetics; Leucovorin; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Methotrexate; Mitotic Index; Thioguanine | 1975 |
[Letter: Acute myeloblastic leukemia: prevision of the efficiency by the combination of daunorubicin-cytosine-arabinoside].
Topics: Cells, Cultured; Clinical Trials as Topic; Cytarabine; Daunorubicin; DNA; Drug Evaluation; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Thymidine | 1975 |
Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Monitoring, Physiologic; Recombinant Proteins; Remission Induction; Survival Rate | 1992 |
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Deoxyadenosines; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
Treatment of acute nonlymphocytic leukemia by combination of recombinant human granulocyte colony-stimulating factor and cytotoxic agents: a report of six cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabine; Daunorubicin; Drug Evaluation; Drug Resistance; Drug Synergism; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction | 1992 |
[Effectiveness of empirical antibiotic therapy in the control of infections in patients with acute leukemia during severe neutropenia].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cytarabine; Daunorubicin; Female; Humans; Immune Tolerance; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Opportunistic Infections; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1992 |
Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Analysis; Time Factors | 1992 |
Analysis of treatment failure in acute nonlymphocytic leukemia patients over fifty years of age. A Southwest Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome | 1992 |
Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Clinical Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous | 1992 |
Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Daunorubicin; Drug Administration Schedule; Feasibility Studies; Humans; Idarubicin; Infusions, Intravenous; Italy; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Thioguanine | 1992 |
DNA as a carrier for anthracyclines in the treatment of acute myelocytic leukemia (AML).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA; DNA Adducts; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Prednisone; Survival Analysis; Thioguanine; Vincristine | 1992 |
A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Thioguanine; Time Factors | 1992 |
Ceftazidime as initial therapy in febrile patients with acute leukemia during induction chemotherapy. Leukemia Group of Middle Sweden.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Ceftazidime; Cytarabine; Daunorubicin; Female; Fever; Fever of Unknown Origin; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Thioguanine | 1992 |
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 1992 |
Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and l
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Daunorubicin; Doxorubicin; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Levamisole; Mercaptopurine; Methotrexate; Nervous System Neoplasms; Prednisone; Survival Analysis; Vincristine | 1992 |
A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1992 |
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Drug Combinations; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Nimustine; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine; United Kingdom; Vincristine | 1990 |
A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Belgium; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; France; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Vincristine | 1990 |
Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Pilot Projects; Randomized Controlled Trials as Topic; Remission Induction; Thioguanine; Vincristine | 1990 |
Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate | 1990 |
Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sex Factors; Survival Analysis | 1990 |
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocytosis; Male; Middle Aged; Remission Induction | 1992 |
[Therapy of acute myeloid leukemia in children--results of the AML II/87 multicenter study].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Survival Analysis; Thioguanine; Transplantation, Autologous; Transplantation, Homologous | 1991 |
Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction | 1991 |
A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine | 1991 |
Allogeneic versus autologous bone marrow transplantation versus chemotherapy for treatment of acute myeloid leukemia in first complete remission (BGM 84 and BGMT 87 studies). The BGMT Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Remission Induction; Transplantation, Autologous; Transplantation, Homologous | 1991 |
Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Cycle; Cell Division; Cytarabine; Daunorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 1991 |
A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; DNA Nucleotidylexotransferase; Female; Fever; Humans; Infant; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Random Allocation; Receptors, Glucocorticoid; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Thioguanine; Tumor Cells, Cultured; Vincristine | 1991 |
Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bromodeoxyuridine; Cell Cycle; Cytarabine; Daunorubicin; DNA; Female; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Neutrophils; Recombinant Proteins | 1991 |
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Probability | 1991 |
Long-term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Thioguanine; Vindesine | 1991 |
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Denmark; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Regression Analysis; Remission Induction; Survival Rate | 1991 |
[Intensification of chemotherapy of acute myeloid leukemia in children: report on the studies of the AML-BFM 78 and AML-BFM 83 protocols].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany, West; Humans; Leukemia, Myeloid, Acute; Methotrexate; Prednisone; Prognosis; Remission Induction; Thioguanine; Time Factors; Vincristine | 1991 |
[Treatment of acute nonlymphocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Time Factors | 1991 |
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Remission Induction; Survival Rate | 1990 |
Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.
Topics: Administration, Oral; Aged; Biological Availability; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic | 1990 |
Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany, West; Humans; Infant; Leukemia, Myeloid, Acute; Life Tables; Multicenter Studies as Topic; Remission Induction; Thioguanine | 1990 |
Intensive sequential chemotherapy for children with acute myelogenous leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Doxorubicin; Humans; Infant; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Multicenter Studies as Topic; Prednisolone; Remission Induction; Survival Rate; United States; Vincristine | 1990 |
Therapy of acute myelogenous leukemia in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Italy; Leukemia, Myeloid, Acute; Life Tables; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine | 1990 |
Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Survival Rate | 1990 |
Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Thioguanine | 1990 |
Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Thioguanine; United States | 1990 |
Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cytarabine; Daunorubicin; Hemodynamics; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Thioguanine; Verapamil | 1990 |
Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-H
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Child; Cytarabine; Daunorubicin; Drug Resistance; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Prospective Studies; Randomized Controlled Trials as Topic; Thioguanine | 1990 |
Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Netherlands; Prospective Studies; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous | 1990 |
Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Germany; Humans; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Multivariate Analysis; Prognosis; Risk Factors | 1990 |
Cure of acute myelocytic leukemia in adults: a reality.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction | 1990 |
The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Pilot Projects; Random Allocation; Remission Induction; Thioguanine | 1990 |
Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
Topics: Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Thioguanine; United States | 1990 |
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Prognosis; Random Allocation; Remission Induction | 1990 |
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Survival Analysis | 1990 |
Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Random Allocation; Remission Induction; Risk; Thioguanine; United Kingdom | 1987 |
The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; England; Etoposide; Humans; Leukemia, Myeloid, Acute; Prednisone; Remission Induction; Thioguanine; Vincristine | 1987 |
Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Prednisolone; Prognosis; Remission Induction; Thioguanine; Vincristine | 1989 |
[Treatment of acute myeloblastic leukemia in aged patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colony-Stimulating Factors; Cytarabine; Daunorubicin; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Middle Aged; Palliative Care; Prognosis | 1989 |
[AML-6 study of the value of cyclic alternating chemotherapy during remission in acute myelocytic leukemia].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged; Vincristine | 1985 |
Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Random Allocation; Remission Induction | 1989 |
A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Remission Induction | 1989 |
Results of the Italian AIEOP/LAM 8204 study for the treatment of childhood AML: an update.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Infant; Italy; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Remission Induction; Thioguanine | 1989 |
A randomized comparison of post-consolidation therapy in acute non-lymphoid leukaemia: a study of the Italian cooperative group GIMEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Humans; Italy; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Random Allocation; Remission Induction; Thioguanine | 1989 |
Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Random Allocation; Thioguanine | 1989 |
[Advances in the treatment of acute myeloid leukemia in children. Experience of the Argentinian Group of Acute Leukemia Treatment and the Latin American Group of Malignant Hemopathies Treatment 1967-1987].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Evaluation Studies as Topic; Humans; Infant; Leukemia, Myeloid, Acute; Methotrexate; Prednisolone; Prednisone; Thioguanine; Vincristine | 1989 |
A two-step timed sequential treatment for acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1989 |
Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Daunorubicin; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction; Survival Analysis | 1989 |
Aclarubicin in the treatment of de-novo acute myelocytic leukaemia.
Topics: Aclarubicin; Adolescent; Adult; Bone Marrow Transplantation; Combined Modality Therapy; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic | 1989 |
Idarubicin in acute leukemia: results of US trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute | 1989 |
Results of chemotherapy for unselected patients with acute myeloblastic leukaemia: effect of exclusions on interpretation of results. The Toronto Leukemia Study Group.
Topics: Administration, Oral; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Evaluation Studies as Topic; Humans; Infusions, Parenteral; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Prognosis; Random Allocation; Thioguanine | 1986 |
Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Central Nervous System Diseases; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Infant; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Random Allocation; Thioguanine | 1986 |
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Topics: Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Prognosis; Thioguanine | 1989 |
Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Random Allocation; Remission Induction | 1989 |
A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Remission Induction | 1989 |
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
Intensive maintenance treatment in acute myelogenous leukemia (AML): single institution experience of a multicenter randomized trial.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytosine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged; Random Allocation; Vincristine | 1988 |
A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Humans; Infections; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia | 1988 |
Therapeutic strategies in acute myelocytic leukemia: a status report of the experience of CALGB. Cancer and Leukemia Group B.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Combinations; Humans; Leukemia, Myeloid, Acute; Remission Induction; Sulfamethoxazole; Time Factors; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 1987 |
Remission induction with cytarabine and daunorubicin with or without 6-thioguanine in adult patients with acute myelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Thioguanine | 1987 |
Long-term results of two Swiss AML studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Immunization; Leukemia, Myeloid, Acute; Male; Switzerland; Vincristine | 1987 |
Aclacinomycin-A in the induction treatment of childhood acute myelogenous leukemia.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Naphthacenes; Prospective Studies; Remission Induction | 1987 |
Remission induction and maintenance modalities in acute myeloid leukemia: a multicenter randomized study.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; France; Humans; Leukemia, Myeloid, Acute; Random Allocation; Remission Induction; Time Factors | 1987 |
Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Germany, West; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Random Allocation; Remission Induction; Thioguanine | 1987 |
Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Germany, West; Humans; Immunization; Leukemia, Myeloid, Acute; Neuraminidase; Prospective Studies; Random Allocation; Remission Induction; Thioguanine | 1987 |
The childhood AML studies BFM-78 and -83: treatment results and risk factor analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany, West; Humans; Leukemia, Myeloid, Acute; Methotrexate; Prednisone; Prognosis; Remission Induction; Risk; Thioguanine; Vincristine | 1987 |
A comparison of cytokinetically based versus intensive chemotherapy for childhood acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Vincristine | 1987 |
Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Thioguanine; Vincristine | 1987 |
Results of induction and consolidation treatment with intermediate and high-dose ara-C and m-AMSA containing regimens in patients with primarily failed or relapsed acute leukemia and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Follow-Up Studies; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Middle Aged | 1986 |
[Risk groups in acute, non-lymphatic leukemia in childhood. Analysis of the results of the cooperative therapeutic studies AML-BFM 78 and 83].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prognosis; Risk; Thioguanine | 1986 |
A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Doxorubicin; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Prospective Studies; Random Allocation; Testosterone Congeners; Thioguanine; Time Factors; Vincristine | 1986 |
Amsacrine: a review.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation; Drug Resistance; Humans; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma | 1986 |
[The role of zorubicine in the treatment of acute myeloid leukemia. Evaluation of 15 years' use].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Daunorubicin; Evaluation Studies as Topic; Humans; Leukemia, Myeloid, Acute | 1987 |
Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Statistics as Topic; Thioguanine | 1987 |
Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Thioguanine | 1985 |
[AML-7 study of the value of intensive remission induction in aged patients with acute myelocytic leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Vincristine | 1985 |
Treatment of acute myelocytic leukemia with a daunorubicin-cytarabine-6 thioguanine regimen without maintenance therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1985 |
Immunotherapy with allogeneic neuraminidase-treated blasts for maintenance in acute myelogenous leukemia (AML). Significant prolongation of remission duration in patients receiving at least 3 cycles of therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Prospective Studies; Random Allocation; Thioguanine | 1985 |
[AML-6 and AML-7 studies on the treatment of acute myelocytic leukemia. Cyclic alternating chemotherapy during remission, and induction of remission and survival of elderly patients].
Topics: Adult; Age Factors; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azaguanine; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Middle Aged; Vincristine | 1985 |
Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Germany, West; Humans; Leukemia, Myeloid, Acute; Middle Aged; Pilot Projects; Random Allocation; Thioguanine; Time Factors | 1985 |
Fetal liver infusion: an adjuvant in the therapy of acute myeloid leukemia (AML).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cell Survival; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Erythrocyte Transfusion; Female; Fetus; Humans; Leukemia, Myeloid, Acute; Liver; Liver Transplantation; Male; Middle Aged; Pregnancy | 1985 |
Prolonging remission in myeloblastic leukemia by tice-strain bacillus Calmette-Guérin.
Topics: Administration, Oral; Adolescent; Adult; BCG Vaccine; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Immunotherapy; Injections, Intravenous; Leukemia, Myeloid, Acute; Methotrexate; Middle Aged; Remission, Spontaneous; Thioguanine; Time Factors; Vincristine | 1974 |
Immunotherapy for acute myelogenous leukaemia.
Topics: Adolescent; Adult; BCG Vaccine; Cytarabine; Daunorubicin; Female; Histocompatibility Testing; Humans; Immunity; Immunotherapy; Injections, Intradermal; Leukemia, Myeloid, Acute; Lymphocyte Activation; Lymphocytes; Male; Middle Aged; Plicamycin; Remission, Spontaneous; Statistics as Topic; Time Factors | 1973 |
Management of adult acute myelogenous leukaemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; BCG Vaccine; Blood Cell Count; Blood Platelets; Child; Cytarabine; Daunorubicin; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Remission, Spontaneous; Thioguanine | 1973 |
A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Amidines; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Evaluation Studies as Topic; Glyoxal; Humans; Hydrazones; Leukemia, Myeloid, Acute; Middle Aged; Remission, Spontaneous; Thioguanine | 1973 |
Combination chemotherapy of acute leukaemia in adults. Comparison of two schedules.
Topics: Administration, Oral; Adult; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Prognosis | 1974 |
A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia.
Topics: Bone Marrow Examination; Cytarabine; Daunorubicin; Drug Therapy, Combination; Guanidines; Humans; Intensive Care Units; Leukemia, Myeloid, Acute; Leukocyte Count; Mitoguazone; Remission, Spontaneous; Thioguanine; Time Factors | 1974 |
Daunorubicin and adriamycin in the treatment of leukemia.
Topics: Adult; Anemia, Aplastic; Arrhythmias, Cardiac; Blood Platelets; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Evaluation Studies as Topic; Female; Hemorrhagic Disorders; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocyte Count; Leukopenia; Male; Remission, Spontaneous; Thrombocytopenia | 1973 |
[Treatment of acute leukemia. Controlled clinical trials and experimental data with a view to a more rational administration of anti-leukemic drugs].
Topics: Clinical Trials as Topic; Cytarabine; Daunorubicin; DNA, Neoplasm; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Prednisolone; Vincristine | 1973 |
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party on Leu
Topics: Adolescent; Adult; Age Factors; Aged; Asparaginase; Blood Platelets; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocytes; Male; Mercaptopurine; Middle Aged; Prednisone; Prognosis; Remission, Spontaneous; Thioguanine; Thrombocytopenia | 1974 |
[Results in the treatment of acute granulocytic leukemias using a combination of daunorubicine-cytosine arabinoside-cyclophosphamide. Apropos of 35 cases].
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Drug Tolerance; Female; Glycosides; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged | 1974 |
[Rubidomycin in cases of promyelocytic acute leukemia in children].
Topics: Child; Child, Preschool; Clinical Trials as Topic; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute | 1969 |
Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia.
Topics: Adolescent; Adult; Aged; Asparaginase; Blood Cell Count; Clinical Trials as Topic; Cytarabine; Daunorubicin; Edema; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Serum Albumin; Vomiting | 1970 |
1088 other study(ies) available for daunorubicin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Validation of AML-score in Older Adults Receiving CPX-351 Intensive Induction Chemotherapy for Treatment of Secondary Acute Myeloid Leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies | 2022 |
CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies.
Topics: Adolescent; Aged; Child; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Prospective Studies | 2022 |
What to use to treat AML: the role of emerging therapies.
Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Approval; Drug Discovery; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Triazines | 2021 |
Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Gemtuzumab; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Polymorphism, Single Nucleotide; Prognosis; Survival Rate; Young Adult | 2022 |
The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias.
Topics: Daunorubicin; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; NADPH Oxidase 2; Prognosis | 2022 |
Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia.
Topics: Anthracyclines; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 2022 |
Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML.
Topics: Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemia.
Topics: Antineoplastic Agents; Cell Self Renewal; Daunorubicin; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Leukotriene B4; Neoplastic Stem Cells | 2022 |
Co-Delivery of Daunorubicin and Homoharringtonine in Folic Acid Modified-Liposomes for Enhancing Therapeutic Effect on Acute Myeloid Leukemia.
Topics: Cell Line, Tumor; Daunorubicin; Folic Acid; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Liposomes | 2023 |
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.
Topics: Cell Line, Tumor; Cysteine; Cystine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Sulfasalazine | 2022 |
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Quality of Life; Retrospective Studies; Sulfonamides | 2022 |
Surface-modified vacuole-based daunorubicin delivery system for acute myeloid leukaemia (AML) and their selective therapeutics.
Topics: Cell Line, Tumor; Daunorubicin; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute; Lysosomes; Saccharomyces cerevisiae; Vacuoles | 2022 |
[Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Nuclear Proteins; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2022 |
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Docosahexaenoic Acids; Eicosapentaenoic Acid; Emulsions; Feasibility Studies; Fish Oils; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2 | 2022 |
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2022 |
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Hospitalization; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary; Retrospective Studies | 2022 |
Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Retrospective Studies | 2022 |
Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.
Topics: Adenosine Triphosphate; Anthracyclines; Antibiotics, Antineoplastic; ATP-Binding Cassette Transporters; Cytarabine; Daunorubicin; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute | 2022 |
Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines.
Topics: Animals; Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; Daunorubicin; fms-Like Tyrosine Kinase 3; Leukemia, Myeloid, Acute; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors | 2022 |
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.
Topics: Animals; Benzamides; Cell Line, Tumor; Daunorubicin; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Focal Adhesion Kinase 2; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteome; Pyrazines; Sulfonamides | 2022 |
SpinTip: A Simple, Robust, and Versatile Preanalytical Method for Microscale Suspension Cell Proteomics.
Topics: Daunorubicin; Humans; Leukemia, Myeloid, Acute; Proteomics | 2022 |
Pruritic papules after induction chemotherapy with daunorubicin and cytarabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Exanthema; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Pruritus; Triamcinolone | 2022 |
DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Topics: Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Mutation; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2 | 2022 |
Topics: Apoptosis; Artesunate; Caspase 3; Caspase 9; Cell Line; Cytarabine; Daunorubicin; Humans; Leukemia; Leukemia, Myeloid, Acute; Mutation; Retrospective Studies | 2022 |
Optimizing outcomes in secondary AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary | 2023 |
Self-Assembled Daunorubicin/Epigallocatechin Gallate Nanocomplex for Synergistic Reversal of Chemoresistance in Leukemia.
Topics: Apoptosis; Catechin; Daunorubicin; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Tea | 2022 |
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Effectiveness Analysis; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Italy; Leukemia, Myeloid, Acute; Sialic Acid Binding Ig-like Lectin 3; State Medicine; Treatment Outcome | 2023 |
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prognosis; Remission Induction | 2023 |
DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis.
Topics: Cell Survival; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Humans; Leukemia, Myeloid, Acute; Mutation; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2 | 2023 |
Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2023 |
Bewersdorf JP, Patel KK, Goshua G, et al. Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood. 2022;139(11):1766-1770.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 2023 |
Pinostrobin induces acute leukemia cell apoptosis via the regulation of miR-410-5p and SFRP5.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Proliferation; Chromatography, Liquid; Daunorubicin; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Tandem Mass Spectrometry | 2023 |
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.
Topics: Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Obesity; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction | 2023 |
CPX-351 for higher risk myelodysplastic syndrome: cytarabine and daunorubicin in disguise?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2023 |
Uy GL, Newell LF, Lin TL, et al. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022;6(17):4989-4993.
Topics: Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Transplants | 2023 |
DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias.
Topics: Chromatin; Daunorubicin; Esters; Humans; Leukemia, Myeloid, Acute | 2023 |
Real-World Experience With CPX-351 Treatment for Acute Myeloid Leukemia in England: An Analysis From the National Cancer Registration and Analysis Service.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; United Kingdom | 2023 |
Inducing a Proinflammatory Response with Bioengineered Yeast Vacuoles with TLR2-Binding Peptides (Vac
Topics: Animals; Apoptosis; Daunorubicin; Drug Carriers; Female; HL-60 Cells; Humans; Inflammation; Leukemia, Myeloid, Acute; Macrophages; Mice; Mice, Inbred BALB C; Nanoparticles; Phagocytosis; Saccharomyces cerevisiae; Toll-Like Receptor 2; Xenograft Model Antitumor Assays | 2023 |
Transcriptional Response to Standard AML Drugs Identifies Synergistic Combinations.
Topics: Aged; Cell Line; Chromatin Assembly and Disassembly; Daunorubicin; ErbB Receptors; Humans; Leukemia, Myeloid, Acute | 2023 |
A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Mice; Quinolones | 2023 |
Research on the preparation process of the cytarabine/daunorubicin dual-encapsulation liposome and its physicochemical properties and performances in vitro/vivo.
Topics: Copper; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes | 2023 |
Regulatory role of RBM39 in acute myeloid leukemia: Mediation through the PI3K/AKT pathway.
Topics: Cell Line, Tumor; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2024 |
A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes.
Topics: Cytarabine; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation Conditioning | 2023 |
Quizartinib (Vanflyta) for acute myeloid leukemia.
Topics: Benzothiazoles; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mutation; Phenylurea Compounds | 2023 |
Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia.
Topics: Animals; Apoptosis; Autophagy; Bone Marrow Cells; Daunorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Mice; MicroRNAs; Neoplasm, Residual; Stromal Cells; Toll-Like Receptor 2; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Muscle aches and pains: do I have leukemia?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Lower Extremity; Male; Myalgia | 2020 |
Benzyl butyl phthalate (BBP) triggers the malignancy of acute myeloid leukemia cells via upregulation of PDK4.
Topics: 5' Untranslated Regions; Adenosine Triphosphate; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinogens; Cell Line, Tumor; Cell Proliferation; Cytarabine; Daunorubicin; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Phthalic Acids; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; RNA, Small Interfering; Up-Regulation | 2020 |
Morphological characteristics, cytogenetic profile, and outcome of RUNX1-RUNX1T1-positive acute myeloid leukemia: Experience of an Indian tertiary care center.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Sarcoma, Myeloid; Survival Rate; Translocation, Genetic; Vincristine | 2020 |
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines | 2020 |
A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia.
Topics: Acetamides; Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Butadienes; Cyclohexylamines; Daunorubicin; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplasm Proteins; Nitriles; Up-Regulation | 2020 |
Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma.
Topics: Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cytarabine; Daunorubicin; Epstein-Barr Virus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Neoplasms, Second Primary; Postoperative Complications; Programmed Cell Death 1 Receptor; Protoporphyria, Erythropoietic; Recurrence; Remission Induction; Virus Activation; Young Adult | 2020 |
[Newly Diagnosed Acute Myeloid Leukemia Patients-Derived Bone Marrow Mesenchymal Stem Cells Suppress Daunorubicin Induced HL-60 Cell Apoptosis via Modulating Caspase-3/Survivin].
Topics: Apoptosis; Bone Marrow Cells; Caspase 3; Cell Proliferation; Daunorubicin; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells; Survivin | 2019 |
Encapsulation of daunorubicin into Saccharomyces cerevisiae-derived lysosome as drug delivery vehicles for acute myeloid leukemia (AML) treatment.
Topics: Cell Proliferation; Cell Survival; Daunorubicin; Drug Compounding; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Lysosomes; Particle Size; rab GTP-Binding Proteins; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2020 |
Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Neoplasms, Second Primary; Treatment Outcome | 2019 |
Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
Topics: Antibiotics, Antineoplastic; Autophagy; Autophagy-Related Protein-1 Homolog; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; HL-60 Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Phosphorylation; U937 Cells | 2020 |
Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Young Adult | 2020 |
Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes | 2020 |
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
Topics: Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2020 |
ATG5 regulates mesenchymal stem cells differentiation and mediates chemosensitivity in acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Autophagy; Autophagy-Related Protein 5; Cell Cycle; Cell Differentiation; Cells, Cultured; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mesenchymal Stem Cells; Middle Aged; Tumor Cells, Cultured; Young Adult | 2020 |
Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 2020 |
Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and β1 integrin activation.
Topics: Adult; Aged; Daunorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Integrin beta1; Kangai-1 Protein; Leukemia, Myeloid, Acute; Male; Middle Aged; p38 Mitogen-Activated Protein Kinases; Protein Kinase C-alpha; RNA-Seq | 2020 |
Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Cohort Studies; Cytarabine; Daunorubicin; DNA Topoisomerases, Type II; Female; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Poly-ADP-Ribose Binding Proteins; RNA, Messenger; Topoisomerase II Inhibitors; Treatment Outcome; Young Adult | 2020 |
[Successful delivery after chemotherapy for acute myeloid leukemia diagnosed in the second trimester].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Cytarabine; Daunorubicin; Female; Humans; Japan; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Second; Remission Induction; Retrospective Studies | 2020 |
TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt/β-catenin signaling.
Topics: Antibiotics, Antineoplastic; Apoptosis; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Healthy Volunteers; Humans; Leukemia, Myeloid, Acute; Lithium Chloride; RNA, Small Interfering; Tripartite Motif Proteins; Ubiquitin-Protein Ligases; Wnt Signaling Pathway | 2020 |
Clinical efficacy of decitabine‑containing induction chemotherapy in de novo non‑elderly acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Survival Analysis; Treatment Outcome; Young Adult | 2020 |
Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Survival; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Array Analysis; SUMO-1 Protein; Sumoylation; Treatment Outcome; Ubiquitin; Young Adult | 2020 |
Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Disorders; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Dexamethasone; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Translocation, Genetic; Tretinoin | 2021 |
Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?
Topics: Alcohol Oxidoreductases; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Carbonyl Reductase (NADPH); Daunorubicin; Humans; Leukemia, Myeloid, Acute | 2020 |
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; SARS-CoV-2 | 2020 |
Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia.
Topics: Animals; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Cell Survival; Daunorubicin; DNA Damage; Drug Synergism; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Vorinostat; Xenograft Model Antitumor Assays | 2020 |
Chemosensitization by 4-hydroxyphenyl retinamide-induced NF-κB inhibition in acute myeloid leukemia cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Proliferation; Daunorubicin; Drug Synergism; Fenretinide; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; NF-kappa B; Tumor Cells, Cultured | 2020 |
Acute pancreatitis induced by combination chemotherapy used for the treatment of acute myeloid leukemia: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dasatinib; Daunorubicin; Female; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Pancreatitis; Tomography, X-Ray Computed | 2020 |
Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia.
Topics: Body Fluids; Daunorubicin; Humans; Kidney; Leukemia, Myeloid, Acute | 2020 |
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
Topics: Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Calreticulin; Cell Line, Tumor; Cytarabine; Daunorubicin; Dendritic Cells; Etoposide; Extracellular Space; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Immunogenic Cell Death; Leukemia, Myeloid, Acute; Lymphocyte Activation; Neoplasm Proteins; Organelles; Protein Transport; T-Lymphocyte Subsets; Vidarabine | 2020 |
Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2020 |
Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism.
Topics: Aldo-Keto Reductase Family 1 Member C3; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Colorectal Neoplasms; Daunorubicin; Drug Synergism; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; HCT116 Cells; Humans; Leukemia, Myeloid, Acute; Staurosporine | 2021 |
Benefit of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2020 |
A pediatric case of acute myeloid leukemia with KMT2A gene rearrangement t(10;11) and 16p11.2 microdeletion syndrome.
Topics: Antineoplastic Agents; Autistic Disorder; Child; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 16; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Histone-Lysine N-Methyltransferase; Humans; Intellectual Disability; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 3; Myeloid-Lymphoid Leukemia Protein; Vault Ribonucleoprotein Particles | 2021 |
Differential sensitivity of acute myeloid leukemia cells to daunorubicin depends on P2X7A versus P2X7B receptor expression.
Topics: Daunorubicin; Gene Expression; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Protein Isoforms; Receptors, Purinergic P2X7; RNA, Messenger | 2020 |
miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Mutation; Nuclear Proteins; Nucleophosmin; Principal Component Analysis; RNA, Small Interfering | 2021 |
Recurrent and reversible bilateral palmar blue discoloration following administration of liposomal daunorubicin-cytarabine (Vyxeos®) for acute myeloid leukemia with myelodysplasia-related changes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Myelodysplastic Syndromes | 2021 |
Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Erythema; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2022 |
Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 2021 |
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2021 |
Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Remission Induction; Sulfonamides; Treatment Outcome | 2021 |
Recognizing the potential for copper-related toxicities from liposomal daunorubicin--cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Copper; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 2021 |
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness.
Topics: Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Cycle Proteins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Microfilament Proteins; Neoplasm Proteins; Prognosis; Protein-Tyrosine Kinases; Survival Rate | 2021 |
Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2021 |
HDAC8 promotes daunorubicin resistance of human acute myeloid leukemia cells via regulation of IL-6 and IL-8.
Topics: Antibiotics, Antineoplastic; Cell Proliferation; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Histone Deacetylases; Humans; Interleukin-6; Interleukin-8; Leukemia, Myeloid, Acute; Repressor Proteins; RNA, Small Interfering; Tumor Cells, Cultured | 2021 |
Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).
Topics: Adult; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2021 |
NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cyclic AMP Response Element-Binding Protein; Daunorubicin; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; NADPH Oxidase 4; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Sulfonamides; U937 Cells | 2021 |
MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin.
Topics: Adult; Antibiotics, Antineoplastic; Apoptosis; Autophagy; Biomarkers, Tumor; Cell Proliferation; Daunorubicin; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Tumor Cells, Cultured | 2021 |
Zwitterion-functionalized hollow mesoporous Prussian blue nanoparticles for targeted and synergetic chemo-photothermal treatment of acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Drug Delivery Systems; Drug Screening Assays, Antitumor; Ferrocyanides; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Nanoparticles; Particle Size; Photothermal Therapy; Polyethyleneimine; Porosity; Surface Properties | 2021 |
CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2021 |
Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2022 |
Platelet Microparticles Decrease Daunorubicin-Induced DNA Damage and Modulate Intrinsic Apoptosis in THP-1 Cells.
Topics: Apoptosis; Blood Platelets; Cell-Derived Microparticles; Cells, Cultured; Daunorubicin; DNA Damage; Down-Regulation; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; THP-1 Cells | 2021 |
Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
Topics: Adult; Aged; Biomarkers, Tumor; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplastic Stem Cells; Prognosis; Retrospective Studies; Young Adult | 2021 |
FLT3 Mutation Testing in Acute Myeloid Leukemia.
Topics: Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Genetic Testing; Headache; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Leukostasis; Male; Middle Aged; Segmental Duplications, Genomic; Tandem Repeat Sequences; Vision Disorders | 2017 |
A three-dimensional
Topics: Benzylamines; Biomarkers; Cell Communication; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cyclams; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Heterocyclic Compounds; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Receptors, CXCR4; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment | 2017 |
Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Kelch-Like ECH-Associated Protein 1; Leukemia, Myeloid, Acute; Mutation; NF-E2-Related Factor 2; Protein Transport; Response Elements; Tumor Cells, Cultured | 2017 |
Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia.
Topics: Animals; Cell Line, Tumor; Daunorubicin; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Liposomes; Mice | 2017 |
A novel immunoliposome mediated by CD123 antibody targeting to acute myeloid leukemia cells.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Daunorubicin; Drug Delivery Systems; Humans; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Liposomes; Rats | 2017 |
Unexpected diagnosis of appendicitis in a paediatric patient with febrile neutropaenia and acute myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Febrile Neutropenia; Humans; Incidental Findings; Leukemia, Myeloid, Acute; Male; Tomography, X-Ray Computed | 2017 |
JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML).
Topics: Age Factors; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Genetic Therapy; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Societies, Medical | 2017 |
Acute myeloid leukaemia masquerading as a primary CNS tumour.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; fms-Like Tyrosine Kinase 3; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Sarcoma, Myeloid; Treatment Outcome | 2017 |
Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; DNA Damage; DNA Repair; Drug Therapy; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplastic Stem Cells; Young Adult | 2017 |
A case report of acute myelogenous leukemia with Turner Syndrome.
Topics: Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cytarabine; Daunorubicin; Female; Humans; Incidental Findings; Karyotype; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Turner Syndrome | 2017 |
Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Daunorubicin; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Humans; Kaplan-Meier Estimate; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Mixed Function Oxygenases; Proto-Oncogene Proteins; RNA Interference; STAT3 Transcription Factor; STAT5 Transcription Factor; THP-1 Cells | 2017 |
Targeting murine leukemic stem cells by antibody functionalized mesoporous silica nanoparticles.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Cell Line, Tumor; Daunorubicin; Drug Compounding; Gene Expression; Leukemia, Myeloid, Acute; Leukocyte Common Antigens; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Nanoparticles; Neoplasms, Experimental; Neoplastic Stem Cells; Protein Binding; Silicon Dioxide; Succinic Anhydrides; Tumor Cells, Cultured | 2018 |
Acute myeloid leukemia presenting as erythema nodosum: A case report.
Topics: Antineoplastic Agents; Bone Marrow Examination; Cytarabine; Daunorubicin; Erythema Nodosum; Fatal Outcome; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction | 2017 |
Major response of PNH to an AML chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cytarabine; Daunorubicin; Hemoglobinuria, Paroxysmal; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 2018 |
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2018 |
In brief: Two new drugs for AML.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Mutation; Treatment Outcome; Triazines | 2018 |
[Complete Remission Rate and Adverse Ractions of Three Different Chemotherapy Regimens in the Treatment of Adult Patients with Newly Diagnosed Non-M3 AML].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction | 2018 |
Genital ulcers as diagnostic clue for acute myeloid leukaemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; Fissure in Ano; Genitalia; Gingival Hyperplasia; Humans; Leukemia, Myeloid, Acute; Treatment Outcome; Young Adult | 2018 |
High dose daunorubicin: New standard of care for FLT3 ITD mutant AML.
Topics: Anthracyclines; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Standard of Care | 2018 |
Characteristics of adult patients treated for acute myeloid leukemia with inv 16 in Casablanca (Morocco).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chromosome Inversion; Chromosomes, Human, Pair 16; Core Binding Factor beta Subunit; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocytosis; Longitudinal Studies; Male; Middle Aged; Morocco; Myosin Heavy Chains; Oncogene Proteins, Fusion; Prognosis; Young Adult | 2018 |
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; United Kingdom; Vidarabine; Young Adult | 2018 |
(1-3)-β-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta-Glucans; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Aspergillosis; Retrospective Studies; Risk Factors; Triazoles; Vidarabine | 2019 |
Benefit of nanomedicine confirmed in sAML.
Topics: Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Nanomedicine | 2018 |
Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Daunorubicin; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Polycomb Repressive Complex 2; Proto-Oncogene Proteins c-mdm2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2018 |
CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
Topics: Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplasm Proteins; THP-1 Cells; Vidarabine | 2018 |
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.
Topics: Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Treatment of Childhood Acute Myeloid Leukemia in Bulgaria.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bulgaria; Child; Child, Preschool; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Retrospective Studies; Survival Rate; Vincristine; Young Adult | 2018 |
Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocytosis; Lomustine; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2018 |
Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Myeloid Cell Leukemia Sequence 1 Protein; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Experimental; Nitrophenols; Oncogene Proteins, Fusion; Piperazines; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Sulfonamides; THP-1 Cells | 2019 |
Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Renal Insufficiency; Treatment Outcome | 2019 |
Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Time Factors | 2019 |
Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Russia; Survival Rate; Young Adult | 2018 |
Health state utilities associated with treatment options for acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hospitalization; Humans; Induction Chemotherapy; Infusions, Intravenous; Interviews as Topic; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Economic; Patient Preference; Pilot Projects; Quality of Life; Socioeconomic Factors; Time Factors; United Kingdom | 2019 |
Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Topics: Aldo-Keto Reductase Family 1 Member C3; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Structure-Activity Relationship | 2019 |
G-quadruplex forming region within WT1 promoter is selectively targeted by daunorubicin and mitoxantrone: A possible mechanism for anti-leukemic effect of drugs.
Topics: Cell Line, Tumor; Circular Dichroism; Daunorubicin; Electrophoresis, Polyacrylamide Gel; Electrophoretic Mobility Shift Assay; G-Quadruplexes; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Promoter Regions, Genetic; WT1 Proteins | 2019 |
Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo.
Topics: Apoptosis; Cell Proliferation; Checkpoint Kinase 1; Cytarabine; Daunorubicin; G2 Phase Cell Cycle Checkpoints; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Protein Kinase Inhibitors; Tumor Cells, Cultured | 2019 |
Acute myeloid leukaemia: an unusual cause of biliary strictures.
Topics: Adolescent; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bile Ducts, Extrahepatic; Cholangiography; Cholangitis; Cholestasis; Constriction, Pathologic; Cytarabine; Daunorubicin; Drug Therapy; Humans; Jaundice, Obstructive; Leukemia, Myeloid, Acute; Male; Treatment Outcome | 2019 |
Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decitabine; Disease-Free Survival; DNA Methylation; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Duplication; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Retrospective Studies; Time Factors | 2019 |
The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Europe; Gemtuzumab; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Sialic Acid Binding Ig-like Lectin 3 | 2019 |
Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment.
Topics: Bone Marrow; Bone Marrow Cells; Cell Line; Cell Line, Tumor; Cytarabine; Cytochrome P-450 CYP3A; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Stromal Cells; Tumor Microenvironment; Up-Regulation | 2019 |
Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.
Topics: Acid Ceramidase; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Survival; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Flow Cytometry; HEK293 Cells; HL-60 Cells; Humans; In Vitro Techniques; Lentivirus; Leukemia, Myeloid, Acute; Mitoxantrone; NF-kappa B; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Tandem Mass Spectrometry | 2019 |
Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate; T-Lymphocytes, Cytotoxic; Young Adult | 2019 |
Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.
Topics: Animals; Cross-Linking Reagents; Daunorubicin; Disulfides; Humans; Lectins, C-Type; Leukemia, Myeloid, Acute; Mice, Inbred BALB C; Micelles; Nanoparticles; Neoplastic Stem Cells; Rats, Sprague-Dawley | 2019 |
Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia.
Topics: Abnormal Karyotype; Adolescent; Allografts; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Gene Expression Regulation, Leukemic; Genes, Mitochondrial; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mitochondrial Proteins; Neoplasm Proteins; Prognosis; Progression-Free Survival; Prospective Studies; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2019 |
HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/β-catenin signaling.
Topics: Antibiotics, Antineoplastic; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Movement; Daunorubicin; Disease Progression; Gene Expression Regulation, Neoplastic; HMGA2 Protein; Humans; Leukemia, Myeloid, Acute; Wnt Signaling Pathway | 2019 |
MicroRNA-33b regulates sensitivity to daunorubicin in acute myelocytic leukemia by regulating eukaryotic translation initiation factor 5A-2.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Daunorubicin; Drug Resistance, Neoplasm; Eukaryotic Translation Initiation Factor 5A; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Peptide Initiation Factors; RNA-Binding Proteins | 2020 |
Prenylation-dependent Ras inhibition by pamidronate inhibits pediatric acute myeloid leukemia stem and differentiated cell growth and survival.
Topics: Anilides; Annexin A5; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzothiazoles; Bone Density Conservation Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Child; Cytarabine; Daunorubicin; Drug Repositioning; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Pamidronate; Phenylurea Compounds; Primary Cell Culture; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; ras Proteins | 2019 |
Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cohort Studies; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Health Resources; Hospitals, Pediatric; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Logistic Models; Male; Odds Ratio; Poisson Distribution; Risk Assessment; Risk Factors; Thioguanine; Treatment Outcome; United States | 2013 |
EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Daunorubicin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; MDS1 and EVI1 Complex Locus Protein; Mice; Myeloid Cells; Proto-Oncogenes; Transcription Factors; Up-Regulation | 2013 |
Dermatic Scedosporium apiospermum infection after autologous bone marrow transplantation.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dermatomycoses; Drugs, Chinese Herbal; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Opportunistic Infections; Postoperative Complications; Pyrimidines; Scedosporium; Skin Ulcer; Transplantation Conditioning; Transplantation, Autologous; Triazoles; Voriconazole; Young Adult | 2013 |
[Analysis on clinical response of IA and DA regimens in the treatment of 74 newly diagnosed acute myeloid leukemia patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2013 |
Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Topics: 5'-Nucleotidase; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Cytidine Deaminase; Daunorubicin; Deoxycytidine Kinase; DNA Methylation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Inactivation, Metabolic; Kaplan-Meier Estimate; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Nucleophosmin; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Survival Analysis; Tandem Repeat Sequences; Topoisomerase I Inhibitors; Young Adult | 2013 |
Single-nucleotide polymorphisms in reductase genes are not associated with response to daunorubicin-based remission induction.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxidoreductases; Polymorphism, Single Nucleotide; Remission Induction; Young Adult | 2013 |
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA Interference; src-Family Kinases; Thiazoles; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays; Young Adult | 2013 |
[IAG regimen for patients with refractory/relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Young Adult | 2013 |
Post-chemotherapeutic resolution of acute myeloid leukaemia-induced gingival enlargement: a case report.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Early Detection of Cancer; Female; Follow-Up Studies; Gingiva; Gingival Hemorrhage; Gingival Overgrowth; Gingivitis, Necrotizing Ulcerative; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Remission Induction | 2012 |
Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.
Topics: Aged; Aged, 80 and over; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Risk; Severity of Illness Index; Treatment Outcome | 2013 |
Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prevalence; Prognosis; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2013 |
Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cells.
Topics: Antibiotics, Antineoplastic; Biomarkers, Tumor; Blood Coagulation; Cell Line, Tumor; Daunorubicin; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Phenotype; Phosphatidylserines | 2013 |
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
Topics: Antibiotics, Antineoplastic; Apoptosis; Casein Kinase II; Cell Growth Processes; Cell Line, Tumor; Daunorubicin; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Phenazines; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Transfection; Tumor Suppressor Protein p53 | 2013 |
inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Inversion; Chromosomes, Human, Pair 2; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Molecular Chaperones; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2014 |
Mutant DNMT3A clone evading chemotherapy and infiltrating central nervous system in a patient with molecularly good-risk acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Clone Cells; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Risk | 2014 |
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use Trials; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Filgrastim; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Methylprednisolone; Middle Aged; Neutropenia; Nucleophosmin; Recombinant Proteins; Remission Induction; Salvage Therapy; Thrombocytopenia | 2014 |
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Severity of Illness Index | 2014 |
Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Blood Cell Count; Critical Care; Cyclophosphamide; Cytarabine; Daunorubicin; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunocompromised Host; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Remission Induction; Retrospective Studies; Young Adult | 2014 |
Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Dexamethasone; Erythroid Cells; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Megakaryocytes; Mitoxantrone; Neoplasms, Second Primary; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Vincristine | 2014 |
Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotoxicity; Caspases; Chemistry, Pharmaceutical; Daunorubicin; Dendrimers; Drug Delivery Systems; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Micelles; Myocardium; Nanomedicine; Neoplastic Stem Cells; Rats; Rats, Sprague-Dawley | 2014 |
Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Base Sequence; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Staging; Prognosis; Prospective Studies; Remission Induction; Survival Rate | 2014 |
Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.
Topics: Anthracyclines; Cell Line, Tumor; Chromatography, High Pressure Liquid; Daunorubicin; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Resistance; Emetine; Flow Cytometry; Folate Receptor 2; Humans; Leukemia, Myeloid, Acute; Light; Liposomes; Male; Methotrexate; Polyethylene Glycols; Prostatic Neoplasms; Scattering, Radiation; Tumor Suppressor Protein p53 | 2014 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
[Contribution of PET/CT for the management of hepatosplenic candidiasis in hematology].
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Candidiasis, Invasive; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Daunorubicin; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hepatitis; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Splenic Diseases; Tomography, X-Ray Computed | 2014 |
Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Daunorubicin; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute; Liposomes; Maleimides; Mice; Mice, Nude; Peptides; Phosphatidylethanolamines; Polyethylene Glycols; Receptors, LDL; Tissue Distribution | 2014 |
Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Bone Marrow Cells; Cell Line, Tumor; Coculture Techniques; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Hematopoietic Stem Cells; Heterografts; Humans; Leukemia, Myeloid, Acute; Male; Mice, Inbred C57BL; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Pyrroles; RNA Interference; Stromal Cells; Sulfonamides | 2014 |
High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Topics: Adolescent; ADP-ribosyl Cyclase 1; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Chromosome Aberrations; Consolidation Chemotherapy; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Prognosis; RUNX1 Translocation Partner 1 Protein; Young Adult | 2014 |
The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cytarabine; Daunorubicin; Disease Models, Animal; Etoposide; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Nude; Microarray Analysis; Reactive Oxygen Species; SUMO-1 Protein; U937 Cells; Xenograft Model Antitumor Assays | 2014 |
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Egg Hypersensitivity; Etoposide; Female; Food Hypersensitivity; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Intestinal Diseases; Leukemia, Myeloid, Acute; Liver Diseases; Male; Middle Aged; Nut Hypersensitivity; Seafood; Tacrolimus; Transplantation Conditioning; Vidarabine | 2014 |
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Diarrhea; Drug Administration Schedule; Drug Evaluation; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult | 2014 |
Acquired factor VII deficiency associated with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bacteremia; Cytarabine; Daunorubicin; Factor VII; Factor VII Deficiency; Fatal Outcome; Granulocytes; Hematoma; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pseudomonas Infections | 2015 |
Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Male; Microarray Analysis; MicroRNAs; Middle Aged; Prognosis; Survival Analysis | 2015 |
Potential crosstalk of Ca2+-ROS-dependent mechanism involved in apoptosis of Kasumi-1 cells mediated by heme oxygenase-1 small interfering RNA.
Topics: Animals; Apoptosis; Calcium; Cell Line, Tumor; Cytochromes c; Daunorubicin; Endoplasmic Reticulum; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Mice; Reactive Oxygen Species; RNA, Small Interfering | 2014 |
Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Clinical Trials as Topic; Cytogenetic Analysis; Daunorubicin; Drug Administration Schedule; Female; Genotype; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis | 2015 |
Eccrine poromatosis in a patient with acute myeloid leukemia following chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Poroma; Stem Cell Transplantation; Sweat Gland Neoplasms | 2014 |
A "body armor" of leukemia cutis.
Topics: Adult; Antineoplastic Agents; Cell Movement; Daunorubicin; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Sarcoma, Myeloid; Skin; Skin Neoplasms; Transplantation, Homologous | 2015 |
Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2015 |
Long-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, India.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Female; Humans; India; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Pleiotropic effects of spongean alkaloids on mechanisms of cell death, cell cycle progression and DNA damage response (DDR) of acute myeloid leukemia (AML) cells.
Topics: Acetonitriles; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cyclohexenes; Daunorubicin; DNA Damage; Drug Synergism; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Oxidative Stress; Phosphorylation; Reactive Oxygen Species; Tumor Cells, Cultured | 2015 |
CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis.
Topics: Adult; Aged; Antineoplastic Agents; Case-Control Studies; Cell Lineage; Cytarabine; Daunorubicin; Female; Gene Expression; Humans; Immunity, Innate; Immunophenotyping; Interferon-gamma; Interleukin-7 Receptor alpha Subunit; Interleukins; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; Chemoradiotherapy; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Staging; Nucleophosmin; Phosphoric Monoester Hydrolases; Prognosis; Radiation, Ionizing; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tandem Repeat Sequences; Tumor Cells, Cultured; Young Adult | 2015 |
Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child Health Services; Child, Preschool; Comparative Effectiveness Research; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Health Information Systems; Hospitals, Pediatric; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Outcome and Process Assessment, Health Care; Young Adult | 2015 |
Evolving treatments in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy | 2015 |
Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fluconazole; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Pre-Exposure Prophylaxis; Remission Induction; Retrospective Studies; Survival Analysis; Triazoles | 2016 |
Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vincristine; Young Adult | 2015 |
Development and molecular characterization of polymeric micro-nanofibrous scaffold of a defined 3-D niche for in vitro chemosensitivity analysis against acute myeloid leukemia cells.
Topics: Biphenyl Compounds; Cell Adhesion; Cell Proliferation; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fibronectins; Humans; Lactic Acid; Leukemia, Myeloid, Acute; Nanocomposites; Nanofibers; Nitrophenols; Piperazines; Polyesters; Polymers; Polyurethanes; Sulfonamides; Tissue Scaffolds | 2015 |
Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Selection; Retrospective Studies; Survival Analysis; Young Adult | 2015 |
Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Delivery, Obstetric; Female; Humans; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic | 2015 |
RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Cytidine Deaminase; Daunorubicin; Deoxycytidine Kinase; Disease-Free Survival; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2015 |
Beyond the first glance: anthracyclines in AML.
Topics: Antibiotics, Antineoplastic; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male | 2015 |
Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Case-Control Studies; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Endostatins; Female; Fibroblast Growth Factors; Gene Expression; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; ROC Curve; Treatment Outcome | 2015 |
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.
Topics: Adoptive Transfer; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; Gene Expression; Humans; Immunocompromised Host; Immunoglobulin Fc Fragments; Interleukin-3 Receptor alpha Subunit; Killer Cells, Natural; Leukemia, Myeloid, Acute; Mice; Survival Analysis; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2015 |
Increased pressure alters plasma membrane dynamics and renders acute myeloid leukemia cells resistant to daunorubicin.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Membrane; Cell Survival; Daunorubicin; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Vapor Pressure | 2015 |
Heme oxygenase-1 plays a crucial role in chemoresistance in acute myeloid leukemia.
Topics: Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Heme Oxygenase-1; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; U937 Cells | 2015 |
N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia.
Topics: Acrylamides; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cytarabine; Daunorubicin; Drug Carriers; Drug Synergism; Drug Therapy, Combination; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Pyrimidines | 2016 |
Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Autoantigens; Cell Line, Tumor; Cytarabine; Daunorubicin; DNA Breaks, Double-Stranded; Female; Humans; Leukemia, Myeloid, Acute; Mi-2 Nucleosome Remodeling and Deacetylase Complex; Mice, Inbred NOD; Mice, SCID; RNA Interference; Tumor Cells, Cultured | 2015 |
High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Hematopoietic Stem Cells; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Macrolides; Mice; Microtubules; Neoplastic Stem Cells; Paclitaxel; Time Factors; Tubulin Modulators | 2015 |
Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Blast Crisis; Cell Line, Tumor; Cell Survival; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Piperidines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; RNA, Small Interfering; Signal Transduction | 2015 |
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Genome, Human; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mutation; Outcome Assessment, Health Care; Polymorphism, Genetic; Prognosis; Recurrence; RNA, Messenger; Sequence Analysis, RNA | 2015 |
Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Daunorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Myeloid, Acute; RNA-Binding Proteins; RNA, Small Interfering; Tumor Cells, Cultured | 2015 |
Limited efficacy of HLA-haploidentical peripheral blood stem cell infusion in treatment of elderly patients with acute myelogenous leukaemia.
Topics: Aged; Cytarabine; Daunorubicin; Female; Histocompatibility Testing; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation | 2017 |
Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2015 |
Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Karyotype; Leukemia, Myeloid, Acute; Treatment Outcome | 2016 |
Interactions Between Nutraceutical Supplements and Standard Acute Myeloid Leukemia Chemotherapeutics.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cytarabine; Daunorubicin; Dietary Supplements; Drug Interactions; Humans; Leukemia, Myeloid, Acute; U937 Cells | 2015 |
The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; China; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Gene Frequency; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Nuclear Proteins; Nucleophosmin; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-kit; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells.
Topics: Adenine; Cytarabine; Daunorubicin; Leukemia, Myeloid, Acute; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Experience with four consecutive BFM-based protocols for treatment of childhood with non-promyelocytic acute myeloblastic leukemia in Argentina.
Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Asparaginase; Child; Child, Preschool; Consolidation Chemotherapy; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Prednisone; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 2016 |
A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies | 2016 |
[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Topics: Cytarabine; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocyte Count; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Guideline Adherence; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Practice Guidelines as Topic | 2016 |
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.
Topics: Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Protein Stability; Sulfonamides | 2016 |
Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cytarabine; Daunorubicin; Echinocandins; Febrile Neutropenia; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lipopeptides; Male; Micafungin; Middle Aged; Mycoses; Prospective Studies; Young Adult | 2016 |
Targeting Notch-1 positive acute leukemia cells by novel fucose-bound liposomes carrying daunorubicin.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Daunorubicin; Female; Fucose; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Mice; Middle Aged; Molecular Targeted Therapy; Receptor, Notch1; Xenograft Model Antitumor Assays; Young Adult | 2016 |
Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Middle Aged; Renal Dialysis | 2016 |
Granulocyte infusion: benefit beyond neutrophils?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Granulocytes; Humans; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Middle Aged; Pulmonary Aspergillosis | 2016 |
Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.
Topics: Antineoplastic Agents; Bone Marrow; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Karyotype; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Real-Time Polymerase Chain Reaction; Recurrence; Remission Induction; Retrospective Studies; Sequence Analysis, DNA | 2016 |
The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies | 2016 |
Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Carcinogenesis; Daunorubicin; Gene Expression Regulation, Leukemic; Gene Knockout Techniques; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Myeloid-Lymphoid Leukemia Protein; Nitrophenols; Oncogene Proteins, Fusion; Piperazines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2016 |
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cause of Death; Clofarabine; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Treatment Outcome | 2017 |
Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Safety; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Alcohol Oxidoreductases; Antibiotics, Antineoplastic; Biotransformation; Daunorubicin; Drug Interactions; Female; Genetic Variation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Treatment Outcome; Young Adult | 2016 |
Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia.
Topics: Animals; Cell Survival; Cytosol; Daunorubicin; DNA Replication; Drug Resistance; Glycolysis; Hexokinase; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Nicotinamide Phosphoribosyltransferase; Proliferating Cell Nuclear Antigen; Protein Binding; Protein Transport | 2016 |
Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cytarabine; Dacarbazine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Iodobenzenes; Leukemia, Myeloid, Acute; Male; Paraganglioma; Radiation Tolerance; Temozolomide | 2017 |
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatin Assembly and Disassembly; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cells; Humans; Immunoblotting; Immunoprecipitation; Leukemia, Myeloid, Acute; Mass Spectrometry; Mice; Mutation; Nuclear Proteins; Nucleophosmin; Nucleosomes | 2016 |
Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Gene Expression; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Survival Analysis; Thioguanine; Tumor Suppressor Protein p53 | 2017 |
NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Daunorubicin; Down-Regulation; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Mutation; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Prednisone; Prognosis; Translocation, Genetic; Up-Regulation; Vincristine | 2017 |
In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
Topics: Animals; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Female; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Melphalan; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Phenylalanine; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Cell Communication; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Lysosomes; Male; Microscopy, Fluorescence; Middle Aged; Nanotubes; NF-kappa B; Signal Transduction; THP-1 Cells; Tumor Cells, Cultured | 2017 |
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytarabine; Daunorubicin; Disease Models, Animal; Female; Flow Cytometry; Humans; Immunoblotting; Leukemia, Myeloid, Acute; Male; Middle Aged; Monomeric GTP-Binding Proteins; Prognosis; Retrospective Studies; SAM Domain and HD Domain-Containing Protein 1; Young Adult | 2017 |
Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Young Adult | 2017 |
Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BRCA1 Protein; Cell Cycle; Checkpoint Kinase 1; Cytarabine; Daunorubicin; DNA Damage; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Panobinostat; Rad51 Recombinase; RNA Interference; Signal Transduction; THP-1 Cells; Transfection | 2017 |
Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mortality; Remission Induction; Republic of Korea; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Dosage; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Proto-Oncogene Proteins; Recurrence; Remission Induction; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2008 |
The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.
Topics: Acrylonitrile; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow; Cell Differentiation; Cell Proliferation; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Fluorescent Antibody Technique; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Point Mutation; Signal Transduction; Styrenes; Tissue Distribution; Tumor Cells, Cultured | 2008 |
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Busulfan; Cytarabine; Daunorubicin; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Prognosis; Proportional Hazards Models; Statistics, Nonparametric | 2008 |
Relapse of acute myeloid leukemia as isolated bilateral testicular granulocytic sarcoma in an adult.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Orchiectomy; Recurrence; Remission Induction; Sarcoma, Myeloid; Testicular Neoplasms | 2008 |
Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Busulfan; Carcinoma, Mucoepidermoid; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Image Processing, Computer-Assisted; Leukemia, Myeloid, Acute; Male; Neck Dissection; Neoplasms, Second Primary; Positron-Emission Tomography; Submandibular Gland Neoplasms; Thioguanine; Tomography, X-Ray Computed; Transplantation Conditioning | 2009 |
c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; Male; MAP Kinase Signaling System; Middle Aged; Mitogen-Activated Protein Kinase 8; Reactive Oxygen Species; U937 Cells | 2008 |
Recurrent episodes of fever and pancytopenia due to haemophagocytosis during maintenance therapy for acute myeloid leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Female; Fever; Humans; Leukemia, Myeloid, Acute; Lymphohistiocytosis, Hemophagocytic; Pancytopenia; Prednisone; Vincristine | 2008 |
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Cytogenetic Analysis; Daunorubicin; Decision Making; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Patient Selection; Practice Guidelines as Topic; Risk Factors; Survival Analysis | 2008 |
Reversal of drug resistance by silencing Survivin gene expression in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Cell Line, Tumor; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Gene Silencing; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Microtubule-Associated Proteins; Reverse Transcriptase Polymerase Chain Reaction; Survivin; Transfection | 2008 |
The effect of cantharidins on leukemic stem cells.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Arylamine N-Acetyltransferase; Basic-Leucine Zipper Transcription Factors; Bridged Bicyclo Compounds, Heterocyclic; Cantharidin; Caspases; Cell Cycle; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Enzyme Inhibitors; Female; Fetal Blood; Humans; Leukemia, Myeloid, Acute; Luminescence; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Phosphorylation; Proto-Oncogene Proteins c-myc; Snail Family Transcription Factors; STAT5 Transcription Factor; Stromal Cells; Survival Rate; Transcription Factors; Transplantation, Heterologous; Tumor Suppressor Protein p53 | 2009 |
Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antigens, Neoplasm; Blast Crisis; Cell Cycle; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Polymorphism, Genetic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Acute myelogenous leukemia presenting as acute infectious meningitis in a 7-year-old boy.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Ceftriaxone; Child; Chromosomes, Human, Pair 10; Cytarabine; Daunorubicin; Diagnosis, Differential; Escherichia coli Infections; Etoposide; Flow Cytometry; Gemtuzumab; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Male; Meningitis, Bacterial; Patient Transfer; Spinal Puncture; Trisomy | 2009 |
Continuous 24-h monitoring of electrocardiogram during anthracycline-based therapy in acute leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxins; Cytarabine; Daunorubicin; Electrocardiography; Female; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Monitoring, Physiologic | 2009 |
Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Leukemia, Myeloid, Acute; Sulfonamides | 2009 |
Laromustine: the return of alkylators to non-myeloablative therapy of AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Leukemia, Myeloid, Acute; Sulfonamides | 2009 |
DNA damage response as a biomarker in treatment of leukemias.
Topics: Adolescent; Adult; Aged; Ataxia Telangiectasia Mutated Proteins; Biomarkers; Cell Cycle Proteins; Child; Daunorubicin; DNA Damage; DNA Topoisomerases; DNA-Binding Proteins; Enzyme Inhibitors; Histones; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Topoisomerase Inhibitors; Tumor Suppressor Proteins | 2009 |
Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Harringtonines; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Young Adult | 2009 |
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; Child; Child, Preschool; Daunorubicin; Female; Follow-Up Studies; Germany; Heterozygote; Homozygote; Humans; Infant; Leukemia, Myeloid, Acute; Male; Methyltransferases; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Risk Factors; Vincristine | 2009 |
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Proliferation; Cytarabine; Daunorubicin; Drug Synergism; Flow Cytometry; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Piperazines; Quinazolines | 2009 |
Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cell Line, Tumor; Cytarabine; Cytotoxins; Daunorubicin; Drug Evaluation, Preclinical; Drug Synergism; Etoposide; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Models, Biological; Nitrophenols; Peptide Initiation Factors; Piperazines; Protein Biosynthesis; Protein Synthesis Inhibitors; Sulfonamides; Triterpenes; U937 Cells | 2010 |
Daunorubicin induces procoagulant response through phosphatidylserine exposure in red blood cells.
Topics: Antineoplastic Agents; Blood Coagulation; Case-Control Studies; Daunorubicin; Dose-Response Relationship, Drug; Erythrocytes; Humans; Leukemia, Myeloid, Acute; Phosphatidylserines; Time Factors | 2010 |
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Resistance, Neoplasm; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leupeptins; Male; Middle Aged; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured; U937 Cells | 2010 |
Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Apoptosis; Daunorubicin; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Tumor Cells, Cultured; Young Adult | 2009 |
Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.
Topics: Antibiotics, Antineoplastic; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cell Cycle; Cell Survival; Cytarabine; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Time Factors | 2009 |
Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Cellular Senescence; Cytarabine; Daunorubicin; Etoposide; Genes, ras; Humans; Leukemia, Myeloid, Acute; Mutation; ras Proteins; Tumor Suppressor Protein p53 | 2009 |
Mees lines and Beau lines after chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cytarabine; Daunorubicin; Docetaxel; Female; Humans; Leukemia, Myeloid, Acute; Nail Diseases; Taxoids | 2010 |
"I am older, not elderly," said the patient with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mercaptopurine | 2010 |
Intrathecal chemotherapy and meningeal relapses in myelomonocytic AML. A single institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Injections, Spinal; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Male; Meninges; Middle Aged; Mitoxantrone; Testis; Young Adult | 2010 |
[Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Erythroblasts; Female; Humans; Leukemia, Myeloid, Acute; Male; Megakaryocytes; Mitoxantrone; Remission Induction; Survival Rate | 2010 |
Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Core Binding Factors; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Stem Cell Transplantation; Survival Rate; Young Adult | 2010 |
Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors.
Topics: Adult; Aged; Animals; Azo Compounds; Cells, Cultured; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycogen Synthase Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Middle Aged; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; RNA, Small Interfering; Stem Cells | 2010 |
Heart transplant in a childhood leukemia survivor: a case report.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Combined Modality Therapy; Daunorubicin; Heart Failure; Heart Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Treatment Outcome; Young Adult | 2010 |
Neurological complications during treatment of childhood cancer: mind Wernicke encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Mercaptopurine; Methotrexate; Prednisone; Radiography; Vincristine; Wernicke Encephalopathy | 2010 |
Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antibodies, Viral; Antigens, Viral; Antineoplastic Agents; Antiviral Agents; Cytarabine; Cytomegalovirus; Cytomegalovirus Infections; Daunorubicin; Female; Humans; Hydroxyurea; Incidence; Italy; Leukemia, Myeloid, Acute; Male; Middle Aged; Monitoring, Physiologic; Phosphoproteins; Treatment Outcome; Viral Matrix Proteins; Young Adult | 2010 |
Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Child; Child, Preschool; Cytarabine; Cytokines; Daunorubicin; Drug Resistance, Neoplasm; Elafin; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinases; Prognosis; Receptors, TNF-Related Apoptosis-Inducing Ligand; Remission Induction; RNA, Messenger; Signal Transduction; Young Adult | 2009 |
Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Trisomy; Young Adult | 2010 |
An unusual case of acute myeloid leukemia: late isolated testicular relapse followed by isolated central nervous system relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Cytarabine; Daunorubicin; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Injections, Spinal; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Testicular Neoplasms; Thioguanine; Treatment Outcome | 2010 |
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2.
Topics: Chromosome Aberrations; Cytarabine; Daunorubicin; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Middle Aged; Translocation, Genetic | 2010 |
Questions regarding frontline therapy of acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Retreatment | 2010 |
Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Retreatment | 2010 |
Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Oxidoreductases; Antibiotics, Antineoplastic; Biotransformation; Blotting, Western; Chromatography, High Pressure Liquid; Daunorubicin; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymerase Chain Reaction; RNA, Messenger | 2010 |
[A case of del(16)(q22) in a patient with acute myeloid leukemia with complex karyotype].
Topics: Antimetabolites, Antineoplastic; Chromosome Deletion; Chromosomes, Human, Pair 16; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Monocyte-Macrophage Precursor Cells; Prognosis | 2010 |
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Trans-Activators; Transcriptional Regulator ERG; Treatment Outcome | 2010 |
Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Gene Expression Profiling; Humans; I-kappa B Proteins; Leukemia, Myeloid, Acute; Lymphocytes; Oligonucleotide Array Sequence Analysis; Pyrimidines | 2011 |
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cytarabine; Cytosine; Daunorubicin; Etoposide; Female; Flavonoids; Flow Cytometry; Gene Expression Profiling; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Vidarabine; Young Adult | 2011 |
Daunorubicin-induced hyperpigmentation.
Topics: Antibiotics, Antineoplastic; Daunorubicin; Drug Eruptions; Humans; Hyperpigmentation; Leukemia, Myeloid, Acute; Male; Middle Aged | 2010 |
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Aza Compounds; Base Sequence; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Genes, p53; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Mutation; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p14ARF; Vidarabine | 2011 |
Marine benthic cyanobacteria contain apoptosis-inducing activity synergizing with daunorubicin to kill leukemia cells, but not cardiomyocytes.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood Platelets; Cardiotonic Agents; Caspases; Cell Line, Tumor; Cyanobacteria; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Hepatocytes; Leukemia, Myeloid, Acute; Myocytes, Cardiac; Rats; Seawater; Thionucleotides; Transcription Factors | 2010 |
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Germany; Humans; Internet; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Predictive Value of Tests; Prognosis; Regression Analysis; Remission Induction; Risk Assessment; Risk Factors; Surveys and Questionnaires; Time Factors | 2010 |
Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Models, Theoretical; Regression Analysis | 2011 |
[Analysis of outocome of pirarubicin-based combination chemotherapy regimen in the treatment of newly diagnosed acute myeloid leukemia-a prospective, open, randomized and multicenter clinical trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prospective Studies | 2010 |
Blood consult: acute myeloid leukemia and the t(8;21)(q22;22).
Topics: Amino Acid Sequence; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation, Missense; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit | 2011 |
[Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Tumor Cells, Cultured; Young Adult | 2010 |
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome | 2011 |
Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cost-Benefit Analysis; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Health Care Costs; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 2011 |
Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; Treatment Outcome | 2011 |
Siblings presenting with progressive congenital aleukemic leukemia cutis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Siblings; Skin Neoplasms; Thioguanine | 2011 |
Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; China; Clinical Chemistry Tests; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Female; Harringtonines; Hematologic Tests; Hepatitis B; Homoharringtonine; Humans; Infant; Leukemia, Myeloid, Acute; Liver Failure; Male; Pancreatitis; Remission Induction; Secondary Prevention | 2011 |
Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Curcumin; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; G1 Phase; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Membrane Potential, Mitochondrial; Middle Aged; Poly(ADP-ribose) Polymerases; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; S Phase | 2011 |
P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Aurora Kinase B; Aurora Kinases; Cell Line, Tumor; Daunorubicin; Drug Resistance, Neoplasm; Female; Histones; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Organophosphates; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Quinazolines | 2011 |
Myeloid sarcoma in a child with acute myeloblastic leukaemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Cytosine; Daunorubicin; Etoposide; Exophthalmos; Humans; Leukemia, Myeloid, Acute; Male; Paranasal Sinus Neoplasms; Parotid Gland; Sarcoma, Myeloid | 2011 |
Treatment strategies in patients with core-binding factor acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Daunorubicin; Disease-Free Survival; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine | 2011 |
Beau's lines.
Topics: Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Nail Diseases; Nails; Treatment Outcome | 2011 |
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm Staging; Pilot Projects; Prognosis; Survival Rate; Young Adult | 2012 |
Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Heme Oxygenase-1; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Reactive Oxygen Species | 2011 |
Unexpected pancytopenia following treatment of acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Erythropoiesis; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Pancytopenia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Translocation, Genetic; Vincristine | 2012 |
Eccrine hidradenitis sine neutrophils: a toxic response to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Eccrine Glands; Female; Hidradenitis; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Neutrophils; Staphylococcal Skin Infections; Staphylococcus epidermidis | 2011 |
Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cell Proliferation; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinases; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction | 2012 |
Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
Topics: Adolescent; Adult; Aged; Animals; Antibiotics, Antineoplastic; Daunorubicin; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mice; Mice, SCID; Middle Aged; Mutation; Nucleophosmin; Prognosis; Treatment Outcome; Xenograft Model Antitumor Assays; Young Adult | 2011 |
Acute isolated transmural neutropenic gastritis.
Topics: Acute Disease; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Daunorubicin; Factor VII Deficiency; Female; Furans; Gastritis; Granulocyte Colony-Stimulating Factor; Humans; Incidental Findings; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Diffuse osteosclerosis-associated acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Middle Aged; Osteosclerosis; Remission Induction; Treatment Outcome | 2012 |
Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells.
Topics: Amino Acid Sequence; Antibiotics, Antineoplastic; Cell Line, Tumor; Daunorubicin; Drug Delivery Systems; Humans; Lectins, C-Type; Leukemia, Myeloid, Acute; Membrane Proteins; Nanoparticles; Neoplastic Stem Cells; Peptides; Protein Binding | 2012 |
Posterior reversible encephalopathy syndrome (PRES) during induction chemotherapy for acute myeloblastic leukemia (AML).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Posterior Leukoencephalopathy Syndrome; Young Adult | 2012 |
Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Daunorubicin; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Homologous; Young Adult | 2012 |
Nine years interval between first and second bone marrow transplantations and subsequent long-term survival--a case of acute myeloid leukemia with MLL-AF6 fusion gene.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clone Cells; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Mercaptopurine; Myeloid-Lymphoid Leukemia Protein; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Prednisolone; Recurrence; Remission Induction; Reoperation; Time Factors; Transplantation, Homologous; Vincristine | 2012 |
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome | 2012 |
Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Fatal Outcome; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Neoplasms, Multiple Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Platelet-Derived Growth Factor beta; Stem Cell Transplantation | 2012 |
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Daunorubicin; DNA Fingerprinting; DNA Mutational Analysis; Gene Duplication; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Nucleophosmin; Prognosis; Risk Assessment; Translocation, Genetic; Young Adult | 2012 |
Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cyclosporine; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Induction Chemotherapy; Karyotype; Leukemia, Myeloid, Acute; Lymphoid Progenitor Cells; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Statistics, Nonparametric; Young Adult | 2012 |
Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2012 |
Drug shortages delay cancer clinical trials.
Topics: Adenine Nucleotides; Aged; Antineoplastic Agents; Arabinonucleosides; Child; Clinical Trials as Topic; Clofarabine; Cytarabine; Daunorubicin; Drug Approval; Drug Industry; Drugs, Generic; Europe; Humans; Leukemia, Myeloid, Acute; National Cancer Institute (U.S.); Patient Selection; Survival Analysis; Time Factors; United States; United States Food and Drug Administration | 2012 |
Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia.
Topics: Activities of Daily Living; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Quality of Life; Treatment Outcome; Young Adult | 2012 |
Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cytarabine; Daunorubicin; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Hepatomegaly; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Middle Aged; Multivariate Analysis; Muscle Proteins; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-bcl-2; Splenomegaly; Treatment Outcome; Up-Regulation; Young Adult | 2012 |
[Lethal pulmonary hemorrhage caused by Stenotrophomonas maltophilia pneumonia in a patient with acute myeloid leukemia].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Fatal Outcome; Gram-Negative Bacterial Infections; Hemorrhage; Humans; Leukemia, Myeloid, Acute; Lung Diseases; Male; Middle Aged; Pneumonia, Bacterial; Stenotrophomonas maltophilia | 2012 |
Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Severity of Illness Index; Survival Analysis | 2012 |
Favorable outcome in a patient with vulvar mucormycosis during acute myeloid leukemia induction with medical management alone.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Mucormycosis; Vulvar Diseases | 2012 |
Disseminated Langerhans cell histiocytosis associated with acute myeloid leukaemia: complete remission with daunorubicin and cytarabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Histiocytosis, Langerhans-Cell; Humans; Leukemia, Myeloid, Acute; Lymph Nodes; Male; Palatine Tonsil; Remission Induction | 2013 |
Influence of chemotherapy on the lipid peroxidation and antioxidant status in patients with acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cytarabine; Daunorubicin; Female; Glutathione Peroxidase; Humans; Leukemia, Myeloid, Acute; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Superoxide Dismutase | 2012 |
An unusual initial manifestation of acute leukemia.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bone Marrow; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Paraneoplastic Syndromes; Skin Diseases, Papulosquamous | 2012 |
An extreme example of focal bone marrow involvement in acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Cytarabine; Daunorubicin; Humans; Ilium; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Sternum | 2013 |
A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Case Management; Child; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Dogs; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Forecasting; France; Haplorhini; Hematology; History, 20th Century; History, 21st Century; Humans; Leukemia, Myeloid, Acute; Male; Medical Oncology; Mercaptopurine; Middle Aged; National Institutes of Health (U.S.); Rats; Remission Induction; United States | 2013 |
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum | 2013 |
Treatment of acute myeloid leukemia: are we making progress?
Topics: Adult; Age Factors; Aged; Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Medical Oncology; Middle Aged; Prognosis; Remission Induction; Treatment Outcome | 2012 |
Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Cells; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; RNA, Messenger | 2013 |
A case report of acute myeloid leukemia after liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Cytarabine; Daunorubicin; Hepatitis B; Humans; Leukemia, Myeloid, Acute; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mitoxantrone; Oxides; Tretinoin | 2013 |
PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Survival; Cells, Cultured; Daunorubicin; Female; Flow Cytometry; Furans; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Pyridines; Pyrimidines; Signal Transduction; Young Adult | 2013 |
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Factors; Time-to-Treatment; Treatment Outcome; Young Adult | 2013 |
The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
Topics: Adolescent; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Child, Preschool; Daunorubicin; Flow Cytometry; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tetrazolium Salts; Thiazoles | 2002 |
A case of acantholytic dermatosis and leukemia cutis: cause or effect?
Topics: Acantholysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Skin; Skin Neoplasms; Treatment Outcome | 2002 |
Acute myelogenous leukemia following treatment with cyclosporin A in a nephrotic patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclosporine; Cytarabine; Daunorubicin; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Nephrotic Syndrome; Treatment Outcome | 2002 |
Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22).
Topics: Adolescent; Adult; Antineoplastic Agents; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Daunorubicin; Female; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Tumor Lysis Syndrome | 2002 |
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Remission Induction; Salvage Therapy | 2003 |
Long-term outcomes of acute myeloid leukemia in adults in Pakistan.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pakistan; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.
Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured | 2003 |
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
Topics: Acute Disease; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Daunorubicin; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Prognosis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Risk Factors; Tandem Repeat Sequences | 2003 |
Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Liposomes; Middle Aged; Ventricular Function, Left | 2003 |
The comprehensive evaluation on four indices of drug resistance in acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Cell Division; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Harringtonines; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Stem Cell Assay | 1999 |
A case of leukemia of the appendix presenting as acute appendicitis.
Topics: Aged; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendicitis; Appendix; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mercaptopurine; Sarcoma, Myeloid | 2003 |
Increased excretion of urine coproporphyrins during daunorubicin administration in patients affected by acute myelogenous leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Coproporphyrins; Daunorubicin; Erythrocytes; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Protoporphyrins | 2003 |
Acute myeloid leukemia presenting as non-neutropenic colitis in an infant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colitis; Colon; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Gastrointestinal Hemorrhage; Humans; Immunohistochemistry; Infant; Leukemia, Myeloid, Acute; Leukemic Infiltration; Leukocyte Common Antigens; Peroxidase; Sigmoidoscopy; Thioguanine | 2003 |
Adult T-biphenotypic acute leukaemia: clinical and biological features and outcome.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Cytogenetic Analysis; Daunorubicin; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Male; Prednisone; Retrospective Studies; Treatment Outcome; Vincristine | 2003 |
Cytologically distinct acute leukemia in sibs exposed to the same leukemogen.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzene; Cyclophosphamide; Daunorubicin; Fatal Outcome; HLA Antigens; Humans; Lacquer; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid, Acute; Male; Methotrexate; Occupational Diseases; Occupational Exposure; Siblings; Smoking; Steroids; Transportation; Vehicle Emissions; Vincristine | 1996 |
Relationship between daunorubicin concentration and apoptosis induction in leukemic cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; Caspase 3; Caspases; Daunorubicin; DNA Fragmentation; Flow Cytometry; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute | 2004 |
Biphasic acute myeloid leukemia with near-tetraploidy and immunophenotypic transformation.
Topics: Adult; Aneuploidy; Antigens, CD; Antigens, CD7; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; CD56 Antigen; Cell Size; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; DNA, Neoplasm; Fatal Outcome; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Transplantation, Homologous | 2004 |
Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Cell Count; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia, Myeloid, Acute | 2004 |
A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors; Treatment Outcome | 2004 |
Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Daunorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Recombinant Proteins; Remission Induction; Skin; Sweet Syndrome | 2004 |
Reversal of P-glycoprotein-mediated MDR by 5,7,3',4',5'-pentamethoxyflavone and SAR.
Topics: Adenosine Triphosphatases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Enzyme Activation; Flavonoids; Humans; Leukemia, Myeloid, Acute; Structure-Activity Relationship; Vincristine | 2004 |
Teaching cases from the Royal Marsden and St Mary's Hospitals case 28: a patient with acute leukemia with rare leukemic cells of unusual morphology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Lymph Nodes; Male; Middle Aged; Prognosis; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic | 2004 |
An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF.
Topics: Antineoplastic Agents; Blood Cells; Blood Coagulation; Cell Death; Cells, Cultured; Cytarabine; Daunorubicin; Granulocyte Precursor Cells; Granulocyte-Macrophage Colony-Stimulating Factor; HL-60 Cells; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Thromboplastin | 2004 |
[Infection control in neutropenia induced by high-dose cytarabine chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Laryngeal Mucosa; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Retrospective Studies; Risk; Streptococcal Infections | 2004 |
Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Retrospective Studies; Survival Analysis | 2005 |
[Influence of cytochrome C on apoptosis induced by daunorubicine in acute myeloid leukemia (AML) cells].
Topics: Antibiotics, Antineoplastic; Apoptosis; Cytochromes c; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Microscopy, Fluorescence; Tumor Cells, Cultured | 2005 |
Flow cytometric measurement of functional and phenotypic P-glycoprotein.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Clinical Trials as Topic; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Leukocyte Common Antigens; Microscopy, Fluorescence; Phenotype; Rhodamine 123 | 2005 |
Determination of caspase-3 activation fails to predict chemosensitivity in primary acute myeloid leukemia blasts.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Caspase 3; Caspases; Cell Death; Cell Line, Tumor; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Activation; Female; Humans; Kinetics; Leukemia, Myeloid, Acute; Male; Middle Aged; Spectrometry, Fluorescence; Tetrazolium Salts; Thiazoles | 2005 |
Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Biomarkers, Tumor; Blast Crisis; Cell Line, Tumor; Chromosome Aberrations; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Pilot Projects; Receptors, Cytokine; Stem Cell Factor; Treatment Outcome | 2006 |
Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.
Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Proliferation; Cytarabine; Daunorubicin; DNA; Etoposide; Flow Cytometry; Fluorescent Dyes; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydrocarbons, Chlorinated; Leukemia; Leukemia, Myeloid, Acute; Microscopy, Fluorescence; Oligopeptides; Organic Chemicals; Radiation-Protective Agents | 2005 |
Concomitant hairy cell and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Genetic Predisposition to Disease; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Stem Cell Transplantation | 2006 |
Acute leukaemia presenting as vulvar ulcers in an adolescent girl.
Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Risk Assessment; Treatment Outcome; Ulcer; Vulvar Diseases | 2005 |
A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia.
Topics: Antibiotics, Antineoplastic; Blast Crisis; Cell Adhesion; Cell Survival; Cells, Cultured; Culture Media, Conditioned; Daunorubicin; Drug Resistance, Neoplasm; Fibronectins; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Membrane Proteins; NF-kappa B; Osteoblasts; RNA, Small Interfering; Signal Transduction; U937 Cells; Wnt Proteins | 2006 |
[Expression of survivin and its location in bone marrow cells of childhood acute leukemia: relationship to therapeutic efficacy].
Topics: Adolescent; Apoptosis; Bone Marrow Cells; Child; Child, Preschool; Daunorubicin; Female; Humans; Immunohistochemistry; Infant; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survivin | 2006 |
Acute promyelocytic leukemia with secondary myelofibrosis -- case report and review of the literature.
Topics: Adult; Antibiotics, Antineoplastic; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Primary Myelofibrosis; Remission Induction | 2006 |
Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Structure-Activity Relationship; Thiazolidinediones; Troglitazone; U937 Cells | 2006 |
Acute myelogenous leukemia associated with Ollier disease.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 21; Cytarabine; Daunorubicin; Enchondromatosis; Etoposide; Gemtuzumab; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplastic Syndromes, Hereditary; Translocation, Genetic | 2008 |
A comparison of the in vitro cytotoxicity of daunorubicin and liposomal daunorubicin in pediatric acute leukemia.
Topics: Adolescent; Child; Child, Preschool; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Liposomes; Male | 2006 |
Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Topics: Acrylamides; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Combinations; Humans; K562 Cells; Leukemia, Myeloid, Acute; Melphalan; Methylnitronitrosoguanidine; Monocytes; NAD; Piperidines | 2006 |
Increased mortality with FLA compared with ADE chemotherapy in high-risk AML.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2006 |
Chemotherapy exposure increases leukemia cell stiffness.
Topics: Actins; Cytoskeleton; Daunorubicin; Dexamethasone; Humans; Jurkat Cells; Leukemia, Myeloid, Acute; Microfluidic Analytical Techniques; Microscopy, Atomic Force; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vascular Diseases | 2007 |
LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.
Topics: Alternative Splicing; Amino Acid Sequence; Apoptosis; Base Sequence; Cell Line, Tumor; Cyclic AMP; Daunorubicin; Drug Resistance, Neoplasm; Exons; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Lymphocyte Activation; Molecular Sequence Data; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger | 2007 |
Diffuse alveolar damage and hemorrhage in acute myelogenous leukemia treated with corticosteroids.
Topics: Adrenal Cortex Hormones; Aged; Antibiotics, Antineoplastic; Cytarabine; Daunorubicin; Female; Hemorrhage; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lung Diseases; Pulmonary Alveoli; Radiography | 2007 |
Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
Topics: Adult; Aged; Apoptosis; Daunorubicin; DNA Damage; Female; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Radiation, Ionizing; Tumor Suppressor Protein p53 | 2007 |
Trisomy 21 as a sole acquired abnormality in an adult Omani patient with CD7- and CD9-positive acute myeloid leukemia.
Topics: Adult; Antigens, CD; Antigens, CD7; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Cytogenetic Analysis; Daunorubicin; Down Syndrome; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Remission Induction; Tetraspanin 29; Treatment Outcome | 2007 |
The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Metabolic Clearance Rate; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis | 2008 |
Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Area Under Curve; Daunorubicin; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged | 2007 |
[A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Evidence-Based Medicine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Quality of Life; Retrospective Studies; Survival Rate; Vincristine | 2007 |
Relationship between in vitro chemosensitivity assessed with MTT assay and clinical outcomes in 103 patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Child; Child, Preschool; Coloring Agents; Cytarabine; Daunorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tetrazolium Salts; Thiazoles; Treatment Outcome | 2007 |
MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2008 |
[Discrepant results of ABO type of red cells and serum in a patient with acute myelogenous leukemia].
Topics: ABO Blood-Group System; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Grouping and Crossmatching; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2008 |
Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Harringtonines; Homoharringtonine; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis | 2008 |
Two cases of post-liver transplant acute myeloid leukemia in Korean adults: review of bibliographies and comparison with post-renal transplant acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Fatal Outcome; Female; Humans; Kidney Transplantation; Korea; Leukemia, Myeloid, Acute; Liver Transplantation; Male; Middle Aged; Treatment Outcome; Tretinoin | 2008 |
Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Chromosome Aberrations; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Furans; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Membrane Proteins; Mutation; Nerve Tissue Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Bone Marrow; Cell Nucleus; Cytarabine; Cytoplasm; Daunorubicin; Electrophoretic Mobility Shift Assay; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Leukemic; Humans; Immunoprecipitation; Leukemia, Myeloid, Acute; Mutation; NF-kappa B; Nuclear Proteins; Nucleophosmin; Tumor Cells, Cultured | 2008 |
Difficulty of peripheral blood stem cell collection after multiple consolidation therapy in acute myeloid leukemia.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Lenograstim; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Tissue and Organ Harvesting | 2008 |
Granulocyte colony stimulating factor increases drug resistance of leukaemic blast cells to daunorubicin.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Chemotherapy, Adjuvant; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myeloid Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Granulocyte Colony-Stimulating Factor | 2008 |
CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Cell Count; Cell Proliferation; Cytarabine; Daunorubicin; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Phenylenediamines; Rats; Rats, Inbred BN | 2008 |
Cytotoxic-induced fulminant hyperpyrexia.
Topics: Adult; Bleomycin; Daunorubicin; Disseminated Intravascular Coagulation; Female; Fever; Humans; Leukemia, Myeloid, Acute; Lymphoma; Middle Aged; Pyrogens | 1980 |
Disturbances of desmofibrinogenesis in pateints suffering from acute myeloblastic leukemia.
Topics: Adolescent; Adult; Cytarabine; Daunorubicin; Factor XIII; Fibrinogen; Free Radicals; Humans; Leukemia, Myeloid, Acute; Middle Aged; Solubility | 1980 |
[Experiences in the induction of remission and in maintenance therapy in acute myeloblastic leukemia in adults with the RAMPO scheme].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Vincristine | 1981 |
8;21 translocation in acute granulocytic leukaemia: cytological, cytochemical and clinical features.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, 6-12 and X; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Staining and Labeling; Thioguanine; Translocation, Genetic | 1984 |
Seven day cytosine arabinoside administered subcutaneously plus daunorubicin for remission induction in AML.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1983 |
Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Thioguanine; Time Factors | 1984 |
[Treatment of acute myeloid leukemia].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Delayed-Action Preparations; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Prednisone; Recurrence; Thioguanine; Vincristine | 1984 |
Prognostic factors in adult patients with acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Chromosome Aberrations; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prednisolone; Prognosis; Vincristine; Zinostatin | 1983 |
[Ring-shaped inclusions in an uncommon variety of acute myeloid leukemia (author's transl)].
Topics: Adolescent; Cytarabine; Daunorubicin; Female; Humans; Inclusion Bodies; Leukemia, Myeloid, Acute; Microscopy, Electron; Vincristine | 1981 |
Histomorphologic study of bone marrow in acute leukemia following chemotherapy and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bone Marrow Transplantation; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Thioguanine; Time Factors; Transplantation, Autologous; Vincristine; Whole-Body Irradiation | 1983 |
Haemopoietic patterns of acute leukaemia in remission: CFU-E and CFU-GM colony formation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Therapy, Combination; Erythrocytes; Female; Granulocytes; Hematopoietic Stem Cells; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Macrophages; Thioguanine; Time Factors | 1983 |
Extensive pulmonary infiltration by leukemic blast cells treated with irradiation.
Topics: Adult; Cerebral Hemorrhage; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Lung; Thioguanine | 1983 |
Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Leukocyte Count; Leukocytosis; Middle Aged | 1983 |
Plasma fibronectin deficiency during chemotherapy of acute myeloid leukaemia.
Topics: Adult; Aged; Bronchopneumonia; Cytarabine; Daunorubicin; Female; Fever; Fibronectins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1983 |
A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Daunorubicin; Doxorubicin; Humans; Leukemia, Myeloid, Acute | 1983 |
[Drug sensitivity of human acute myelocytic leukemia cells (HL-60) and normal human myelocytes (CFU-C) in a co-culture].
Topics: Adult; Cells, Cultured; Cytarabine; Daunorubicin; Drug Resistance; Female; Head and Neck Neoplasms; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vincristine | 1983 |
[Adriamycin-aclacinomycin therapy (AA therapy) for acute leukemia unresponsive to BH-AC-DMP therapy].
Topics: Aclarubicin; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone | 1983 |
Veno-occlusive disease of the liver in children following chemotherapy for acute myelocytic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Budd-Chiari Syndrome; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Daunorubicin; Drug Therapy, Combination; Female; Hepatic Veins; Humans; Leukemia, Myeloid, Acute; Liver Diseases; Male; Radionuclide Imaging; Thioguanine | 1983 |
Urinary excretion of beta-aminoisobutyrate and pseudouridine in acute and chronic myeloid leukemia.
Topics: Adult; Aminoisobutyric Acids; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Pseudouridine; Uridine | 1983 |
Graft-versus-host reaction in 3 adult leukaemia patients after transfusion of blood cell products.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Leukocytes; Male; Methotrexate; Middle Aged; Neutropenia; Prednisolone; Prednisone; Thioguanine; Transfusion Reaction; Vincristine | 1983 |
Acute myeloid leukemia in adults: experience at AIIMS.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Vincristine | 1983 |
[Daunomycin and atrial fibrillation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Child; Daunorubicin; Electrocardiography; Female; Heart Failure; Humans; Leukemia, Myeloid, Acute | 1983 |
Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Risk; Sepsis; Statistics as Topic; Thioguanine | 1984 |
[Clinical studies of BH-AC-DMP in adult acute nonlymphocytic leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1983 |
[Immediate cardiac toxicity of rubidazone. A case reversible by isoproterenol].
Topics: Antibiotics, Antineoplastic; Daunorubicin; Drug Hypersensitivity; Female; Hemodynamics; Humans; Isoproterenol; Leukemia, Myeloid, Acute; Middle Aged; Shock, Cardiogenic | 1983 |
[Use of carminomycin in adults with acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Carubicin; Cyclophosphamide; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisolone; Purines | 1984 |
Primary colonic plasmacytoma associated with acute myelogenous leukemia.
Topics: Adult; Colon; Colonic Neoplasms; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Plasmacytoma; Prednisolone | 1984 |
A stage classification for prognosis in adult acute myelogenous leukaemia based upon patients' age, bone marrow karyotype and clinical features.
Topics: Adolescent; Adult; Age Factors; Aged; Bone Marrow Cells; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Thioguanine | 1984 |
Macromolecular and cell cycle effects of different classes of agents inducing the maturation of human myeloblastic leukemia (ML-1) cells.
Topics: Cell Cycle; Cell Differentiation; Cell Line; Cycloheximide; Cytarabine; Dactinomycin; Daunorubicin; DNA Replication; Humans; Kinetics; Leucine; Leukemia, Myeloid, Acute; Protein Biosynthesis; Thymidine; Transcription, Genetic; Tretinoin; Tritium; Uridine | 1984 |
Chemotherapeutic susceptibility of human bone marrow progenitor cells and human myelogenous leukemia cells (HL-60) in co-culture: preliminary report.
Topics: Bone Marrow; Cell Communication; Cell Line; Cell Survival; Cells, Cultured; Daunorubicin; Drug Evaluation, Preclinical; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Vincristine | 1984 |
Acute myelogenous leukemia in pregnancy.
Topics: Adult; Cesarean Section; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Recurrence | 1984 |
Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Daunorubicin; DNA Replication; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Thioguanine | 1984 |
[Treatment of adult acute promyelocytic leukemia during the period of 1974-1982].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Deoxycytidine Monophosphate; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1984 |
[A case of refractory acute myeloblastic leukemia who achieved partial remission by high dose cytosine arabinoside].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Vincristine | 1984 |
Acute leukaemia in a defined geographic area--incidence, clinical history and prognosis.
Topics: Adolescent; Adult; Age Factors; Aged; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Preleukemia; Sweden; Thioguanine; Vincristine | 1984 |
[Differential cell growth inhibition and terminal differentiation induction by chemotherapeutic agents of a human acute myelogenous leukemia cell line (HL-60) in vitro].
Topics: Anthraquinones; Antineoplastic Agents; Cell Differentiation; Cell Division; Cell Line; Cell Survival; Cytarabine; Dactinomycin; Daunorubicin; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Phagocytes; Thioguanine; Vincristine | 1984 |
Non-cardiotoxic anthracycline regimens in the treatment of acute myeloblastic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1984 |
[Double minute chromosomes (DMs) in a case of acute myelocytic leukemia (M2: FAB classification)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Vincristine | 1984 |
[Analysis of the effect of cellular morphology on obtaining a complete remission in 99 cases of acute leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Middle Aged; Platelet Count; Prognosis | 1984 |
Daunorubicin accumulation by human myeloblasts varying in anthracycline resistance.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line; Daunorubicin; Drug Resistance; Humans; Leukemia P388; Leukemia, Myeloid, Acute; Naphthacenes | 1984 |
Bone marrow fibre content in acute myeloid leukaemia before and after treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Collagen; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Podophyllotoxin; Primary Myelofibrosis; Reticulin; Thioguanine | 1984 |
Treatment of acute non-lymphocytic leukemia with DCMP intensive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1984 |
[Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies | 1984 |
Life-threatening hypophosphatemia in a patient with acute myelogenous leukemia.
Topics: Acetazolamide; Cytarabine; Daunorubicin; Female; Glucose; Humans; Leukemia, Myeloid, Acute; Middle Aged; Phosphates; Sepsis; Sodium Chloride; Starvation | 1980 |
Retrospective analysis of treatment of acute myeloblastic leukemia in patients more than 55 years old.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thioguanine | 1982 |
[Acute leukaemia during pregnancy: favourable course of pregnancy in two patients treated with cytosine arabinoside and anthracyclines (author's transl)].
Topics: Adult; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Fetus; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Pregnancy; Pregnancy Complications; Remission, Spontaneous; Risk; Vincristine | 1980 |
Evaluation of drug-antibody conjugates in the treatment of human myelosarcomas transplanted in nude mice.
Topics: Animals; Antibodies, Neoplasm; Antibody Specificity; Antineoplastic Agents; Chlorambucil; Daunorubicin; Drug Combinations; Drug Therapy, Combination; Female; Humans; Immunotherapy; Leukemia, Experimental; Leukemia, Myeloid, Acute; Male; Methotrexate; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 1980 |
The efficiency of strict reverse isolation and antimicrobial decontamination in remission induction therapy of acute leukemia.
Topics: Acute Disease; Adult; Cytarabine; Daunorubicin; Decontamination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Patient Isolation; Retrospective Studies | 1980 |
High rate of long-term survivals in AML treated by chemotherapy and androgenotherapy: a pilot study.
Topics: Adolescent; Adult; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisone; Stanozolol; Vincristine; Virilism | 1980 |
Acute myeloblastic leukemia in elderly patients: treatment and prognostic factors.
Topics: Aged; Aldehydes; Cytarabine; Daunorubicin; Female; Humans; Infections; Infusions, Parenteral; Injections, Intravenous; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Pyruvaldehyde; Sex Factors | 1980 |
Predicting response to combination chemotherapy in acute myeloblastic leukemia--- a way to individualize treatment.
Topics: Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute | 1980 |
[Present-day treatment of acute leukemia in children].
Topics: Antineoplastic Agents; Asparaginase; Child; Cyclophosphamide; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisolone; Radiotherapy Dosage; Vincristine | 1980 |
Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia.
Topics: Adult; Biotransformation; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute | 1980 |
[Morphological characteristics of the pathomorphosis of acute leukemias treated with rubomycin and carminomycin].
Topics: Autopsy; Carubicin; Daunorubicin; Drug Evaluation; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute | 1980 |
Lithium and granulocytopenia during induction therapy of acute myelogenous leukemia: update of an ongoing trial.
Topics: Agranulocytosis; Bacterial Infections; Cytarabine; Daunorubicin; Fever; Humans; Leukemia, Myeloid, Acute; Lithium; Middle Aged; Neutropenia; Thrombocytopenia; Time Factors | 1980 |
A seven year laboratory and clinical experience with lithium carbonate as an adjuvant to cancer chemotherapy.
Topics: Bone Marrow Cells; Cells, Cultured; Cytarabine; Daunorubicin; Drug Therapy, Combination; Granulocytes; Humans; Leukemia, Myeloid, Acute; Leukocytosis; Lithium; Lymphoma, Non-Hodgkin; Methotrexate | 1980 |
Prediction of response to chemotherapy in acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Bone Marrow Cells; Cell Division; Child; Clone Cells; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis | 1980 |
Acute promyelocytic leukemia--clinical management of 15 patients.
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Doxorubicin; Female; Heparin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1980 |
Posttransfusion hepatitis in acute myelogenous leukemia. Effect on survival.
Topics: Adolescent; Adult; Aspartate Aminotransferases; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Hepatitis B; Humans; Infant; Leukemia, Myeloid, Acute; Liver Function Tests; Male; Middle Aged; Prognosis; Retrospective Studies; Thioguanine | 1980 |
Treatment of psoriasis with daunorubicin and cytarabine.
Topics: Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Psoriasis | 1980 |
Selective use of daunorubicin for remission-induction chemotherapy in acute non-lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine | 1980 |
[Results of treatment of exacerbation of myelocytic leukemia according to the TRAMPCO program].
Topics: Adult; Aged; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Prednisone; Thioguanine; Vincristine | 1980 |
[Results of complex treatment of adults with myeloblastic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisone; Vincristine | 1980 |
[Treatment of acute myeloblastic leukemia by the combination of daunorubicin (or rubidazone) and cytosine arabinoside (apropos of 76 cases)].
Topics: Acute Disease; Adult; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1980 |
Absence of the influence of age on remission rate and duration of remission in a group of thirty-four patients with acute myeloid leukaemia.
Topics: Adult; Age Factors; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine | 1980 |
Acute leukemia: early recognition can spell survival.
Topics: Aged; Antibiotics, Antineoplastic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 1981 |
Re-induction of complete remissions in adults with acute non-lymphocytic leukemia.
Topics: Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Thioguanine | 1981 |
[The trials of determination of acute leukemia blasts sensitivity against cytostatics (author's transl)].
Topics: Adult; Antineoplastic Agents; Asparaginase; Cells, Cultured; Cytarabine; Daunorubicin; Drug Evaluation, Preclinical; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Lymphocytes; Methotrexate; Middle Aged; Vincristine | 1981 |
Individual nuclear uptake patterns for adriamycin and daunomycin in human leukemia and lymphoma cells.
Topics: Cell Nucleus; Daunorubicin; Doxorubicin; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma | 1981 |
Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Female; Granulocytes; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Platelet Count; Platelet Transfusion; Thioguanine; Time Factors | 1981 |
Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP).
Topics: Aged; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pneumonia; Prednisone; Sepsis; Time Factors; Vincristine | 1981 |
Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Bone Marrow; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1980 |
Double minute chromosomes in a case of acute myelogenous leukemia resistant to chemotherapy.
Topics: Aged; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute | 1981 |
[Detection of cardiotoxic effect of rubidomycin under clinical conditions].
Topics: Adolescent; Adult; Daunorubicin; Depression, Chemical; Female; Heart Rate; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myocardial Contraction | 1981 |
Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
Topics: Animals; Cell Division; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia L1210; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice; Rats | 1981 |
[Cardiotoxic aspects of daunorubicin used in the treatment of acute myeloblastic and lymphoblastic leukoses].
Topics: Adult; Aged; Arrhythmias, Cardiac; Daunorubicin; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myocarditis | 1981 |
Bone marrow biopsy.
Topics: Bone Marrow; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 1981 |
Reducing the cardiotoxicity of anthracyclines by complex-binding to DNA: report of three cases.
Topics: Adult; Antibiotics, Antineoplastic; Daunorubicin; DNA; DNA Adducts; Doxorubicin; Female; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes | 1981 |
Eastern Cooperative Oncology Group study of the cytochemistry of adult acute myeloid leukemia by correlation of subtypes with response and survival.
Topics: Adult; Cytarabine; Daunorubicin; Histocytochemistry; Humans; Leukemia, Myeloid, Acute; Nervous System Neoplasms; Prognosis; Thioguanine; Vincristine | 1981 |
[Cardiac toxicity due to daunomycin].
Topics: Adult; Cardiomyopathies; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute | 1980 |
DNA damage by anthracycline drugs in human leukemia cells.
Topics: Carubicin; Cells, Cultured; Daunorubicin; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Evaluation; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prognosis | 1981 |
Effects of cytosine arabinoside on DNA synthesis as predictor for acute myelocytic leukemia (AML) patients' response to chemotherapy.
Topics: Bone Marrow; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Daunorubicin; DNA, Neoplasm; Doxorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Thymidine | 1981 |
Successful pregnancy in acute promyelocytic leukemia.
Topics: Adolescent; Daunorubicin; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Postpartum Period; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Recurrence | 1982 |
[Remission induction by ACM-A and BH-AC on acute promyelocytic leukemia which is resistant to DNR and CA (author's transl)].
Topics: Aclarubicin; Adult; Cytarabine; Daunorubicin; Drug Resistance; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Male; Naphthacenes | 1981 |
Treatment of acute myeloid leukaemia in children.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Thioguanine | 1982 |
Causes of initial remission induction failure in acute myelogenous leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Bacterial Infections; Cytarabine; Daunorubicin; Doxorubicin; Hemorrhage; Humans; Leukemia, Myeloid, Acute; Mycoses; Pneumonia; Prednisone; Vincristine | 1982 |
Retrospective analysis of 158 cases of adult acute leukaemia: factors influencing prognosis and treatment response.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Karyotyping; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Prognosis; Regression Analysis; Retrospective Studies; Thioguanine; Vincristine | 1982 |
[Carminomycin in the therapy of leukemias].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carubicin; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Time Factors | 1982 |
[Treatment of acute promyelocytic leukemia: comparison of the therapeutic effect of daunorubicin and "DCMP" regimen in remission induction treatment].
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisone | 1982 |
Multicentre study on intensified remission induction therapy for acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Time Factors | 1982 |
Uptake and metabolism of daunorubicin by human leukemia cells.
Topics: Acute Disease; Animals; Biotransformation; Cell Line; Chromatography, High Pressure Liquid; Daunorubicin; Humans; Leukemia; Leukemia, Experimental; Leukemia, Myeloid, Acute; Time Factors | 1982 |
[Treatment of acute leukemias].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Prognosis; Vincristine | 1982 |
Whether or not to administer Amphotericin to an immunosuppressed patient with hematologic malignancy and undiagnosed fever.
Topics: Agranulocytosis; Amphotericin B; Cytarabine; Daunorubicin; Decision Making; Esophagitis; Fever of Unknown Origin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses | 1981 |
[Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
Topics: Aclarubicin; Adult; Aged; Antibiotics, Antineoplastic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Random Allocation | 1982 |
The treatment of acute myelocytic leukemia in patients 30 years of age and younger.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Cytarabine; Daunorubicin; Doxorubicin; Drug Combinations; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Sulfamethoxazole; Thioguanine; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1982 |
Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Division; Cells, Cultured; Cytarabine; Daunorubicin; DNA Polymerase II; DNA, Neoplasm; Drug Screening Assays, Antitumor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Thioguanine | 1995 |
Acute nonlymphocytic leukemia complicated by Garcin's syndrome.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cranial Nerve Neoplasms; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Paralysis; Prednisolone; Recurrence; Syndrome; Zinostatin | 1995 |
[A case of acute myeloblastic leukemia invaded uterine cervix-diagnosed by changes in peripheral blood after G-CSF administration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Daunorubicin; Diagnosis, Differential; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Mercaptopurine; Middle Aged; Neoplasm Invasiveness; Prednisolone; Prednisone; Recombinant Proteins; Uterine Cervical Neoplasms; Vincristine | 1993 |
[Complete remission during administration of rhG-CSF in acute myeloblastic leukemia with pneumonia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Pancytopenia; Pneumonia; Prednisolone; Recombinant Proteins; Remission Induction | 1994 |
Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.
Topics: Antineoplastic Agents; Cell Cycle; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Male; Tumor Cells, Cultured | 1994 |
All-trans retinoic acid potentiates megakaryocyte colony formation: in vitro and in vivo effects after administration to acute promyelocytic leukemia patients.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Megakaryocytes; Tretinoin | 1994 |
The effect of basic and acidic fibroblast growth factors (bFGF and aFGF) on the growth of leukemic blast progenitors in acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Division; Cells, Cultured; Colony-Forming Units Assay; Colony-Stimulating Factors; Daunorubicin; Female; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Hematopoietic Stem Cells; Heparin; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins | 1995 |
Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells.
Topics: Apoptosis; Caffeine; Carboplatin; Cluster Analysis; Coloring Agents; Daunorubicin; Drug Resistance, Neoplasm; Flow Cytometry; G2 Phase; Gamma Rays; Gene Expression Regulation, Leukemic; Glutathione; GTP-Binding Proteins; HL-60 Cells; Humans; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Lymphoma, Non-Hodgkin; Multivariate Analysis; Oncogene Proteins v-fos; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; ras Proteins; S Phase; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1995 |
Dose-intensive treatment of acute myelogenous leukemia: improved survival?
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Patient Selection; Prognosis; Remission Induction; Sex Factors | 1995 |
Granulocyte colony-stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Interleukin-6; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphoma, Non-Hodgkin; Macrophage Colony-Stimulating Factor; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 1993 |
Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Daunorubicin; Drug Resistance; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Phenotype | 1993 |
Posttransfusion hepatitis after induction chemotherapy in acute nonlymphoblastic leukemia: implications for long-term management and outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hepatitis; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Time Factors; Transfusion Reaction; Treatment Outcome | 1995 |
Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia.
Topics: Adult; Aged; Cell Survival; Cytarabine; Daunorubicin; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Genetic Techniques; Humans; Hydrocortisone; Kinetics; Leukemia, Myeloid, Acute; Male; Middle Aged; Tretinoin; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Daunorubicin; Drug Resistance, Multiple; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Molecular Weight; Neoplasm Proteins; Tumor Cells, Cultured | 1995 |
Parallel studies of clonogenic leukaemia cells and the leukaemia cell population as a whole in acute myelogenous leukaemia.
Topics: Cell Cycle; Cell Division; Cytarabine; Daunorubicin; Gene Expression; Genes, myc; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-myb; Proto-Oncogene Proteins c-myc; Tritium; Tumor Stem Cell Assay | 1994 |
Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Catalase; Cell Survival; Computer Simulation; Daunorubicin; Drug Resistance, Multiple; Electron Spin Resonance Spectroscopy; Glutathione Peroxidase; Humans; Hydrogen Peroxide; Leukemia, Myeloid, Acute; Oxidants; Pentose Phosphate Pathway; Peroxides; Reactive Oxygen Species; tert-Butylhydroperoxide; Tumor Cells, Cultured | 1995 |
Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.
Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Daunorubicin; DNA Damage; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Molecular Weight | 1994 |
Acute myelogenous leukemia in pregnancy: fetal blood sampling and early effects of chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fetal Blood; Fetal Growth Retardation; Fetus; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Pregnancy; Pregnancy Complications, Neoplastic; Ultrasonography, Prenatal | 1994 |
Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Child; Daunorubicin; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Middle Aged; Neoplastic Stem Cells; Protein Kinase C; Rhodamine 123; Rhodamines; Staurosporine; Tumor Cells, Cultured | 1994 |
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Cladribine; Cytarabine; Daunorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluoresceins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1994 |
Teratogenic effects in a case of maternal treatment for acute myelocytic leukaemia--neonatal and infantile course.
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Craniosynostoses; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Phenotype; Pregnancy; Pregnancy Complications, Neoplastic; Thioguanine | 1994 |
Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Manitoba; Middle Aged; Multivariate Analysis; Neutropenia; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 1994 |
Acute myeloid leukaemia in patients with trisomy 21 (Down syndrome) treated by bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child, Preschool; Combined Modality Therapy; Cytosine; Daunorubicin; Down Syndrome; Female; Follow-Up Studies; Health Care Rationing; Humans; Infant; Leukemia, Myeloid, Acute; Male; Thioguanine; Treatment Outcome | 1994 |
Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carrier Proteins; Cell Survival; Cyclosporine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Middle Aged; Tumor Cells, Cultured; Verapamil | 1993 |
Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL.
Topics: Cell Survival; Cyclosporine; Daunorubicin; Drug Resistance; Drug Synergism; Female; Glycerol; Humans; Leukemia, Myeloid, Acute; Male; Tumor Cells, Cultured | 1994 |
The multiface morphology of acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cytarabine; Daunorubicin; Fatal Outcome; Female; Hematopoietic Stem Cells; Humans; Immunophenotyping; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction | 1993 |
Treatment of refractory undifferentiated acute myelogenous leukemia with all-trans-retinoic acid.
Topics: Aged; Base Sequence; Biopsy; Bone Marrow; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Data; Remission Induction; Tretinoin | 1994 |
Combination chemotherapy with DATV regimen in treatment of adult acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine; Vincristine | 1993 |
Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Chromosome Banding; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Peroxidase; Remission Induction; Thioguanine; Treatment Outcome | 1993 |
Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
Topics: Acute Disease; Aged; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 1994 |
Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia.
Topics: Adolescent; Adult; Daunorubicin; Drug Resistance; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors; Tumor Cells, Cultured; Verapamil | 1994 |
[The comparative evaluation of the efficacy of different therapeutic plans in acute nonlymphocytic leukemias].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Evaluation; Hematopoiesis; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Prednisolone; Remission Induction; Time Factors; Vincristine | 1993 |
Translocation (2;4)(p23;q25): an additional case of a new recurrent anomaly in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 4; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Translocation, Genetic | 1993 |
[Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Rate; Vinblastine; Vincristine | 1994 |
Comparative effects of racemic verapamil vs R-verapamil on normal and leukemic progenitors.
Topics: Bone Marrow Cells; Colony-Forming Units Assay; Daunorubicin; Drug Therapy, Combination; Erythroid Precursor Cells; Humans; Leukemia; Leukemia, Myeloid, Acute; Stem Cells; Stereoisomerism; Tumor Stem Cell Assay; Verapamil | 1993 |
Dynamics of interaction between DNA-specific antitumor agents and serum-contained cytokines in the initiation of ML-1 human myeloblastic leukemia cell differentiation.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Differentiation; Cytarabine; Cytokines; Dactinomycin; Daunorubicin; DNA, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Monocytes; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1993 |
Prediction of chemotherapy response in human leukemia using in vitro chemosensitivity test.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Coloring Agents; Cytarabine; Daunorubicin; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Tetrazolium Salts; Thiazoles | 1993 |
Changes in the oral microflora during cytotoxic chemotherapy in children being treated for acute leukemia.
Topics: Adolescent; Analysis of Variance; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Candida albicans; Candidiasis, Oral; Chi-Square Distribution; Child; Child, Preschool; Chlorhexidine; Colony Count, Microbial; Cytarabine; Daunorubicin; Etoposide; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Mouth; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Streptococcus mutans; Thioguanine; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine | 1993 |
Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Pilot Projects; Prospective Studies; Recurrence; Salvage Therapy; Tumor Stem Cell Assay | 1993 |
Prognostic significance of myeloperoxidase containing blast cells in acute myelogenous leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peroxidase; Prognosis; Recurrence; Remission Induction | 1993 |
Malignant fibrous histiocytoma following bone marrow transplantation for acute leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Combined Modality Therapy; Cytarabine; Daunorubicin; Graft vs Host Disease; Histiocytoma, Benign Fibrous; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Radiography | 1993 |
[Alterations in morphological and phenotypical features of leukemic cells relapse 7 years after onset in a case of acute non-lymphocytic leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Kidney Neoplasms; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Neoplasms, Second Primary; Prednisolone | 1993 |
Disseminated subcutaneous Nocardia asteroides abscesses in a patient after bone marrow transplantation.
Topics: Abscess; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Immunocompromised Host; Incidence; Leukemia, Myeloid, Acute; Mercaptopurine; Neutropenia; Nocardia asteroides; Nocardia Infections; Opportunistic Infections; Prednisolone; Remission Induction; Skin Diseases, Infectious | 1993 |
Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Base Sequence; Blast Crisis; Daunorubicin; Drug Resistance, Multiple; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 1996 |
Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Fungemia; Fungi; Humans; Intestinal Mucosa; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Mycoses; Remission Induction; Retrospective Studies | 1995 |
[Acute myelogenous leukemia with diabetes insipidus without desmopression administration by anti-leukemic chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Deamino Arginine Vasopressin; Diabetes Insipidus; Female; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Renal Agents | 1995 |
Translocation (12;15)(p13;q13) in a patient with relapsed acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Recurrence; Translocation, Genetic | 1996 |
Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo.
Topics: Antigens, CD34; Daunorubicin; Drug Resistance, Multiple; Humans; Idarubicin; Leukemia, Myeloid, Acute; Morpholines; Rhodamine 123; Rhodamines; Triamterene | 1996 |
Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Daunorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Medical Futility; Probability; Survival Rate; Treatment Outcome | 1996 |
Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Daunorubicin; Drug Resistance, Multiple; Humans; Leukemia, Myeloid, Acute; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 1996 |
Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy.
Topics: Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blotting, Northern; Blotting, Western; Cytarabine; Daunorubicin; Down-Regulation; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydrocortisone; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Remission Induction; RNA, Messenger; Transcription, Genetic; Transcriptional Activation; Tretinoin; Tumor Cells, Cultured | 1996 |
Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines.
Topics: Acetylcysteine; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buthionine Sulfoximine; Cell Differentiation; Daunorubicin; DNA Damage; DNA Nucleotidylexotransferase; DNA, Neoplasm; Free Radical Scavengers; Humans; Leukemia, Myeloid, Acute; Methionine Sulfoximine; Nucleosomes; Pyrrolidines; Thiocarbamates; Tumor Cells, Cultured; Verapamil | 1996 |
Intensive induction and consolidation chemotherapy in a young woman with acute myeloid leukemia and severe chronic renal failure.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Mitoxantrone | 1996 |
Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Daunorubicin; DNA Topoisomerases, Type II; Etoposide; Humans; Hydrogen-Ion Concentration; Idarubicin; Leukemia, Myeloid, Acute; Podophyllotoxin; Precipitin Tests; Topoisomerase II Inhibitors | 1996 |
Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Topics: Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Blast Crisis; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Humans; Hydrogen-Ion Concentration; Idarubicin; Isoenzymes; Leukemia, Myeloid, Acute; Poly-ADP-Ribose Binding Proteins; Prognosis; Tumor Cells, Cultured | 1996 |
Bilateral submandibular salivary gland enlargement during chemotherapy for acute myeloid leukaemia--beneficial effect of propranolol.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Propranolol; Submandibular Gland | 1996 |
Clonality switch in acute myeloid leukemia.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Clone Cells; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Dosage Compensation, Genetic; Female; Hematopoiesis; Heterozygote; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Prednisolone; Remission Induction; Thioguanine; Vincristine | 1996 |
Marked bone marrow eosinophilia at the time of relapse of acute myeloblastic leukaemia in association with the appearance of translocation t(12;20)(q24;q11).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Eosinophilia; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Remission Induction; Translocation, Genetic | 1996 |
Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carrier State; Chronic Disease; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Doxorubicin; Etoposide; Female; Hepatic Encephalopathy; Hepatitis B; Humans; Leucovorin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Vincristine | 1996 |
Topoisomerase activities in undifferentiated acute myeloblastic leukemias and monocytic differentiated leukemias.
Topics: Bone Marrow; Daunorubicin; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Humans; Idarubicin; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Topoisomerase II Inhibitors | 1997 |
[8;21 translocation acute myelocytic leukemia developing in the second trimester of pregnancy with successful delivery].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Female; Humans; Infant, Newborn; Labor, Obstetric; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Pregnancy; Pregnancy Complications, Neoplastic; Remission Induction; Translocation, Genetic | 1996 |
[The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Mitoxantrone; Neoplasm, Residual; Oncogene Proteins; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prednisolone; Recombinant Fusion Proteins; RNA, Messenger; Translocation, Genetic | 1997 |
[Early establishment of bone marrow hypoplasia by antileukemic chemotherapy with concurrent rhG-CSF in a case of acute myelogenous leukemia complicated with intestinal perforation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Duodenal Diseases; Granulocyte Colony-Stimulating Factor; Humans; Intestinal Perforation; Karyotyping; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Recombinant Proteins; Remission Induction | 1997 |
[Growth inhibitory effects of ubenimex on leukemic cell lines resistant to chemotherapeutic agents].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Division; Cytarabine; Daunorubicin; Depression, Chemical; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leucine; Leukemia, Myeloid, Acute; Mercaptopurine; Tumor Cells, Cultured | 1996 |
Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression.
Topics: Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Fluorescent Dyes; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rhodamines | 1997 |
Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vincristine | 1997 |
Altered intracellular distribution of daunorubicin in immature acute myeloid leukemia cells.
Topics: Antibiotics, Antineoplastic; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Blood Cells; Cell Nucleus; Colchicine; Cytochalasin B; Cytoplasm; Daunorubicin; Deoxyglucose; Fluorescent Antibody Technique, Indirect; Humans; Leukemia, Myeloid, Acute; Microscopy, Confocal; Monensin; Nigericin; Sodium Azide; Temperature; Tumor Cells, Cultured | 1997 |
Isolation and characterization of daunorubicin-resistant AML-2 sublines.
Topics: Adenosine Triphosphate; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Cell Separation; Cyanides; Cyclosporine; Daunorubicin; DNA Primers; Drug Resistance, Multiple; Humans; Leukemia, Myeloid, Acute; Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1997 |
Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Microscopy, Fluorescence; Tumor Cells, Cultured | 1997 |
[Treatment of acute myelogenous leukemia in patients more than 80 years old].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Quality of Life; Remission Induction | 1997 |
Disseminated tuberculosis treated with amikacin in a patient with acute myelocytic leukemia.
Topics: Abscess; Adrenal Gland Diseases; Aged; Amikacin; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Tuberculosis; Tuberculosis, Hepatic; Tuberculosis, Pulmonary | 1997 |
Acute myeloblastic leukemia in adults.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine; Treatment Outcome | 1995 |
Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Erythema; Female; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence | 1997 |
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Chromatography, High Pressure Liquid; Daunorubicin; Half-Life; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged; Regression Analysis | 1997 |
Functional multidrug resistance in acute myeloblastic leukaemia: a standardized flow cytometric assay for intracellular daunorubicin accumulation.
Topics: Antibiotics, Antineoplastic; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Microspheres | 1998 |
[Giant platelet-like cell fragments produced from abnormal promyelocytes in acute myelogenous leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Granulocytes; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Platelet Count; Prednisolone; Remission Induction | 1998 |
[Retrospective analysis of elderly patients > or = 60 years of age with acute leukemia].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; DNA; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Retrospective Studies; Vincristine | 1998 |
[Detection of multidrug resistance in patients with leukemia by using flow cytometry and RNA in situ hybridization].
Topics: Adult; Cyclosporine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression; Genes, MDR; Humans; Immunosuppressive Agents; In Situ Hybridization; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 1996 |
[Consolidation therapy with high-dose cytarabine and daunorubicin for prolonged disease free survival in acute myelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged | 1996 |
Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 11; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Platelet Count; Treatment Outcome; Trisomy | 1998 |
Physical performance in long-term survivors of acute leukaemia in childhood.
Topics: Adolescent; Antibiotics, Antineoplastic; Child; Child, Preschool; Daunorubicin; Doxorubicin; Echocardiography; Electrocardiography; Female; Heart Rate; Humans; Infant; Leukemia, Myeloid, Acute; Male; Oxygen Consumption; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quality of Life; Spirometry; Time Factors | 1998 |
Multidrug resistance phenotype in leukaemic cells from patients with acute myelocytic leukaemia can be detected with 99Tc(m)-MIBI.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Drug Resistance, Multiple; Humans; Leukemia, Myeloid, Acute; Technetium Tc 99m Sestamibi; Tumor Cells, Cultured | 1998 |
Multiple inflammatory pseudotumors of the liver associated with acute myeloblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cytarabine; Daunorubicin; Diagnosis, Differential; Granuloma, Plasma Cell; Humans; Leukemia, Myeloid, Acute; Liver Abscess; Liver Diseases; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mercaptopurine; Prednisolone; Tomography, X-Ray Computed | 1998 |
[Prognostic significance of CD7 expression in adult acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antigens, CD7; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Prognosis; Survival Rate; Thioguanine; Tretinoin | 1998 |
Remission of Crohn's disease following allogeneic bone marrow transplant for acute leukaemia.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bone Marrow Purging; Bone Marrow Transplantation; Crohn Disease; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Thioguanine; Transplantation, Homologous | 1998 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine | 1999 |
Chemotherapy-induced inflammation in seborrheic keratoses mimicking disseminated herpes zoster.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Daunorubicin; Diagnosis, Differential; Drug Eruptions; Female; Herpes Zoster; Humans; Keratosis, Seborrheic; Leukemia, Myeloid, Acute; Skin; Substance Withdrawal Syndrome | 1999 |
Transient effusive-constrictive pericarditis due to chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Echocardiography; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pericarditis, Constrictive; Tomography, X-Ray Computed | 1999 |
De novo acute myelogenous leukemia with trilineage myelodysplasia associated with t(8;21)(q22;q22).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Translocation, Genetic | 1999 |
Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance.
Topics: Antibiotics, Antineoplastic; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Bone Marrow Cells; Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Daunorubicin; Drug Resistance, Multiple; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Idarubicin; Idoxuridine; Leukemia, Myeloid, Acute; Verapamil | 1999 |
Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML.
Topics: Acridines; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Bone Marrow; Cell Survival; Cyclosporine; Daunorubicin; Gene Expression Regulation, Neoplastic; Humans; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Tetrahydroisoquinolines; Tumor Cells, Cultured | 1999 |
Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Blast Crisis; Bone Marrow Cells; Cyclosporine; Cyclosporins; Daunorubicin; Drug Resistance, Multiple; Flow Cytometry; Genes, MDR; Humans; Leukemia, Myeloid, Acute; Multidrug Resistance-Associated Proteins; Reproducibility of Results | 1999 |
The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Idarubicin; Immunohistochemistry; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Survival Rate; Tretinoin; Vault Ribonucleoprotein Particles | 1999 |
[Necrotizing fasciitis in sacrococcygeal pilonidal sinus in a patient with bone marrow aplasia. Treatment by large excision and closing by local flaps].
Topics: Adult; Anemia, Aplastic; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Fasciitis, Necrotizing; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Pilonidal Sinus; Sacrococcygeal Region; Surgical Flaps | 1999 |
Extramedullary myeloid cell tumour: presentation as anterior chest wall mass during AML relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Soft Tissue Neoplasms; Thoracic Neoplasms | 1999 |
In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Topics: Antineoplastic Agents; Blast Crisis; Calcium Channel Blockers; Daunorubicin; Dihydropyridines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Verapamil | 2000 |
[Cytoprotective effect of amifostine in children during induction therapy according to BFM-83: report on cases].
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Retrospective Studies | 1998 |
Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines.
Topics: Alkynes; Antineoplastic Agents; Camptothecin; Cell Survival; Cisplatin; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Glutathione Transferase; Glycine; Humans; Leukemia, Myeloid, Acute; Metallothionein; Paraquat; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Superoxide Dismutase; Tumor Cells, Cultured; Vincristine | 2000 |
Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Liver Neoplasms; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Prednisolone; Remission Induction; Reoperation | 2000 |
[Retrospective study of acute myelogenous leukemia in elderly patients: treatment and outcome of 83 consecutive patients].
Topics: Age Factors; Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Therapy, Combination; Gene Deletion; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin | 2000 |
Do de novo acute myeloid leukemias with normal cytogenetics involve two main prognostic categories distinguished by the presence of erythroblastic and/or megakaryocytic dysplasia?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Erythroblasts; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Megakaryocytes; Middle Aged; Prognosis; Treatment Outcome | 2000 |
[A study on apoptotic cell death during chemotherapy of patients with acute leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Tretinoin; Vincristine | 1998 |
[Clinical study of childhood acute myelogenous leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Daunorubicin; Doxorubicin; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Prognosis; Retrospective Studies | 1998 |
[Study on combined chemosensitivity test in acute non-lymphocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1998 |
Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: implication of granzyme B and perforin.
Topics: Antigens, CD34; Antineoplastic Agents; Cell Survival; Coumarins; Cytarabine; Cytotoxicity Tests, Immunologic; Daunorubicin; DNA, Antisense; Edetic Acid; Etoposide; Flow Cytometry; Granzymes; HeLa Cells; Humans; Isocoumarins; Jurkat Cells; K562 Cells; Leukemia, Myeloid, Acute; Magnesium Chloride; Membrane Glycoproteins; Perforin; Pore Forming Cytotoxic Proteins; Serine Endopeptidases; Tumor Cells, Cultured; U937 Cells | 2000 |
[Childhood acute myeloblastic leukemias. Report of 21 cases].
Topics: Adolescent; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis | 2000 |
Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.
Topics: Antibiotics, Antineoplastic; Daunorubicin; Drug Administration Schedule; Erythema; Female; Foot; Hand; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Paresthesia; Salvage Therapy | 2000 |
Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic l
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Death; Clone Cells; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction; Vidarabine | 2000 |
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2001 |
Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5).
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Cycle; Cell Division; Coculture Techniques; Colony-Forming Units Assay; Culture Media, Conditioned; Cytarabine; Daunorubicin; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Leukocyte Common Antigens; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; Stromal Cells; Tumor Cells, Cultured | 2001 |
Cell cycle regulatory protein expression in fresh acute myeloid leukemia cells and after drug exposure.
Topics: Apoptosis; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cyclin D; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Cytarabine; Daunorubicin; DNA Damage; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Microtubule-Associated Proteins; Protein Serine-Threonine Kinases; Retinoblastoma Protein; Stem Cell Factor; Tumor Suppressor Proteins | 2001 |
[Primary pulmonary manifestation of extramedullary acute myelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bronchoalveolar Lavage Fluid; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Middle Aged; Prednisolone; Radiography; Thioguanine; Vincristine | 2001 |
In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Child; Daunorubicin; Drug Combinations; Emulsions; Female; Humans; K562 Cells; Leukemia, Myeloid, Acute; Lipoproteins, LDL; Male; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; Tumor Stem Cell Assay | 2001 |
Cocaine-contaminated allogeneic bone marrow transplantation.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bone Marrow Transplantation; Cocaine-Related Disorders; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Female; Graft Survival; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Marijuana Abuse; Middle Aged; Recurrence; Salvage Therapy; Thrombocythemia, Essential; Tissue and Organ Procurement; Tissue Donors; Transplantation, Homologous | 2001 |
An adjustment for a post-randomization variable in the comparison of two treatments for survival.
Topics: Antibiotics, Antineoplastic; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Likelihood Functions; Models, Biological; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2001 |
Generalized hyperpigmentation with daunorubicin chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Black People; Daunorubicin; Humans; Hyperpigmentation; Leukemia, Myeloid, Acute; Male | 2002 |
Herpesvirus-6 encephalitis complicated by Wernicke-Korsakoff syndrome in a pediatric recipient of unrelated cord blood transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Encephalitis, Viral; Etoposide; Fatal Outcome; Female; Fetal Blood; Foscarnet; Ganciclovir; Hematopoietic Stem Cell Transplantation; Herpesvirus 6, Human; Humans; Immunocompromised Host; Korsakoff Syndrome; Leukemia, Myeloid, Acute; Recurrence; Roseolovirus Infections; Transplantation Conditioning; Transplantation, Homologous; Virus Activation | 2001 |
[Intermediate doses of cytosine arabinoside in the treatment of acute non-lymphoblastic leukaemia in children].
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Poland; Prednisone; Remission Induction; Retrospective Studies; Risk Factors; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
Bone marrow transplantation in acute leukemia using intensive chemoradiotherapy (SCARI--UCLA).
Topics: ABO Blood-Group System; Adolescent; Adult; Bone Marrow Cells; Bone Marrow Transplantation; Candidiasis; Child; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Daunorubicin; Graft vs Host Reaction; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged; Radiation Chimera; Thioguanine; Transplantation, Homologous | 1976 |
Bone marrow transplantation with intensive combination chemotherapy/radiation therapy (SCARI) in acute leukemia.
Topics: Adolescent; Adult; Bone Marrow Cells; Bone Marrow Transplantation; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Graft vs Host Reaction; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Thioguanine; Time Factors; Transplantation, Homologous | 1977 |
Bone-marrow-profileration patterns in acute myeloblastic leukaemia determined by pulse cytophotometry.
Topics: Autoradiography; Bone Marrow; Bone Marrow Cells; Cell Count; Cell Division; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Photometry; Remission, Spontaneous; Thioguanine; Tritium | 1975 |
Quality and quantity of survival in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Allopurinol; Bacterial Infections; Cytarabine; Daunorubicin; Drug Therapy, Combination; Focal Infection, Dental; Follow-Up Studies; Humans; Length of Stay; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Philosophy; Quality of Life; Remission, Spontaneous | 1975 |
Letter: Early onset of daunorubicin (daunomycin) cardiotoxicity.
Topics: Adult; Daunorubicin; Female; Heart Arrest; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Time Factors | 1975 |
Symptomatic hypophosphatemia secondary to 5-azacytidine therapy of acute nonlymphocytic leukemia.
Topics: Adult; Azacitidine; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Phosphates; Prednisone; Pregnancy; Pregnancy Complications; Thioguanine; Vincristine | 1976 |
High remission-induction rate in acute myeloid leukaemia.
Topics: Administration, Oral; Adult; Age Factors; Aged; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine; Time Factors | 1977 |
Chemotherapeutic remissions in Wistar Furth rat acute myelogenous leukemia: a model for human AML.
Topics: Animals; Antineoplastic Agents; Busulfan; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Dexamethasone; Disease Models, Animal; Doxorubicin; Leukemia, Experimental; Leukemia, Myeloid, Acute; Methotrexate; Rats; Remission, Spontaneous; Vinblastine; Vincristine | 1977 |
D.A.T. (daunorubicin, cytarabine, 6-thioguanine) in acute myeloid leukaemia.
Topics: Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous; Thioguanine | 1978 |
The nature of remission in acute myeloblastic leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission, Spontaneous; Thioguanine; Transplantation, Homologous | 1979 |
Acute eosinophilic leukemia. An ultrastructural study.
Topics: Adult; Bone Marrow; Cytarabine; Daunorubicin; Eosinophils; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Prednisone; Recurrence | 1978 |
A 13-years remission in chronic myelocytic leukemia after a single course of busulfan.
Topics: Adult; Busulfan; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Remission, Spontaneous; Time Factors | 1978 |
Drug-induced kinetic perturbations of the marrow blasts in acute leukemia. Effects of the daunorubicin, cytosine arabinoside and 6-thioguanine combination.
Topics: Adolescent; Adult; Bone Marrow; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitotic Index; Thioguanine | 1979 |
Oscillations of marrow culture growth in acute myeloid leukemia during remission induction and remission.
Topics: Adult; Bone Marrow; Colony-Forming Units Assay; Culture Techniques; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Thioguanine | 1979 |
Acute promyelocytic leukemia in childhood. Report of a case with a review of the literature.
Topics: Bone Marrow; Child; Cytodiagnosis; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Sepsis; Thrombocytopenia | 1979 |
Childhood cancer: the improving prognosis.
Topics: Asparaginase; Child; Cyclophosphamide; Cytosine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Hodgkin Disease; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Melphalan; Mercaptopurine; Methotrexate; Neoplasms; Nitrogen Mustard Compounds; Osteosarcoma; Prednisone; Procarbazine; Prognosis; Remission, Spontaneous; Rhabdomyosarcoma; Teniposide; Thioguanine; Vincristine; Wilms Tumor | 1976 |
Anthracycline cardiotoxicity and acute myelogenous leukaemia.
Topics: Adult; Daunorubicin; Doxorubicin; Heart Failure; Humans; Leukemia, Myeloid, Acute | 1977 |
[Induction and maintenance treatment of acute myelogenous leukemia in adults by sequential use of combination chemotherapy (author's transl)].
Topics: Adult; Aged; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Remission, Spontaneous; Thioguanine; Time Factors; Vincristine | 1977 |
Multiple-drug chemotherapy for acute leukemia The TRAMPCOL regimen: results in 86 patients.
Topics: Adolescent; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Methotrexate; Prednisolone; Remission, Spontaneous; Thioguanine; Vincristine | 1977 |
Prolonged remission maintenance in acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Remission, Spontaneous; Thioguanine; Vincristine | 1977 |
[Treatment of acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Aging; Asparaginase; Child; Child, Preschool; Daunorubicin; Humans; Infant; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Methotrexate; Remission, Spontaneous; Time Factors | 1977 |
A phase 1 and 2 trial of rubidazone in patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Bone Marrow; Daunorubicin; Doxorubicin; Drug Evaluation; Female; Heart Failure; Humans; Kidney; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Mucous Membrane; Remission, Spontaneous; Time Factors | 1977 |
Chemoimmunotherapy in acute myelocytic leukemia.
Topics: Antineoplastic Agents; Asparaginase; Child; Daunorubicin; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Remission, Spontaneous; Vincristine | 1977 |
Acute myelogenous leukemia as a late complication of the multimodality therapy for Hodgkin's disease.
Topics: Adult; Biopsy; Bone Marrow; Cytarabine; Daunorubicin; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Male; Mechlorethamine; Prednisone; Procarbazine; Radiotherapy; Thrombocytopenia; Vinblastine; Vincristine | 1977 |
[Treatment of acute myelogenous leukemia in adults; an account of the years 1968 to 1975].
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Life Expectancy; Male; Middle Aged; Remission, Spontaneous; Thioguanine; Vincristine | 1977 |
Time relationship between last dose of daunorubicin and congestive heart failure.
Topics: Adolescent; Adult; Child; Child, Preschool; Daunorubicin; Heart Failure; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Time Factors | 1977 |
Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission, Spontaneous; Thioguanine | 1977 |
Nuclear labelling of leukaemic blast cells with tritiated thymidine triphosphate after daunomycin.
Topics: Aged; Bone Marrow; Bone Marrow Cells; Cell Nucleus; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Mitotic Index; Thymine Nucleotides; Time Factors | 1977 |
[Results and problems in the treatment of childhood leukaemia (author's transl)].
Topics: Age Factors; Child; Cytarabine; Daunorubicin; Humans; Hungary; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Thioguanine; Vincristine | 1978 |
[Long term remission in acute myelogenous leukemia in adults].
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Prognosis; Remission, Spontaneous; Vincristine | 1978 |
Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.
Topics: BCG Vaccine; Cytarabine; Daunorubicin; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Remission, Spontaneous; Time Factors | 1978 |
[Trysomy of chromosome 1 long arms plus chromosome 9 inversion in leukaemic cells (author's transl)].
Topics: Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Trisomy | 1978 |
[Delivery of a normal child after chemotherapy of acute promyelocytic leukaemia during pregnancy (author's transl)].
Topics: Cesarean Section; Cytarabine; Daunorubicin; Female; Humans; Infant, Newborn; Infant, Premature; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Hematologic; Remission, Spontaneous | 1978 |
[Studies on the cardiotoxicity of daunomycin in patients with acute leukemia].
Topics: Arrhythmias, Cardiac; Child; Child, Preschool; Daunorubicin; Electrocardiography; Female; Heart; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male | 1978 |
[Acute hyperuricemia as an oncological emergency].
Topics: Adult; Allopurinol; Daunorubicin; Drug Therapy, Combination; Humans; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Prednisone; Uric Acid | 1978 |
[Spontaneous intracerebral hematoma during acute promyelocytic leukemia].
Topics: Adult; Cerebral Hemorrhage; Daunorubicin; Disseminated Intravascular Coagulation; Hematoma; Humans; Leukemia, Myeloid, Acute; Male | 1978 |
[Progress in the treatment of acute leukemias].
Topics: Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine | 1978 |
Vincristine (NSC-67574), cytosine arabinoside (NSC-63878), 6 thioguanine (NSC-752) and daunorubicin (NSC-82151) (VAT-D): a pilot study of combination chemotherapy for remission induction in acute myeloid leukemia in adults.
Topics: Adolescent; Adult; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Pilot Projects; Remission, Spontaneous; Thioguanine; Vincristine | 1978 |
Normal and leukemic hemopoiesis compared.
Topics: Cell Survival; Colony-Forming Units Assay; Daunorubicin; Doxorubicin; Erythropoiesis; Granulocytes; Hematopoiesis; Humans; In Vitro Techniques; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Phytohemagglutinins | 1978 |
[Treatment of therapy-resistant acute non-lymphocytic leukemia with PADOC (author's transl)].
Topics: Adult; Aged; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Vincristine | 1978 |
[A case of acute promyelocytic leukemia with skin nodules and mammary tumors during hematologic remission (author's transl)].
Topics: Adult; Breast Neoplasms; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous; Skin Neoplasms | 1978 |
Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction.
Topics: Adolescent; Adult; Blood Coagulation Factors; Blood Coagulation Tests; Chemical Precipitation; Daunorubicin; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Female; Heparin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Plasma; Prednisone; Remission, Spontaneous | 1978 |
Normal infant after treatment of acute myeloid leukaemia in pregnancy with daunorubicin.
Topics: Adult; Cytosine; Daunorubicin; Female; Fetus; Humans; Infant, Newborn; Labor, Induced; Leukemia, Myeloid, Acute; Male; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Thioguanine | 1978 |
[PADOC therapy of aged patients with acute non-lymphocytic leukemia (author's transl)].
Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Vincristine | 1978 |
[Therapy of adult myeloblastic leukemia in complete remission with modified TRAP, COAP and POMP cycles].
Topics: Adult; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Thioguanine; Vincristine | 1978 |
[Treatment of acute myeloblastic leukemia with cytosine arabinoside combined with daunorubicin or ifosfamide or thioguanine].
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Ifosfamide; Leukemia, Myeloid, Acute; Middle Aged; Thioguanine | 1978 |
Multiple determinants of antimetabolite action in humans.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Cytarabine; Daunorubicin; Deamination; DNA; Doxorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Neoplasms, Experimental | 1979 |
Tn polyagglutination preceding acute leukemia.
Topics: Aged; Cytarabine; Daunorubicin; Hemagglutination; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Splenectomy; Thioguanine; Thrombocytopenia | 1979 |
[Notes on the paper by M. Gstöttner, H. Frisch, and F. Dienstl Normal newborn after cytostatic therapy for acute promyelocytic leukemia during pregnancy. Blut 36, 171-4 (1978)].
Topics: Adult; Daunorubicin; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Trimester, Second | 1979 |
[Prognosis improvements in children with acute myelocytic leucemia after more intensive induction therapy (author's transl)].
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prognosis; Thioguanine | 1979 |
[Treatment of myeloblastic leukemia after 65 years. Results in 9 cases].
Topics: Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission, Spontaneous | 1979 |
[Occurrence of infectious complications during therapy for acute leukemia].
Topics: Antineoplastic Agents; Bacterial Infections; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Neutropenia; Prednisone; Thioguanine | 1979 |
Serial studies on in vitro colony formation in patients with acute leukemia in relation to the maintenance of remission.
Topics: Acute Disease; Adult; Child; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission, Spontaneous | 1978 |
Acute myelogenous leukemia: morphologic classification and response to therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Platinum; Thioguanine | 1979 |
Disseminated intravascular coagulation in acute promyelocytic leukemia. Possibility of treatment with glucocorticoids at high doses.
Topics: Daunorubicin; Disseminated Intravascular Coagulation; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Methylprednisolone; Prednisone | 1978 |
Prognostic value of colony-stimulating and colony-forming cells in peripheral blood in acute non-lymphoblastic leukemia.
Topics: Adult; Aged; Cell Division; Cells, Cultured; Clone Cells; Colony-Stimulating Factors; Cytarabine; Daunorubicin; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Count; Leukocytes; Male; Middle Aged; Prognosis; Remission, Spontaneous | 1977 |
Effect of antileukaemic chemotherapy on helper and suppressor activity of T cells on immunoglobulin production by B cells.
Topics: Aged; Antineoplastic Agents; B-Lymphocytes; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Immunoglobulin G; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Lymphocyte Cooperation; Middle Aged; T-Lymphocytes; Thioguanine | 1978 |
Cytotoxicity of adriamycin and daunorubicin for normal and leukemia progenitor cells of man.
Topics: Animals; Cell Survival; Colony-Forming Units Assay; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Granulocytes; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mercaptoethanol; T-Lymphocytes | 1979 |
Deficiency of antibody-dependent cellular cytotoxicity and mitogen-induced cellular cytotoxicity effector cell function in patients with acute myelogenous leukemia in remission.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cytarabine; Cytotoxicity, Immunologic; Daunorubicin; Drug Therapy, Combination; Humans; Immunity, Cellular; Immunoglobulin Fc Fragments; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Middle Aged; Phytohemagglutinins; Remission, Spontaneous; T-Lymphocytes; Thioguanine; Time Factors | 1979 |
Current treatment of acute leukemia.
Topics: Bone Marrow Transplantation; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Meningeal Neoplasms; Methotrexate; Neoplasm Metastasis; Prednisone; Vincristine | 1978 |
Transurethral passage of Aspergillus fungus balls in acute myelocytic leukemia.
Topics: Aspergillosis; Aspergillus fumigatus; Cytarabine; Daunorubicin; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Urethra; Urine | 1979 |
Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia.
Topics: Adolescent; Bone Marrow Transplantation; Budd-Chiari Syndrome; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Liver; Lymph Nodes; Remission, Spontaneous; Transplantation, Homologous | 1979 |
Acute promyelocytic leukemia: results of therapy and analysis of 13 cases.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Blood Platelets; Cytarabine; Daunorubicin; Doxorubicin; Female; Fibrinogen; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission, Spontaneous | 1977 |
Granulocyte function in myeloblastic leukaemia.
Topics: BCG Vaccine; Candida albicans; Cytarabine; Daunorubicin; Granulocytes; Humans; Hydrocortisone; Leukemia, Myeloid, Acute; Leukocytes; Mycobacterium bovis; Phagocytosis | 1975 |
The effect of cytotoxic drugs on neutrophil phagocytosis in vitro and in patients with acute myelogenous leukaemia.
Topics: Antineoplastic Agents; Candida albicans; Cell Survival; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Methotrexate; Neutrophils; Phagocytosis | 1976 |
Perspectives and prospectives in the management of acute leukemia.
Topics: BCG Vaccine; Cytarabine; Daunorubicin; Humans; Immunotherapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Life Expectancy; Mycobacterium bovis; Nucleotides, Cyclic; Prednisone; Remission, Spontaneous; Vincristine | 1976 |
[Hematologic intensive care units for cancer patients. Their role in the efficacy of cytostatic chemotherapy].
Topics: Antineoplastic Agents; Blood Transfusion; Bone Marrow Cells; Bone Marrow Transplantation; Cross Infection; Cytarabine; Daunorubicin; Hemorrhage; Humans; Immunosuppression Therapy; Infection Control; Intensive Care Units; Leukemia, Myeloid, Acute; Patient Isolators; Thioguanine | 1975 |
Fibrinogen survival with 75-seleniomethionine in acute myeloblastic leukemia during polychemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Cytarabine; Daunorubicin; Fibrinogen; Humans; Leukemia, Myeloid, Acute; Prednisolone; Selenomethionine | 1976 |
epsilon-Amino-caproic acid in the management of acute promyelocytic leukaemia.
Topics: Adult; Aminocaproates; Aminocaproic Acid; Cytarabine; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Vincristine | 1976 |
Sequential therapy for induction and maintenance of remission in acute myeloblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Remission, Spontaneous; Time Factors; Vincristine | 1975 |
Methoxy-9-ellipticine lactate in refractory acute myeloid leukaemia.
Topics: Administration, Oral; Adolescent; Alkaloids; Antineoplastic Agents; Carbazoles; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Mercaptopurine; Methyl Ethers; Prednisone; Remission, Spontaneous; Time Factors | 1975 |
Treatment of therapy-resistant acute myeloid leukaemia with 7 and 8 cytostatics.
Topics: Adolescent; Adult; Aged; Candidiasis; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance; Drug Therapy, Combination; Esophagitis, Peptic; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Leukocyte Count; Leukopenia; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Stomach Ulcer; Thioguanine; Vincristine | 1975 |
Treatment of acute myelogenous leukaemia in adults. A retrospective study of 70 patients (1968-1973).
Topics: Adult; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thioguanine | 1975 |
Drugs five years later: cytarabine.
Topics: Acute Disease; Adult; Animals; Bone Marrow Diseases; Central Nervous System Diseases; Cyclophosphamide; Cytarabine; Daunorubicin; DNA, Neoplasm; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine; Virus Diseases | 1975 |
Cell kinetics and practical consequences for therapy of acute leukemia.
Topics: Adrenal Cortex Hormones; Asparaginase; Bone Marrow; Bone Marrow Cells; Cell Division; Cells, Cultured; Cytarabine; Daunorubicin; DNA; DNA, Neoplasm; Drug Therapy, Combination; Humans; Kinetics; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Mitosis; Prognosis; Vincristine | 1975 |
[Therapy of non-lymphoid acute leukemias].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Body Weight; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission, Spontaneous; Thioguanine; Vincristine | 1975 |
[Our recent therapeutic experiences in acute leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Middle Aged; Prednisone; Vincristine | 1975 |
[Treatment of 17 cases of non-lymphoblastic acute leukemia with a combination of daunorubicin, cytosine and arabinoside].
Topics: Adolescent; Adult; Aged; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged | 1975 |
[General remarks on the treatment of acute leukemias].
Topics: Asparaginase; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisone; Thioguanine; Vincristine | 1975 |
Treatment of acute leukemia in adults.
Topics: Adolescent; Adult; Aged; Asparaginase; Carmustine; Child; Cytarabine; Daunorubicin; Female; Humans; Hydroxyurea; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Remission, Spontaneous; Thioguanine; Vincristine | 1975 |
[Possibility for the prevention of cardio toxic effect of Cerubidin].
Topics: Daunorubicin; Digoxin; Heart; Heart Diseases; Humans; Leukemia, Myeloid, Acute | 1975 |
Fever in acute myelogenous leukemia.
Topics: Agranulocytosis; Anti-Bacterial Agents; Candidiasis; Cytarabine; Daunorubicin; Fever; Humans; Klebsiella Infections; Leukemia, Myeloid, Acute; Pseudomonas Infections; Thioguanine | 1975 |
Adriamycin in the treatment of childhood acute leukemia. A Southwest Oncology Group study.
Topics: Adolescent; Alopecia; Bone Marrow; Child; Child, Preschool; Daunorubicin; Doxorubicin; Female; Fever; Heart; Humans; Infant; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Nausea; Remission, Spontaneous; Stomatitis | 1975 |
[Letter: New combination drug therapy of acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoguazone; Remission, Spontaneous; Vincristine | 1975 |
Hypoplastic acute myelogenous leukaemia.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Female; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous | 1975 |
A comparative study of acute myeloblastic leukaemia in children and adults.
Topics: Adolescent; Adult; Age Factors; Aged; Blood Cell Count; Blood Platelets; Bone Marrow Cells; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine | 1975 |
Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine.
Topics: Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Remission, Spontaneous; Thioguanine | 1975 |
[Results of combined chemotherapy in treatment-resistant leukaemia of adults (author's transl)].
Topics: Acute Disease; Adolescent; Adult; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Myeloid, Acute; Methotrexate; Middle Aged; Prednisone; Remission, Spontaneous; Thioguanine; Time Factors; Vincristine | 1975 |
[Changes in the blood coagulation system in patients with acute leukemia during treatment with rubomycin].
Topics: Blood Coagulation; Blood Platelets; Daunorubicin; Female; Hemorrhage; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Middle Aged | 1975 |
[Use of rubomycin in the treatment of children with acute leukemia].
Topics: Adolescent; Cardiovascular System; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Daunorubicin; Female; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Liver; Male | 1975 |
Daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myelogenous leukemia in adults.
Topics: Adolescent; Adult; Age Factors; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Inosine; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Remission, Spontaneous; Thioinosine | 1975 |
Acute myeloid leukemia in the adult.
Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Thioguanine | 1975 |
[The therapy of acute myelogenous leukemia].
Topics: Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Lomustine; Thioguanine | 1975 |
[Daunomycin monotherapy in acute promyelocytic leukemia].
Topics: Adult; Blood Platelets; Blood Transfusion; Daunorubicin; Female; Hemorrhagic Disorders; Heparin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous | 1976 |
Clinical study of rubidazone (22 050 R.P.), a new daunorubicin-derived compound, in 170 patients with acute leukemias and other malignancies.
Topics: Antibiotics, Antineoplastic; Child; Child, Preschool; Daunorubicin; Dose-Response Relationship, Drug; Drug Evaluation; Heart; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Lymphoma; Remission, Spontaneous; Rhabdomyosarcoma | 1976 |
Manipulation of the mitotic cycle in the treatment of acute myelogenous leukaemia.
Topics: Adolescent; Adult; Bone Marrow Examination; Child; Child, Preschool; Cytarabine; Daunorubicin; DNA; Doxorubicin; Female; Humans; Infant; Infant, Newborn; Infusions, Parenteral; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitosis; Remission, Spontaneous; Time Factors | 1976 |
[Emergency treatment of acute promyelocytic leukemia and its hemorrhagic complications. Apropos of 30 cases].
Topics: Blood Transfusion; Cerebral Hemorrhage; Daunorubicin; Disseminated Intravascular Coagulation; Emergencies; Heparin; Humans; Leukemia, Myeloid, Acute | 1975 |
Serial quantitative observations of leukemic and normal hematopoietic cells in the bone marrow of acute leukemia under chemotherapy.
Topics: Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Remission, Spontaneous; Vincristine | 1976 |
[Neonatal leukemia. Report of seven cases (author's transl)].
Topics: Cytarabine; Daunorubicin; Humans; Infant, Newborn; Infant, Newborn, Diseases; Leukemia, Myeloid, Acute | 1976 |
[Results in the treatment of acute leukemias at the Internal Clinic B in the period 1970-1975].
Topics: Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Hospitals, University; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Prednisone; Remission, Spontaneous; Vincristine | 1976 |
Acquired resistance to daunorubicin in a patient with acute myelogenous leukaemia.
Topics: Cells, Cultured; Daunorubicin; DNA; Drug Resistance; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Leukocyte Count; Time Factors | 1976 |
The effect of daunomycin on cell proliferation and protein synthesis of human leukemic blast cells.
Topics: Adult; Aged; Bone Marrow; Bone Marrow Cells; Cell Division; Daunorubicin; DNA, Neoplasm; Female; Humans; Leucine; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitotic Index; Neoplasm Proteins; Time Factors | 1976 |
[Treatment of acute promyelocytic leukemia (author's transl)].
Topics: Adult; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male | 1976 |
Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone-DCMP two step therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission, Spontaneous | 1976 |
Endomyocardial fibrosis associated with daunorubicin therapy.
Topics: Adult; Cytarabine; Daunorubicin; Endomyocardial Fibrosis; Female; Humans; Leukemia, Myeloid, Acute | 1976 |
Chemoimmunotherapy for maintenance in acute myeloblastic leukemia.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Cytarabine; Daunorubicin; Female; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine; Time Factors | 1976 |
Sequencing of cytosine arabinoside (NSC-63878) and daunorubicin (NSC-82151) in acute myelogenous leukemia.
Topics: Adolescent; Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1976 |
[Treatment of acute myeloid leukemia with daunomycin (38 cases)].
Topics: Adolescent; Adult; Aged; Child; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1976 |
Acute granulocytic leukemia: treatment of the disease.
Topics: Adolescent; Adult; Age Factors; Blood Transfusion; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Immunotherapy; Infant; Leukemia, Myeloid, Acute; Lomustine; Meningitis; Middle Aged; Prognosis; Thioguanine | 1976 |
[The treatment of acute myelocytic leukemia during the first recurrence by means of a new cytostatic combination].
Topics: Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Leukemia, Myeloid, Acute; Podophyllotoxin; Thioguanine; Vincristine | 1976 |
Short induction treatment in acute granulocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Fever; Hemorrhage; Humans; Leucovorin; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Pyruvaldehyde; Remission, Spontaneous; Sepsis | 1975 |
Cytomegalovirus infection in children with blood diseases.
Topics: Adolescent; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Daunorubicin; Female; gamma-Globulins; Humans; Immune Tolerance; Immunization, Passive; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Opportunistic Infections; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Thioguanine; Vincristine | 1992 |
Usefulness of bone-marrow biopsy during induction therapy for acute myeloid leukemia.
Topics: Biopsy, Needle; Bone Marrow Examination; Cytarabine; Daunorubicin; Evaluation Studies as Topic; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Time Factors | 1992 |
Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cytarabine; Daunorubicin; Drug Resistance; Gene Expression; Humans; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction | 1992 |
In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous leukemia (AML).
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cefoperazone; Cyclosporine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Middle Aged; Mitoxantrone; Stem Cells; Tumor Cells, Cultured; Verapamil | 1992 |
A discrepancy between the instantaneous and the overall collection efficiency of the Fenwal CS3000 for peripheral blood stem cell apheresis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Cells; Blood Component Removal; Blood Transfusion, Autologous; Bone Marrow Diseases; Cyclophosphamide; Cytarabine; Daunorubicin; Evaluation Studies as Topic; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Neoplasms; Thioguanine | 1992 |
Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Daunorubicin; Drug Resistance; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Middle Aged; Neoplastic Stem Cells; Prognosis; Tumor Cells, Cultured | 1992 |
Bradycardia due to anthracyclines.
Topics: Amphotericin B; Bradycardia; Daunorubicin; Female; Humans; Kidney Neoplasms; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Plasmacytoma | 1992 |
Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Middle Aged; Mitoxantrone; Neoplasm Proteins; Remission Induction | 1992 |
[Treatment of various types of acute leukemia in adult. An analysis of 98 cases. The Leukemia Cooperation Group of Beijing City].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Vincristine | 1992 |
[A regimen of DATV in the treatment of acute nonlymphocytic leukemia with high complete remission rate].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Thioguanine; Vincristine | 1992 |
Acute myelogenous leukemia: proliferation stop or cell lysis during the first hours of treatment?
Topics: Cell Death; Cell Division; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors | 1992 |
Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Child; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peptide Hydrolases; Plasminogen Activator Inhibitor 2; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 1992 |
Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy.
Topics: Actuarial Analysis; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bone Marrow Transplantation; Cause of Death; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Middle Aged; Norway; Recurrence; Remission Induction; Survival Analysis; Survival Rate; Thioguanine | 1992 |
[Cure of acute myeloblastic leukemia in a child with Down syndrome and tetralogy of Fallot].
Topics: Abnormalities, Multiple; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Down Syndrome; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction; Tetralogy of Fallot; Thioguanine | 1992 |
Fulminant hepatic failure after high-dose cytosine arabinoside and mitoxantrone treatment for relapse of acute myelogenous leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Liver; Liver Failure, Acute; Mitoxantrone; Necrosis; Recurrence; Thioguanine | 1992 |
[Evaluation of 58 patients with acute leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 1992 |
[Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission Induction; Sepsis; Survival Rate | 1992 |
Serial changes of the serum macrophage colony-stimulating factor level after cytoreductive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Leukopenia; Macrophage Colony-Stimulating Factor; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Predictive Value of Tests; Prednisone; Remission Induction; Vindesine | 1992 |
Cutaneous pigmentation after daunorubicin chemotherapy.
Topics: Adult; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Nail Diseases; Pigmentation Disorders | 1992 |
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Survival Rate | 1992 |
Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Topics: Cell Division; Daunorubicin; Drug Resistance; Humans; Idarubicin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured; Verapamil | 1992 |
Expression of glutathione transferase pi as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Glutathione Transferase; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Thioguanine; Time Factors | 1992 |
Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug.
Topics: Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mitoxantrone | 1992 |
[Short-term intensive consolidation chemotherapy in the treatment of acute non-lymphocytic leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Remission Induction; Survival Rate | 1992 |
Electrical alternans of the T-U wave without change in the QRS complex.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Cytarabine; Daunorubicin; Electrocardiography; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged | 1992 |
Therapy of acute myelogenous leukemia: results of combination chemotherapy with cytarabine, daunorubicin and 6-mercaptopurine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Remission Induction | 1991 |
[Allogeneic bone marrow transplantation in the treatment of leukemia: analysis of 10 cases].
Topics: Adolescent; Adult; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Whole-Body Irradiation | 1991 |
Enhanced expression of DNA topoisomerase II by recombinant human granulocyte colony-stimulating factor in human leukemia cells.
Topics: Blotting, Northern; Cyclophosphamide; Daunorubicin; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Gene Expression; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Recombinant Proteins; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1990 |
Novel translocation (2;4) with consistent involvement of 2p23 in acute nonlymphocytic leukemia (M2).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 4; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Translocation, Genetic | 1992 |
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Middle Aged; Pilot Projects; Prognosis; Remission Induction; Time Factors | 1991 |
Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Deoxycytidine; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Tumor Cells, Cultured | 1991 |
Cell kinetics with in vivo bromodeoxyuridine and flow cytometry: clinical significance in acute non-lymphoblastic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bromodeoxyuridine; Cells; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Infusions, Intravenous; Kinetics; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Vincristine | 1991 |
[Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Evaluation Studies as Topic; Female; Humans; Infant; Leukemia, Myeloid, Acute; Life Tables; Male; Methotrexate; Mitoxantrone; Remission Induction; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous | 1991 |
Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Northern; Bone Marrow; Cytarabine; Daunorubicin; Gene Expression; Humans; Interleukin-1; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Transcription, Genetic | 1991 |
Daunorubicin, amsacrine, and sinus arrest.
Topics: Adult; Daunorubicin; Electrocardiography; Heart Arrest; Humans; Leukemia, Myeloid, Acute; Male | 1991 |
Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes.
Topics: Adolescent; Adult; Aged; Cost-Benefit Analysis; Costs and Cost Analysis; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Models, Theoretical; Prospective Studies; Remission Induction; Retrospective Studies | 1991 |
[Gastroenterologic findings in graft versus host disease after allogenic bone marrow transplantation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Gastrointestinal Diseases; Graft vs Host Disease; Humans; Infant, Newborn; Intestinal Mucosa; Leukemia, Myeloid, Acute; Liver; Pregnancy; Pregnancy Complications, Neoplastic; Sigmoidoscopy | 1991 |
[Torsade de pointes ventricular tachycardia in a patient with acute myelocytic leukemia].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Electrocardiography; Female; Humans; Leukemia, Myeloid, Acute; Tachycardia | 1991 |
Recurrent bilateral parotitis in acute myeloid leukemia.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Parotitis; Recurrence | 1991 |
Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.
Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Daunorubicin; Drug Resistance; Female; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Middle Aged; Verapamil | 1990 |
Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype.
Topics: Cell Division; Daunorubicin; Drug Resistance; Flow Cytometry; Humans; Kinetics; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Phenotype; Tamoxifen; Tumor Cells, Cultured; Verapamil; Vinblastine | 1991 |
Detection of single-stranded DNA damage using monoclonal anti-thymidine antibody.
Topics: Animals; Antibodies, Monoclonal; Daunorubicin; DNA Damage; DNA Repair; DNA, Single-Stranded; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred BALB C; Thymidine | 1991 |
High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Prognosis; Remission Induction | 1991 |
In vitro chemosensitivity of newly diagnosed and relapsing acute non-lymphoid leukemia patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Idoxuridine; Iodine Radioisotopes; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1991 |
[Successful pregnancy after 6 years complete remission in patient with acute myeloblastic leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Pregnancy; Remission Induction | 1991 |
Tissue factor released from leukemic cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Endotoxins; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Thromboplastin; Tumor Cells, Cultured | 1991 |
First and second complete remissions in a HIV positive patient following remission induction therapy for acute non-lymphoblastic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; HIV Seropositivity; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Remission Induction; Substance Abuse, Intravenous | 1991 |
Glutathione S-transferase activity of leukemic cells as a prognostic factor for response to chemotherapy in acute leukemias.
Topics: Bone Marrow; Daunorubicin; Doxorubicin; Glutathione Transferase; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis | 1991 |
Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Factor X; Factor X Deficiency; Female; Fibrinogen; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1991 |
Aspergillus appendicitis in acute myeloid leukaemia.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Appendix; Aspergillosis; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Ileal Diseases; Iliac Vein; Intestinal Perforation; Ischemia; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neutropenia; Thrombosis | 1990 |
Drug sensitivity test for acute myeloblastic leukemia by an efficient leukemic blast colony assay using 5637-conditioned medium as a stimulator.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Culture Media; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Tumor Stem Cell Assay | 1990 |
Etoposide in remission induction of adult acute myeloid leukemia.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Thioguanine; Time Factors | 1990 |
Carcinoma of the small intestine following treated acute myeloid leukaemia.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Daunorubicin; Humans; Ileal Neoplasms; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Thioguanine | 1990 |
How to improve therapy for adult acute myeloid leukemia: studies of the AML Cooperative Group in the Federal Republic of Germany.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Cytarabine; Daunorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Leukemia, Myeloid, Acute; Middle Aged; Survival Rate; Thioguanine | 1990 |
Immunologic and morphologic typing as prognostic factor in M1 acute myeloblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Cytarabine; Daunorubicin; Female; Histocytochemistry; Humans; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Vincristine | 1990 |
Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.
Topics: Adult; Antineoplastic Agents; Cell Division; Daunorubicin; DNA Damage; DNA, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1990 |
Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate | 1990 |
Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study.
Topics: Bone Marrow; Bromodeoxyuridine; Cell Cycle; Cytarabine; Daunorubicin; Female; Humans; Kinetics; Leukemia, Myeloid, Acute; Male; S Phase | 1990 |
Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Chromatography, High Pressure Liquid; Daunorubicin; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Tumor Cells, Cultured | 1990 |
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Rate; Thioguanine | 1990 |
Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.
Topics: Acute Disease; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Time Factors | 1990 |
Cellular pharmacokinetics of daunomycin in human leukemic blasts in vitro and in vivo.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Thioguanine; Tumor Cells, Cultured | 1990 |
Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; France; Humans; Leukemia, Myeloid, Acute; Life Tables; Middle Aged; Neutropenia; Survival Rate | 1990 |
Acute nonlymphocytic leukemia in adults: results obtained with TAD remission induction therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Middle Aged; Netherlands; Remission Induction; Survival Rate; Thioguanine | 1990 |
Treatment of advanced myelodysplastic syndromes: trend toward more aggressive chemotherapy?
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Preleukemia; Remission Induction; Thioguanine | 1990 |
Effect of antifungal therapy on hematological recovery after intensive antileukemic chemotherapy.
Topics: Agranulocytosis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Depression, Chemical; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Mitoxantrone; Mycoses; Thioguanine; Thrombocytopenia | 1990 |
Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): assessment in vitro after stimulation with colony stimulating factors (CSFs).
Topics: Colony-Stimulating Factors; Daunorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1990 |
Prognostic value of dysmyelopoietic features in de novo acute myeloid leukaemia: a report on 132 patients.
Topics: Adolescent; Adult; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Cytarabine; Daunorubicin; Female; Hemoglobins; Humans; Karyotyping; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Prognosis; Remission Induction; Survival Rate | 1990 |
Chemotherapy of adult acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine | 1990 |
Acute non-lymphoblastic leukemia in children: prognostic factors and results of chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction | 1990 |
Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Male; Tumor Cells, Cultured | 1990 |
High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Transplantation, Autologous; Transplantation, Homologous | 1990 |
[Individualized chemotherapy of adult acute nonlymphocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission Induction | 1990 |
[Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Female; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Survival Rate; Thioguanine | 1990 |
[Therapeutic results in acute myelogenous leukemia in the years from 1970 to 1982].
Topics: Adolescent; Adult; Blood Transfusion; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Transfusion; Prednisone; Retrospective Studies; Thioguanine; Vincristine | 1985 |
Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low molecular weight heparinoid Org 10172.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chondroitin Sulfates; Cytarabine; Daunorubicin; Dermatan Sulfate; Disseminated Intravascular Coagulation; Drug Evaluation; Glycosaminoglycans; Heparinoids; Heparitin Sulfate; Humans; Leukemia, Myeloid, Acute; Middle Aged; Thioguanine; Time Factors | 1986 |
Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug.
Topics: Cell Line; Daunorubicin; DNA; Doxorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Manganese; Membrane Proteins; Phosphorylation; RNA | 1986 |
Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Whole-Body Irradiation | 1987 |
Acute nonlymphocytic leukemia: evidence of clonogenic cells in peripheral blood in early complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Remission Induction; Translocation, Genetic | 1989 |
[Hepatocellular carcinoma treated with a curative segmentectomy five years after complete remission of acute myeloblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Cytarabine; Daunorubicin; Embolization, Therapeutic; Hepatectomy; Hepatitis B Surface Antigens; Humans; Leukemia, Myeloid, Acute; Liver Neoplasms; Male; Mercaptopurine; Middle Aged; Neoplasms, Multiple Primary; Prednisolone; Remission Induction | 1989 |
The optimization of collection of peripheral blood stem cells for autotransplantation in acute myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Bone Marrow Diseases; Cell Count; Combined Modality Therapy; Cytarabine; Daunorubicin; Evaluation Studies as Topic; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thioguanine; Transplantation, Autologous | 1989 |
The role of peripheral blood stem cells as rescue after myeloablative therapy.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Combined Modality Therapy; Cytarabine; Daunorubicin; Evaluation Studies as Topic; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Transplantation, Autologous | 1989 |
A comparison of two assays for the in vitro chemosensitivity testing of human acute non-lymphoblastic leukemia cells.
Topics: Adult; Aged; Colorimetry; Cytarabine; Daunorubicin; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Tetrazolium Salts; Thymidine; Tumor Cells, Cultured | 1989 |
[Chemotherapy of adult ANLL].
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Remission Induction; Survival Rate; Vincristine | 1989 |
[The curative treatment of adult acute nonlymphocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission Induction | 1989 |
[Comparison of conventional chemotherapy and short-term intensive chemotherapy in adult acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Remission Induction; Survival Rate | 1989 |
Standard induction and low dose ara-C treatment in patients over 60 with AML or MDS.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Retrospective Studies | 1989 |
Phenotype switch in acute leukemia patients after intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1989 |
The use of bone marrow cells grown in long-term culture for autologous bone marrow transplantation in acute myeloid leukaemia: an update.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cells, Cultured; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Pilot Projects; Remission Induction; Risk; Thioguanine; Transplantation, Autologous | 1989 |
Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 1989 |
Therapeutic medical reasoning.
Topics: Adolescent; Cesarean Section; Cytarabine; Daunorubicin; Decision Making; Decision Support Techniques; Female; Humans; Judgment; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic | 1989 |
Cures of leukemia with aggressive postremission treatment: an update of timed sequential therapy (Ac-D-Ac).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 1989 |
Fractionated anthracycline therapy in acute myeloblastic leukaemia in adults.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Cytarabine; Daunorubicin; Drug Administration Schedule; Heart Ventricles; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Thioguanine | 1989 |
Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA; DNA Adducts; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Metabolic Clearance Rate | 1989 |
[Cancer curable by chemotherapy: acute myelogenous leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Evaluation; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Leukopenia; Mercaptopurine; Prednisolone; Prognosis; Remission Induction | 1989 |
[4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Leukopenia; Male; Middle Aged; Prednisolone; Remission Induction; Thioguanine; Thrombocytopenia | 1989 |
Effects of verapamil on the cellular accumulation of daunorubicin in blast cells and on the chemosensitivity of leukaemic blast progenitors in acute myelogenous leukaemia.
Topics: Adult; Aged; Cell Survival; Daunorubicin; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Verapamil | 1989 |
Clinical significance of fibrinopeptide A in acute lymphocytic and non-lymphocytic leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Fibrinogen; Fibrinopeptide A; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Longitudinal Studies; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radioimmunoassay; Thioguanine; Time Factors | 1989 |
[The continuous-DCMP therapy for acute nonlymphocytic leukemia in elderly patients--comparison with younger patients].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1989 |
Development of drug resistance in cultured clonogenic leukemic blast cells during the clinical course of myeloblastic leukemia.
Topics: Aclarubicin; Adult; Aged; Daunorubicin; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Neoplastic Stem Cells; Tumor Cells, Cultured | 1989 |
Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome.
Topics: Age Factors; Anemia, Aplastic; Anemia, Refractory, with Excess of Blasts; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Multivariate Analysis; Neural Tube Defects; Preleukemia; Prognosis; Regression Analysis; Survival Rate; Thioguanine | 1989 |
[Neutropenic enterocolitis in adults with acute leukemia].
Topics: Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Daunorubicin; Enterocolitis, Pseudomembranous; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Neutropenia; Prednisolone | 1989 |
Increased proteolysis of antithrombin III Vicenza during disseminated intravascular coagulation in acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Antithrombin III Deficiency; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Leukemia, Myeloid, Acute; Thioguanine; Thrombin; Thrombophlebitis | 1989 |
Inappropriate increase in erythropoietin titers during chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Erythropoietin; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Vincristine | 1989 |
Acute myelogenous leukemia treated with daunomycin associated with nephrotic syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Kidney; Leukemia, Myeloid, Acute; Male; Nephrotic Syndrome | 1989 |
High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1989 |
Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.
Topics: Cell Transformation, Neoplastic; Daunorubicin; Humans; Infusions, Intravenous; Intracellular Fluid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1989 |
[Left ventricular thrombosis in a case of daunomycin cardiomyopathy].
Topics: Daunorubicin; Down Syndrome; Echocardiography; Female; Heart Diseases; Heart Ventricles; Humans; Infant; Leukemia, Myeloid, Acute; Thrombosis | 1985 |
Adenosine diphosphate ribosyl transferase in marrow cells of patients with acute myeloid leukemia is related to differentiation and drug sensitivity.
Topics: Bone Marrow; Cell Differentiation; Cell Division; Clinical Enzyme Tests; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Nucleotidyltransferases; Poly(ADP-ribose) Polymerases; Prognosis; Tumor Stem Cell Assay | 1985 |
Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Nervous System Diseases | 1986 |
Bone-marrow regeneration after therapy-induced hypoplasia monitored by serum measurements of lactoferrin, lysozyme and myeloperoxidase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Doxorubicin; Hematopoiesis; Humans; Lactoferrin; Lactoglobulins; Leukemia, Myeloid, Acute; Leukocyte Count; Muramidase; Neutrophils; Peroxidase; Prednisolone; Thioguanine; Time Factors; Vincristine | 1986 |
Long term results in acute non-lymphocytic leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male | 1988 |
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Prednisone; Prognosis; Prospective Studies; Recurrence; Regression Analysis; Retrospective Studies; Vincristine | 1987 |
Second long-term remission achieved with low-dose Ara-C in children with relapsed acute nonlymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Thioguanine | 1987 |
[Concentration and pharmacokinetics of daunorubicin in leukemic cells in vivo].
Topics: Daunorubicin; Humans; Kinetics; Leukemia, Myeloid, Acute | 1985 |
Caring for patients with acute myelocytic leukemia.
Topics: Bone Marrow; Daunorubicin; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Oral Hygiene; Uric Acid | 1988 |
Daunorubicin or doxorubicin in acute myelogenous leukemia?
Topics: Daunorubicin; Doxorubicin; Humans; Leukemia, Myeloid, Acute | 1988 |
Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Bone Marrow; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged | 1988 |
In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry.
Topics: Adolescent; Adult; Aged; Bone Marrow; Chromatography, High Pressure Liquid; Daunorubicin; Female; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged | 1988 |
A new combination of two intercalating agents (mitoxantrone + daunomycin) in adult refractory acute leukemia: the DON protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Female; Humans; Intercalating Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Vincristine | 1988 |
Relationship between the in vitro sensitivity to cytosine arabinoside of blast progenitors and the outcome of treatment in acute myeloblastic leukaemia patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged | 1988 |
Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bone Marrow Examination; Cytarabine; Daunorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Remission Induction; Thioguanine | 1988 |
[DCTP(II) combination chemotherapy of adult acute nonlymphocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Remission Induction; Thioguanine | 1988 |
[Differentiating effect of the oral administration of vitamin D and vitamin A in acute myelocytic leukemia after BHAC-DMP therapy].
Topics: Administration, Oral; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisolone; Vitamin A; Vitamin D | 1988 |
In vitro sensitivity of clonogenic cells in resisting and relapsing patients with acute myelogenous leukaemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Clone Cells; Cytarabine; Daunorubicin; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1988 |
A comparative pathological study of liver injury after different combination chemotherapies for leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Liver; Melphalan; Prednisolone; Prednisone; Thioguanine | 1988 |
[Acute graft-versus-host disease in a patient with acute myeloblastic leukemia following consolidation therapy and platelet transfusions].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Platelet Transfusion; Prednisolone; Transfusion Reaction | 1988 |
[Dissociation between the effect on myeloblastoma and the hematologic effect of Ara-C therapy: report of an autopsied myeloblastic leukemia case with around five-year course].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Remission Induction; Tumor Cells, Cultured; Uterine Neoplasms | 1988 |
[Comparative analysis of 3 therapeutic regimens based on the combination of an anthracycline and cytosine arabinoside for remission induction in myeloblastic leukemia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Remission Induction; Thioguanine; Vincristine | 1988 |
Results of aggressive chemotherapy for myelodysplastic syndromes.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Remission Induction; Vincristine | 1988 |
Association between the secondary colony-plating efficiency of blast progenitors and the remission induction outcome of acute myeloblastic leukemia patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Neoplastic Stem Cells; Prednisolone; Prognosis; Remission Induction; Tumor Stem Cell Assay | 1988 |
Treatment of acute non-lymphocytic leukemia with alternating non-cross resistant chemotherapy.
Topics: Aclarubicin; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Prognosis; Remission Induction; Vincristine | 1988 |
[Induction and intensive combined therapy of acute myeloid leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dacarbazine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Nimustine; Nitrosourea Compounds; Vincristine | 1988 |
Fetal liver infusion in acute myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Fetus; Humans; Leukemia, Myeloid, Acute; Liver; Liver Transplantation | 1987 |
Acute promyelocytic leukemia. Therapy results and prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence | 1988 |
Thrombotic thrombocytopenic purpura subsequent to acute myelogenous leukemia chemotherapy.
Topics: Antineoplastic Agents; Blood Transfusion; Cytarabine; Daunorubicin; Erythrocyte Transfusion; Female; Humans; Leukemia, Myeloid, Acute; Microcirculation; Mitomycins; Platelet Transfusion; Purpura; Thrombocytopenia | 1986 |
Intensive timed chemotherapy protocol for 37 resistant or relapsing acute myeloid leukemias.
Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
[Pregnancy complicated with acute promyelocytic leukemia case report].
Topics: Adult; Blood Transfusion; Bone Marrow Cells; Cesarean Section; Daunorubicin; Disseminated Intravascular Coagulation; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Prednisolone; Pregnancy; Pregnancy Complications, Neoplastic | 1986 |
Effects of cytochalasins and colchicine on the accumulation and retention of daunomycin and vincristine in drug resistant tumor cells.
Topics: Animals; Cell Line; Cell Survival; Colchicine; Cytochalasin B; Cytochalasin D; Cytochalasins; Daunorubicin; Drug Resistance; Humans; Leukemia; Leukemia P388; Leukemia, Myeloid, Acute; Mice; Verapamil; Vincristine | 1986 |
Comparative uptake, retention and cytotoxicity of daunorubicin by human myeloid cells.
Topics: Azides; Cell Line; Chromatography, High Pressure Liquid; Daunorubicin; Glucose; Humans; Hydrogen-Ion Concentration; Kinetics; Leukemia, Myeloid, Acute; Sodium Azide | 1986 |
Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: a method analysis.
Topics: Adolescent; Adult; Aged; Blood Specimen Collection; Chromatography, High Pressure Liquid; Daunorubicin; Female; Humans; Kinetics; Leukemia, Myeloid, Acute; Leukocytes; Male; Mathematics; Middle Aged; Models, Biological | 1986 |
Acute promyelocytic leukemia. M.D. Anderson Hospital experience.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Doxorubicin; Female; Hemorrhage; Hospitals, Teaching; Hospitals, University; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Prognosis; Risk; Texas; Time Factors; Vincristine | 1986 |
Typhlitis: selective surgical management.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Child; Colitis; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Risk | 1986 |
[A 33-year-old male with myelo-monoblastic leukemia developing hematuria and proteinuria].
Topics: Adult; Daunorubicin; Hematuria; Humans; Leukemia, Myeloid, Acute; Lung Diseases, Fungal; Male; Nephrosis, Lipoid; Proteinuria | 1986 |
Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Tumor Stem Cell Assay | 1986 |
[An unusual way of manifesting acute granulocytic leukemia: granulocytic sarcoma of the breast. Apropos of a case with trisomy 22].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, 21-22 and Y; Cytarabine; Daunorubicin; Female; Granulocytes; Humans; Karyotyping; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neoplasms, Multiple Primary; Trisomy | 1986 |
Relapsing process in FAB subtypes of adult acute leukemia and its relationship to treatment regimens.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prednisolone; Time Factors | 1986 |
Inducibility of terminal differentiation in daunomycin- and cytosine arabinoside-resistant mouse myeloid leukemia M1 cells.
Topics: Animals; Calcitriol; Cell Differentiation; Cell Division; Cell Line; Cytarabine; Daunorubicin; Dexamethasone; Drug Resistance; Leukemia, Myeloid, Acute; Methylnitronitrosoguanidine; Mice; Organophosphorus Compounds; Poly I; Pyridinium Compounds | 1986 |
Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Vincristine | 1986 |
A short-term chemosensitivity test with different labeled precursors of DNA or protein synthesis: correlation with clinical response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Leucine; Leukemia, Myeloid, Acute; Protein Biosynthesis; Thioguanine; Thymidine | 1986 |
Interstitial pneumonitis due to leukaemic cell necrosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lung; Necrosis; Pulmonary Fibrosis | 1986 |
Mechanism of interaction between antineoplastic agents and natural differentiation factors in the induction of human leukemic cell maturation.
Topics: Antineoplastic Agents; Blood Physiological Phenomena; Cell Cycle; Cell Differentiation; Cells, Cultured; Culture Media; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Leukocytes; Proto-Oncogenes; RNA, Messenger | 1986 |
Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisone; Prognosis; Statistics as Topic | 1986 |
[Acute promyelocytic leukemia. Analysis and results of treatment with daunorubicin in 29 patients].
Topics: Adolescent; Adult; Aged; Child; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
Control of proliferating potential of myeloid leukemia cells during long-term treatment with vitamin D3 analogues and other differentiation inducers in combination with antileukemic drugs: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cell Differentiation; Cell Division; Cytarabine; Dactinomycin; Daunorubicin; Dexamethasone; Hydroxycholecalciferols; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice; Time Factors | 1987 |
A comparison of in vitro sensitivity of acute myeloid leukemia precursors to mitoxantrone, 4'deoxydoxorubicin, 4-demethoxydaunorubicin and daunorubicin.
Topics: Adult; Antineoplastic Agents; Colony-Forming Units Assay; Daunorubicin; Doxorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Tumor Stem Cell Assay | 1986 |
High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Drug Resistance; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prognosis; Thioguanine | 1987 |
Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance.
Topics: Antibiotics, Antineoplastic; Cell Line; Daunorubicin; Doxorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Naphthacenes; Solubility; Verapamil | 1987 |
[Multiple liver abscesses successfully treated by intraportal administration of amphotericin B in a case of AML (M2)].
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liver Abscess; Male; Mercaptopurine; Portal System; Prednisolone | 1986 |
[Diagnosis and intensive treatment of acute leukemia in pregnancy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Thioguanine; Vincristine | 1987 |
Effects on leukemic clonogenic cells in murine myeloid leukemia of 1-beta-D-arabinofuranosylcytosine and the anthracyclines adriamycin, daunomycin, aclacinomycin A, and 4'-epidoxorubicin.
Topics: Aclarubicin; Animals; Antibiotics, Antineoplastic; Clone Cells; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Doxorubicin; Epirubicin; Kinetics; Leukemia, Myeloid, Acute; Mice; Naphthacenes | 1987 |
[Termination rules in therapeutic trials. Application of sequential methods in 2 clinical trials in hematology].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Random Allocation; Research Design | 1987 |
Prognostic value of in vitro uptake and retention of cytosine arabinoside in acute myelogenous leukemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Prognosis | 1987 |
Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Time Factors; Translocation, Genetic; Vincristine | 1987 |
High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Thioguanine | 1987 |
The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Time Factors | 1987 |
Intensive treatment of acute leukemia in adults 70 years of age and older.
Topics: Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisone; Remission Induction; Vincristine | 1987 |
Prognostic factors in childhood acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Prednisolone; Remission Induction; Risk; Time Factors; Vincristine | 1987 |
Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Kinetics; Leukemia, Myeloid, Acute; Vincristine | 1987 |
Pharmacokinetic study of cytosine arabinoside in patients with acute myelogeneous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosyluracil; Cytarabine; Daunorubicin; Humans; Kinetics; Leukemia, Myeloid, Acute; Mitoxantrone; Thioguanine | 1987 |
Determination of the cellular uptake of daunorubicin in human leukemia in vivo: method of examination and first results.
Topics: Cell Separation; Chromatography, High Pressure Liquid; Daunorubicin; Flow Cytometry; Humans; Kinetics; Leukemia, Myeloid, Acute; Leukocytes; Time Factors | 1987 |
Contribution of clonogenic leukemic cell characteristics to therapy outcome in patients with acute myeloblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction; Thioguanine; Tumor Stem Cell Assay | 1987 |
4-Demethoxydaunorubicin (idarubicin) in relapsed and refractory acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male | 1987 |
Acute myelocytic leukemia in adults: a long-term analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Time Factors | 1987 |
Prediction of induction and duration of complete remission in acute myelogenous leukemia: value of clonogenic cell properties.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Tumor Stem Cell Assay | 1987 |
Postremission induction intensive sequential chemotherapy for children with AML--treatment results and prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Prednisolone; Prognosis; Remission Induction; Thioguanine; Time Factors; Vincristine | 1987 |
Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction; Thioguanine | 1987 |
Incomplete Reiter's syndrome following chemotherapy of acute myeloid leukaemia.
Topics: Adult; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Reactive; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Thioguanine | 1986 |
Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Blast Crisis; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 1987 |
Kinetics of daunomycin in leukemia cells and leukocytes in vivo in the rat.
Topics: Animals; Bone Marrow; Daunorubicin; Dose-Response Relationship, Drug; Female; Leukemia, Myeloid, Acute; Leukocytes; Liver; Myocardium; Rats; Rats, Inbred BN; Spleen | 1987 |
Prognostic value of clonogenic assay for induction and duration of complete remission in acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Time Factors; Tumor Cells, Cultured | 1987 |
Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 1987 |
Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
Topics: Antibiotics, Antineoplastic; Biotransformation; Daunorubicin; Humans; Idarubicin; Injections, Intravenous; Kinetics; Leukemia, Myeloid, Acute | 1987 |
Pattern of bone marrow regeneration following chemotherapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Regeneration; Thioguanine | 1987 |
[Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 1987 |
TAD-induction therapy for 175 adults with acute myeloid leukemia, followed by consolidation and maintenance therapy. The joint study of Ulm and Tübingen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Prednisolone; Prednisone; Thioguanine; Vincristine | 1986 |
Age adapted induction and intensified consolidation therapy in acute myelogenous leukemia.
Topics: Aclarubicin; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Prognosis | 1986 |
Idarubicin in refractory acute leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Parenteral; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
Aclacinomycin-A in the induction treatment of childhood AML.
Topics: Aclarubicin; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infusions, Parenteral; Leukemia, Myeloid, Acute; Male; Naphthacenes; Thioguanine | 1986 |
[Therapy of acute leukemia in the adult. Role of anthracyclines].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute | 1987 |
Acute promyelocytic leukemia in 57 previously untreated patients.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Heparin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Transfusion; Prognosis; Respiratory Insufficiency; Time Factors | 1985 |
Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Fever; Humans; Intercalating Agents; Intestinal Obstruction; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Middle Aged; Nausea; Time Factors; Vomiting | 1985 |
Phase I-II evaluation of carminomycin in adults with acute leukemia.
Topics: Acute Disease; Adult; Aged; Carubicin; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1985 |
Cytokinetic studies in acute leukemia during early induction therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Division; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Peptichemio; Prednisone; Time Factors; Vincristine | 1985 |
Myxoedema in a case of acute myeloid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Myxedema; Thioguanine; Thyroxine | 1985 |
Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antithrombin III; Blood Coagulation Disorders; Daunorubicin; Diagnosis, Differential; Disseminated Intravascular Coagulation; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Granulocytes; Humans; Leukemia, Myeloid, Acute; Middle Aged; Pancreatic Elastase; Thrombin Time | 1985 |
Increased tumor growth and drug uptake predicts for response to continuous infusion high-dose cytarabine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Division; Cytarabine; Daunorubicin; DNA; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged | 1985 |
Early onset of daunomycin cardiotoxicity in a case of acute myelogeneous leukemia associated with Sweet's syndrome.
Topics: Daunorubicin; Electrocardiography; Heart; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Skin Diseases; Syndrome | 1985 |
In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
Topics: Aclarubicin; Aged; Bone Marrow; Cells, Cultured; Child; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Middle Aged; Naphthacenes | 1985 |
Plasma fibronectin in acute myeloid leukaemia.
Topics: Adult; Aged; Blood Transfusion; Cytarabine; Daunorubicin; Female; Fibronectins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precipitin Tests; Thioguanine | 1985 |
Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry.
Topics: Adolescent; Adult; Aged; Animals; Bone Marrow; Daunorubicin; Doxorubicin; Female; Flow Cytometry; Humans; In Vitro Techniques; Lasers; Leukemia; Leukemia P388; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged | 1985 |
Preliminary results in secondary acute non-lymphocytic leukemia (ANLL) treated with Idarubicin.
Topics: Adult; Aged; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local | 1985 |
Uptake and metabolism of daunorubicin by human myelocytic cells.
Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Cell Line; Daunorubicin; Humans; Hydrogen-Ion Concentration; Isoelectric Focusing; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute | 1985 |
High-dose cytarabine in consolidation chemotherapy or with bone marrow transplantation for patients with acute leukemia: preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Graft vs Host Disease; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Fibrosis; Recurrence; T-Lymphocytes; Thioguanine; Whole-Body Irradiation | 1985 |
Daunorubicin reductase activity in human normal lymphocytes, myeloblasts and leukemic cell lines.
Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Bone Marrow; Cell Line; Daunorubicin; Humans; Hydrogen-Ion Concentration; Isoelectric Focusing; Leukemia; Leukemia, Myeloid, Acute; Lymphocytes | 1985 |
[Thrombocyte replacement in hematologic diseases].
Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Blood Platelets; Blood Transfusion; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Doxorubicin; Fever; Hematologic Diseases; Hemorrhage; Histocompatibility; HLA Antigens; Humans; Leukemia; Leukemia, Myeloid, Acute; Middle Aged; Plateletpheresis | 1985 |
[In vivo concentrations of an antimitotic, daunorubicin, in peripheral and bone marrow human leukemia cells].
Topics: Bone Marrow; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neutrophils | 1985 |
Philadelphia-chromosome-positive preleukaemic state.
Topics: Adult; Blood Cell Count; Bone Marrow Cells; Bone Marrow Examination; Chromosome Aberrations; Cytarabine; Cytogenetics; Daunorubicin; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Prednisone; Thioguanine; Vincristine | 1972 |
Fatal outcome after combined therapy for myeloblastic leukaemia and toxoplasmosis.
Topics: Autopsy; Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; Humans; Leucovorin; Leukemia, Myeloid, Acute; Pyrimethamine; Toxoplasmosis | 1973 |
Fatal outcome after combined therapy for myeloblastic leukaemia and toxoplasmosis.
Topics: Aged; Antineoplastic Agents; Bone Marrow Diseases; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Pyrimethamine; Sulfamethazine; Toxoplasmosis | 1973 |
Editorial: Immunotherapy for acute myeloid leukaemia.
Topics: Antibodies, Neoplasm; Antibody Formation; Antigen-Antibody Complex; Antigens, Neoplasm; BCG Vaccine; Cell Transformation, Neoplastic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Immunologic Deficiency Syndromes; Immunotherapy; Leukemia, Myeloid, Acute; Remission, Spontaneous; Thioguanine | 1974 |
Letter: Adriamycin in acute leukaemia.
Topics: Adolescent; Adult; Child; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Humans; Infusions, Parenteral; Injections, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Remission, Spontaneous | 1974 |
Value of the combined cytological and cytochemical classification in the management of acute childhood leukemia.
Topics: Bone Marrow Examination; Child; Child, Preschool; Daunorubicin; Drug Therapy, Combination; Evaluation Studies as Topic; Hematopoietic Stem Cells; Histocytochemistry; Humans; Infant; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Periodic Acid; Peroxidases; Prednisone; Prognosis; Remission, Spontaneous; Retrospective Studies; Staining and Labeling; Vincristine | 1974 |
[1973 treatment of acute leukemias].
Topics: Chlorambucil; Colchicine; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Vinblastine; Vincristine | 1974 |
Adult acute leukaemia.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Cytosine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Humans; Injections, Intravenous; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Remission, Spontaneous; Staining and Labeling; Thioguanine; Vincristine | 1974 |
Blood and neoplastic diseases. Acute myeloblastic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Blood Transfusion; Bloodletting; Cell Count; Cyclophosphamide; Cytosine; Daunorubicin; Drug Therapy, Combination; Graft vs Host Reaction; Humans; Leukemia, Myeloid, Acute; Leukocytes; Life Expectancy; Middle Aged; Mitosis; Prednisolone; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine | 1974 |
Daunorubicin in acute myelocytic leukaemia.
Topics: Daunorubicin; Heart; Humans; Leukemia, Myeloid, Acute | 1969 |
High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.
Topics: Adult; Aged; Alopecia; Bone Marrow; Bone Marrow Cells; Daunorubicin; Drug Eruptions; Erythrocytes; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Leukocyte Count; Leukocytes; Male; Middle Aged; Oxidoreductases; Pharyngitis; Prognosis; Remission, Spontaneous; Vomiting | 1972 |
Cardiac ultrastructural changes induced by daunorubicin therapy.
Topics: Adolescent; Adult; Cardiomegaly; Child; Child, Preschool; Chromatin; Daunorubicin; Female; Heart; Heart Failure; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Microscopy, Electron; Myocardium | 1973 |
Acute leukemias and Burkitt's lymphoma. Present status of therapy.
Topics: Antineoplastic Agents; Asparaginase; Burkitt Lymphoma; Choriocarcinoma; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Female; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Melphalan; Mercaptopurine; Methotrexate; Prednisone; Pregnancy; Vincristine; Wilms Tumor | 1968 |
Daunomycin in the treatment of acute leukaemia and neoplastic diseases in childhood.
Topics: Adenocarcinoma; Age Factors; Child; Child, Preschool; Daunorubicin; Female; Hemangiosarcoma; Hodgkin Disease; Humans; Infant; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Peritoneal Neoplasms; Sarcoma, Ewing; Teratoma; Testicular Neoplasms; Wilms Tumor | 1968 |
Septicaemia due to Pasteurella pneumotropica.
Topics: Ampicillin; Cephaloridine; Chloramphenicol; Culture Media; Cytarabine; Daunorubicin; Erythromycin; Gentamicins; Humans; Kanamycin; Leukemia, Myeloid, Acute; Male; Microbial Sensitivity Tests; Middle Aged; Pasteurella Infections; Polymyxins; Sepsis; Tetracycline | 1973 |
[A case of spinal chloroma revealing acute leukemia].
Topics: Adult; Asparaginase; Betamethasone; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Spinal Cord Compression; Spinal Neoplasms | 1974 |
[Difficulties of remission induction treatment of acute myeloblastic leukemia].
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine | 1974 |
Adriamycin in the treatment of acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission, Spontaneous | 1972 |
[Clinical trial of daunomycin in acute leukemia in adults].
Topics: Adolescent; Adult; Aged; Daunorubicin; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Vincristine | 1972 |
[Therapeutic trials in acute myeloblastic leukosis. Analysis of a group of 51 patients treated with daunomycin].
Topics: Cytarabine; Daunorubicin; Evaluation Studies as Topic; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisone; Remission, Spontaneous | 1972 |
Characteristics of cell proliferation in acute leukemia.
Topics: Adolescent; Adult; Autoradiography; Bone Marrow Cells; Cell Division; Child; Child, Preschool; Cytarabine; Daunorubicin; DNA, Neoplasm; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisone; Thymidine; Tritium; Vincristine | 1972 |
The treatment of acute granulocytic leukemia in adults.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors; Vincristine | 1972 |
Acute granulocytic leukemia in adults.
Topics: Adult; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Prednisone; Remission, Spontaneous; Thioguanine; Time Factors; Vincristine | 1972 |
[Role of daunomycin in the treatment of acute leukemia in children].
Topics: Bone Marrow Diseases; Child; Daunorubicin; Dexamethasone; Drug Synergism; Evaluation Studies as Topic; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Prednisone; Vincristine | 1972 |
Daunorubicin metabolism in acute myelocytic leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Blood Proteins; Chromatography, Thin Layer; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Leukocytes; Middle Aged; Nucleotides; Oxidoreductases; Remission, Spontaneous | 1972 |
[Should acute myeloblastic leukemias be treated in elderly patients?].
Topics: Age Factors; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Combinations; Drug Tolerance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Remission, Spontaneous | 1972 |
Treatment of acute granulocytic leukemia in adults.
Topics: Adult; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Vincristine | 1972 |
[Research on optimal dosage schemes in clinical experimentation with antineoplastic agents].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Combinations; Glycosides; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Naphthacenes; Neoplasms | 1972 |
[Clinical trial of chemotherapeutic combinations based on the notion of attempted cellular synchronization. Preliminary administration of an antimitotic followed by the use of cycle-dependent or phase dependent product(s)].
Topics: Amino Sugars; Anthraquinones; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Daunorubicin; DNA; Drug Combinations; Drug Tolerance; Female; Hodgkin Disease; Humans; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mitosis; Neoplasm Metastasis; Neoplasms; Plants, Medicinal; Plants, Toxic; Podophyllum; Prednisone; Prognosis; Time Factors | 1972 |
[Therapy of acute leukemias in children. 1].
Topics: Acute Disease; Asparaginase; Child; Daunorubicin; Drug Synergism; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisone; Remission, Spontaneous; Vincristine | 1972 |
[Effect of daunomycin and adriamycin in cytostatic combination therapy of acute leukoses of the adult].
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Blood Coagulation Disorders; Bone Marrow Diseases; Carbenicillin; Cytarabine; Daunorubicin; Drug Synergism; Female; Glycosides; Hair; Heart Diseases; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Remission, Spontaneous; Skin Diseases; Vincristine | 1972 |
[Trial treatment of acute myeloblastic leukemia with the cytosine arabinoside-cyclophosphamide association. (Apropos of 30 cases)].
Topics: Adolescent; Adult; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous | 1972 |
DNA synthesis in normal and leucemic cells as related to therapy with cytotoxic drugs.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; DNA; DNA Nucleotidyltransferases; DNA, Neoplasm; Doxorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Methotrexate; Prednisolone; Tetrahydrofolate Dehydrogenase; Thymidine Kinase; Thymine Nucleotides | 1972 |
[Effects of dauno-rubidomycin and adriamycin on enzymes of DNA synthesis in leukocytes in vivo and in culture].
Topics: Cells, Cultured; Daunorubicin; DNA; DNA Nucleotidyltransferases; Doxorubicin; Humans; In Vitro Techniques; Lectins; Leukemia, Myeloid, Acute; Leukocytes; Lymphocytes; RNA; Thymidine Kinase | 1972 |
Intensive chemotherapy of acute myelogenous leukaemia.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Vincristine | 1972 |
[57 cases of acute leukemia. Trial treatment with a semisynthetic daunorubicin derivative: 22,050 R.P].
Topics: Adolescent; Adult; Aged; Blood Cell Count; Blood Platelets; Blood Transfusion; Bone Marrow Examination; Child; Child, Preschool; Daunorubicin; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission, Spontaneous; Tachycardia | 1972 |
[Treatment of acute myeloblastic leukemia with daunorubicin and cytosine-arabinoside].
Topics: Adolescent; Adult; Aged; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1972 |
Lymphosarcoma terminating in acute myelogenous leukemia.
Topics: Adult; Cobalt Isotopes; Cyclophosphamide; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Radioisotope Teletherapy; Radiotherapy Dosage; Uracil Mustard | 1972 |
Mode of action of chemotherapy in vivo on human acute leukemia. I. Daunomycin.
Topics: Autoradiography; Blood Transfusion, Autologous; Bone Marrow; Bone Marrow Cells; Cytidine; Daunorubicin; Humans; In Vitro Techniques; Injections, Intravenous; Leukemia, Myeloid, Acute; Leukocytes; Mitosis; Thymidine; Time Factors; Tritium | 1973 |
Treatment of acute myeloid leukaemia with cytosine arabinoside and daunomycin in combination.
Topics: Adult; Aged; Aspergillosis; Bacterial Infections; Candidiasis; Cytarabine; Daunorubicin; Female; Humans; Infant; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1972 |
[The effects of daunomycin in the treatment of acute monocytic leukemia in childhood--with special reference to ultracytochemical observations].
Topics: Acid Phosphatase; Child, Preschool; Daunorubicin; Histocytochemistry; Humans; Leukemia, Myeloid, Acute; Male; Microscopy, Electron; Peroxidases | 1972 |
[Therapy of acute leukemia. Opinion of Prof. Franco Mandelli].
Topics: Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Synergism; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Prognosis; Remission, Spontaneous; Thioguanine; Vincristine | 1973 |
Induction and maintenance of remission in acute leukemia. Effectiveness of combination therapy in 227 patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Remission, Spontaneous; Time Factors; Vincristine | 1973 |
Treatment of acute myeloblastic leukaemia with RP 22050.
Topics: Adult; Child; Daunorubicin; Doxorubicin; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous; Time Factors | 1972 |
Acute promyelocytic leukemia: results of treatment by daunorubicin.
Topics: Adult; Bone Marrow Examination; Cell Nucleus; Child; Cytoplasmic Granules; Daunorubicin; Esterases; Female; Histocytochemistry; Humans; Leukemia, Myeloid, Acute; Male; Peroxidases | 1973 |
Remission of leukemia associated with polycythemia vera.
Topics: Adult; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Phosphorus Isotopes; Polycythemia Vera; Remission, Spontaneous; Thioguanine; Vincristine | 1973 |
Combination chemotherapy with cytosine arabinoside and rubidomycin in 30 cases of acute granulocytic leukemia.
Topics: Adult; Aged; Anemia, Aplastic; Cerebral Hemorrhage; Child; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous | 1973 |
Acute leukemia presenting as a breast mass.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Biopsy, Needle; Breast Neoplasms; Child; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Menarche; Mercaptopurine; Methotrexate; Prednisolone; Sulfates; Vincristine | 1973 |
Daunorubicin-prednisone remission induction with hydroxyurea maintenance in acute non-lymphocytic leukemia.
Topics: Adult; Age Factors; Daunorubicin; Female; Humans; Hydroxyurea; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphocyte Activation; Male; Prednisone; Remission, Spontaneous; Sex Factors | 1973 |
[Otitis and leukemia].
Topics: Adult; Antineoplastic Agents; Cytarabine; Daunorubicin; Ear Neoplasms; Gentamicins; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Otitis; Otitis Externa; Punctures | 1973 |
Acute myeloid leukemia with two Philadelphia chromosomes in forty-six stemline. Remarks on the karyotypic analysis and chemotherapy.
Topics: Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Clone Cells; Cytogenetics; Daunorubicin; Diploidy; Humans; Karyotyping; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitosis; Prednisone; Time Factors; Vincristine | 1973 |
Treatment of acute myeloid leukaemia according to the Hammersmith protocol: preliminary report.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Cytarabine; Daunorubicin; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; London; Middle Aged; Prednisolone; Remission, Spontaneous; Thioguanine | 1973 |
[Treatment of acute myeloblastic leukemia].
Topics: Antineoplastic Agents; Asparaginase; Blood Platelets; Blood Transfusion; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous | 1973 |
[The effects of cytosine arabinoside and daunomycin on cell kinetics in childhood acute myeloblastic leukemia].
Topics: Bone Marrow; Bone Marrow Cells; Child; Child, Preschool; Cytarabine; Daunorubicin; Humans; In Vitro Techniques; Kinetics; Leukemia, Myeloid, Acute; Leukocytes; Mitosis | 1973 |
[Acute myelogenous leukaemia of adults: diagnosis, prognosis and treatment (author's transl)].
Topics: Adult; Cytarabine; Daunorubicin; Diagnosis, Differential; Drug Evaluation; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Muramidase; Prognosis; Remission, Spontaneous; Thymidine; Tritium | 1973 |
Serial in vitro marrow culture in acute myelocytic leukemia.
Topics: Adolescent; Adult; Bone Marrow Cells; Bone Marrow Examination; Cell Count; Cell Division; Child; Clone Cells; Culture Techniques; Cytarabine; Daunorubicin; Drug Therapy, Combination; Embryo, Mammalian; Female; Humans; Kidney; Leukemia, Myeloid, Acute; Leukocytes; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Remission, Spontaneous; Thioguanine; Vincristine | 1973 |
Acute granulocytic leukemia in elderly patients.
Topics: Adult; Age Factors; Aged; Bone Marrow Examination; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission, Spontaneous; Retrospective Studies; Time Factors | 1973 |
Perturbation of generation cycle of human leukaemic blast cells in vivo by daunomycin.
Topics: Adult; Aged; Autoradiography; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Nucleus; Daunorubicin; Depression, Chemical; DNA; Female; Half-Life; Humans; Kinetics; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitosis; Spectrophotometry; Stimulation, Chemical; Thymidine; Time Factors; Tritium | 1973 |
Active immunotherapy used alone for maintenance of patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Bone Marrow Examination; Cytarabine; Daunorubicin; Female; Humans; Immunization; Immunotherapy; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Radiation Effects; Recurrence; Remission, Spontaneous; Time Factors | 1973 |
Factors that influence the appearance of central nervous system leukemia.
Topics: Central Nervous System Diseases; Cerebrospinal Fluid; Cobalt Radioisotopes; Daunorubicin; Humans; Injections, Spinal; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocyte Count; Mercaptopurine; Methotrexate; Prednisone; Radioisotope Teletherapy; Recurrence; Retrospective Studies; Vincristine | 1973 |
[Therapy of acute leukemias].
Topics: Adrenal Cortex Hormones; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Thioguanine; Vincristine | 1973 |
Cell-mediated immunity in acute nonlymphocytic leukemia: relationship to host factors, therapy, and prognosis.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Daunorubicin; Female; Humans; Hypersensitivity, Delayed; Immunity, Cellular; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Nitrobenzenes; Prednisone; Prognosis; Remission, Spontaneous; Sex Factors; Skin Tests; Vincristine | 1974 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Models, Animal; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Fluorouracil; Hodgkin Disease; Humans; Leukemia; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Male; Mechlorethamine; Melphalan; Mice; Mice, Inbred AKR; Multiple Myeloma; Nitrosourea Compounds; Prednisone; Remission, Spontaneous; Vinblastine; Vincristine | 1974 |
Adult acute leukaemia--a suitable case for treatment?
Topics: Acute Disease; Adult; Aged; Agranulocytosis; Anemia; Blood Platelet Disorders; Blood Transfusion; Bone Marrow Diseases; Cytarabine; Daunorubicin; Female; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mouth Diseases; Ulcer | 1973 |
[Therapy of acute leukemia. Results of the Swiss study group for clinical cancer research (SAKK)].
Topics: Age Factors; Bone Marrow Examination; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Mercaptopurine; Nitrosourea Compounds; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine | 1974 |
Hyponatraemia syndrome in acute myeloid leukaemia.
Topics: Adult; Ampicillin; Blood Cell Count; Body Weight; Bone Marrow Cells; Chlorides; Cloxacillin; Cytarabine; Daunorubicin; Diet; Female; Fever; Food Analysis; Gentamicins; Humans; Hyponatremia; Leukemia, Myeloid, Acute; Male; Middle Aged; Nitrogen; Osmolar Concentration; Potassium; Sodium; Syndrome; Urea | 1974 |
Combined chemotherapy of acute myeloblastic leukemia.
Topics: Adult; Age Factors; Asparaginase; Child; Cytarabine; Daunorubicin; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Prednisone; Remission, Spontaneous; Vincristine | 1973 |
Eventual control of clinical leukemia.
Topics: Administration, Oral; Africa; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Injections, Spinal; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methotrexate; Prednisone; United States; Vincristine | 1973 |
Clinical classification and evaluation of treatment response in acute myeloid leukaemia on the basis of differences of leukaemic cell differentiation.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell Division; Cell Survival; Cytarabine; Daunorubicin; Depression, Chemical; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Infant; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocyte Activation; Male; Middle Aged; Prognosis; Stimulation, Chemical; Thioguanine; Vincristine | 1973 |
Therapy of adult acute leukemia with daunorubicin and L-asparaginase.
Topics: Adolescent; Adult; Aged; Asparaginase; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1974 |
Trisomy 8 in acute myeloblastic leukemia and sideroachrestic anemia.
Topics: Aged; Anemia, Myelophthisic; Anemia, Sideroblastic; Bone Marrow Examination; Cells, Cultured; Chromosomes, Human, 6-12 and X; Cytarabine; Daunorubicin; Female; Folic Acid; Humans; Karyotyping; Lectins; Leukemia, Myeloid, Acute; Leukocytes; Middle Aged; Prednisolone; Pyridoxal Phosphate; Pyridoxine; Thioguanine; Trisomy | 1974 |
[Therapeutical induced cytochemical changes in acute leukemia].
Topics: Adolescent; Adult; Aminosalicylic Acids; Asparaginase; Blood Cells; Bone Marrow; Bone Marrow Cells; Daunorubicin; Diagnosis, Differential; Doxorubicin; Esterases; Histocytochemistry; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Methotrexate; Middle Aged; Peroxidases; Prednisolone; Thioguanine; Vincristine | 1974 |
The treatment of acute myeliod leukaemia.
Topics: Adolescent; Adult; Blood Cell Count; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Remission, Spontaneous | 1974 |
[Kinetic effect of cytostatic drugs on the generation cycle of human leukaemic blast cells in vivo. A review].
Topics: Antineoplastic Agents; Asparaginase; Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; DNA Nucleotidyltransferases; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Methotrexate; Mitosis; Prednisone; Thymidine; Time Factors; Vincristine | 1974 |
[Treatment of acute myeloblastic leukemia. 79 cases treated by cytosine-rubidomycin combination].
Topics: Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission, Spontaneous; Statistics as Topic; Time Factors | 1974 |
Development of pulmonary aspergillomas coinciding with induction of remission in acute myeloid leukaemia.
Topics: Aged; Aspergillosis; Autopsy; Cytarabine; Daunorubicin; Diagnosis, Differential; Humans; Leukemia, Myeloid, Acute; Lung; Male; Radionuclide Imaging; Remission, Spontaneous; Strontium Radioisotopes | 1974 |
[Acute lymphatic leukemia in adults. Therapy and prognosis in comparison with acute myelogenous leukemia].
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Asparaginase; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Methylprednisolone; Middle Aged; Paresis; Prognosis; Radiotherapy Dosage; Remission, Spontaneous; Vincristine | 1974 |
Agar culture studies in 127 cases of untreated acute leukemia: the prognostic value of reclassification of leukemia according to in vitro growth characteristics.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Bone Marrow; Bone Marrow Cells; Cell Division; Cells, Cultured; Child; Clone Cells; Cytarabine; Daunorubicin; Densitometry; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Remission, Spontaneous; Vincristine | 1974 |
Chromosomes and causation of human cancer and leukemia. IX. Prognostic and therapeutic value of chromosomal findings in acute myeloblastic leukemia.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Bone Marrow Cells; Carmustine; Chromosome Aberrations; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitosis; Nitrosourea Compounds; Prednisone; Prognosis; Thioguanine; Time Factors; Vincristine | 1974 |
[Treatment of acute myeloblastic leukemia in patients over 60. Apropos of 22 cases].
Topics: Cytarabine; Daunorubicin; Drug Synergism; Glyoxal; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Remission, Spontaneous | 1974 |
[The study on the treatment of acute promyelocytic leukemia--the use of daunorubicin together with heparin (author's transl)].
Topics: Adult; Daunorubicin; Drug Therapy, Combination; Female; Heparin; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged | 1974 |
Prognosis of acute leukaemia in adults.
Topics: Acute Disease; Adult; Age Factors; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Prognosis; Remission, Spontaneous; Thioguanine; Vincristine | 1974 |
Studies of leukemic cell populations in culture.
Topics: Autoradiography; Bone Marrow Cells; Cell Adhesion; Cell Division; Cell Separation; Cells, Cultured; Culture Media; Cytarabine; Daunorubicin; Freezing; Humans; Lectins; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Male; Mercaptopurine; Middle Aged; Prednisone; Radiation Effects; Thymidine; Tritium; Ultrafiltration | 1974 |
[Treatment of acute myeloblastic leukemia. Evaluation of six years of cooperative studies in Argentina (author's transl)].
Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Infant; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prednisone; Remission, Spontaneous; Vincristine | 1974 |
Hypouricaemia and proximal renal tubular dysfunction in acute myeloid leukaemia.
Topics: Amino Acids; Calcium; Creatinine; Cytarabine; Daunorubicin; Female; Humans; Hydrogen-Ion Concentration; Kidney Diseases; Kidney Tubules, Proximal; Leukemia, Myeloid, Acute; Middle Aged; Muramidase; Phosphates; Phosphorus; Pyrazinamide; Uric Acid | 1974 |
The treatment of acute leukemia.
Topics: Adolescent; Adult; Antimetabolites; Antineoplastic Agents; Asparaginase; Body Weight; Child; Child, Preschool; Cyclophosphamide; Daunorubicin; Female; Gestational Age; Humans; Infant; Infant, Newborn; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Prednisone; Pregnancy; Remission, Spontaneous; Time Factors; Vincristine | 1974 |
[Our experience in the treatment of acute myeloblastic leukemia].
Topics: Antineoplastic Agents; Busulfan; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Thioguanine; Vincristine | 1974 |
Comparative results obtained in the treatment of acute leukemia.
Topics: Antineoplastic Agents; Asparaginase; Carmustine; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Meningitis; Methotrexate; Prednisone; Thioguanine; Vincristine | 1973 |
A new agent active in the treatment of acute myeloblastic leukemia 22 050 RP.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous | 1973 |
Comparative results obtained in the treatment of acute lymphoid leukemia, acute myleoid leukemia, and acute monocytoid leukemia.
Topics: Adult; Antineoplastic Agents; Asparaginase; Child; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Humans; Immunotherapy; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Prednisone; Remission, Spontaneous; Thioguanine; Time Factors; Vincristine | 1973 |
Preliminary results of a trial on acute myeloid leukemia comparing the effect of cytosine arabinoside, the combination of cytosine arabinoside and thioguanine and the combination of cytosine arabinoside and daunorubicine.
Topics: Age Factors; Bone Marrow Examination; Cytarabine; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Thioguanine | 1973 |
Chemotherapy of acute myelocytic leukemia in adults.
Topics: Adolescent; Adult; Aged; Anhydrides; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1974 |
Immunotherapy for acute myelogenous leukaemia.
Topics: Adult; Antineoplastic Agents; Cell Separation; Cytosine; Daunorubicin; Follow-Up Studies; Freezing; Humans; Immunization; Immunotherapy; Leukemia, Myeloid, Acute; Remission, Spontaneous | 1973 |
[Treatment of complications induced by chemotherapy of acute leukemias].
Topics: Agranulocytosis; Anemia, Aplastic; Anti-Bacterial Agents; Antineoplastic Agents; Asparaginase; Blood Platelets; Blood Transfusion; Cytarabine; Daunorubicin; Drug Therapy, Combination; Hemorrhage; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Mercaptopurine; Methotrexate; Prednisone; Thrombocytopenia; Vincristine | 1974 |
[Combination chemotherapy for acute myelogenous leukemia in adults (author's transl)].
Topics: Adolescent; Adult; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prednisolone; Remission, Spontaneous; Thioinosine | 1974 |
[Letter: Polychemotherapeutic treatment in acute myeloblastic leukemia].
Topics: Cytosine; Daunorubicin; Drug Synergism; Drug Therapy, Combination; Glyoxal; Humans; Leucovorin; Leukemia, Myeloid, Acute; Methotrexate; Remission, Spontaneous | 1973 |
Treatment of the acute leukemias.
Topics: Adjuvants, Immunologic; Asparaginase; Bacterial Vaccines; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Mycobacterium bovis; Prednisone; Remission, Spontaneous; Thioguanine; Vincristine | 1972 |
[Treatment of acute myeloid leukemia in adults with a combination of daunomycin and cytosine-arabinoside].
Topics: Adult; Aged; Bone Marrow Cells; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous | 1972 |
Immunotherapy of acute myelogenous leukemia in man.
Topics: Antigens, Neoplasm; BCG Vaccine; Cross Reactions; Cytarabine; Daunorubicin; Evaluation Studies as Topic; Humans; Immunity, Cellular; Immunization; Leukemia, Myeloid, Acute; Mycobacterium bovis; Remission, Spontaneous | 1973 |
Acute promyelocytic leukemia: a model for understanding the role of the malignant cell in hemostasis.
Topics: Blood Coagulation Tests; Bone Marrow; Bone Marrow Cells; Bone Marrow Examination; Daunorubicin; Disseminated Intravascular Coagulation; Fibrinogen; Hemorrhage; Hemorrhagic Disorders; Hemostasis; Heparin; History, 20th Century; Humans; Leukemia, Myeloid, Acute; Thromboplastin | 1974 |
Active specific immunotherapy for acute myelogenous leukaemia.
Topics: Adjuvants, Immunologic; Antigens, Bacterial; Antigens, Neoplasm; BCG Vaccine; Cytarabine; Daunorubicin; Freezing; Humans; Immunization; Immunotherapy; Leukemia, Myeloid, Acute; Leukocytes; Mycobacterium bovis; Neoplasm Transplantation; Radiation Effects; Remission, Spontaneous; Thioguanine; Time Factors; Transplantation, Homologous | 1974 |
Acute myelogenous leukemia in two patients treated with azathioprine for nonmalignant diseases.
Topics: Adult; Azathioprine; Blood Cell Count; Blood Platelets; Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; Graft Rejection; Hepatitis; Humans; Immunosuppression Therapy; Kidney Transplantation; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Prednisone; Thioguanine; Transplantation, Homologous | 1974 |
Marrow transplantation for the treatment of acute leukemia using HL-A-identical siblings.
Topics: Acute Kidney Injury; Antilymphocyte Serum; Bone Marrow Cells; Bone Marrow Transplantation; Cyclophosphamide; Daunorubicin; Female; Graft Rejection; Graft vs Host Disease; Histocompatibility; Humans; Immunosuppression Therapy; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Methotrexate; Pneumonia; Recurrence; Sepsis; T-Lymphocytes; Transplantation Immunology; Transplantation, Homologous | 1974 |
[Cytosine arabinoside alone and in association to other drugs in the therapy of acute myeloblastic leukemia].
Topics: Cyclophosphamide; Cytarabine; Daunorubicin; Drug Interactions; Humans; Leukemia, Myeloid, Acute; Vincristine | 1972 |
Heteromorphic pair of metacentric chromosomes with fused arms and the Philadelphia chromosome in a case of acute myeloid leukemia.
Topics: Blood Transfusion; Bone Marrow Cells; Cells, Cultured; Chromosome Aberrations; Chromosomes, Human, 19-20; Chromosomes, Human, 21-22 and Y; Daunorubicin; Female; Humans; Karyotyping; Lectins; Leukemia, Myeloid, Acute; Middle Aged; Prednisone; Vincristine | 1972 |
Daunomycin treatment in acute leukemia.
Topics: Child; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute | 1967 |
Urinary polyamines in cancer patients.
Topics: Brain Neoplasms; Chemistry, Clinical; Daunorubicin; Female; Hodgkin Disease; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Ovarian Neoplasms; Polyamines; Pregnancy; Remission, Spontaneous; Spermidine; Spermine; Teratoma | 1971 |
Observations on toxicity and clinical trials with daunomycin.
Topics: Adult; Animals; Child; Daunorubicin; Dogs; Haplorhini; Humans; Injections, Intravenous; Leukemia; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mice; Neoplasms; Neuroblastoma | 1967 |
[Cytochemical modifications in the blood of patients with acute leukemia treated with daunomycin, vincristine and cortisone].
Topics: Cortisone; Daunorubicin; Histocytochemistry; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Vincristine | 1969 |
[Results obtained with the clinical use of adriamycin].
Topics: Adult; Aged; Amino Sugars; Antibiotics, Antineoplastic; Daunorubicin; Female; Glycosides; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Naphthacenes; Neoplasms; Plasmacytoma; Remission, Spontaneous | 1971 |
[Chemotherapy of acute leukemia].
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Antineoplastic Agents; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Thrombocythemia, Essential; Vincristine | 1967 |
Treatment of the acute leukemias.
Topics: Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Nitroso Compounds; Prednisone; Urea; Vincristine | 1967 |
Summary: recent advances in the treatment of acute leukemia and Burkitt's tumor.
Topics: Antineoplastic Agents; Asparaginase; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Nitroso Compounds; Prednisone; Urea; Vincristine | 1967 |
Daunomycin--preliminary results of the treatment of acute leukemias in adults.
Topics: Adolescent; Adult; Aged; Daunorubicin; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone | 1968 |
Treatment of acute leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Burkitt Lymphoma; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Prognosis; Thioguanine; Time Factors; Vincristine | 1968 |
[Recent acquisitions in treatment of acute leukemias].
Topics: Adult; Aminopterin; Antineoplastic Agents; Child; Cyclophosphamide; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Prednisone; Vincristine | 1967 |
[Rubidomycin-daunomycin, a new antibiotic with antineoplastic effect].
Topics: Animals; Antibiotics, Antineoplastic; Biological Assay; Chemical Phenomena; Chemistry; Daunorubicin; DNA; Drug Synergism; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Neoplasms, Experimental; Pregnancy; Pregnancy, Animal; RNA | 1968 |
[Rubidomycin-daunomycin therapy in acute myeloblastic leukemia].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Bone Marrow Examination; Daunorubicin; Diagnosis, Differential; Drug Synergism; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male | 1968 |
Clinical study of daunomycin and prednisone for induction of remission in children with advanced leukemia.
Topics: Antineoplastic Agents; Bone Marrow Examination; Cellulitis; Chemical Phenomena; Chemistry; Child; Daunorubicin; Humans; Injections, Intravenous; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukopenia; Prednisone; Stomatitis; Thrombocytopenia; Time Factors | 1969 |
Chemotherapeutic goals in acute leukemia.
Topics: Acute Disease; Antineoplastic Agents; Daunorubicin; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisone | 1969 |
Treatment of AGL.
Topics: Adult; Afibrinogenemia; Aged; Anemia; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Humans; Hydroxyzine; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukopenia; Mercaptopurine; Methotrexate; Middle Aged; Polycythemia Vera; Prednisone; Primary Myelofibrosis; Splenomegaly; Vincristine | 1969 |
Treatment of AGL.
Topics: Aminopterin; Cortisone; Cytarabine; Daunorubicin; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Infections; Leukemia, Myeloid, Acute; Patient Isolators; Steroids; Transfusion Reaction | 1969 |
Daunorubicine in acute myelogenous leukemia in adults.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Bone Marrow Cells; Daunorubicin; DNA, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; RNA, Neoplasm | 1969 |
[Rubidomycin in the treatment of leukemias in children (preliminary clinical observation)].
Topics: Antibiotics, Antineoplastic; Child; Child, Preschool; Daunorubicin; Female; Hemorrhagic Disorders; Humans; Leukemia, Myeloid, Acute; Male; Prednisone | 1969 |
[Chimiotherapy of cancers (operational research of its efficiency and its place in therapeutic strategy of neoplasic diseases)].
Topics: Agranulocytosis; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cyclophosphamide; Daunorubicin; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocyte Count; Methotrexate; Neoplasms; Neoplastic Cells, Circulating; Prednisone; Vinblastine; Vincristine | 1969 |
[Experiences with daunomycin and cytosine arabinoside in the therapy of acute myeloid leukemias].
Topics: Adolescent; Adult; Cytarabine; Daunorubicin; Female; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1968 |
[On the use of daunomycin in the therapy of acute leukemias].
Topics: Adult; Aged; Child, Preschool; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged | 1969 |
[Treatment of acute granulocytic leukemias with daunomycin].
Topics: Adolescent; Adult; Aged; Child; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1969 |
[Rubidomycin in acute leukemia in children].
Topics: Agranulocytosis; Child; Child, Preschool; Daunorubicin; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Retrospective Studies | 1969 |
[Treatment of acute myeloblastic leukemia by rubidomycin. Statistics on 35 cases].
Topics: Adolescent; Adult; Aged; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged | 1969 |
[Clinical experience with vinblastine and vincristine].
Topics: Adolescent; Adult; Daunorubicin; Female; Hodgkin Disease; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisone; Vinblastine; Vincristine | 1968 |
Daunorubicin in the treatment of adult acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Chromosome Aberrations; Daunorubicin; Female; Humans; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Thrombocytopenia; Vincristine | 1970 |
Daunorubicin in acute leukaemia.
Topics: Adolescent; Adult; Aged; Child; Daunorubicin; Female; Humans; Injections, Intravenous; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged | 1970 |
The treatment of acute lymphocytic leukemia.
Topics: Animals; Antineoplastic Agents; Asparaginase; Blood Platelets; Bone Marrow Cells; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Models, Animal; Drug Synergism; Hemorrhage; Humans; Infections; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Mice; Prednisone; Prognosis; Thrombocytopenia; Vincristine | 1970 |
[Trial of adriamycin in the treatment of acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Aged; Amino Sugars; Anthraquinones; Anti-Bacterial Agents; Bone Marrow Diseases; Cardiovascular Diseases; Chemical Phenomena; Chemistry; Child; Child, Preschool; Daunorubicin; Female; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1970 |
Treatment of acute myeloblastic leukaemia.
Topics: Acute Disease; Adult; Child; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute | 1970 |
The potentiality of out-of-cycle acute leukemic cells to synthesize DNA.
Topics: Adult; Aged; Autoradiography; Child; Cyclophosphamide; Daunorubicin; DNA Replication; Female; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Male; Methotrexate; Middle Aged; Prednisone; Radiation Effects; Thymidine; Tritium; Ultraviolet Rays; Vincristine | 1970 |
Vincristine, prednisone, and daunomycin in acute leukemia of childhood.
Topics: Acute Disease; Adolescent; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Child; Daunorubicin; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukocyte Count; Prednisone; Vincristine | 1971 |
[Therapeutic evolution of 63 cases of recent acute myeloblastic leukemias].
Topics: Acute Disease; Aged; Antineoplastic Agents; Asparaginase; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Prednisone; Vincristine | 1971 |
Rubidomycin in blastic phases of acute promyelocytic and myeloblastic leukemia in children.
Topics: Adolescent; Amino Sugars; Antibiotics, Antineoplastic; Child; Child, Preschool; Daunorubicin; Glycosides; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Prednisone; Remission, Spontaneous | 1971 |
Treatment of acute myelogenous leukaemia in adults.
Topics: Adult; BCG Vaccine; Cell Division; Cytarabine; Daunorubicin; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Neoplasm Transplantation; Transplantation, Autologous; Transplantation, Homologous | 1971 |
The disappearance of ring sideroblasts in myeloblastic leukaemia in remission.
Topics: Adult; Asparaginase; Blood Transfusion; Bone Marrow; Cytarabine; Daunorubicin; Erythrocytes; Erythrocytes, Abnormal; Female; Humans; Iron; Leukemia, Myeloid, Acute; Mercaptopurine; Prednisone; Remission, Spontaneous | 1971 |
[Meningeal leukemia--report of an adult case].
Topics: Betamethasone; Bone Marrow Examination; Candidiasis; Daunorubicin; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Meninges; Meningitis; Mercaptopurine; Methotrexate; Middle Aged; Remission, Spontaneous | 1971 |
[Comparative evaluation of various methods of treating acute leukemia].
Topics: Adolescent; Cyclophosphamide; Daunorubicin; Female; Humans; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Vincristine | 1971 |
Blood group change in acute myeloid leukaemia.
Topics: ABO Blood-Group System; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Middle Aged; Sepsis | 1971 |
[Therapy of acute leukemia. 4. Remission induction and remission maintenance therapy].
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Middle Aged; Remission, Spontaneous; Vincristine | 1971 |
[Treatment of acute granulocytic leukoses with daunomycin: 14 cases].
Topics: Adult; Bone Marrow; Bone Marrow Cells; Child; Child, Preschool; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous | 1969 |
[Therapeutic results with daunomycin-vincristine-prednisolone in acute leucoses].
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Daunorubicin; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukopenia; Male; Middle Aged; Prednisolone; Thrombocytopenia; Vincristine | 1971 |
DNA synthesis in leukemic cells under the action of cytotoxic agents in vitro and in vivo.
Topics: Adult; Aged; Antineoplastic Agents; Cells, Cultured; Cytarabine; Daunorubicin; DNA, Neoplasm; Female; Glucocorticoids; Humans; In Vitro Techniques; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Male; Methotrexate; Middle Aged; Prognosis; Thymine Nucleotides; Tritium | 1971 |
Result of a cooperative study with L-asparaginase in human leukemias. Report of the section "oncology" of the Paul-Ehrlich-Society for Chemotherapy.
Topics: Asparaginase; Blood Chemical Analysis; Blood Platelets; Blood Sedimentation; Body Weight; Central Nervous System Diseases; Daunorubicin; Erythrocyte Count; Hepatomegaly; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocyte Count; Nausea; Splenomegaly; Time Factors; Vincristine; Vomiting | 1970 |
Treatment of acute leukemia with L-asparaginase--preliminary results on 84 cases.
Topics: Acute Disease; Asparaginase; Asparagine; Blood Coagulation Disorders; Cells, Cultured; Central Nervous System Diseases; Chemical and Drug Induced Liver Injury; Daunorubicin; Humans; Kidney Diseases; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Liver Function Tests; Methotrexate; Prednisone; Valine; Vincristine | 1970 |
Comparison of CNS-leukaemia in children with acute leukaemia, induced either with rubidomycin or L-asparaginase.
Topics: Asparaginase; Central Nervous System Diseases; Child; Child, Preschool; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Methotrexate; Neoplasm Metastasis; Prednisolone; Remission, Spontaneous; Vincristine | 1971 |
Treatment of adult leukemia with L-asparaginase (NSC-109229).
Topics: Adolescent; Adult; Aged; Allopurinol; Anaphylaxis; Asparaginase; Blood Coagulation Disorders; Cytarabine; Daunorubicin; Drug Hypersensitivity; Female; Fever; Gastrointestinal Hemorrhage; Hallucinations; Humans; Hyperglycemia; Injections, Intravenous; Jaundice; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Liver; Male; Mercaptopurine; Methotrexate; Middle Aged; Oral Hemorrhage; Prednisone; Thioguanine; Uremia; Vincristine; Vomiting | 1971 |